




(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2019/12/05
(87) Date publication PCT/PCT Publication Date: 2020/06/11
(85) Entrée phase nationale/National Entry: 2021/06/04
(86) N° demande PCT/PCT Application No.: US 2019/064786
(87) N° publication PCT/PCT Publication No.: 2020/118115
(30) Priorité/Priority: 2018/12/06 (US62/776,302)

(51) Cl.Int./Int.Cl. *C12N 9/10* (2006.01),
A61K 48/00 (2006.01), *C12N 15/86* (2006.01)
(71) Demandeur/Applicant:
ARCTURUS THERAPEUTICS, INC., US
(72) Inventeurs/Inventors:
PEREZ-GARCIA, CARLOS G., US;
TACHIKAWA, KIYOSHI, US;
MATSUDA, DAIKI, US;
CHIVUKULA, PADMANABH, US
(74) Agent: BLAKE, CASSELS & GRAYDON LLP

(54) Titre : COMPOSITIONS ET METHODES POUR TRAITER UNE DEFICIENCE EN ORNITHINE
TRANSCARBAMYLASE
(54) Title: COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY



(57) Abrégé/Abstract:

The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5' UTR derived from a gene expressed by *Arabidopsis thaliana* for use in treating OTC deficiency in a patient.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

11 June 2020 (11.06.2020)



(10) International Publication Number

WO 2020/118115 A1

(51) International Patent Classification:

C12N 9/10 (2006.01) *C12N 15/86* (2006.01)*A61K 48/00* (2006.01)

(21) International Application Number:

PCT/US2019/064786

(22) International Filing Date:

05 December 2019 (05.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/776,302 06 December 2018 (06.12.2018) US

(71) Applicant: ARCTURUS THERAPEUTICS, INC.

[US/US]; 10628 Science Center Drive, Suite 250, San Diego, CA 92121 (US).

(72) Inventors: PEREZ-GARCIA, Carlos, G.;

10628 Science Center Drive, Suite 250, San Diego, CA 92121 (US).


TACHIKAWA, Kiyoshi; 10628 Science Center Drive, Suite 250, San Diego, CA 92121 (US). MATSUDA, Dai-ki; 10628 Science Center Drive, Suite 250, San Diego, CA 92121 (US). CHIVUKULA, Padmanabh; 10628 Science Center Drive, Suite 250, San Diego, CA 92121 (US).

(74) Agent: SHERIN, Mridula, P. et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Plaza, Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY

FIG. 1



(57) Abstract: The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5' UTR derived from a gene expressed by *Arabidopsis thaliana* for use in treating OTC deficiency in a patient.

[Continued on next page]



WO 2020/118115 A1

WO 2020/118115 A1

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 62/776,302, filed December 6, 2018. The content of the application is incorporated herein by reference in its entirety.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 25, 2019 is named 049386_523001WO_SL.txt and is 363 kilobytes in size.

BACKGROUND

[0003] Ornithine transcarbamylase (OTC) is a mitochondrial enzyme present in mammals which plays an essential role in detoxifying the organism from toxic ammonia. OTC mRNA has a mitochondrial signaling peptide (MSP) that is critical to redirect the nascent pre-peptide from the cytosol into the mitochondria. OTC protein exist as a precursor in the cytosol, the presence of the MSP redirects the pro-peptide into the mitochondria, where it undergoes excision of the signaling peptide and delivery of the functional protein into the mitochondrial matrix. OTC is one of six enzymes that play a role in the breakdown of proteins and removal of ammonia from the body, a process known as the urea cycle, a metabolic process that occurs in hepatocytes. OTC is responsible for converting carbamoyl phosphate and ornithine into citrulline.

[0004] Deficiency of the OTC enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Excess ammonia, which is a neurotoxin, travels to the central nervous system through the blood, resulting in the symptoms and physical findings associated with OTC deficiency. These symptoms can include vomiting, refusal to eat, progressive lethargy, or coma. If left untreated a hyperammonemic episode may progress to coma and life-threatening complications.

[0005] The severity and age of onset of OTC deficiency vary from person to person, even within the same family. A severe form of the disorder affects some infants, typically males, shortly after birth (neonatal period). A milder form of the disorder affects some children later in infancy. Both males and females may develop symptoms of OTC deficiency during childhood. Presently, the treatment of OTC deficiency is aimed at preventing excessive ammonia from being formed or from removing excessive ammonia during a hyperammonemic episode. Long-term therapy for OTC deficiency combines dietary restrictions and the stimulation of alternative methods of converting and excreting nitrogen from the body (alternative pathways therapy).

[0006] Dietary restrictions in individuals with OTC deficiency are aimed at limiting the amount of protein intake to avoid the development of excess ammonia. However, enough protein must be taken in by an affected infant to ensure proper growth. Infants with OTC deficiency are placed on a low protein, high calorie diet supplemented by essential amino acids.

[0007] In addition to dietary restrictions, individuals with OTC deficiency are treated by medications that stimulate the removal of nitrogen from the body. These medications provide an alternative method to the urea cycle in converting and removing nitrogen waste. These medications are unpalatable to many patients and are often administered via a tube that is placed in the stomach through the abdominal wall (gastrostomy tube) or a narrow tube that reaches the stomach via the nose (nasogastric tube).

[0008] In cases where there is no improvement or in cases where hyperammonemic coma develops, the removal of wastes by filtering an affected individual's blood through a machine (hemodialysis) may be necessary. Hemodialysis is also used to treat infants, children, and adults who are first diagnosed with OTC deficiency during hyperammonemic coma.

[0009] In some cases, liver transplantation, may be an appropriate treatment option. Liver transplantation can cure the hyperammonemia in OTC deficiency. However, this operation is risky and may result in post-operative complications. Also, after liver transplantation, patients will need to follow a medication regimen throughout their lives for immunosuppression.

[0010] Novel approaches and therapies are still needed for the treatment of OTC enzyme deficiency. Strategies are needed which overcome the challenges and limitations associated

with, for example, gene therapy. Poor stability, getting enough OTC in the mitochondria and efficient delivery to the target cells are still challenges.

SUMMARY

[0011] The present disclosure provides a modified human OTC protein of SEQ ID NO: 4 having improved properties for the treatment of OTC deficiency in a patient. SEQ ID NO: 4 has been modified from wild-type OTC to remove one or more predicted ubiquitination sites resulting in a protein that is less susceptible to ubiquitination and degradation by ubiquitin ligases. However, the modified OTC protein of SEQ ID NO: 4 maintains the catalytic enzyme activity of human wild type OTC. The removal of predicted ubiquitination sites preferably comprises replacing N-terminus residues that have been found to support ubiquitination such as asparagine, arginine, leucine, lysine or phenylalanine with N-terminus residues that have been found to be stabilizing against ubiquitination such as alanine, glycine, methionine, serine, threonine, valine and proline. Stabilization of the modified OTC protein of SEQ ID NO: 4 in this manner is particularly advantageous for preserving the stability of the modified OTC protein during its transport from the cytosol to the mitochondria wherein it exerts its enzymatic activity.

[0012] Preferably, the protein of SEQ ID NO: 4 described herein is produced from a nucleic acid encoding the protein of SEQ ID NO: 4. The nucleic acid may be RNA or DNA that encodes the protein of SEQ ID NO: 4. Preferably the nucleic acid is a heterologous mRNA construct comprising an open reading frame encoding for the modified protein of SEQ ID NO: 4. Preferably, the open reading frame is a codon-optimized open reading frame. Preferably, the open reading frame sequence is optimized to have a theoretical minimum of uridines possible to encode for the modified protein. Preferably, the heterologous mRNA construct comprises a 5' cap, a 5'UTR, a 3'UTR, an open reading frame encoding a modified protein of SEQ ID NO: 4 and a 3' poly A tail. Preferably, the 5'UTR derived from a gene expressed by *Arabidopsis thaliana*. Preferably the 5' UTR derived from a gene expressed by *Arabidopsis thaliana* is found in Table 2.

[0013] The present disclosure also provides mRNA (also referred to herein as mRNA constructs or mRNA sequences) comprising an optimized coding region encoding wild type human ornithine transcarbamylase (OTC) protein of SEQ ID NO: 3 or an OTC protein sequence that is at least 95% identical over the full length of SEQ ID NO: 3 and having OTC

protein enzymatic activity wherein the mRNA sequences comprise a 5'UTR derived from a gene expressed by *Arabidopsis thaliana*.

[0014] The mRNA constructs described herein provide high-efficiency expression of the OTC proteins described herein. The expression can be *in vitro*, *ex vivo*, or *in vivo*.

[0015] The present disclosure also provides pharmaceutical compositions comprising the mRNA sequences described herein and methods of treating ornithine transcarbamylase (OTC) deficiency by administering the pharmaceutical compositions comprising the mRNA sequences described herein to a patient in need thereof wherein the OTC protein of SEQ ID NO: 3 or SEQ ID NO: 4 is expressed in the patient.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] FIGS. 1A-B shows scatter plots illustrating ornithine transcarbamylase (OTC) protein expression in hepatocyte cell lines Hepa1,6 (mouse) and Hep3B (human) at 24 hours (FIG. 1A) and 48 hours (FIG. 1B) using In-Cell Western (ICW) assays.

[0017] FIGS. 2A-B shows scatter plots illustrating the correlation of protein stability compounds screened in Hepa1,6 cells (FIG. 2A) and Hep3B cells (FIG. 2B) at 24h in Round 1.

[0018] FIGS. 3A-B shows scatter plots illustrating the correlation of protein stability compounds screened in human primary hepatocytes at 24h and 48h in Round 2 (newly optimized compounds based on Round 1) as shown with FIG. 3A and FIG. 3B.

[0019] FIGS. 4A-B shows scatter plots illustrating the correlation of protein stability compounds screened in human primary hepatocytes at 24h and 48h in Round 3 (newly optimized compounds based on rounds 1 and 2) as shown with FIG. 4A and FIG. 4B.

[0020] FIG. 5 is a plot illustrating OTC protein expression levels in human primary hepatocytes transfected with lead OTC mRNAs. 1799.1 is an mRNA having the sequence of SEQ ID NO: 175 wherein 100% of the uridines in SEQ ID NO: 175 are N¹-methylpseudouridine (N1MPU).

[0021] FIGS. 6A-B shows bar graphs depicting time course OTC expression levels in spf/ash mice dosed at 10mg/kg with human-specific OTC-mRNA epitopes (FIG. 6A) or mouse-specific OTC-mRNA epitopes (FIG. 6B).

[0022] FIG. 7 is a bar graph depicting OTC expression levels in spf/ash mice dosed at 3 mg/kg with OTC-mRNAs using two different chemistries wherein 100% of the uridines are N¹-methylpseudouridine (N1MPU) and 100% of the uridines are 5-methoxyuridine (5MeOU).

[0023] FIG. 8 is a graph depicting OTC expression levels in Balb/c mice dosed with OTC-mRNAs at three different doses and using two different chemistries (N1MPU and 5MeOU).

[0024] FIG. 9 is a graph depicting urinary orotate levels measured in spf/ash mice dosed with OTC-mRNA 1799.7 at three different doses: 0.3 mg/kg, 1 mg/kg and 3mg/kg. 1799.1 is an mRNA having the sequence of SEQ ID NO: 175 wherein 100% of the uridines in SEQ ID NO: 175 are 5MeOU.

[0025] FIG. 10 is a scatter plot comparing human OTC expression levels and Urinary Orotate at 96h in spf/ash mice dosed with OTC-mRNAs at 1mg/kg and 3mg/kg using two different chemistries (N1MPU and 5MeOU).

[0026] FIG. 11 is a western blot illustrating the protein expression levels of OTC-mRNAs in spf/ash mice dosed at 1mg/kg and 3mg/kg with lead OTC-mRNAs.

[0027] FIG. 12 is a western blot illustrating the protein expression levels in mitochondrial vs cytosolic fractions of spf/ash mice treated with lead OTC-mRNAs.

[0028] FIG. 13 is a plot illustrating the time course of expression of urinary orotate levels in spf/ash mice treated with lead OTC-mRNA.

[0029] FIG. 14 is a plot illustrating the survival of OTC-deficient mice (spf/ash) on a high protein diet during treatment with three different doses of OTC-mRNA 1799.7.

[0030] FIG. 15 is a plot illustrating hOTC expression levels in male C57BL/6 mice dosed with OTC-mRNAs (2262) having different modifications.

DETAILED DESCRIPTION

[0031] Definitions:

[0032] The term “ornithine transcarbamylase” as used interchangeably herein with “OTC” or “hOTC”, or “OTC_HUMAN” generally refers to the human protein associated with

UniProtKB-P00480. The amino acid sequence for the wild type human OTC protein is represented herein by SEQ ID NO: 3.

[0033] The term “nucleic acid,” in its broadest sense, includes any compound and/or substance that comprise a polymer of nucleotides. These polymers are often referred to as polynucleotides. Exemplary nucleic acids or polynucleotides described herein include, but are not limited to, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a β -D-ribo configuration, α -LNA having an α -L-ribo configuration (a diastereomer of LNA), 2'-amino-LNA having a 2'-amino functionalization, and 2'-amino- α -LNA having a 2'-amino functionalization) or hybrids thereof.

[0034] As used herein, the term “polynucleotide” is generally used to refer to a nucleic acid (e.g., DNA or RNA). When RNA, such as mRNA, is specifically being referred to, the term polyribonucleotide may be used. The terms polynucleotide, polyribonucleotide, nucleic acid, ribo nucleic acid, DNA, RNA, mRNA, and the like include such molecules that may be comprised of standard or unmodified residues; nonstandard or modified residues (e.g., analogs); and mixtures of standard and nonstandard (e.g., analogs) residues. In certain embodiments a polynucleotide or a polyribonucleotide is a modified polynucleotide or a polyribonucleotide. In the context of the present disclosure, for each RNA (polyribonucleotide) sequence listed herein, the corresponding DNA (polydeoxyribonucleotide or polynucleotide) sequence is contemplated and vice versa. “Polynucleotide” may be used interchangeably with the “oligomer”. Polynucleotide sequences shown herein are from left to right, 5' to 3', unless stated otherwise.

[0035] As used herein, the term “messenger RNA” (mRNA) refers to any polynucleotide which encodes a protein or polypeptide of interest and which is capable of being translated to produce the encoded protein or polypeptide of interest *in vitro*, *in vivo*, *in situ* or *ex vivo*.

[0036] As used herein, the term “translation” is the process in which ribosomes create polypeptides. In translation, messenger RNA (mRNA) is decoded by transfer RNAs (tRNAs) in a ribosome complex to produce a specific amino acid chain, or polypeptide. The coding region of a polynucleotide sequence (DNA or RNA), also known as the coding sequence or CDS, is capable of being converted to a protein or a fragment thereof by the process of translation.

[0037] As used herein, the term “codon-optimized” means a natural (or purposefully designed variant of a natural) coding sequence which has been redesigned by choosing different codons without altering the encoded protein amino acid sequence. Codon optimized sequence can increase the protein expression levels (Gustafsson et al., *Codon bias and heterologous protein expression*. 2004, Trends Biotechnol 22: 346-53) of the encoded proteins amongst providing other advantages. Variables such as high codon adaptation index (CAI), LowU method, mRNA secondary structures, cis-regulatory sequences, GC content and many other similar variables have been shown to somewhat correlate with protein expression levels (Villalobos et al., *Gene Designer: a synthetic biology tool for constructing artificial DNA segments*. 2006, BMC Bioinformatics 7:285). High CAI (codon adaptation index) method picks a most frequently used synonymous codon for an entire protein coding sequence. The most frequently used codon for each amino acid is deduced from 74,218 protein-coding genes from a human genome. The Low U method targets only U-containing codons that can be replaced with a synonymous codon with fewer U moieties. If there are a few choices for the replacement, the more frequently used codon will be selected. The remaining codons in the sequence are not changed by the Low U method. This method may be used in conjunction with the disclosed mRNAs to design coding sequences that are to be synthesized with, for example, 5-methoxyuridine or N¹-methylpseudouridine.

[0038] As used herein, “modified” refers to a change in the state or structure of a molecule disclosed herein. The molecule may be changed in many ways including chemically, structurally or functionally. Preferably a polynucleotide or polypeptide of the disclosure are modified as compared to the native form of the polynucleotide or polypeptide or as compared to a reference polypeptide sequence or polynucleotide sequence. For example, mRNA disclosed herein may be modified by codon optimization, or by the insertion of non-natural nucleosides or nucleotides. Polypeptides may be modified, for example, by site specific amino acid deletions or substitutions to alter the properties of the polypeptide.

[0039] As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical or similar. The term “homologous” necessarily refers to a comparison between

at least two sequences (polynucleotide or polypeptide sequences). In accordance with the present disclosure, two polynucleotide sequences are considered to be homologous if the polypeptides they encode are at least about 50%, 60%, 70%, 80%, 90%, 95%, or even 99% for at least one stretch of at least about 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. In accordance with the present disclosure, two protein sequences are considered to be homologous if the proteins are at least about 50%, 60%, 70%, 80%, or 90% identical for at least one stretch of at least about 20 amino acids.

[0040] As used herein, the term “identity” refers to the overall relatedness between polymeric molecules, e.g., between oligonucleotide molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two polynucleotide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes. In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., *SIAM J Applied Math.*, 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., *Nucleic Acids Research*, **12**(1), 387 (1984), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., *J. Molec. Biol.*, **215**, 403 (1990).

[0041] An “effective amount” of the mRNA sequence encoding an open reading frame (ORF) protein or a corresponding composition thereof is generally that amount of mRNA that provides efficient ORF protein production in a cell. Preferably protein production using an mRNA composition described herein is more efficient than a composition containing a corresponding wild type mRNA encoding an ORF protein. Increased efficiency may be demonstrated by increased cell transfection (i.e., the percentage of cells transfected with the nucleic acid), increased protein translation from the nucleic acid, decreased nucleic acid degradation (as demonstrated, e.g., by increased duration of protein translation from a modified nucleic acid), or reduced innate immune response of the host cell. When referring to an ORF protein described herein, an effective amount is that amount of ORF protein that overcomes an ORF protein deficiency in a cell.

[0042] As used herein, the term “*in vitro*” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).

[0043] As used herein, the term “*in vivo*” refers to events that occur within an organism (e.g., animal, plant, or microbe or cell or tissue thereof).

[0044] As used herein, the term “isolated” refers to a substance or entity that has been separated from at least some of the components with which it was associated (whether in nature or in an experimental setting). Isolated substances may have varying levels of purity in reference to the substances from which they have been associated. Isolated substances and/or entities may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, isolated agents are more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is “pure” if it is substantially free of other components. Substantially isolated: By “substantially isolated” is meant that the compound is substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compound described herein. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at

least about 99% by weight of the compound described herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

[0045] As used herein, the term “subject” or “patient” refers to any organism to which a composition in accordance with the present disclosure may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and/or plants. Preferably “patient” refers to a human subject who may seek or be in need of treatment, requires treatment, is receiving treatment, will receive treatment, or a subject who is under care by a trained professional for a particular disease or condition.

[0046] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0047] As used herein, the term “preventing” refers to partially or completely delaying onset of an infection, disease, disorder and/or condition; partially or completely delaying onset of one or more symptoms, features, or clinical manifestations of a particular infection, disease, disorder, and/or condition; partially or completely delaying onset of one or more symptoms, features, or manifestations of a particular infection, disease, disorder, and/or condition; partially or completely delaying progression from an infection, a particular disease, disorder and/or condition; and/or decreasing the risk of developing pathology associated with the infection, the disease, disorder, and/or condition.

[0048] As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0049] As used herein, the term “therapeutically effective amount” means an amount of an agent to be delivered (e.g., nucleic acid, protein or peptide, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering

from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition.

[0050] As used herein, a “total daily dose” is an amount given or prescribed in a 24 hr period. It may be administered as a single unit dose.

[0051] As used herein, the term “treating” refers to partially or completely alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of OTC deficiency. Treatment may be administered to a subject who does not exhibit signs of OTC deficiency and/or to a subject who exhibits only early signs of OTC deficiency for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.

[0052] As used herein, the terms “transfect” or “transfection” mean the intracellular introduction of a nucleic acid into a cell, or preferably into a target cell. The introduced nucleic acid may be stably or transiently maintained in the target cell. The term “transfection efficiency” refers to the relative amount of nucleic acid up-taken by the target cell which is subject to transfection. In practice, transfection efficiency is estimated by the amount of a reporter nucleic acid product expressed by the target cells following transfection. Preferred are compositions with high transfection efficacies and in particular those compositions that minimize adverse effects which are mediated by transfection of non-target cells and tissues.

[0053] As used herein, the term “target cell” refers to a cell or tissue to which a composition of the disclosure is to be directed or targeted. In some embodiments, the target cells are deficient in a protein or enzyme of interest. For example, where it is desired to deliver a nucleic acid to a hepatocyte, the hepatocyte represents the target cell. In some embodiments, the nucleic acids and compositions of the present disclosure transfect the target cells on a discriminatory basis (i.e., do not transfect non-target cells). The compositions and methods of the present disclosure may be prepared to preferentially target a variety of target cells, which include, but are not limited to, hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells (e.g., meninges, astrocytes, motor neurons, cells of the dorsal root ganglia and anterior horn motor neurons), photoreceptor cells (e.g., rods and cones), retinal pigmented epithelial cells,

secretory cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes and tumor cells.

[0054] Following transfection of one or more target cells by the compositions and nucleic acids described herein, expression of the protein encoded by such nucleic acid may be preferably stimulated and the capability of such target cells to express the protein of interest is enhanced. For example, transfection of a target cell with an OTC mRNA will allow expression of the OTC protein product following translation of the nucleic acid. The nucleic acids of the compositions and/or methods provided herein preferably encode a product (e.g., a protein, enzyme, polypeptide, peptide, functional RNA, and/or antisense molecule), and preferably encode a product whose *in vivo* production is desired.

[0055] As used herein “an OTC protein enzymatic activity” refers to enzyme activity that catalyzes the reaction between carbamoyl phosphate and ornithine to form citrulline as part of the urea cycle in mammals.

[0056] As used herein, the term “about” or “approximately” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

Polynucleotide Sequences

[0057] The present disclosure provides improved methods and compositions for the treatment of Ornithine transcarbamylase (OTC) deficiency using, for example, mRNA therapy. The present disclosure provides methods of treating ornithine transcarbamylase (OTC) deficiency, comprising administering to a subject in need of treatment a composition comprising an mRNA sequence described herein encoding a human ornithine transcarbamylase (OTC) protein, modified forms of human OTC protein or active fragments of OTC protein at an effective dose and an administration interval such that at least one symptom or feature of the OTC deficiency is reduced in intensity, severity, or frequency or has delayed onset. The present disclosure also provides modified OTC proteins encoded by the mRNA sequences wherein the modified OTC proteins have improved properties such as enhanced stability and

resistance to protein degradation and increased half-life as compared to wild type human OTC proteins.

[0058] Preferably, the administration of an mRNA composition described herein results in an increased OTC protein expression or activity of the subject as compared to a control level. Preferably, the control level is a baseline serum OTC protein expression or activity level in the subject prior to the treatment and/or the control level is indicative of the average serum OTC protein expression or activity level in OTC patients without treatment.

[0059] Preferably, administration of a mRNA described herein composition results in a reduced urinary orotic acid level in the subject as compared to a control orotic acid level. Preferably, the control orotic acid level is a baseline urinary orotic acid level in the subject prior to the treatment and/or the control orotic acid level is a reference level indicative of the average urinary orotic acid level in OTC patients without treatment.

[0060] Preferably, the OTC proteins encoded by the mRNA described herein are produced from a heterologous mRNA construct comprising an open reading frame (ORF) also referred to herein as a “coding sequence” (CDS) encoding for an OTC protein. Preferably, the coding sequence is codon-optimized. Preferably, coding sequence is optimized to have a theoretical minimum of uridines possible to encode for an OTC protein. Preferably, the mRNA constructs described herein comprise one or more of the following features: a 5' cap; a 5'UTR, a 5'UTR enhancer sequence, a Kozak sequence or a partial Kozak sequence, a 3'UTR, an open reading frame encoding an OTC protein and a poly A tail. Preferably, the mRNA constructs described herein can provide high-efficiency expression of an OTC protein. The expression can be *in vitro*, *ex vivo*, or *in vivo*.

[0061] Preferably, a human OTC protein encoded by an mRNA described herein comprises a modified human OTC protein of SEQ ID NO: 4 shown in Table 1. SEQ ID NO: 4 has been modified from wild-type OTC of SEQ ID NO: 3 (Table 1) to remove one or more predicted ubiquitination sites resulting in a protein that is less susceptible to ubiquitination and degradation by ubiquitin ligases. The removal of predicted ubiquitination sites preferably comprises replacing N-terminus residues that have been found to support ubiquitination such as asparagine, arginine, leucine, lysine or phenylalanine with N-terminus residues that have been found to be stabilizing against ubiquitination such as alanine, glycine, methionine, serine, threonine, valine and proline. Stabilization of the modified OTC protein of SEQ ID

NO: 4 in this manner is particularly advantageous for preserving the stability of the modified OTC protein during its transport from the cytosol to the mitochondria wherein it exerts its enzymatic activity.

[0062] Preferably, an OTC protein encoded by an mRNA described herein comprises a protein sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to human wild type OTC protein of SEQ ID NO: 3 as shown in Table 1, while retaining the OTC protein activity of catalyzing the synthesis of citrulline (in the liver and small intestine) from carbamyl phosphate and ornithine.

Table 1: Selected OTC Nucleotide and Peptide Sequences

mRNA coding sequence for wild type human OTC	<u>AUGCUGUUUAUCUGAGGAUCCUGUUAAACAAUGCAGCUUUUAGAAA</u> <u>UGGUCACAACUUAUGGUUCGAAAUUUUCGGUGUGGACAACCACUAC</u> <u>AAAAUAAAGUGCAGCUGAAGGGCCGUGACCUUCUCACUCUAAAAAAC</u> UUUACCGGAGAAGAAAUUAAAUUAUUGCUAUGGCUAUCAGCAGAUCU GAAAUUUAGGAUAAAACAGAAAGGAGAGUAUUUGCCUUUAUUGCAAG GGAAGUCCUUAAGGCAUGAUUUUUGAGAAAAAGAAGUACUCGAACAAGA UUGUCUACAGAAACAGGCUUUGCACUUCUGGGAGGACAUCUUGUUU UCUUACCACACAAGAUUUCAUUUGGGUGUGAAUGAAAGUCUCACGG ACACGGCCCGUGUAUUGUCUAGCAUGGCAGAUGCAGUAUUGGCUCA GUGUAUAAACAAUCAGAUUUGGACACCCUGGCUAAAGAAGCAUCCAU CCCAUUUAUCAUUGGGCUGUCAGAUUUGUACCAUCCAUUCCAGAUCCU GGCUGAUUACCUACGCUCUCCAGGAACACUAUAGCUCUCUGAAAGGUCU UACCCUCAGCUGGAUCGGGGAUGGGAACAUAUCCUGCACUCCAUAU GAUGAGCGCAGCGAAAUUCGGAUUGCACCUUCAGGCAGCUACUCCAAA GGGUUAUGAGCCGAUGCUAGUGUAACCAAGUUGGCAGAGCAGUAUG CCAAAGAGAAUGGUACCAAGCUGUUGCUGACAAAUGAUCCAUUGGAA GCAGCGCAUGGAGGCAUGUAUUAUUAUACAGACACUUGGAUAAGCAU GGGACAAGAAGAGGAGAAGAAAAAGCGGCUCCAGGCUUCCAAGGUU ACCAGGUUACAAUGAAGACUGCUAAAGUUGCUGCCUCUGACUGGACA UUUUUACACUGCUUGCCCAGAAAGCCAGAAGAAGUGGAUGAUGAAGU CUUUUAUUCUCCUCGAUCACUAGUGUUCCCAGAGGCAGAAAACAGAA AGUGGACAAUCAUGGCUGUCAUGGUGUCCUGCUGACAGAUUACUCA CCUCAGCUCCAGAAGCCUAAAUUUUGA (SEQ ID NO: 1)
DNA coding sequence for wild type human OTC	<u>ATGCTGTTTAATCTGAGGATCCTGTTAAACAATGCAGCTTTTAGAAATGG</u> <u>TCACAATTCATGGTTCGAAATTTTCGGTGTGGACAACCACTACAAAATA</u> AAGTGCAGCTGAAGGGCCGTGACCTTCTCACTCTAAAAAATTTACCGG AGAAGAAATTAAATATATGCTATGGCTATCAGCAGATCTGAAATTTAGG ATAAAACAGAAAGGAGAGTATTTGCCTTTATTGCAAGGGAAGTCCTTAG GCATGATTTTTGAGAAAAGAAGTACTCGAACAAGATTGTCTACAGAAAC AGGCTTTGCACTTCTGGGAGGACATCCTTGTCTTACCACACAAGATA TTCATTTGGGTGTGAATGAAAGTCTACGGACACGGCCCGTGTATTGTCT AGCATGGCAGATGCAGTATTGGCTCGAGTGTATAACAATCAGATTTGG ACACCCTGGCTAAAGAAGCATCCATCCCAATTATCAATGGGCTGTCAGA TTTGTACCATCCTATCCAGATCCTGGCTGATTACCTCACGCTCCAGGAAC

	ACTATAGCTCTCTGAAAGGTCTTACCCTCAGCTGGATCGGGGATGGGAA CAATATCCTGCACTCCATCATGATGAGCGCAGCGAAATTCGGAATGCAC CTTCAGGCAGCTACTCCAAAGGGTTATGAGCCGGATGCTAGTGTAACCA AGTTGGCAGAGCAGTATGCCAAAGAGAATGGTACCAAGCTGTTGCTGAC AAATGATCCATTGGAAGCAGCGCATGGAGGCAATGTATTAATTACAGAC ACTTGGATAAGCATGGGACAAGAAGAGGAGAAGAAAAAGCGGCTCCAG GCTTTCCAAGGTTACCAGGTTACAATGAAGACTGCTAAAGTTGCTGCCTC TGACTGGACATTTTACACTGCTTGCCAGAAAAGCCAGAAGAAGTGGAT GATGAAGTCTTTATTCTCCTCGATCACTAGTGTTCCAGAGGCAGAAAA CAGAAAGTGGACAATCATGGCTGTCATGGTGTCCCTGCTGACAGATTAC TCACCTCAGCTCCAGAAGCCTAAATTTTGA (SEQ ID NO: 2)
Human wild type OTC amino acid sequence (The signal peptide for mitochondrial import is underlined*)	<u>MLFNLRLILLNNAAFRNGHNFMRNFRCGQPLQ</u> NKVQLKGRDLLTKNFTG EEIKYMLWLSADLKFRKQKGEYLP LLQGKSLGMIFEKRSTRRLSTETGFA LLGGHPCFLTQQDIHLGVNESLTDARVLSSMADAVLARVYKQSDLDLAK EASIPF GLSDLYHPIQLADYLT LQEHYSSLKGLT LSWIGDGNNILHSIMMS AAKFGMHLQAATPKGYEPDASVTKLAEQYAKENGTKLLLTNDPLEAAHGG NVLITDTWISMGQEEKKRLQAFQGYQVTMKTAKVAASDWTFLHCLPRK PEEVDDDEVFYSRSLVFPEAENRKWTIMAVMVSLLDYSPQLQPKPF (SEQ ID NO: 3)
Modified OTC amino acid sequence (The signal peptide for mitochondrial import is underlined*)	<u>MLVFNLRLILLNNAAFRNGHNFMRNFRCGQPLQ</u> NRVQLKGRDLLTKNFTGE EIRYMLWLSADLKFRKQKGEYLP LLQGKSLGMIFEKRSTRRLSTETGFALLGGH PCFLTQQDIHLGVNESLTDARVLSSMADAVLARVYKQSDLDLAK EASIPINGLS DLYHPIQLADYLT LQEHYSSLKGLT LSWIGDGNNILHSIMMSAAKFGMHLQAAT PKGYEPDASVTKLAEQYAKENGTKLLLTNDPLEAAHGGNVLITDTWISMGQEEK KKRLQAFQGYQVTMKTAKVAASDWTFLHCLPRKPEEVDDDEVFYSRSLVFPEAEN RKWTIMAVMVSLLDYSPQLQPKPF (SEQ ID NO: 4)

* The OTC protein comprises a signal peptide which is translated and which is responsible for translocation to the mitochondria. This signal peptide is represented by the first 32 amino acids as underlined in SEQ ID NO: 3 and SEQ ID NO: 4. The signal sequence of SEQ ID NO: 4 has also been modified as compared to SEQ ID NO: 3. An amino acid, valine is inserted at position 3 of SEQ ID NO: 4. This modification provides better mitochondrial localization of the modified OTC of SEQ ID NO: 4 as compared to wild type human OTC of SEQ ID NO: 3.

[0063] Preferably, the open reading frame (ORF) or coding sequence (CDS) of an mRNA sequence described herein encodes an amino acid sequence that is substantially identical to the modified OTC protein of SEQ ID NO: 4.

[0064] Preferably, the open reading frame (ORF) or coding sequence (CDS) of an mRNA sequence described herein encodes an amino acid sequence that is substantially identical to wild type human OTC protein of SEQ ID NO: 3. Preferably, an OTC protein encoded by an

mRNA described herein comprises a protein sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a modified human OTC protein of SEQ ID NO: 3 shown in Table 1 while retaining the OTC protein activity of catalyzing the synthesis of citrulline (in the liver and small intestine) from carbamyl phosphate and ornithine.

[0065] Preferably, the ORF or CDS of an mRNA described herein encodes an amino acid sequence that is substantially identical to modified human OTC protein of SEQ ID NO: 4.

[0066] Preferably, the ORF or CDS of an mRNA described herein encoding a human OTC protein comprises a codon optimized polynucleotide sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the mRNA coding sequence of SEQ ID NO: 1 of Table 1.

[0067] Preferably an mRNA described herein further comprises a sequence immediately downstream (i.e., in the 3' direction from) of the CDS that creates a triple stop codon. The triple stop codon may be incorporated to enhance the efficiency of translation. In some embodiments, the translatable oligomer may comprise the sequence AUAAGUGAA (**SEQ ID NO: 25**) immediately downstream of an OTC CDS of an mRNA sequence described herein.

[0068] Preferably, an mRNA described herein further comprises a 5' untranslated region (UTR) sequence. As is understood in the art, the 5' and/or 3' UTR may affect an mRNA's stability or efficiency of translation. The 5' UTR may be derived from an mRNA molecule known in the art to be relatively stable (e.g., histone, tubulin, globin, glyceraldehyde 1-phosphate dehydrogenase (GAPDH), actin, or citric acid cycle enzymes) to increase the stability of the translatable oligomer. In other embodiments, a 5' UTR sequence may include a partial sequence of a cytomegalovirus (CMV) immediate-early 1 (IE1) gene.

[0069] Preferably, the 5' UTR comprises a sequence selected from the 5' UTRs of human IL-6, alanine aminotransferase 1, human apolipoprotein E, human fibrinogen alpha chain, human transthyretin, human haptoglobin, human alpha-1-antichymotrypsin, human antithrombin, human alpha-1-antitrypsin, human albumin, human beta globin, human complement C3, human complement C5, SynK (thylakoid potassium channel protein derived from the cyanobacteria, *Synechocystis sp.*), mouse beta globin, mouse albumin, and a tobacco etch virus, or fragments of any of the foregoing. Preferably, the 5' UTR is derived from a tobacco

etch virus (TEV). Preferably, an mRNA described herein comprises a 5' UTR sequence that is derived from a gene expressed by *Arabidopsis thaliana*. Preferably, the 5' UTR sequence of a gene expressed by *Arabidopsis thaliana* is AT1G58420. Preferred 5' UTR sequences comprise SEQ ID NOS: 5-10, 125-127 and 227-247: as shown in Table 2.

Table 2
5'UTR sequences

Name	Sequence	Seq ID No.:
EV	UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCA UUCUACUUCUAUUGCAGCAAUUUAAAUAUUUCUUUUAAAAGCA AAAGCAAUUUUCUGAAAAUUUACCAUUUACGAACGAUAG	SEQ ID NO: 5
AT1G58420	AUUUUUACAUCAAAACAAAAGCCGCCA	SEQ ID NO: 6
ARC5-2	CUUAAGGGGGCGCUGCCUACGAGGUGGCAGCCAUCUCCUUCU CGGCAUCAAGCUUACCAUGGUGCCCCAGGCCUGCUCUUGGUCC CGCUGCUGGUGUUCUUUUUUCUGCUUCGGCAAGUUCUUUUAUC ACCAUUUUUUGACAAGCUGGGGGCGUGGAGCCCCAUCGACAUCCA CCACCUGUCCUGUUUUUACAACCUUGUGGUGGAGGACGAGGGCU GCACCAACCUGAGCGGGUUCUCCUAC	SEQ ID NO: 7
HCV	UGAGUGUCGU ACAGCCUCCA GGCCCCCCCC UCCCGGGAGA GCCAUAGUGG UCUGCGGAACCGUGAGUAC ACCGGAAUUG CCGGGAAGAC UGGGUCCUUU CUUGGAUAAA CCCACUCUAUGCCCGGCCAU UUGGGCGUGC CCCCAGCAAGA CUGCUAGCCG AGUAGUGUUG GGUUGCG	SEQ ID NO: 8
HUMAN ALBUMIN	AAUUUUUGGUUAAAGAAGUAUUAUAGUCUAAUUUCCCUCCG UUUGUCCUAGCUUUUUCUCUUCUGUCAACCCACACGCCUUUGG CACA	SEQ ID NO: 9
EMCV	CUCCCUCCCC CCCCCUAAC GUUACUGGCC GAAGCCGCUU GGAAUAAGGC CGGUGUGCGU UUGUCUAUUAU GUUAAUUUCC ACCAUAUUGC CGUCUUUUGG CAAUGUGAGG GCCCGGAAAC CUGGCCCUGU CUUCUUGACG AGCAUUCUA GGGGUCUUUC CCCUCUCGCC AAAGGAAUGC AAGGUCUGUU GAAUGUCGUG AAGGAAGCAG UUCCUCUGGA AGCUUCUUGA AGACAAACAA CGUCUGUAGC GACCCUUUGC AGGCAGCGGA ACCCCCCACC UGGCGACAGG UGCCUCUGCG GCCAAAAGCC ACGUGUAUAA GAUACACCUG CAAAGGCGGC ACAACCCAG UGCCACGUUG UGAGUUGGAU AGUUGUGGAA AGAGUCAAAU GGCUCUCCUC AAGCGUAUUC AACAAGGGGC UGAAGGAUGC CCAGAAGGUA CCCCAUUGUA UGGGAUCUGA UCUGGGGCCU CGGUGCACA GCUUUACGUG UGUUUAGUCG AGGUUAAAAA ACGUCUAGGC CCCCGAACC ACGGGGACGU GGUUUUCCUU UGAAAAACAC GAUGAUAAU	SEQ ID NO: 10
AT1G67090	CACAAAGAGUAAAGAAGAACA	SEQ ID NO: 125

Name	Sequence	Seq ID No.:
AT1G35720	AACACUAAAAGUAGAAGAAAA	SEQ ID NO: 126
AT5G45900	CUCAGAAAGAUAGAUCAGCC	SEQ ID NO: 127
AT5G61250	AACCAAUCGAAAGAAACCAAA	SEQ ID NO: 230
AT5G46430	CUCUAAUCACCAGGAGUAAAA	SEQ ID NO: 231
AT5G47110	GAGAGAGAUCUUAACAAAAAA	SEQ ID NO: 232
AT1G03110	UGUGUAACAACAACAACAACA	SEQ ID NO: 233
AT3G12380	CCGCAGUAGGAAGAGAAAGCC	SEQ ID NO: 234
AT5G45910	AAAAAAAAAAGAAAUCAUAAA	SEQ ID NO: 235
AT1G07260	GAGAGAAGAAAGAAGAAGACG	SEQ ID NO: 236
AT3G55500	CAAUUAAAAAUACUUACCAAA	SEQ ID NO: 237
AT3G46230	GCAAACAGAGUAAGCGAAACG	SEQ ID NO: 238
AT2G36170	GCGAAGAAGACGAACGCAAAG	SEQ ID NO: 239
AT1G10660	UUAGGACUGUAUUGACUGGCC	SEQ ID NO: 240
AT4G14340	AUCAUCGGAAUUCGGAAAAAG	SEQ ID NO: 241
AT1G49310	AAAACAAAAGUAAAAGCAGAC	SEQ ID NO: 242
AT4G14360	UUUAUCUCAAUAAGAAGGCA	SEQ ID NO: 243
AT1G28520	GGUGGGGAGGUGAGAUUUCUU	SEQ ID NO: 244
AT1G20160	UGAUUAGGAAACUACAAAGCC	SEQ ID NO: 245
AT5G37370	CAUUUUUCAAUUUCAUAAAAC	SEQ ID NO: 246
AT4G11320	UUACUUUUUAGCCCAACAAAA	SEQ ID NO: 247
AT5G40850	GGCGUGUGUGUGUGUUGUUGA	SEQ ID NO: 248
AT1G06150	GUGGUGAAGGGGAAGGUUUAG	SEQ ID NO: 249

Name	Sequence	Seq ID No.:
AT2G26080	UUGUUUUUUUUUGGUUUGGUU	SEQ ID NO:250

[0070] Preferably the 5'UTR sequence comprises SEQ ID NO: 6 (AT1G58420).

[0071] Preferably, an mRNA described herein comprises a translation enhancer sequence. Translation enhancer sequences enhance the translation efficiency of a mRNA described herein and thereby provide increased production of the protein encoded by the mRNA. The translation enhancer region may be located in the 5' or 3' UTR of an mRNA sequence. Examples of translation enhancer regions include naturally-occurring enhancer regions from TEV 5'UTR and Xenopus beta-globin 3'UTR. Preferred 5' UTR enhancer sequences include but are not limited to those derived from mRNAs encoding human heat shock proteins (HSP) including HSP70-P2, HSP70-M1 HSP72-M2, HSP17.9 and HSP70-P1. Preferred translation enhancer sequences used in accordance with the embodiments of the present disclosure are represented by SEQ ID NOS 11-15 as shown in Table 3.

Table 3
5'UTR enhancers

Name	Sequence	Seq ID No.:
HSP70-P2	GUCAGCUUUCAAACUCUUUGUUUCUUGUUUGUUGAUUGAGAAUA	SEQ ID NO: 11
HSP70-M1	CUCUCGCCUGAGAAAAAAAUCCACGAACCAUUUCUCAGCAACCAG CAGCACG	SEQ ID NO: 12
HSP72-M2	ACCUGUGAGGGUUCGAAGGAAGUAGCAGUGUUUUUUGUUCUAGA GGAAGAG	SEQ ID NO: 13
HSP17.9	ACACAGAAACAUUCGCAAAAACAAAUCCCAGUAUCAAUUUCUUCU CUUUUUUUCAUUUUCGCAAAGAC	SEQ ID NO: 14
HSP70-P1	CAGAAAAAUUUGCUACAUUGUUUCACAAACUCAAUAUUUAUUCAU UUUUUU	SEQ ID NO: 15

[0072] Preferably, an mRNA described herein comprises a Kozak sequence. As is understood in the art, a Kozak sequence is a short consensus sequence centered around the translational initiation site of eukaryotic mRNAs that allows for efficient initiation of translation of the mRNA. The ribosomal translation machinery recognizes the AUG initiation codon in the context of the Kozak sequence. A Kozak sequence, may be inserted upstream of the coding sequence for OTC, downstream of a 5' UTR or inserted upstream of the coding sequence for OTC and downstream of a 5' UTR. Preferably, an mRNA described herein comprises a Kozak sequence having the amino acid sequence GCCACC (SEQ ID NO: 23).

Preferably an mRNA described herein comprises a partial Kozak sequence “p” having the amino acid sequence GCCA (SEQ ID NO: 24).

[0073] Preferably an mRNA described herein comprises a 3'UTR. Preferably, the 3' UTR comprises a sequence selected from the 3' UTRs of alanine aminotransferase 1, human apolipoprotein E, human fibrinogen alpha chain, human haptoglobin, human antithrombin, human alpha globin, human beta globin, human complement C3, human growth factor, human hepcidin, MALAT-1, mouse beta globin, mouse albumin, and *Xenopus* beta globin, or fragments of any of the foregoing. Preferably, the 3' UTR is derived from *Xenopus* beta globin. Preferred 3' UTR sequences include SEQ ID NOS 16-22 as shown in Table 4.

Table 4
3'UTR sequences

Name	Sequence	Seq ID No.:
XBG	CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCU CAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAUACCAA CUUACACUUAACAAAUGUUGUCCCCCAAAUGUAGCCAUUC GUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU	SEQ ID NO: 16
HUMAN HAPTOGLOBIN	UGCAAGGCUGGCCGGAAGCCCUUGCCUGAAAGCAAGAUUU CAGCCUGGAAGAGGGCAAAGUGGACGGGAGUGGACAGGAG UGGAUGCGAUAGAUGUGGUUUGAAGCUGAUGGGUGCCA GCCCUGCAUUGCUGAGUCAUAUAAAGAGCUUUCUUUU GACCAU	SEQ ID NO: 17
HUMAN APOLIPOPROTEIN E	ACGCCGAAGCCUGCAGCCAUGCGACCCACGCCACCCCGUGC CUCCUGCCUCCGCGCAGCCUGCAGCGGGAGACCCUGUCCCC GCCCCAGCCGUCCUCCUGGGGUGGACCCUAGUUUAAUAAA GAUUCACCAAGUUUCACGCA	SEQ ID NO: 18
HCV	UAGAGCGGCAAACCCUAGCUACACUCCAUAAGCUAGUUUCU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU UUUCUUGGUGGCUCCAUCUUAAGCCCUAGUCACGGCUAGCU GUGAAAGGUCCGUGAGCCGCAUGACUGCAGAGAGUGCCGU AACUGGUCUCUCUGCAGAUCAUGU	SEQ ID NO: 19
MOUSE ALBUMIN	ACACAUCACAACCACAACCUUCUCAGGCUACCCUGAGAAAA AAAGACAUGAAGACUCAGGACUCAUCUUUUCUGUUGGUGU AAAAUCAACACCCUAAGGAACACAAAUUUCUUUAAACAUUU GACUUCUUGUCUCUGUGCUGCAAUUAUAAAAAUGGAAA GAAUCUAC	SEQ ID NO: 20
HUMAN ALPHA GLOBIN	GCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCU CCCAACGGGCCCUCUCCCCUCCUUGCACCGGCCCUUCCUG GUCUUUGAAUAAAGUCUGAGUGGGCAGCA	SEQ ID NO: 21
EMCV	UAGUGCAGUCAC UGGCACAACG CGUUGCCCGG UAAGCCAAUC GGGUAUACAC GGUCGUCAUACUGCAGACAG GGUUCUUCUA CUUUGCAAGA UAGUCUAGAG UAGUAAAAUA AAUAGUAUAAG	SEQ ID NO: 22

[0074] Preferably, an mRNA described herein comprises a 3' tail region, which can serve to protect the mRNA from exonuclease degradation. The tail region may be a 3' poly(A) and/or 3' poly(C) region. Preferably, the tail region is a 3' poly(A) tail. As used herein a "3' poly(A) tail" is a polymer of sequential adenine nucleotides that can range in size from, for example: 10 to 250 sequential adenine nucleotides; 60-125 sequential adenine nucleotides, 90-125 sequential adenine nucleotides, 95-125 sequential adenine nucleotides, 95-121 sequential adenine nucleotides, 100 to 121 sequential adenine nucleotides, 110-121 sequential

sequences comprising chemically modified nucleotides have been shown to improve mRNA expression, expression rates, half-life and/or expressed protein concentrations. mRNA sequences comprising chemically modified nucleotides have also been useful to optimize protein localization thereby avoiding deleterious bio-responses such as the immune response and/or degradation pathways.

[0077] Examples of modified or chemically-modified nucleotides include 5-hydroxycytidines, 5-alkylcytidines, 5-hydroxyalkylcytidines, 5-carboxycytidines, 5-formylcytidines, 5-alkoxycytidines, 5-alkynylcytidines, 5-halocytidines, 2-thiocytidines, N⁴-alkylcytidines, N⁴-aminocytidines, N⁴-acetylcytidines, and N⁴,N⁴-dialkylcytidines.

[0078] Examples of modified or chemically-modified nucleotides include 5-hydroxycytidine, 5-methylcytidine, 5-hydroxymethylcytidine, 5-carboxycytidine, 5-formylcytidine, 5-methoxycytidine, 5-propynylcytidine, 5-bromocytidine, 5-iodocytidine, 2-thiocytidine; N⁴-methylcytidine, N⁴-aminocytidine, N⁴-acetylcytidine, and N⁴,N⁴-dimethylcytidine.

[0079] Examples of modified or chemically-modified nucleotides include 5-hydroxyuridines, 5-alkyluridines, 5-hydroxyalkyluridines, 5-carboxyuridines, 5-carboxyalkylesteruridines, 5-formyluridines, 5-alkoxyuridines, 5-alkynyluridines, 5-halouridines, 2-thiouridines, and 6-alkyluridines.

[0080] Examples of modified or chemically-modified nucleotides include 5-hydroxyuridine, 5-methyluridine, 5-hydroxymethyluridine, 5-carboxyuridine, 5-carboxymethylesteruridine, 5-formyluridine, 5-methoxyuridine (also referred to herein as “5MeOU”), 5-propynyluridine, 5-bromouridine, 5-fluorouridine, 5-iodouridine, 2-thiouridine, and 6-methyluridine.


[0081] Examples of modified or chemically-modified nucleotides include 5-methoxycarbonylmethyl-2-thiouridine, 5-methylaminomethyl-2-thiouridine, 5-carbamoylmethyluridine, 5-carbamoylmethyl-2'-O-methyluridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethyluridine, 5-methyldihydrouridine, 5-taurinomethyluridine, 5-taurinomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 2'-O-methylpseudouridine, 2-thio-2'-O-methyluridine, and 3,2'-O-dimethyluridine.

[0082] Examples of modified or chemically-modified nucleotides include N⁶-methyladenosine, 2-aminoadenosine, 3-methyladenosine, 8-azaadenosine, 7-deazaadenosine,

REPLACEMENT SHEET

adenine nucleotides; sequential adenine nucleotides, 112-121 sequential adenine nucleotides; 114-121 adenine sequential nucleotides; and 115 to 121 sequential adenine nucleotides. Preferably a 3' poly A tail as described herein comprise 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, or 125 sequential adenine nucleotides. 3' Poly(A) tails can be added using a variety of methods known in the art, *e.g.*, using poly(A) polymerase to add tails to synthetic or *in vitro* transcribed RNA. Other methods include the use of a transcription vector to encode poly A tails or the use of a ligase (*e.g.*, via splint ligation using a T4 RNA ligase and/or T4 DNA ligase), wherein poly(A) may be ligated to the 3' end of a sense RNA. Preferably, a combination of any of the above methods is utilized.

[0075] Preferably, an mRNA described herein comprises a 5' cap. 5'-ends capped with various groups and their analogues are known in the art. The 5' cap may be selected from m7GpppA, m7GpppC; unmethylated cap analogs (*e.g.*, GpppG); dimethylated cap analog (*e.g.*, m2,7GpppG), a trimethylated cap analog (*e.g.*, m2,2,7GpppG), dimethylated symmetrical cap analogs (*e.g.*, m7Gpppm7G), or anti reverse cap analogs (*e.g.*, ARCA; m7, 2'OmeGpppG, m72'dGpppG, m7,3'OmeGpppG, m7,3'dGpppG and their tetraphosphate derivatives) (see, *e.g.*, Jemielity, J. et al., RNA 9: 1108-1122 (2003). The 5' cap may be an ARCA cap (3'-OMe-m7G(5')pppG). The 5' cap may be an mCAP (m7G(5')ppp(5')G, N⁷-Methyl-Guanosine-5'-Triphosphate-5'-Guanosine). The 5' cap may be resistant to hydrolysis. A preferred 5' cap is referred to herein as "m7GpppGm cap" also referred to herein as "Cap1" and has the following core structure:



[0076] Preferably an mRNA described herein comprises one or more chemically modified nucleotides. Examples of nucleic acid monomers include non-natural, modified, and chemically-modified nucleotides, including any such nucleotides known in the art. mRNA

8-oxoadenosine, 8-bromoadenosine, 2-methylthio-N⁶-methyladenosine, N⁶-isopentenyladenosine, 2-methylthio-N⁶-isopentenyladenosine, N⁶-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N⁶-(cis-hydroxyisopentenyl)adenosine, N⁶-glycinylicarbamoyladenosine, N⁶-threonylicarbamoyladenosine, N⁶-methyl-N⁶-threonylicarbamoyladenosine, 2-methylthio-N⁶-threonylicarbamoyladenosine, N⁶,N⁶-dimethyladenosine, N⁶-hydroxynorvalylicarbamoyladenosine, 2-methylthio-N⁶-hydroxynorvalylicarbamoyladenosine, N⁶-acetyladenosine, 7-methyladenine, 2-methylthioadenine, 2-methoxyadenine, alpha-thioadenosine, 2'-O-methyladenosine, N⁶,2'-O-dimethyladenosine, N⁶,N⁶,2'-O-trimethyladenosine, 1,2'-O-dimethyladenosine, 2'-O-ribosyladenosine, 2-amino-N⁶-methylpurine, 1-thioadenosine, 2'-F-araadenosine, 2'-F-adenosine, 2'-OH-araadenosine, and N⁶-(19-amino-pentaoxanonadecyl)adenosine.

[0083] Examples of modified or chemically-modified nucleotides include N¹-alkylguanosines, N²-alkylguanosines, thienoguanosines, 7-deazaguanosines, 8-oxoguanosines, 8-bromoguanosines, O⁶-alkylguanosines, xanthosines, inosines, and N¹-alkylinosines.

[0084] Examples of modified or chemically-modified nucleotides include N¹-methylguanosine, N²-methylguanosine, thienoguanosine, 7-deazaguanosine, 8-oxoguanosine, 8-bromoguanosine, O⁶-methylguanosine, xanthosine, inosine, and N¹-methylinosine.

[0085] Examples of modified or chemically-modified nucleotides include pseudouridines. Examples of pseudouridines include N¹-alkylpseudouridines, N¹-cycloalkylpseudouridines, N¹-hydroxypseudouridines, N¹-hydroxyalkylpseudouridines, N¹-phenylpseudouridines, N¹-phenylalkylpseudouridines, N¹-aminoalkylpseudouridines, N³-alkylpseudouridines, N⁶-alkylpseudouridines, N⁶-alkoxypseudouridines, N⁶-hydroxypseudouridines, N⁶-hydroxyalkylpseudouridines, N⁶-morpholinopseudouridines, N⁶-phenylpseudouridines, and N⁶-halopseudouridines. Examples of pseudouridines include N¹-alkyl-N⁶-alkylpseudouridines, N¹-alkyl-N⁶-alkoxypseudouridines, N¹-alkyl-N⁶-hydroxypseudouridines, N¹-alkyl-N⁶-hydroxyalkylpseudouridines, N¹-alkyl-N⁶-morpholinopseudouridines, N¹-alkyl-N⁶-phenylpseudouridines, and N¹-alkyl-N⁶-halopseudouridines. In these examples, the alkyl, cycloalkyl, and phenyl substituents may be unsubstituted, or further substituted with alkyl, halo, haloalkyl, amino, or nitro substituents.

[0086] Examples of pseudouridines include N¹-methylpseudouridine (also referred to herein as “N1MPU”), N¹-ethylpseudouridine, N¹-propylpseudouridine, N¹-cyclopropylpseudouridine, N¹-phenylpseudouridine, N¹-aminomethylpseudouridine, N³-methylpseudouridine, N¹-hydroxypseudouridine, and N¹-hydroxymethylpseudouridine.

[0087] Examples of nucleic acid monomers include modified and chemically-modified nucleotides, including any such nucleotides known in the art.

[0088] Examples of modified and chemically-modified nucleotide monomers include any such nucleotides known in the art, for example, 2'-O-methyl ribonucleotides, 2'-O-methyl purine nucleotides, 2'-deoxy-2'-fluoro ribonucleotides, 2'-deoxy-2'-fluoro pyrimidine nucleotides, 2'-deoxy ribonucleotides, 2'-deoxy purine nucleotides, universal base nucleotides, 5-C-methyl-nucleotides, and inverted deoxyabasic monomer residues.

[0089] Examples of modified and chemically-modified nucleotide monomers include 3'-end stabilized nucleotides, 3'-glyceryl nucleotides, 3'-inverted abasic nucleotides, and 3'-inverted thymidine.

[0090] Examples of modified and chemically-modified nucleotide monomers include locked nucleic acid nucleotides (LNA), 2'-O,4'-C-methylene-(D-ribofuranosyl) nucleotides, 2'-methoxyethoxy (MOE) nucleotides, 2'-methyl-thio-ethyl, 2'-deoxy-2'-fluoro nucleotides, and 2'-O-methyl nucleotides. In an exemplary embodiment, the modified monomer is a locked nucleic acid nucleotide (LNA).

[0091] Examples of modified and chemically-modified nucleotide monomers include 2',4'-constrained 2'-O-methoxyethyl (cMOE) and 2'-O-Ethyl (cEt) modified DNAs.

[0092] Examples of modified and chemically-modified nucleotide monomers include 2'-amino nucleotides, 2'-O-amino nucleotides, 2'-C-allyl nucleotides, and 2'-O-allyl nucleotides.

[0093] Examples of modified and chemically-modified nucleotide monomers include N⁶-methyladenosine nucleotides.

[0094] Examples of modified and chemically-modified nucleotide monomers include nucleotide monomers with modified bases 5-(3-amino)propyluridine, 5-(2-mercapto)ethyluridine, 5-bromouridine; 8-bromoguanosine, or 7-deazaadenosine.

[0095] Examples of modified and chemically-modified nucleotide monomers include 2'-O-aminopropyl substituted nucleotides.

[0096] Examples of modified and chemically-modified nucleotide monomers include replacing the 2'-OH group of a nucleotide with a 2'-R, a 2'-OR, a 2'-halogen, a 2'-SR, or a 2'-amino, where R can be H, alkyl, alkenyl, or alkynyl.

[0097] Example of base modifications described above can be combined with additional modifications of nucleoside or nucleotide structure, including sugar modifications and linkage modifications. Certain modified or chemically-modified nucleotide monomers may be found in nature.

[0098] Preferred nucleotide modifications include N¹-methylpseudouridine and 5-methoxyuridine.

The constructs for preferred mRNA sequences are provided in Table 5.

Table 5: Exemplary mRNA Constructs

mRNA Construct No.	Cap	5'UTR	Kozak*	OTC Protein Encoded	3'UTR	3' Poly A Tail	mRNA Construct SEQ ID NO:
563	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	26
564	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	27
565	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	28
566	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	29
567	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	30
568	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	31
569	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	32
570	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	33
571	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	34
572	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	35
573	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	36
574	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	37
575	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	38
708	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	39

mRNA Construct No.	Cap	5'UTR	Kozak*	OTC Protein Encoded	3'UTR	3' Poly A Tail	mRNA Construct SEQ ID NO:
709	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	40
710	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	41
711	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	42
712	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	43
713	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	44
714	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	45
715	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	46
716	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	47
717	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	48
718	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	49
719	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	50
720	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	51
721	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	52
722	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	53
723	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	54
724	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	55
725	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	56
726	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	57
727	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	58
728	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	59
729	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	60
1787	Cap1	ARC5-2	No	SEQ ID NO: 3	Hu haptoglob	Yes	61
1788	Cap1	AT1G58420	P	SEQ ID NO: 3	Hu ApoE	Yes	62
1789	Cap1	ARC5-2	No	SEQ ID NO: 3	Hu haptoglob	Yes	63
1790	Cap1	AT1G58420	P	SEQ ID NO: 3	Hu ApoE	Yes	64
1791	Cap1	ARC5-2	No	SEQ ID NO: 3	Hu haptoglob	Yes	65
1792	Cap1	HCV5'	P	SEQ ID NO: 3	HCV3'	Yes	66
1793	Cap1	AT1G58420	P	SEQ ID NO: 3	Hu a-glob	Yes	67
1794	Cap1	AT1G58420	P	SEQ ID NO: 3	Hu a-glob	Yes	68

mRNA Construct No.	Cap	5'UTR	Kozak*	OTC Protein Encoded	3'UTR	3' Poly A Tail	mRNA Construct SEQ ID NO:
1795	Cap1	AT1G58420	P	SEQ ID NO: 3	Hu a-glob	Yes	69
1796	Cap1	Hu alb	No	SEQ ID NO: 3	Ms Alb	Yes	70
1797	Cap1	Hu alb	No	SEQ ID NO: 3	Ms Alb	Yes	71
1798	Cap1	Hu alb	No	SEQ ID NO: 3	Ms Alb	Yes	72
1799	Cap1	AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	73
1800	Cap1	Hu alb	No	SEQ ID NO: 3	Ms Alb	Yes	74
1801	Cap1	AT1G58420	P	SEQ ID NO: 3	Hu ApoE	Yes	75
1802	Cap1	ARC5-2	No	SEQ ID NO: 3	Hu haptoglob	Yes	76
1803	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	77
1804	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	78
1805	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	79
1806	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	80
1808	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	81
1809	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	82
1816	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	83
1822	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	84
1823	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	85
1840	Cap1	EMCV	No	SEQ ID NO: 3	EMCV	Yes	86
1841	Cap1	EMCV	No	SEQ ID NO: 3	EMCV	Yes	87
1842	Cap1	EMCV	No	SEQ ID NO: 3	EMCV	Yes	88
1843	Cap1	HSP70-P2-TEV	Yes	SEQ ID NO: 3	XBG	Yes	89
1844	Cap1	HSP70-M1-TEV	Yes	SEQ ID NO: 3	XBG	Yes	90
1845	Cap1	HSP70-M2-TEV	Yes	SEQ ID NO: 3	XBG	Yes	91
1846	Cap1	HSP17.9-TEV	Yes	SEQ ID NO: 3	XBG	Yes	92
1847	Cap1	HSP70-P1-TEV	Yes	SEQ ID NO: 3	XBG	Yes	93
1882	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	94
1883	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	95
1884	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	96

mRNA Construct No.	Cap	5'UTR	Kozak*	OTC Protein Encoded	3'UTR	3' Poly A Tail	mRNA Construct SEQ ID NO:
1885	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	97
1886	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	98
1887	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	99
1888	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	100
1889	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	101
1890	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	102
1891	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	103
1898	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	104
1899	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	105
1900	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	106
1903	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	107
1904	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	108
1905	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	109
1906	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	110
1907	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	111
1908	Cap1	TEV	P	SEQ ID NO: 3	XBG	Yes	112
1915	Cap1	HSP70-P1-AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	113
1916	Cap1	HSP70-P1-AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	114
1917	Cap1	HSP70-P1-AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	115
1918	Cap1	HSP70-P1-AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	116
1919	Cap1	AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	117
1920	Cap1	AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	118
1921	Cap1	AT1G58420	Yes	SEQ ID NO: 4**	Hu a-glob	Yes	119
1925	Cap1	TEV	Yes	SEQ ID NO: 3	XBG	Yes	120
1926	Cap1	AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	121
1927	Cap1	AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	122
1928	Cap1	AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	123

mRNA Construct No.	Cap	5'UTR	Kozak*	OTC Protein Encoded	3'UTR	3' Poly A Tail	mRNA Construct SEQ ID NO:
1929	Cap1	HSP70-P1-AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	124
2016	Cap1	AT1G58420	Yes	SEQ ID NO: 3	Hu a-glob	Yes	253
2260	Cap1	AT1G58420	Yes	SEQ ID NO: 4**	Hu a-glob	Yes	251
2262	Cap1	AT1G58420	Yes	SEQ IS NO: 4**	Hu a-glob	Yes	252

*Kozak sequence defined as GCCACC (SEQ ID NO: 23). Partial (P) Kozak defined as GCCA (SEQ ID NO: 24).

** Construct encodes modified human OTC protein of SEQ ID NO: 4.

[0099] Preferred mRNA sequences include all of the mRNA sequences listed in Table 5. Preferred mRNA sequences include all of the mRNA sequences listed wherein, 0% to 100%, preferably 1% to 100%, preferably 25% to 100%, preferably 50% to 100% and preferably 75% to 100% of the uracil nucleotides of the mRNA sequences are modified. Preferably, 1% to 100% of the uracil nucleotides are N¹-methylpseudouridine or 5-methoxyuridine. Preferably 100% of the uracil nucleotides are N¹-methylpseudouridine. Preferably 100% of the uracil nucleotides are 5-methoxyuridine.

[0100] Preferred mRNA sequences comprise a 5' cap, a 5'UTR that is derived from a gene expressed by *Arabidopsis thaliana*, an optional translation enhancer sequence, an optional Kozak sequence or partial Kozak sequence, a codon optimized coding sequence (CDS/ORF) coding for an OTC protein, a 3' UTR and a poly A tail. Preferably the codon optimized CDS encodes a protein of SEQ ID NO: 3 or SEQ ID NO: 4. Preferably, the 5' UTR that is derived from a gene expressed by *Arabidopsis thaliana* is selected from found in Table 5. Preferably, the 5' UTR that is derived from a gene expressed by *Arabidopsis thaliana* is selected from the group consisting of: SEQ ID NO: 6, SEQ ID NOS: 125-127 and SEQ ID NOS: 227-247. Preferably the 5' UTR sequence is AT1G58420 having the sequence of SEQ ID NO: 6. Preferably, the uracil content of the codon optimized sequence has been reduced with respect to the percentages of uracil content of SEQ ID NO: 1. Preferably, 0% to 100% of the uracil nucleotides of the mRNA sequences are modified. Preferably, 0% to 100% of the uracil nucleotides are N¹-methylpseudouridine or 5-methoxyuridine. Preferably 100% of

the uracil nucleotides are N¹-methylpseudouridine. Preferably 100% of the uracil nucleotides are 5-methoxyuridine.

[0101] Preferred mRNA constructs comprise codon optimized coding sequences and a 5' UTR from a gene expressed by *Arabidopsis thaliana* and are selected from: SEQ ID NOS: 62, 67, 68, 69, 73, 113-119, 121-127.

[0102] A preferred mRNA construct of the disclosure comprises mRNA construct 1921 (SEQ ID NO: 119) having an optimized ORF encoding the modified human OTC protein of SEQ ID NO: 4 and comprising a 3' Poly A tail of 121 nucleotides. Another preferred mRNA construct comprises construct 2260 (SEQ ID NO: 251) encoding the modified human OTC protein of SEQ ID NO: 4 and comprising a 3' Poly A tail of 100 nucleotides. Another preferred mRNA construct comprises construct 2262 (SEQ ID NO: 252) encoding the modified human OTC protein of SEQ ID NO: 4 and comprising a 3' Poly A tail of 100 nucleotides.

[0103] A preferred mRNA sequence of the disclosure includes the mRNA construct 1799 (SEQ ID NO: 73) having a codon optimized ORF encoding wild type human OTC of SEQ ID NO: 3 and having a 3' Poly A tail of 121 nucleotides. Another preferred mRNA construct of the disclosure includes the mRNA construct 2016 (SEQ ID NO: 253) having a codon optimized ORF encoding wild type human OTC of SEQ ID NO: 3 and comprising a 3' Poly A tail of 100 nucleotides.

[0104] Preferably 100% of the uridine nucleotides of mRNA constructs 1799, 2016, 1921, 2260 and 2262, are N¹-methylpseudouridine. Preferably 100% of the uracil nucleotides of mRNA constructs 1799, 2016, 1921, 2260 and 2262, are 5-methoxyuridine.

[0105] The mRNA for use in accordance with this disclosure can exhibit increased translation efficiency. As used herein, translation efficiency refers to a measure of the production of a protein or polypeptide by translation of an mRNA in accordance with the disclosure. Preferably, an mRNA of the disclosure can exhibit at least 2-fold, 3-fold, 5-fold, or 10-fold increased translation efficiency in vivo as compared to mRNA encoding SEQ ID NO: 3 or SEQ ID NO: 4 that is not codon optimized in accordance with the disclosure and/or that does not comprise the preferred UTRs of the disclosure. Preferably an mRNA of the disclosure can provide at least a 2-fold, 3-fold, 5-fold, or 10-fold increased polypeptide or protein level in vivo as compared to mRNA encoding SEQ ID NO: 3 or SEQ ID NO: 4 that is

not codon optimized and/or does not comprise the preferred UTRs of the disclosure. Preferably, an mRNA of the disclosure can provide increased levels of a polypeptide or protein *in vivo* as compared to mRNA encoding SEQ ID NO: 3 or SEQ ID NO: 4 that is not codon optimized in accordance with the disclosure and/or that does not comprise the preferred UTRs of the disclosure. For example, the level of a polypeptide or protein can be increased by 10%, or 20%, or 30%, or 40%, or 50%, or more.

[0106] Preferably the mRNA of the disclosure can provide increased functional half-life in the cytoplasm of mammalian cells over mRNA encoding SEQ ID NO: 3 or SEQ ID NO: 4 that is not codon optimized in accordance with the disclosure and/or that does not comprise the preferred UTRs of the disclosure. The inventive translatable molecules can have increased half-life of activity as compared to mRNA encoding SEQ ID NO: 3 or SEQ ID NO: 4 that is not codon optimized in accordance with the disclosure and/or that does not comprise the preferred UTRs of the disclosure.

[0107] Preferably, the mRNA of the disclosure can reduce cellular innate immune response as compared to mRNA encoding SEQ ID NO: 3 or SEQ ID NO: 4 that is not codon optimized in accordance with the disclosure and/or that does not comprise the preferred UTRs of the disclosure.

[0108] Preferably, the mRNA of the disclosure can reduce the dose levels required for efficacious therapy as compared to mRNA encoding SEQ ID NO: 3 or SEQ ID NO: 4 that is not codon optimized in accordance with the disclosure and/or that does not comprise the preferred UTRs of the disclosure.

Design and Synthesis of the mRNA sequences

[0109] mRNA for use in accordance with the disclosure may be prepared according to any available technique including, but not limited to chemical synthesis, *in vitro* transcription (IVT) or enzymatic or chemical cleavage of a longer precursor, etc. Methods of synthesizing RNAs are known in the art.

[0110] In some embodiments, mRNA is produced from a primary complementary DNA (cDNA) construct. The process of design and synthesis of the primary cDNA constructs described herein generally includes the steps of gene construction, mRNA production (either with or without modifications) and purification. In the IVT method, a target polynucleotide

sequence encoding an OTC protein is first selected for incorporation into a vector which will be amplified to produce a cDNA template. Optionally, the target polynucleotide sequence and/or any flanking sequences may be codon optimized. The cDNA template is then used to produce mRNA through *in vitro* transcription (IVT). After production, the mRNA may undergo purification and clean-up processes. The steps of which are provided in more detail below.

[0111] The step of gene construction may include, but is not limited to gene synthesis, vector amplification, plasmid purification, plasmid linearization and clean-up, and cDNA template synthesis and clean-up. Once a human OTC protein (e.g. SEQ ID NO: 3 or SEQ ID NO: 4) is selected for production, a primary construct is designed. Within the primary construct, a first region of linked nucleosides encoding the polypeptide of interest may be constructed using an open reading frame (ORF) of a selected nucleic acid (DNA or RNA) transcript. The ORF may comprise the wild type ORF, an isoform, variant or a fragment thereof. As used herein, an “open reading frame” or “ORF” is meant to refer to a nucleic acid sequence (DNA or RNA) which is capable of encoding a polypeptide of interest. ORFs often begin with the start codon, ATG and end with a nonsense or termination codon or signal.

[0112] Further, nucleotide sequence of any region of the mRNA or DNA template may be codon optimized. Codon optimization methods are known in the art and may be useful in efforts to achieve one or more of several goals. These goals include to match codon frequencies in target and host organisms to ensure proper folding, to bias GC content to increase mRNA stability or reduce secondary structures, to minimize tandem repeat codons or base runs that may impair gene construction or expression, to customize transcriptional and translational control regions, to insert or remove protein trafficking sequences, to remove/add post translation modification sites in encoded protein (e.g. glycosylation sites), to add, remove or shuffle protein domains, to insert or delete restriction sites, to modify ribosome binding sites and mRNA degradation sites, to adjust translational rates to allow the various domains of the protein to fold properly, or to reduce or eliminate problematic secondary structures within the mRNA. Suitable codon optimization tools, algorithms and services are known in the art.

[0113] Preferably, the primary cDNA template may include reducing the occurrence or frequency of appearance of certain nucleotides in the template strand. For example, the occurrence of a nucleotide in a template may be reduced to a level below 25% of nucleotides

in the template. In further examples, the occurrence of a nucleotide in a template may be reduced to a level below 20% of nucleotides in the template. In some examples, the occurrence of a nucleotide in a template may be reduced to a level below 16% of nucleotides in the template. Preferably, the occurrence of a nucleotide in a template may be reduced to a level below 15%, and preferably may be reduced to a level below 12% of nucleotides in the template.

[0114] For example, the present disclosure provides nucleic acids wherein with altered uracil content at least one codon in the wild-type sequence has been replaced with an alternative codon to generate a uracil-altered sequence. Altered uracil sequences can have at least one of the following properties:

- (i) an increase or decrease in global uracil content (i.e., the percentage of uracil of the total nucleotide content in the nucleic acid of a section of the nucleic acid, e.g., the open reading frame); or,

- (ii) an increase or decrease in local uracil content (i.e., changes in uracil content are limited to specific subsequences); or,

- (iii) a change in uracil distribution without a change in the global uracil content; or,

- (iv) a change in uracil clustering (e.g., number of clusters, location of clusters, or distance between clusters); or,

- (v) combinations thereof.

[0115] Preferably, the percentage of uracil nucleobases in the nucleic acid sequence is reduced with respect to the percentage of uracil nucleobases in the wild-type nucleic acid sequence. For example, 30% of nucleobases may be uracil in the wild-type sequence but the nucleobases that are uracil are preferably lower than 15%, preferably lower than 12% and preferably lower than 10% of the nucleobases in the in the nucleic acid sequences of the disclosure. The percentage uracil content can be determined by dividing the number of uracil in a sequence by the total number of nucleotides and multiplying by 100.

[0116] Preferably, the percentage of uracil nucleobases in a subsequence of the nucleic acid sequence is reduced with respect to the percentage of uracil nucleobases in the corresponding subsequence of the wild-type sequence. For example, the wild-type sequence may have a 5'-end region (e.g., 30 codons) with a local uracil content of 30%, and the uracil content in that

same region could be reduced to preferably 15% or lower, preferably 12% or lower and preferably 10% or lower in the nucleic acid sequences of the disclosure.

[0117] Preferably, codons in the nucleic acid sequence of the invention reduce or modify, for example, the number, size, location, or distribution of uracil clusters that could have deleterious effects on protein translation. Although lower uracil content is desirable, in certain aspects, the uracil content, and in particular the local uracil content, of some subsequences of the wild-type sequence can be greater than the wild-type sequence and still maintain beneficial features (e.g., increased expression).

[0118] Preferably, the uracil-modified sequence induces a lower Toll-Like Receptor (TLR) response when compared to the wild-type sequence. Several TLRs recognize and respond to nucleic acids. Double-stranded (ds)RNA, a frequent viral constituent, has been shown to activate TLR3. Single-stranded (ss)RNA activates TLR7. RNA oligonucleotides, for example RNA with phosphorothioate internucleotide linkages, are ligands of human TLR8. DNA containing unmethylated CpG motifs, characteristic of bacterial and viral DNA, activate TLR9.

[0119] As used herein, the term “TLR response” is defined as the recognition of single-stranded RNA by a TLR7 receptor, and preferably encompasses the degradation of the RNA and/or physiological responses caused by the recognition of the single-stranded RNA by the receptor. Methods to determine and quantify the binding of an RNA to a TLR7 are known in the art. Similarly, methods to determine whether an RNA has triggered a TLR7-mediated physiological response (e.g., cytokine secretion) are well known in the art. Preferably, a TLR response can be mediated by TLR3, TLR8, or TLR9 instead of TLR7. Suppression of TLR7-mediated response can be accomplished via nucleoside modification. RNA undergoes over a hundred different nucleoside modifications in nature. Human rRNA, for example, has ten times more pseudouracil ('P) and 25 times more 2'-O-methylated nucleosides than bacterial rRNA. Bacterial mRNA contains no nucleoside modifications, whereas mammalian mRNAs have modified nucleosides such as 5-methylcytidine (m5C), N6-methyladenosine (m6A), inosine and many 2'-O-methylated nucleosides in addition to N7-methylguanosine (m7G).

[0120] Preferably, the uracil content of polynucleotides disclosed herein and preferably polynucleotides encoding the modified OTC protein of SEQ ID NO: 4 is less than 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%,

32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 90%, 80%, 70%, 60%, 5%, 4%, 3%, 2% or 1% of the total nucleobases in the sequence in the reference sequence. Preferably, the uracil content of polynucleotides disclosed herein and preferably polynucleotides encoding the modified OTC protein of SEQ ID NO: 4, is between about 5% and about 25%. Preferably, the uracil content of polynucleotides disclosed herein and preferably polynucleotides encoding the modified OTC protein of SEQ ID NO: 4 is about 15% and about 25%.

[0121] The cDNA templates may be transcribed to produce an mRNA sequence described herein using an *in vitro* transcription (IVT) system. The system typically comprises a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor and a polymerase. The NTPs may be selected from, but are not limited to, those described herein including natural and unnatural (modified) NTPs. The polymerase may be selected from, but is not limited to, T7 RNA polymerase, T3 RNA polymerase and mutant polymerases such as, but not limited to, polymerases able to incorporate modified nucleic acids.

[0122] The primary cDNA template or transcribed mRNA sequence may also undergo capping and/or tailing reactions. A capping reaction may be performed by methods known in the art to add a 5' cap to the 5' end of the primary construct. Methods for capping include, but are not limited to, using a Vaccinia Capping enzyme (New England Biolabs, Ipswich, Mass.) or CLEANCAP® technology (TriLink Biotechnologies). A poly-A tailing reaction may be performed by methods known in the art, such as, but not limited to, 2' O-methyltransferase and by methods as described herein. If the primary construct generated from cDNA does not include a poly-T, it may be beneficial to perform the poly-A-tailing reaction before the primary construct is cleaned.

[0123] Codon optimized cDNA constructs encoding an ornithine transcarbamylase (OTC) protein are particularly suitable for generating mRNA sequences described herein. For example, such cDNA constructs may be used as the basis to transcribe, *in vitro*, a polyribonucleotide encoding an ornithine transcarbamylase (OTC) protein. Table 6 provides a listing of exemplary cDNA ORF templates used for *in vitro* transcription of the mRNA sequences listed in Table 5.

Table 6: Exemplary cDNA Templates

DNA Construct No***:	SEQ ID NO:	Protein encoded by cDNA template SEQ ID NO:
p563	128	SEQ ID NO: 3*
p564	129	SEQ ID NO: 3*
p565	130	SEQ ID NO: 3*
p566	131	SEQ ID NO: 3*
p567	132	SEQ ID NO: 3*
p568	133	SEQ ID NO: 3*
p569	134	SEQ ID NO: 3*
p570	135	SEQ ID NO: 3*
p571	136	SEQ ID NO: 3*
p572	137	SEQ ID NO: 3*
p573	138	SEQ ID NO: 3*
p574	139	SEQ ID NO: 3*
p575	140	SEQ ID NO: 3*
p708	141	SEQ ID NO: 3*
p709	142	SEQ ID NO: 3*
p710	143	SEQ ID NO: 3*
p711	144	SEQ ID NO: 3*
p712	145	SEQ ID NO: 3*
p713	146	SEQ ID NO: 3*
p714	147	SEQ ID NO: 3*
p715	148	SEQ ID NO: 3*
p716	149	SEQ ID NO: 3*
p717	150	SEQ ID NO: 3*
p718	151	SEQ ID NO: 3*
p719	152	SEQ ID NO: 3*
p720	153	SEQ ID NO: 3*
p721	154	SEQ ID NO: 3*
p722	155	SEQ ID NO: 3*

DNA Construct No***:	SEQ ID NO:	Protein encoded by cDNA template SEQ ID NO:
p723	156	SEQ ID NO: 3*
p724	157	SEQ ID NO: 3*
p725	158	SEQ ID NO: 3*
p726	159	SEQ ID NO: 3*
p727	160	SEQ ID NO: 3*
p728	161	SEQ ID NO: 3*
p729	162	SEQ ID NO: 3*
p1787	163	SEQ ID NO: 3*
p1788	164	SEQ ID NO: 3*
p1789	165	SEQ ID NO: 3*
p1790	166	SEQ ID NO: 3*
p1791	167	SEQ ID NO: 3*
p1792	168	SEQ ID NO: 3*
p1793	169	SEQ ID NO: 3*
p1794	170	SEQ ID NO: 3*
p1795	171	SEQ ID NO: 3*
p1796	172	SEQ ID NO: 3*
p1797	173	SEQ ID NO: 3*
p1798	174	SEQ ID NO: 3*
p1799	175	SEQ ID NO: 3*
p1800	176	SEQ ID NO: 3*
p1801	177	SEQ ID NO: 3*
p1802	178	SEQ ID NO: 3*
p1803	179	SEQ ID NO: 3*
p1804	180	SEQ ID NO: 3*
p1805	181	SEQ ID NO: 3*
p1806	182	SEQ ID NO: 3*
p1808	183	SEQ ID NO: 3*
p1809	184	SEQ ID NO: 3*

DNA Construct No***:	SEQ ID NO:	Protein encoded by cDNA template SEQ ID NO:
p1816	185	SEQ ID NO: 3*
p1822	186	SEQ ID NO: 3*
p1823	187	SEQ ID NO: 3*
p1840	188	SEQ ID NO: 3*
p1841	189	SEQ ID NO: 3*
p1842	190	SEQ ID NO: 3*
p1843	191	SEQ ID NO: 3*
p1844	192	SEQ ID NO: 3*
p1845	193	SEQ ID NO: 3*
p1846	194	SEQ ID NO: 3*
p1847	195	SEQ ID NO: 3*
p1882	196	SEQ ID NO: 3*
p1883	197	SEQ ID NO: 3*
p1884	198	SEQ ID NO: 3*
p1885	199	SEQ ID NO: 3*
p1886	200	SEQ ID NO: 3*
p1887	201	SEQ ID NO: 3*
p1888	202	SEQ ID NO: 3*
p1889	203	SEQ ID NO: 3*
p1890	204	SEQ ID NO: 3*
p1891	205	SEQ ID NO: 3*
p1898	206	SEQ ID NO: 3*
p1899	207	SEQ ID NO: 3*
p1900	208	SEQ ID NO: 3*
p1903	209	SEQ ID NO: 3*
p1904	210	SEQ ID NO: 3*
p1905	211	SEQ ID NO: 3*
p1906	212	SEQ ID NO: 3*
p1907	213	SEQ ID NO: 3*

DNA Construct No***:	SEQ ID NO:	Protein encoded by cDNA template SEQ ID NO:
p1908	214	SEQ ID NO: 3*
p1915	215	SEQ ID NO: 3*
p1916	216	SEQ ID NO: 3*
p1917	217	SEQ ID NO: 3*
p1918	218	SEQ ID NO: 3*
p1919	219	SEQ ID NO: 3*
p1920	220	SEQ ID NO: 3*
p1921	221	SEQ ID NO: 4**
p1925	222	SEQ ID NO: 3*
p1926	223	SEQ ID NO: 3*
p1927	224	SEQ ID NO: 3*
p1928	225	SEQ ID NO: 3*
p1929	226	SEQ ID NO: 3*
p2016	175	SEQ ID NO: 3*
p2260	221	SEQ ID NO: 4**
p2262	221	SEQ ID NO: 4**

*SEQ ID NO: 3 is the amino acid sequence for wild type human OTC.

**SEQ ID NO: 4 is the amino acid sequence for modified human OTC.

*** The entire plasmid sequence is not included.

[0124] Preferred cDNA template sequences include the DNA sequence of SEQ ID NO: 175 (p1779) having an optimized coding sequence encoding wild type human OTC of SEQ ID NO: 3. Preferred cDNA template sequences also include cDNA sequence of SEQ ID NO: 221 (p1921), having an optimized coding sequence encoding a modified OTC protein of SEQ ID NO: 4.

[0125] The present disclosure also provides polynucleotides (e.g. DNA, RNA, cDNA, mRNA) encoding a human OTC protein that may be operably linked to one or more regulatory nucleotide sequences in an expression construct, such as a vector or plasmid. In certain embodiments, such constructs are DNA constructs. Regulatory nucleotide sequences will generally be appropriate for a host cell used for expression. Numerous types of

appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells.

[0126] Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the embodiments of the present disclosure. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter.

[0127] An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. Preferably, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

[0128] The present disclosure also provides expression vectors comprising a nucleotide sequence encoding an ornithine transcarbamylase (OTC) protein that is preferably operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the encoded polypeptide.

[0129] Accordingly, the term regulatory sequence includes promoters, enhancers, and other expression control elements. The design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed.

[0130] The present disclosure also provides a host cell transfected with an mRNA or DNA described herein which encodes an ornithine transcarbamylase (OTC) polypeptide described herein. Preferably, the human OTC polypeptide has the sequence of SEQ ID NO: 4. The host cell may be any prokaryotic or eukaryotic cell. For example, an ornithine transcarbamylase (OTC) polypeptide may be expressed in bacterial cells such as *E. coli*, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

[0131] The present disclosure also provides a host cell comprising a vector comprising a polynucleotide which encodes an mRNA sequence of any one of SEQ ID NOs: 26-229.

[0132] The present disclosure also provides methods of producing a human wild type OTC protein of SEQ ID NO: 3 or a modified human OTC protein SEQ ID NO: 4. Preferably, the OTC protein is SEQ ID NO: 4 and is encoded by mRNA of SEQ ID NO 119. For example, a host cell transfected with an expression vector encoding an OTC protein can be cultured under appropriate conditions to allow expression of the polypeptide to occur. The polypeptide may be secreted and isolated from a mixture of cells and medium containing the polypeptides. Alternatively, the polypeptides may be retained in the cytoplasm or in a membrane fraction and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art.

[0133] The expressed OTC proteins described herein can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the OTC polypeptide.

Lipid-Based Formulations

[0134] Lipid-based formulations have been increasingly recognized as one of the most promising delivery systems (also referred to herein as a delivery vehicle or carrier) for RNA due to their biocompatibility and their ease of large-scale production. Cationic lipids have been widely studied as synthetic materials for delivery of RNA. After mixing together, nucleic acids are condensed by cationic lipids to form lipid/nucleic acid complexes known as lipoplexes. These lipid complexes are able to protect genetic material from the action of nucleases and to deliver it into cells by interacting with the negatively charged cell membrane. Lipoplexes can be prepared by directly mixing positively charged lipids at physiological pH with negatively charged nucleic acids.

[0135] Conventional liposomes consist of a lipid bilayer that can be composed of cationic, anionic, or neutral (phospho)lipids and cholesterol, which encloses an aqueous core. Both the lipid bilayer and the aqueous space can incorporate hydrophobic or hydrophilic compounds, respectively. Liposome characteristics and behavior in vivo can be modified by addition of a hydrophilic polymer coating, e.g. polyethylene glycol (PEG), to the liposome surface to confer steric stabilization. Furthermore, liposomes can be used for specific targeting by

attaching ligands (e.g., antibodies, peptides, and carbohydrates) to its surface or to the terminal end of the attached PEG chains (Front Pharmacol. 2015 Dec 1;6:286).

[0136] Liposomes are colloidal lipid-based and surfactant-based delivery systems composed of a phospholipid bilayer surrounding an aqueous compartment. They may present as spherical vesicles and can range in size from 20 nm to a few microns. Cationic lipid-based liposomes are able to complex with negatively charged nucleic acids via electrostatic interactions, resulting in complexes that offer biocompatibility, low toxicity, and the possibility of the large-scale production required for *in vivo* clinical applications. Liposomes can fuse with the plasma membrane for uptake; once inside the cell, the liposomes are processed via the endocytic pathway and the genetic material is then released from the endosome/carrier into the cytoplasm. Liposomes have long been perceived as drug delivery vehicles because of their superior biocompatibility, given that liposomes are basically analogs of biological membranes, and can be prepared from both natural and synthetic phospholipids (Int J Nanomedicine. 2014; 9: 1833-1843).

[0137] Cationic liposomes have been traditionally the most commonly used non-viral delivery systems for oligonucleotides, including plasmid DNA, antisense oligos, and siRNA/small hairpin RNA (shRNA). Cationic lipids, such as DOTAP, (1,2-dioleoyl-3-trimethylammonium-propane) and DOTMA (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate) can form complexes or lipoplexes with negatively charged nucleic acids to form nanoparticles by electrostatic interaction, providing high *in vitro* transfection efficiency. Furthermore, neutral lipid-based nanoliposomes for RNA delivery as e.g. neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)-based nanoliposomes were developed. (Adv Drug Deliv. Rev. 2014 Feb; 66: 110-116.)

[0138] Preferably, the mRNA constructs described herein are lipid formulated. The lipid formulation is preferably selected from, but not limited to, liposomes, lipoplexes, copolymers, such as PLGA, and lipid nanoparticles. Preferably a lipid nanoparticle (LNP) comprises:


- (a) a nucleic acid,
- (b) a cationic lipid,
- (c) an aggregation reducing agent (such as polyethylene glycol (PEG) lipid or PEG-modified lipid),

(d) optionally a non-cationic lipid (such as a neutral lipid), and

(e) optionally, a sterol.

Preferably, the lipid nanoparticle formulation consists of (i) at least one cationic lipid; (ii) a neutral lipid; (iii) a sterol, e.g., cholesterol; and (iv) a PEG-lipid, in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; 0.5-15% PEG-lipid.

[0139] Some examples of lipids and lipid compositions for delivery of an active molecule of this disclosure are given in WO 2015/074085, U.S. 2018/0169268, WO 2018/119163, WO 20185/118102, U.S. 2018/0222863, WO 2016/081029, WO 2017/023817, WO 2017/117530, each of which is hereby incorporated by reference in its entirety. In certain embodiments, the lipid is a compound of the following Formula I:



Formula I

wherein

R₁ and R₂ both consist of a linear alkyl consisting of 1 to 14 carbons, or an alkenyl or alkynyl consisting of 2 to 14 carbons;

L₁ and L₂ both consist of a linear alkylene or alkenylene consisting of 5 to 18 carbons, or forming a heterocycle with N;

X is S;


L₃ consists of a bond or a linear alkylene consisting of 1 to 6 carbons, or forming a heterocycle with N;

R₃ consists of a linear or branched alkylene consisting of 1 to 6 carbons; and


R₄ and R₅ are the same or different, each consisting of a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;

or a pharmaceutically acceptable salt thereof.


[0140] The lipid formulation of may contain one or more ionizable cationic lipids selected from among the following (also referred to herein as “ATX lipids”):




REPLACEMENT SHEET




ATX-025




ATX-026




ATX-027




ATX-028




ATX-031




ATX-032




ATX-081



ATX-095





[0141] The lipid nanoparticle preferably includes a cationic lipid suitable for forming a lipid nanoparticle. Preferably, the cationic lipid carries a net positive charge at about physiological pH. The cationic lipid may be, for example, N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), 1,2-dioleoyltrimethylammoniumpropane chloride (DOTAP) (also known as N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride and 1,2-Dioleoyloxy-3-trimethylaminopropane chloride salt), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleoyloxy)propylamine (DODMA), 1,2-DiLinoleoyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-di-γ-linolenyloxy-N,N-dimethylaminopropane (γ-DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleoyoxy-3-(dimethylamino)acetoxyp propane (DLin-DAC), 1,2-Dilinoleoyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S- DMA), 1-Linoleoyl-2-linoleoyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleoyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleoyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleoyloxo-3-(2-N,N- dimethylamino)ethoxypropane (DLin-EG-DM A), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediy)l)didodecan-2-ol (C12-200), 2,2-

dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate (DLin-M-C3-DMA), 3-(((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 Ether), 4-(((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylbutan-1-amine (MC4 Ether), or any combination of any of the foregoing. Other cationic lipids include, but are not limited to, N,N-distearyl-N,N-dimethylammonium bromide (DDAB), 3P-(N-(N',N'-dimethylaminoethane)- carbamoyl)cholesterol (DC-Choi), N-(1-(2,3-dioleoyloxy)propyl)-N-2-(sperminecarboxamido)ethyl)-N,N-dimethylammonium trifluoroacetate (DOSPA), dioctadecylamidoglycyl carboxyspermine (DOGS), 1,2-dioleoyl-sn-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-dimethylammonium propane (DODAP), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DMRIE), and 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC). Additionally, commercial preparations of cationic lipids can be used, such as, e.g., LIPOFECTIN (including DOTMA and DOPE, available from GIBCO/BRL), and Lipofectamine (comprising DOSPA and DOPE, available from GIBCO/BRL).

[0142] Other suitable cationic lipids are disclosed in International Publication Nos. WO 09/086558, WO 09/127060, WO 10/048536, WO 10/054406, WO 10/088537, WO 10/129709, and WO 2011/153493; U.S. Patent Publication Nos. 2011/0256175, 2012/0128760, and 2012/0027803; U.S. Patent Nos. 8,158,601; and Love *et al.*, PNAS, 107(5), 1864-69, 2010.

[0143] Other suitable amino lipids include those having alternative fatty acid groups and other dialkylamino groups, including those, in which the alkyl substituents are different (e.g., N-ethyl- N-methylamino-, and N-propyl-N-ethylamino-). In general, amino lipids having less saturated acyl chains are more easily sized, particularly when the complexes must be sized below about 0.3 microns, for purposes of filter sterilization. Amino lipids containing unsaturated fatty acids with carbon chain lengths in the range of C14 to C22 may be used. Other scaffolds can also be used to separate the amino group and the fatty acid or fatty alkyl portion of the amino lipid.

[0144] Preferably, the LNP comprises the cationic lipid with formula (III) according to the patent application PCT/EP2017/064066. In this context, the disclosure of PCT/EP2017/064066 is also incorporated herein by reference.

[0145] Preferably, amino or cationic lipids of the disclosure have at least one protonatable or deprotonatable group, such that the lipid is positively charged at a pH at or below physiological pH (e.g. pH 7.4), and neutral at a second pH, preferably at or above physiological pH. It will, of course, be understood that the addition or removal of protons as a function of pH is an equilibrium process, and that the reference to a charged or a neutral lipid refers to the nature of the predominant species and does not require that all of the lipid be present in the charged or neutral form. Lipids that have more than one protonatable or deprotonatable group, or which are zwitterionic, are not excluded from use in the disclosure. In certain embodiments, the protonatable lipids have a pKa of the protonatable group in the range of about 4 to about 11, e.g., a pKa of about 5 to about 7.

[0146] The cationic lipid can comprise from about 20 mol % to about 70 or 75 mol % or from about 45 to about 65 mol % or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or about 70 mol % of the total lipid present in the particle. In another embodiment, the lipid nanoparticles include from about 25% to about 75% on a molar basis of cationic lipid, e.g., from about 20 to about 70%, from about 35 to about 65%, from about 45 to about 65%, about 60%, about 57.5%, about 57.1%, about 50% or about 40% on a molar basis (based upon 100% total moles of lipid in the lipid nanoparticle). In one embodiment, the ratio of cationic lipid to nucleic acid is from about 3 to about 15, such as from about 5 to about 13 or from about 7 to about 11.

Pharmaceutical Compositions

[0147] Preferably, the disclosure provides pharmaceutical compositions containing a codon optimized mRNA encoding a human OTC protein of SEQ ID NO: 3 or SEQ ID NO: 4, preferably formulated in a lipid delivery system or lipid carrier and preferably comprising pharmaceutically acceptable excipients. Pharmaceutical compositions disclosed herein preferably facilitate expression of mRNA *in vivo*.

[0148] Suitable routes of administration include, for example, oral, rectal, vaginal, transmucosal, pulmonary including intratracheal or inhaled, or intestinal administration; parenteral delivery, including intradermal, transdermal (topical), intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, or intranasal.

[0149] Preferably, the intramuscular administration is to a muscle selected from the group consisting of skeletal muscle, smooth muscle and cardiac muscle. In some embodiments the administration results in delivery of the mRNA to a muscle cell. In some embodiments the administration results in delivery of the mRNA to a hepatocyte (i.e., liver cell). In a particular embodiment, the intramuscular administration results in delivery of the mRNA to a muscle cell.

[0150] Preferably, mRNAs and lipid formulations thereof may be administered in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a targeted tissue, preferably in a sustained release formulation. Local delivery can be affected in various ways, depending on the tissue to be targeted. For example, aerosols containing compositions of the present disclosure can be inhaled (for nasal, tracheal, or bronchial delivery); can be supplied in liquid, tablet or capsule form for administration to the stomach or intestines, can be supplied in suppository form for rectal or vaginal application; or can even be delivered to the eye by use of creams, drops, or even injection. Formulations containing provided compositions complexed with therapeutic molecules or ligands can even be surgically administered, for example in association with a polymer or other structure or substance that can allow the compositions to diffuse from the site of implantation to surrounding cells. Alternatively, they can be applied surgically without the use of polymers or supports.

[0151] Pharmaceutical compositions may be administered to any desired tissue. In some embodiments, the OTC mRNA delivered by provided liposomes or compositions is expressed in the tissue in which the liposomes and/or compositions were administered. In some embodiments, the mRNA delivered is expressed in a tissue different from the tissue in which the liposomes and/or compositions were administered. Exemplary tissues in which delivered mRNA may be delivered and/or expressed include, but are not limited to the liver, kidney, heart, spleen, serum, brain, skeletal muscle, lymph nodes, skin, and/or cerebrospinal fluid.

[0152] Preferably, a pharmaceutical composition can contain a polynucleotide described herein such as a primary DNA construct or mRNA described herein within a viral or bacterial vector.

[0153] Preferably, the primary DNA construct for an mRNA described herein or an mRNA described herein can be formulated using one or more excipients to: (1) increase stability; (2)

increase cell transfection; (3) permit a sustained or delayed release (e.g., from a depot formulation of the polynucleotide, primary construct, or mRNA); (4) alter the biodistribution (e.g., target the polynucleotide, primary construct, or mRNA to specific tissues or cell types); (5) increase the translation of encoded protein in vivo; and/or (6) alter the release profile of encoded protein in vivo.

[0154] In addition to traditional excipients such as any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, excipients of the present disclosure can include, without limitation, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with primary DNA construct, or mRNA (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics and combinations thereof.

[0155] Accordingly, the formulations described herein can include one or more excipients, each in an amount that together increases the stability of the primary DNA construct, or mRNA, increases cell transfection by the primary construct, or mRNA, increases the expression of polynucleotide, primary construct, or mRNA encoded protein, and/or alters the release profile of polynucleotide, primary construct, or mRNA encoded proteins. Further, the primary construct and mRNA of the present disclosure may be formulated using self-assembled nucleic acid nanoparticles.

[0156] Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of associating the active ingredient with an excipient and/or one or more other accessory ingredients.

[0157] A pharmaceutical composition in accordance with the present disclosure may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” refers to a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient may generally be equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage including, but not limited to, one-half or one-third of such a dosage.

[0158] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w/w) of the active ingredient.

[0159] Pharmaceutical formulations may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes, but is not limited to, any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, and the like, as suited to the particular dosage form desired.

[0160] Various excipients for formulating pharmaceutical compositions and techniques for preparing the composition are known in the art (see Remington: The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro, Lippincott, Williams & Wilkins, Baltimore, Md., 2006; incorporated herein by reference in its entirety). The use of a conventional excipient medium may be contemplated within the scope of the embodiments of the present disclosure, except insofar as any conventional excipient medium may be incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition.

[0161] Therapeutic Uses

[0162] The mRNA sequences, primary DNA constructs that transcribe the mRNA sequences described herein and pharmaceutical compositions thereof provide numerous in vivo and in vitro methods and are useful to treat OTC deficiency. The treatment may comprise treating a human patient with OTC deficiency. Similarly, compositions described herein, may be used in vitro or ex vivo to study OTC deficiency in cell or animal-based models. For example, cells deficient for OTC expression can be used to analyze the ability to restore OTC expression and/or activity, as well as the time period over which expression and/or activity persists. Such cells and animal models are also suitable to identify other factors involved in the pathway, whether binding partners or factors in the same biochemical pathway. In other

embodiments, compositions described herein can be used to study or track mitochondrial delivery.

[0163] Polynucleotides described herein, such as a DNA construct or template or an mRNA sequence described herein can be delivered to patients or cells experiencing OTC deficiency. Preferably the mRNA sequence comprises SEQ ID NO: 119 encoding a modified OTC protein of SEQ ID NO: 4. Preferably the DNA sequence comprises SEQ ID NO: 221 encoding a modified OTC protein of SEQ ID NO: 4.

[0164] Following administration, OTC is expressed in the cells or subject. Preferably, compositions described herein are delivered to mitochondria. Preferably compositions described herein are delivered to liver cells.

[0165] Preferably the therapeutic methods described herein decrease ammonia levels in plasma and/or urine in a subject in need thereof or in cells in culture, such as a subject having an OTC deficiency. Preferably, the therapeutic methods described herein decrease orotic acid levels in plasma and/or urine in a subject in need thereof or in cells in culture. Preferably, the therapeutic methods described herein increase citrulline in plasma and/or urine in a subject in need thereof or in cells in culture. Preferably, ammonia levels, orotic acid levels and/or citrulline levels are used as biomarkers to (i) identify subjects in need of treatment and/or (ii) to evaluate efficacy of treatment using the mRNA or DNA templates described herein.

[0166] Examples of mRNA sequences for use with these methods include those listed in Table 5. Preferably cDNA templates used to transcribe the mRNA sequences described herein are listed in Table 6. Preferred mRNA sequences for administering to patients for treatment of OTC deficiency are SEQ ID NOS: 1799 and SEQ ID NOS: 1921. Preferably the preferred mRNA sequences of SEQ ID NO: 1799 and SEQ ID NO: 1921.

[0167] Dosing

[0168] An effective dose of a mRNA, a protein or pharmaceutical formulations thereof of the present disclosure can be an amount that is sufficient to treat ORF protein deficiency in a cell and/or in a patient. A therapeutically effective dose can be an amount of an agent or formulation that is sufficient to cause a therapeutic effect. A therapeutically effective dose can be administered in one or more separate administrations, and by different routes. Generally, a therapeutically effective amount is sufficient to achieve a meaningful benefit to

the subject (e.g., treating, modulating, curing, preventing and/or ameliorating phenylketonuria). For example, a therapeutically effective amount may be an amount sufficient to achieve a desired therapeutic and/or prophylactic effect. Generally, the amount of a therapeutic agent administered to a subject in need thereof will depend upon the characteristics of the subject. Such characteristics include the condition, disease severity, general health, age, sex and body weight of the subject. One of ordinary skill in the art will be readily able to determine appropriate dosages depending on these and other related factors. In addition, both objective and subjective assays may optionally be employed to identify optimal dosage ranges.

[0169] Methods provided herein contemplate single as well as multiple administrations of a therapeutically effective amount of an mRNA sequence described herein. Pharmaceutical compositions comprising an mRNA sequence encoding an ORF protein described herein can be administered at regular intervals, depending on the nature, severity and extent of the subject's condition. Preferably, a therapeutically effective amount an mRNA sequence of the present disclosure may be administered periodically at regular intervals (e.g., once every year, once every six months, once every four months, once every three months, once every two months, once a month), biweekly, weekly, daily, twice a day, three times a day, four times a day, five times a day, six times a day, or continuously.

[0170] Preferably, the pharmaceutical compositions of the mRNA of the present disclosure are formulated such that they are suitable for extended-release of the translatable compound encoding a modified protein described herein contained therein. Such extended-release compositions may be conveniently administered to a subject at extended dosing intervals. For instance, in one embodiment, the pharmaceutical compositions of the present disclosure are administered to a subject twice a day, daily or every other day. In some embodiments, the pharmaceutical compositions of the present disclosure are administered to a subject twice a week, once a week, every 10 days, every two weeks, every 28 days, every month, every six weeks, every eight weeks, every other month, every three months, every four months, every six months, every nine months or once a year. Also contemplated herein are pharmaceutical compositions which are formulated for depot administration (e.g., subcutaneously, intramuscularly) to either deliver or release an mRNA sequence encoding an OTC protein described herein over extended periods of time. Preferably, the extended-release means

employed are combined with modifications made to the translatable compound encoding an OTC protein described herein to enhance stability.

[0171] A therapeutically effective dose, upon administration, can result in serum or plasma levels of OTC of 1-1000 pg/ml, or 1-1000 ng/ml, or 1-1000 µg/ml, or more. In some embodiments, administering a therapeutically effective dose of a composition comprising an mRNA sequence described herein can result in increased liver modified protein levels in a treated subject. Preferably, administering a composition comprising a mRNA described herein results in a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% increase in liver modified protein levels relative to a baseline modified protein level in the subject prior to treatment. Preferably, administering a therapeutically effective dose of a composition comprising an mRNA described herein will result an increase in liver OTC levels relative to baseline liver OTC levels in the subject prior to treatment. In some embodiments, the increase in liver OTC levels relative to baseline liver OTC levels will be at least 5%, 10%, 20%, 30%, 40%, 50%, 100%, 200%, or more.

[0172] Preferably, a therapeutically effective dose, when administered regularly, results in increased expression of OTC in the liver as compared to baseline levels prior to treatment. Preferably, administering a therapeutically effective dose of a composition comprising an mRNA sequence described herein results in the expression of a modified protein level at or above about 10 ng/mg, about 20 ng/mg, about 50 ng/mg, about 100 ng/mg, about 150 ng/mg, about 200 ng/mg, about 250 ng/mg, about 300 ng/mg, about 350 ng/mg, about 400 ng/mg, about 450 ng/mg, about 500 ng/mg, about 600 ng/mg, about 700 ng/mg, about 800 ng/mg, about 900 ng/mg, about 1000 ng/mg, about 1200 ng/mg or about 1500 ng/mg of the total protein in the liver of a treated subject.

[0173] Preferably, a therapeutically effective dose, when administered regularly, results in a reduction of orotic acid levels in a biological sample. In some embodiments, administering a therapeutically effective dose of a composition comprising an mRNA described herein results in a reduction of orotic acid levels in a biological sample (e.g., urine, plasma or serum sample) by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% as compared to baseline orotic acid levels before treatment. Preferably,

the biological sample is selected from plasma, serum, whole blood, urine, or cerebrospinal fluid. Preferably, administering a therapeutically effective dose of a composition comprising an mRNA described herein results in reduction of orotic acid levels to about 1000 $\mu\text{mol/L}$ or less, about 900 $\mu\text{mol/L}$ or less, about 800 $\mu\text{mol/L}$ or less, about 700 $\mu\text{mol/L}$ or less, about 600 $\mu\text{mol/L}$ or less, about 500 $\mu\text{mol/L}$ or less, about 400 $\mu\text{mol/L}$ or less, about 300 $\mu\text{mol/L}$ or less, about 200 $\mu\text{mol/L}$ or less, about 100 $\mu\text{mol/L}$ or less or about 50 $\mu\text{mol/L}$ or less in serum or plasma. Preferably, a therapeutically effective dose, when administered regularly results in reduction of orotic acid levels to about 600 $\mu\text{mol/L}$ or less in serum or plasma. In another exemplary embodiment, a therapeutically effective dose, when administered regularly results in reduction of orotic acid levels to about 360 $\mu\text{mol/L}$ or less in serum or plasma. Preferably, a therapeutically effective dose, when administered regularly results in reduction of orotic acid levels to about 120 $\mu\text{mol/L}$ or less in serum or plasma.

[0174] A therapeutically effective dose of an mRNA described herein in vivo can be a dose of about 0.001 to about 500 mg/kg body weight. For instance, the therapeutically effective dose may be about 0.001-0.01 mg/kg body weight, or 0.01-0.1 mg/kg, or 0.1-1 mg/kg, or 1-10 mg/kg, or 10-100 mg/kg. Preferably, a Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR)-mRNA (see WO 2015/074085 and U.S. 2018/0169268), encoding an OTC protein described herein, is provided at a dose ranging from about 0.1 to about 10 mg/kg body weight.

[0175] Combinations

[0176] The cDNA primary constructs, mRNA or encoded OTC proteins described herein may be used in combination with one or more other therapeutic, prophylactic, diagnostic, or imaging agents. By “in combination with,” it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope of the present disclosure. Compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. Preferably, the methods of treatment of the present disclosure encompass the delivery of pharmaceutical, prophylactic, diagnostic, or imaging compositions in combination with agents that may improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. As a non-limiting example, mRNA disclosed herein and

preferably an mRNA sequence comprising SEQ ID NO: 119, encoding a modified OTC protein of SEQ ID NO: 4 may be used in combination with a pharmaceutical agent for the treatment of OTC deficiency. The pharmaceutical agent includes, but is not limited to one or more of: sodium phenylbutyrate, glycerol phenylbutyrate, sodium phenylacetate, sodium benzoate, arginine, citrulline, Multiple vitamins, calcium supplements or combined with low protein/high caloric diet. In general, it is expected that agents utilized in combination with be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually. In one embodiment, the combinations, each or together may be administered according to the split dosing regimens as are known in the art.

EXAMPLES

Example 1: Material and Methods

In vitro transcription protocol

[0177] The mRNAs were synthesized *in vitro* using T7RNA polymerase- mediated DNA-dependent RNA transcription where uridine triphosphate (UTP) was substituted and unsubstituted with modified UTPs such as 5 methoxy UTP (5MeOU), N1-methoxy methyl pseudo UTP (N1-MOM), 5-hydroxy methyl UTP, 5-carboxy UTP, and mixture of modifications using linearized template for each UTR combination. The mRNA was purified using column chromatography, the DNA and double stranded mRNA contamination of all mRNAs was removed using an enzymatic reaction, and the mRNA was concentrated, and buffer exchanged.

Preparation of lipid encapsulated mRNA

[0178] Lipid encapsulated mRNA particles were prepared by mixing lipids (ATX lipid: DSPC: Cholesterol: PEG-DMG) in ethanol with OTC mRNA dissolved in Citrate buffer. The mixed material was instantaneously diluted with Phosphate Buffer. Ethanol was removed by dialysis against phosphate buffer using regenerated cellulose membrane (100 kD MWCO) or by tangential flow filtration (TFF) using modified polyethersulfone (mPES) hollow fiber membranes (100 kD MWCO). Once the ethanol was completely removed, the buffer was exchanged with HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer containing 50 mM NaCl and 9% sucrose, pH 7.3. The formulation was concentrated followed by 0.2 µm filtration using PES filters. The mRNA concentration in the formulation was then

measured by Ribogreen fluorimetric assay following which the concentration was adjusted to a final desired concentration by diluting with HEPES buffer containing 50 mM NaCl, 9% sucrose, pH 7.3 containing glycerol. The final formulation was then filtered through a 0.2 μ m filter and filled into glass vials, stoppered, capped and placed at $-70 \pm 5^\circ\text{C}$. The frozen formulations were characterized for their mRNA content and percent encapsulation by Ribogreen assay, mRNA integrity by fragment analyzer, lipid content by high performance liquid chromatography (HPLC), particle size by dynamic light scattering on a Malvern Zetasizer Nano ZS, pH and Osmolality.

In-Cell Western (ICW)

[0179] 96-well collagen plates were used to seed the cells at the appropriate density in Dulbecco's Modified Eagle Media (DMEM)/ Fetal Bovine Serum (FBS) culture media. At the optimal confluence, cells were transfected with the targeted mRNAs diluted in the transfection reagent mix (MessengerMax and Opti-MEM). Cells were placed in the CO₂ incubator and allowed to grow. At the desire timepoint, media was removed, and cells were fixed in 4% fresh paraformaldehyde (PFA) for 20 min. After that, fixative was removed, and cells were permeabilize in tris buffered saline with TWEEN (TBST) for 5 min several times. When permeabilization washes were complete, cells were incubated with a blocking buffer (ODYSSEY® Blocking Buffer (PBS) (Li-Cor, Lincoln, NE)) for 45 min. Primary antibody was then added and incubated for 1 h at room temperature. Cells were then washed several times in TBST and incubated for 1 h with a secondary antibody diluted in blocking buffer and containing a CellTag 700 stain. To finalize, cells were washed several times in TBST followed by a last wash in tris-buffered saline (TBS). The plate was imaged using the Licor detection system and data was normalized to the total number of cells labeled by the CellTag 700.

Example 2: UTRs screening in Hepa1.6 and Hep3B – Correlation at 24h and 48h.

[0180] A UTR library was screened *in vitro* using mRNA construct #571 comprising the sequence of SEQ ID NO: 34 as CDS (coding sequence). In-Cell Western assays as described in Example 1 were used to transfect the different mRNAs into Hepa1,6 and Hep3B using commercially available transfection reagents. OTC protein expression levels were measured by near-infrared fluorescent imaging systems. Commercially available antibodies for OTC were used for detection. Untransfected and reference sequences were used as internal controls. FIG. 1, Panel A is a scatter plot of OTC protein expression levels found in Hepa1,6

and Hep3B cells at 24 hours. FIG. 1, Panel B is a scatter plot of OTC protein expression levels found in Hepa1,6 and Hep3B cells at 48 hours. The aim of the screening was to determine an UTR-specific impact on OTC expression levels in a human (Hep3B) and a mouse (Hepa1,6) liver cell line that will be beneficial to determine which UTRs would work best in both models, in particular, its translatability from mouse-to-human. Top expressing UTRs were used in further profiling studies.

Example 3: Round 1 of protein stability compounds screened in Hepa1,6 and Hep3B at 24h – Correlation.

[0181] *In vitro* screening of certain mRNA constructs of Table 5 that were designed based on a protein-stability approach was performed. The mRNA constructs were tested in two different chemistries N¹-methylpseudouridine (N1MPU) and 5-methoxyuridine (5MeOU) meaning that 100% of the uridines in each mRNA were N1MPU only or 5MeOU only (not a combination of 5MeOU or N1MPU). In-Cell Western (ICW) assays as described in Example 1 were used to transfect the different mRNAs into Hepa1,6 and Hep3B using commercially available transfection reagents. OTC protein expression levels were measured by near-infrared fluorescent imaging systems. Commercially available antibodies for OTC were used for detection. Untransfected and reference sequences were used as internal controls. FIG. 2, panel A is a scatter plot showing the correlation of OTC protein expression levels in Hepa1,6 cells at 24 hours as a function of mRNAs tested in N1MPU and 5MeOU chemistries. FIG. 2, panel B is a scatter plot showing the correlation of OTC protein expression levels in Hep3B cells at 24 hours as a function of mRNAs tested in N1MPU and 5MeOU chemistries. These figures exhibit the degree of variability in expression levels when mRNAs from two different chemistries are tested in a mouse and a human liver cell line. It can be seen that that in this experiment, most of the compounds express better when an N1MPU chemistry is used in the mRNA.

Example 4: Round 2 of protein stability compounds screened in Human Primary Hepatocytes at 24h and 48h – Correlation.

[0182] *In vitro* screening of certain mRNA constructs of Table 5 that were designed based on a protein stability approach was performed. The mRNAs were tested in two different chemistries, 100% of the Uridines are N1MPU indicated by the name of mRNA constructs followed by “.1” and 100% of the uridines are 5MeOU indicated by the name of mRNA constructs followed by “.7”. In-Cell Western (ICW) assays as described in Example 1 were

used to transfect the different mRNAs into human primary hepatocytes using commercially available transfection reagents. OTC protein expression levels were measured by near-infrared fluorescent imaging systems. Commercially available antibodies for OTC were used for detection. Untransfected and reference sequences were used as internal controls. (FIG. 3, Panels A and B). The results indicate that, in contrast to the experiments conducted in cancer cell lines (Hepa1,6; Hep3B; Example 3, both chemistries express similarly in human primary hepatocytes.

Example 5: Round 3 of protein stability compounds screening in Human Primary Hepatocytes at 24h and 48h – Correlation.

[0183] *In vitro* screening of novel compounds designed based on a protein stability approach was performed. mRNAs were tested in two different chemistries, N1MPU indicated by the name of mRNA constructs followed by “.1” and 5MeOU indicated by the name of mRNA constructs followed by “.7”. In-Cell Western (ICW) assays as described in Example 1 were used to transfect the different mRNAs into human primary hepatocytes using commercially-available transfection reagents. OTC protein expression levels were measured by near-infrared fluorescent imaging systems. Commercially available antibodies for OTC protein were used for detection. Untransfected and reference sequences were used as internal controls. (FIG. 4, Panels A and B). The results indicate that, in contrast to the experiments conducted in cancer cell lines (Hepa1,6; Hep3B; Example 3), both chemistries express similarly in human primary hepatocyte.

Example 6: OTC protein-expression levels in human primary cells transfected with OTC mRNA constructs 1799.7 (5MeOU chemistry) encoding the OTC protein of SEQ ID NO: 3 and 1921.7 (5MeOU chemistry) encoding the modified OTC protein of SEQ ID NO: 4.

[0184] In-Cell Western (ICW) assays as described in Example 1 were used to transfect OTC mRNAs into human primary hepatocytes using commercially available transfection reagents. OTC protein expression levels were measured by near-infrared fluorescent imaging systems during a time course study up to 96h. Commercially available OTC antibodies were used for detection. Untransfected cells were used as internal control. Plot shows OTC protein levels normalized to untransfected controls. (FIG. 5). The purpose of this study was to evaluate the half-life of the unmodified versus the modified protein sequence (encoded by constructs

1799.7, 1921.7, respectively) under *in vitro* conditions in transfected human primary hepatocytes. The results indicate that 1921.7 demonstrated more stable expression than 1799.7

Example 7: OTC expression levels measured by multiple reaction monitoring (MRM) mass spectrometry in spf/ash mice dosed at 10mg/kg. Spf/ash mice received an IV injection with either PBS or lipid-formulated (as described in Example 1) OTC-mRNAs at a 10 mg/kg dosing. WT mice were used as internal controls to determine endogenous levels. A time course (6h, 24h and 48h) was performed, and expression levels were measured by MRM using human and mouse specific epitopes for OTC. Graphs were made that represent the amount of protein (ng/mg tissue) detected by MRM specific for human OTC (FIG. 6, Panel A) or mouse (FIG. 6, Panel B). Human- and mouse-specific heavy peptides were designed to measure total levels of OTC in both species. This data set shows quantitative levels of human-specific OTC derived from translation of delivered mRNAs are detected. This expression maintains a high level of stability up to 48h.

Example 8: OTC expression levels measured by western blot in WT mice dosed at 3mg/kg.

[0185] Spf/ash mice received an IV injection with either phosphate buffered saline (PBS) or lipid-formulated OTC-mRNAs at a 3mg/kg dosing using two different chemistries (N1MPU and 5MeOU). WT mice were used as internal controls to determine endogenous levels. Animals were sacrificed 24 h post-dose. OTC expression levels were measured by Western Blot (WB) using an OTC specific antibody. In the results provided in FIG. 7, the bars represent the percentage of expression relative to WT levels (100%). The data generated in this figure shows that WT levels of total OTC in a mouse background were achieved for several codon-optimized sequences.

Example 9: OTC expression levels measured by MRM in a dose range finding study.

[0186] Balb/c mice received an IV injection with either PBS or lipid-formulated OTC-mRNAs at three different doses: 0.3 mg/kg, 1 mg/kg and 3mg/kg and using two different chemistries (N1MPU and 5MeOU). Animals were sacrificed 24 h post-dose and expression levels were measured by MRM using human and mouse specific epitopes for OTC. The graph in FIG. 8 represents the percentage of expression of human OTC (ng) per mg of liver

tissue in Balb/c mice. The horizontal dotted line represents the relative mouse OTC levels in Balb/c mice. (FIG. 8). Expression levels of hOTC protein for mRNA construct 713 5MeOU and mRNA construct 571 N1MPU are indicated by arrows in FIG. 8. In this figure, the MRM was used to quantitatively determine human-selective and mouse-selective OTC protein levels. The data generated in this figure shows, in a dose dependent manner, that WT levels of human OTC in a mouse background are achieved with the codon-optimized sequences disclosed herein.

Example 10: Urinary Orotate levels measured in PBS and treated spf/ash mice.

[0187] Spf/ash mice received an IV injection with either PBS or lipid-formulated OTC-mRNA construct 1799.7 (5MeOU chemistry) at three different doses: 0.3 mg/kg, 1 mg/kg and 3mg/kg. WT and spf/ash mice were used to determine baseline and high urinary orotate levels, respectively. A spf/ash time course was determined, and urinary orotate levels were measured at each timepoint. The results can be seen in FIG. 9. Urinary orotate was normalized to creatinine, which is represented in the graph in the Y axis throughout the time course and serve as a proof-of-concept of functional restoration of OTC activity post-injection. At 3 mg/kg, a sustainable reduction of urinary orotate levels up to 14 days was observed.

Example 11: Pharmacokinetic/Pharmacodynamic (PK/PD) analysis comparing human OTC expression levels and Urinary Orotate at 96h.

[0188] Spf/ash mice received an IV injection with either PBS or certain lipid-formulated OTC-mRNAs from Table 5 at 1 mg/kg and 3 mg/kg using two different chemistries (N1MPU and 5MeOU). WT mice were used as internal controls. Human-specific OTC levels were measured by MRM whereas urinary orotate was determined in each sample and normalized to creatinine. PK/PD is plotted in FIG. 10. PK/PD analysis shows the correlation between protein expression levels and reduction of urinary orotate in a compound-specific manner. Construct 1799.7 shows a high PK/PD correlation.

Example 12: Fractioning of spf/ash mice *in vivo* samples treated with selected mRNAs.

[0189] Spf/ash mice received an IV injection with either PBS or lipid-formulated (as described in Example 1) OTC-mRNAs at 1 mg/kg and 3 mg/kg. WT mice were used as

internal controls. Sample fractioning was performed on the liver samples, separating a cytosolic and a mitochondrial fraction. OTC levels were measured by WB using human specific (hOTC) and crossreactive (crOTC) antibodies (FIG. 11). Cyclooxygenase IV (CoxIV) was used as a mitochondrial control. OTC protein expression levels were measured by near-infrared fluorescent imaging systems and normalized to total protein. WB indicates differences in OTC expression levels within mitochondrial and cytosolic fractions when 2016 and 2260 mRNAs were delivered in the spf/ash mice. These results indicate that both compounds can efficiently target the mitochondria.

Example 13: Plot of the mitochondrial vs cytosolic fractions of spf/ash mice samples treated with mRNA constructs 2016 and 2260.

[0190] Spf/ash mice received an IV injection with either PBS or lipid-formulated OTC-mRNAs at 3 mg/kg. WT mice were used as internal controls. Sample fractioning was performed on the liver samples, separating a cytosolic and a mitochondrial fraction. OTC levels were measured by western blot using a human specific antibody. OTC protein expression levels were measured by near-infrared fluorescent imaging systems and both fractions normalized to total protein were plotted (FIG. 12). The plot of protein expression levels shown in FIG. 11 (Example 12), indicate that even though both compounds, 2016 and 2260, deliver similar protein levels in the cytosol, it is in the mitochondria where 2260 delivers more human OTC than 2016. The 2260 includes a modified mitochondrial signaling peptide sequence of the invention.

Example 14: Urinary orotate levels in spf/ash mice treated with mRNA construct 2260.

[0191] Spf/ash mice received an IV injection with either PBS or lipid-formulated (as described in Example 1) OTC-mRNA at 1 mg/kg and 3 mg/kg. WT mice were included as an internal control. Urinary orotate levels were measured at 0, 1, 3, 7 and 14 days, and levels were normalized to creatinine (FIG. 13). The functional read-out of this assay shows that urinary orotate levels are reduced for up to 14 days with compound 2260, in a dose dependent manner.

Example 15: Survival of spf/ash mice on a high protein diet during treatment with OTC-mRNA construct 1799.7 (5MeOU chemistry).

[0192] Spf/ash mice received an IV injection with either PBS or lipid-formulated OTC-mRNA (1799.7) at three doses: 0.3 mg/kg, 1 mg/kg and 3 mg/kg. Mice were under a high protein diet since day 0 to the end of the study. Treated animals were injected by IV on days 0, 7, 14, 21 and 28 (arrows). Survival rates were determined every week. The plot in FIG. 14 summarizes the entire study timeline and the survival rates observed for the different groups. The results show that animals treated with human OTC mRNAs described herein have a higher chance to survive during a hyperammonemic crisis, suggesting the protective role of OTC mRNAs described herein in detoxifying the animals from toxic ammonia. This survival rate was dose-dependent, and animals treated with a 3 mg/kg dose have a higher survival rate than animals treated at 1 mg/kg or 0.3 mg/kg.

Example 16: Comparison of hOTC expression levels with different modifications.

[0193] Lipid-formulated OTC-mRNA construct 2262 doses were injected by IV in 8 week-old male C57BL/6 mice at a dose of 1 mg/kg. Different chemistries were used in this study as indicated in the bottom axis of the chart provided in FIG. 15. The mice livers were harvested at 24 hours post IV-administration, and western blot was performed using a hOTC specific antibody. Levels were normalized to total protein (FIG. 15). Each construct was formulated as a lipid nanoparticle comprising an ATX lipid as described in Example 1. This dataset indicates the impact of different uridine chemistries on the expression levels of our codon-optimized mRNAs.

[0194] The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.

[0195] While this disclosure has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the disclosure encompassed by the appended claims. It should also be understood that the embodiments described herein are not mutually exclusive and that features from the various embodiments may be combined in whole or in part in accordance with the disclosure.

SEQUENCE LISTING

mRNA coding sequence for wild type human OTC (SEQ ID NO: 1)

AUGCUGUUUAAUCUGAGGAUCCUGUUAAACAAUGCAGCUUUUAGAAAUGGUC
 ACAACUUCAUGGUUCGAAAUUUUUCGGUGUGGACAACCACUACAAAUAAGU
 GCAGCUGAAGGGCCGUGACCUUCUCACUCUAAAAAAC
 UUUACCGGAGAAGAAAUUAUAUAUAGCUAUGGCUAUCAGCAGAUCUGAAAU
 UUAGGAUAAAACAGAAAGGAGAGUAUUUGCCUUUAUUGCAAGGGAAGUCCUU
 AGGCAUGAUUUUUGAGAAAAGAAGUACUCGAACAAGAUUGUCUACAGAAACA
 GGCUUUGCACUUCUGGGAGGACAUCUUGUUUUUCUUACCACACAAGAUUUUCA
 UUUGGGUGUGAAUGAAAGUCUCACGGACACGGCCCGUGUAUUGUCUAGCAUG
 GCAGAUGCAGUAUUGGCUCGAGUGUAUAAACAAUCAGAUUUGGACACCCUGG
 CUAAAGAAGCAUCCAUCCCAAUAUCAUUGGGCUGUCAGAUUUGUACCAUCCU
 AUCCAGAUCUGGCUGAUUACCUCACGCUCCAGGAACACUAUAGCUCUCUGAA
 AGGUCUUACCCUCAGCUGGAUCGGGGAUGGGAACAAUAUCCUGCACUCCAUCA
 UGAUGAGCGCAGCGAAAUUCGGAAUGCACCUUCAGGCAGCUACUCCAAAGGGU
 UAUGAGCCGGAUGCUAGUGUAACCAAGUUGGCAGAGCAGUAUGCCAAAGAGA
 AUGGUACCAAGCUGUUGCUGACAAUAUGAUCCAUGGAAGCAGCGCAUGGAGG
 CAAUGUAUUAAUACAGACACUUGGAUAAGCAUGGGACAAGAAGAGGAGAAG
 AAAAAGCGGCUCCAGGCUUCCAAGGUUACCAGGUUACAAUGAAGACUGCUA
 AAGUUGCUGCCUCUGACUGGACAUUUUUACACUGCUUGCCCAGAAAGCCAGAA
 GAAGUGGAUGAUGAAGUCUUUUUAUUCUCCUCGAUCACUAGUGUUCCAGAGG
 CAGAAAACAGAAAGUGGACAAUCAUGGCUGUCAUGGUGUCCCUGCUGACAGA
 UUACUCACCUCAGCUCCAGAAGCCUAAAUUUUGA

DNA coding sequence for wild type human OTC (SEQ ID NO: 2)

ATGCTGTTTAATCTGAGGATCCTGTAAACAATGCAGCTTTTAGAAATGGTCACA
 ACTTCATGGTTCGAAATTTTCGGTGTGGACAACCCTACAAAATAAAGTGCAGCT
 GAAGGGCCGTGACCTTCTCACTCTAAAAAACTTTACCGGAGAAGAAATTAAATA
 TATGCTATGGCTATCAGCAGATCTGAAATTTAGGATAAAACAGAAAGGAGAGTA
 TTTGCCTTTATTGCAAGGGAAGTCCTTAGGCATGATTTTTTGAGAAAAGAAGTACT
 CGAACAAGATTGTCTACAGAAACAGGCTTTGCACTTCTGGGAGGACATCCTTGTT
 TTCTTACCACACAAGATATTCATTTGGGTGTGAATGAAAGTCTCACGGACACGGC
 CCGTGTATTGTCTAGCATGGCAGATGCAGTATTGGCTCGAGTGTATAACAATCA
 GATTTGGACACCCTGGCTAAAGAAGCATCCATCCCAATTATCAATGGGCTGTCAG
 ATTTGTACCATCCTATCCAGATCCTGGCTGATTACCTCACGCTCCAGGAACACTA
 TAGCTCTCTGAAAGGTCTTACCCTCAGCTGGATCGGGGATGGGAACAATATCCTG
 CACTCCATCATGATGAGCGCAGCGAAATTCGGAATGCACCTTCAGGCAGCTACTC
 CAAAGGGTTATGAGCCGGATGCTAGTGTAAACCAAGTTGGCAGAGCAGTATGCCA
 AAGAGAATGGTACCAAGCTGTTGCTGACAAATGATCCATTGGAAGCAGCGCATG
 GAGGCAATGTATTAATTACAGACACTTGGATAAGCATGGGACAAGAAGAGGAGA
 AGAAAAAGCGGCTCCAGGCTTTCCAAGGTTACCAGGTTACAATGAAGACTGCTA
 AAGTTGCTGCCTCTGACTGGACATTTTTACACTGCTTGCCCAGAAAGCCAGAAGA
 AGTGGATGATGAAGTCTTTTATTCTCCTCGATCACTAGTGTTCAGAGGCAGAA
 AACAGAAAGTGGACAATCATGGCTGTCATGGTGTCCCTGCTGACAGATTACTCAC
 CTCAGCTCCAGAAGCCTAAATTTTGA

Human wild type OTC amino acid sequence

(The signal peptide for mitochondrial import is underlined*) (SEQ ID NO: 3)

MLFNLRIILLNNAAFRNGHNFMVNRNFRCGOPLQNKVQLKGRDLLTLKNFTGEEIK
YMLWLSADLKFRKQKGEYLPLLQGKSLGMIFEKRSTRTRLSTETGFALLGGHPCFL
TTQDIHLGVNESLTDARVLSSMADAVLARVYKQSDLDTLAKEASIPIF
GLSDLYHPIQILADYLTQLQEHYSSLKGLTSLWIGDGNNILHSIMMSAAKFGMHLQAA
TPKGYEPDASVTKLAEQYAKENGTKLLLTNDPLEAAHGGNVLITDTWISMGQEEEEK
KKRLQAFQGYQVTMKTAKVAASDWTFLHCLPRKPEEVDDEVFYSRSLVFPEAENR
KWTIMAVMVSLTLDYSPQLQKPKF

Modified OTC amino acid sequence

(The signal peptide for mitochondrial import is underlined*) (SEQ ID NO: 4)

MLVFNLRIILLNNAAFRNGHNFMVNRNFRCGOPLQNRVQLKGRDLLTLKNFTGEEI
RYMLWLSADLKFRKQKGEYLPLLQGKSLGMIFEKRSTRTRLSTETGFALLGGHPCF
LTTQDIHLGVNESLTDARVLSSMADAVLARVYKQSDLDTLAKEASIPIINGLSLDLYH
PIQILADYLTQLQEHYSSLKGLTSLWIGDGNNILHSIMMSAAKFGMHLQAATPKGYEP
DASVTKLAEQYAKENGTKLLLTNDPLEAAHGGNVLITDTWISMGQEEEEKKKRLQAF
QGYQVTMKTAKVAASDWTFLHCLPRKPEEVDDEVFYSRSLVFPEAENRKWTIMA
VMVSLTLDYSPQLQKPKF

TEV (SEQ ID NO: 5)

TCAACACAACATATACAAAACAAACGAATCTCAAGCAATCAAGCATTCTACTTCT
ATTGCAGCAATTTAAATCATTTCTTTTAAAGCAAAAGCAATTTTCTGAAAATTTTC
ACCATTTACGAACGATAG

AT1G58420 (SEQ ID NO: 6)

ATTATTACATCAAAACAAAAAGCCGCCA

ARC5-2 (SEQ ID NO: 7)

CTTAAGGGGGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATCAAGCT
TACCATGGTGCCCCAGGCCCTGCTCTTGTCCCGCTGCTGGTGTTCCCCCTCTGCT
TCGGCAAGTTCCCCATCTACACCATCCCCGACAAGCTGGGGCCGTGGAGCCCCAT
CGACATCCACCACCTGTCTGCCCCAACACCTCGTGGTCGAGGACGAGGGCTG
CACCAACCTGAGCGGGTTCTCTAC

HCV (SEQ ID NO: 8)

TGAGTGTCTG ACAGCCTCCA GGCCCCCCCC TCCCGGGAGA GCCATAGTGG
TCTGCGGAACCGGTGAGTAC ACCGGAATTG CCGGGAAGAC TGGGTCCTTT
CTTGATAAA CCCACTCTATGCCCGGCCAT TTGGGCGTGC CCCCACAAGA
CTGCTAGCCG AGTAGTGTTG GGTTCG

HUMAN ALBUMIN (SEQ ID NO: 9)

AATTATTGGTTAAAGAAGTATATTAGTGCTAATTTCCCTCCGTTTGTCTAGCTTT
TCTCTTCTGTCAACCCACACGCCTTTGGCACA

EMCV (SEQ ID NO: 10)

CTCCCTCCCC CCCCCCTAAC GTTACTGGCC GAAGCCGCTT GGAATAAGGC
CGGTGTGCGT TTGTCTATAT GTTATTTTCC ACCATATTGC CGTCTTTTGG
CAATGTGAGG GCCCGGAAAC CTGGCCCTGT CTTCTTGACG AGCATTCTTA
GGGGTCTTTC CCCTCTCGCC AAAGGAATGC AAGGTCTGTT GAATGTCGTG

AAGGAAGCAG TTCCTCTGGA AGCTTCTTGA AGACAAACAA CGTCTGTAGC
 GACCCTTTGC AGGCAGCGGA ACCCCCCACC TGGCGACAGG TGCTCTGCG
 GCCAAAAGCC ACGTGTATAA GATACACCTG CAAAGGCGGC ACAACCCAG
 TGCCACGTTG TGAGTTGGAT AGTTGTGGAA AGAGTCAAAT GGCTCTCCTC
 AAGCGTATTC AACAAGGGGC TGAAGGATGC CCAGAAGGTA CCCCATTGTA
 TGGGATCTGA TCTGGGGCCT CGGTGCACAT GCTTTACGTG TGTTTAGTCG
 AGGTTAAAAA ACGTCTAGGC CCCCCGAACC ACGGGGACGT GGTTTTCTT
 TGAAAAACAC GATGATAAT

HSP70-P2 (SEQ ID NO: 11)

GTCAGCTTTCAAACTCTTTGTTTCTTGTTTGTGATTGAGAATA

HSP70-M1 (SEQ ID NO: 12)

CTCTCGCCTGAGAAAAAAATCCACGAACCAATTTCTCAGCAACCAGCAGCACG

HSP72-M2 (SEQ ID NO: 13)

ACCTGTGAGGGTTCGAAGGAAGTAGCAGTGTTTTTTGTTCTAGAGGAAGAG

HSP17.9 (SEQ ID NO: 14)

ACACAGAAACATTCGCAAAAACAAAATCCCAGTATCAAATTCTTCTTTTTTTT
 CATATTTTCGCAAAGAC

HSP70-P1 (SEQ ID NO: 15)

CAGAAAAATTTGCTACATTGTTTCACAACTTCAAATATTATTCAATTTATT

XBG (SEQ ID NO: 16)

CTAGTGACTIONACTAGGATCTGGTTACCACTAAACCAGCCTCAAGAACACCCGAA
 TGGAGTCTCTAAGCTACATAATACCAACTTACACTTACAAAATGTTGTCCCCCAA
 AATGTAGCCATTCGTATCTGCTCCTAATAAAAAGAAAGTTTCTTCACAT

HUMAN HAPTOGLOBIN (SEQ ID NO: 17)

TGCAAGGCTGGCCGGAAGCCCTTGCCTGAAAGCAAGATTTACGCCTGGAAGAGG
 GCAAAGTGGACGGGAGTGGACAGGAGTGGATGCGATAAGATGTGGTTTGAAGCT
 GATGGGTGCCAGCCCTGCATTGCTGAGTCAATCAATAAAGAGCTTCTTTTGACC
 CAT

HUMAN APOLIPOPROTEIN E (SEQ ID NO: 18)

ACGCCGAAGCCTGCAGCCATGCGACCCACGCCACCCCGTGCCTCCTGCCTCCGC
 GCAGCCTGCAGCGGGAGACCCTGTCCCCGCCAGCCGTCTCCTGGGGTGGAC
 CCTAGTTTAATAAAGATTACCAAGTTTCACGCA

HCV (SEQ ID NO: 19)

TAGAGCGGCAAACCCTAGCTACACTCCATAGCTAGTTTCTTTTTTTTTTGT
 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTTTCTTTTCTTTTCTTTTCTTT
 TTCTTGGTGGCTCCATCTTAGCCCTAGTCACGGCTAGCTGTGAAAGGTCCGTGAG
 CCGCATGACTGCAGAGAGTGCCGTAACCTGGTCTCTCTGCAGATCATGT

MOUSE ALBUMIN (SEQ ID NO: 20)

ACACATCACAAACCACAACCTTCTCAGGCTACCCTGAGAAAAAAGACATGAAGA
 CTCAGGACTCATCTTTTCTGTTGGTGTAATAACACCCCTAAGGAACACAAATT

TCTTTAAACATTTGACTTCTTGTCTCTGTGCTGCAATTAATAAAAAATGGAAAGA
ATCTAC

HUMAN ALPHA GLOBIN (SEQ ID NO: 21)

GCTGGAGCCTCGGTAGCCGTTCTCCTGCCCGCTGGGCCTCCCAACGGGGCCCTCC
TCCCCTCCTTGACACCGGCCCTTCCTGGTCTTTGAATAAAGTCTGAGTGGGCAGCA

EMCV (SEQ ID NO: 22)

TAGTGCAGTCAC TGGCACAACG CGTTGCCCCGG TAAGCCAATC GGGTATACAC
GGTCGTCATACTGCAGACAG GGTCTTCTA CTTTGCAAGA TAGTCTAGAG
TAGTAAAATA AATAGTATAAG

(SEQ ID NO: 23)

GCCACC

(SEQ ID NO: 24)

GCCA

(SEQ ID NO: 25)

AUAAGUGAA

>mARM563 (SEQ ID NO: 26)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUUAAUCUGAGGAUCCUG
UUAACAAUUGCAGCUUUUAGAAAUGGUCACAACUUCAUGGUUCGAAUUUUC
GGUGUGGACAACCACUACAAAUAAGUGCAGCUGAAGGGCCGUGACCUUCUC
ACUCUAAAAAACUUUACCGGAGAAGAAAUUAAAUAUAUGCUAUGGCUAUCAG
CAGAUUCUGAAAUUUAGGAUAAAACAGAAAGGAGAGUAUUUGCCUUUAUUGCA
AGGGAAGUCCUUAGGCAUGAUUUUUGAGAAAAGAAGUACUCGAACAAGAUUG
UCUACAGAAACAGGCUUUGCACUUCUGGGAGGACAUCUUGUUUUCUUAACCAC
ACAAGAUAUUCAUUUGGGUGUGAAUGAAAGUCUCACGGACACGGCCCGUGUA
UUGUCUAGCAUGGCAGAUAGCAGUAUUGGCUCGAGUGUAUAAACAAUCAGAUU
UGGACACCCUGGCUAAAGAAGCAUCCAUCCCAAUUAUCAUUGGGCUGUCAGAU
UUGUACCAUCCUAUCCAGAUCCUGGCUGAUUACCUCACGCUCCAGGAACACUA
UAGCUCUCUGAAAGGUCUUACCCUCAGCUGGAUCGGGGAUGGGAACAAUAUCC
UGCACUCCAUCAUGAUGAGCGCAGCGAAAUUCGGAAUGCACCUUCAGGCAGCU
ACUCCAAAGGGUUAUGAGCCGGAUGCUAGUGUAACCAAGUUGGCAGAGCAGU
AUGCCAAAGAGAAUGGUACCAAGCUGUUGCUGACAAAUGAUCCAUUGGAAGC
AGCGCAUGGAGGCAAUGUAUUAAUUACAGACACUUGGAUAAGCAUGGGACAA
GAAGAGGAGAAGAAAAAGCGGCUCAGGCUUCCAAGGUUACCAGGUUACAA
UGAAGACUGCUAAAGUUGCUGCCUCUGACUGGACAUUUUUACACUGCUUGCCC
AGAAAGCCAGAGAAGUGGAUGAUGAAGUCUUUUUUAUUCUCCUCGAUCACUAG
UGUUCCCAGAGGCAGAAAACAGAAAGUGGACAAUCAUGGCUGUCAUGGUGUC
CCUGCUGACAGAUUACUCACCUCAGCUCCAGAAGCCUAAAUUUUGACUCGAGC
UAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAA
UGGAGUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCC
AAAAGUAGCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUU
CUAG

>mARM564 (SEQ ID NO: 27)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUCUUUAAUCUGCGCAUCUUA
CUGAACAACGCCGCAUUCGGAACGGUCACAACUUCAUGGUCCGCAAUUUCCG
CUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGACGGGAUCUGCUGA
CACUGAAGAACUUCACCGGAGAAGAGAUCAAGUACAUGCUGUGGCUCAGCGCA
GACUUGAAGUUCGGAUCAAGCAGAAGGGAGAAUACUUGCCCCUGCUGCAAG
GAAAGUCGCUGGGAAUGAUUUUUGAGAAGCGGUCAACUCGCACCAGACUCUCC
ACCGAAACUGGUUUCGCACUGCUUGGCGGGCACCCUUGCUUCCUGACGACUCA
GGACAUCACCUCGGCGUGAACGAAUCGCUAACCGAUACCGCCAGAGUGCUIU
CUUCCAUGGCCGACGCGGUGCUGGCCAGGGUGUACAAGCAGUCCGACCUCGAU
ACCUUGGCAAAGGAGGCUUCCAUUCCCAUCAUCAACGGCCUGAGCGACCUGUA
CCACCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGCAAGAGCACUACAGCA
GCCUGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGGAAACAAUAUUCUGCA
CUCCAUCAUGAUGUCCGCCGCGAAGUUCGGAAUGCAUCUGCAAGCCGCCACUC
CAAAAGGAUACGAACCGGAUGCGUCCGUGACCAAGUUGGCGGAACAGUACGCG
AAGGAGAACGGAACCAAGCUUCUGCUGACUAAACGACCCCCUCGAGGCUGCGCA
UGGGGGCAACGUGCUGAUUACCGACACCUGGAUCUCCAUGGGGCAGGAGGAA
GAGAAGAAGAAGAGACUGCAGGCAUUCAGGGGUACCAGGUCACCAUGAAAA
CCGCAAAAGUGGCAGCUUCGGACUGGACUUCUCCUGCAUUGCCUGCCGAGGAAG
CCGGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGGUCCUGGUGUCCCC
CGAGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCUUGCUGA
CUGACUAUAGCCCGCAGCUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACU
GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
GCCAUUCGUAUCUGCUCCUAAUAAAAGAAAGUUUCUUCACAUUCUAG

>mARM565 (SEQ ID NO: 28)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUUAAACCUACGUUUUUG
CUCAACAUAUGCAGCCUUUAGAAACGGACAUAAACUUUAUGGUUCGAAACUUUC
GCUGCGGGCAGCCACUGCAGAACAAGGUCCAGCUGAAGGGAGAGAUUUGCUC
ACGCUGAAGAACUUUACUGGCGAAGAAAUCAAGUAUAUGCUGUGGUUGUCCG
CGGACCUCAGUUUCGGAUUAAGCAGAAAGGGGAGUAUCUGCCACUGCUGCA
AGGAAAGAGCCUCGGCAUGAUCUUCGAGAAGCGGAGCACUCGGACCAGGCUGA
GUACCGAAACUGGCUUCGCAUUGUUGGGUGGACAUCCAUGUUUUCUGACAAC
GCAGGACAUUCAUCUGGGCGUGAACGAGAGUCUGACGGACACAGCUCGCGUUC
UGUCCUCUAUGGCUGAUGCGGUGUUGGCCCGGGUCUAUAAGCAGUCCGAUUU
GGACACCUUGGCUAAGGAAGCUAGCAUACCGAUUAUCAUUGGGCUGUCCGACC
UGUAUCACCCUAUUCAAAUCCUGGCCGACUACCUCACACUGCAAGAACACUAU
AGCUCAUUGAAGGGACUGACCCUGAGCUGGAUAGGGGACGGAACAACAUC
UACAUAGCAUUAUGAUGUCCGCUGCCAAGUUUGGCAUGCAUCUUAAGCCGCC
ACGCCAAAGGGUUAUGAGCCCGACGCGUCAGUGACAAAGCUGGCCGAGCAGUA
CGCUAAGGAGAAUGGUACCAAAUUAUCUGCUGACUAAUGAUCCACUGGAGGCU
GCACAUGGCGGCAAUGUACUGAUCACCGACACAUGGAUCUCGAUGGGCCAGGA
GGAAGAAAAGAAAGAGGCUUCAGGCCUCCAAGGCUACCAGGUCACCAUG
AAAACAGCUAAGGUUGCAGCAUCUGAUUGGACCUIUCUGCACUGUCUGCCAAG
GAAGCCCGAAGAGGUGGACGAUGAAGUAUUCUAUAGCCACGGAGUUUGGUG

UUCCCUGAGGCUGAAAAUAGGAAGUGGACAAUUAUGGCCGUA AUGGUGUCCC
 UGUUAACCGACUACUCUCCGCAACUGCAGAAACCUAAGUUUUAGCUCGAGCUA
 GUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUG
 GAGUCUCUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAA
 AAUGUAGCCAUUCGU AUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCU
 AG

>mARM566 (SEQ ID NO: 29)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUUAACUUAAGGAUCCUG
 CUGAACAAACGCCGCUUUUCGUAAACGGUCAUAACUUUAUGGUCCGGAACUUUAG
 AUGUGGCCAGCCGCUAGCAGAACAAGGUUCAGCUGAAGGGGAGGGAUUCUGCUG
 ACCUUGAAGAACUUUACCGGCCAAGAGAUCAAGUACAUGUUGUGGCUGAGCG
 CCGAUCUGAAGUUUAGGAUUAAGCAGAAGGGGGAGUAUUUGCCACUGCUGCA
 AGGAAAAUCCUUGGGGAUGAUCUUCGAGAAGCGCUCCACUAGAACCCGGCUAA
 GCACAGAAACCGGCUUCGCACUUCUGGGUGGACAUCCUGUUUUCUGACGACG
 CAGGAUAUACACCUGGGCGUGAAUGAGAGUCUGACGGACACAGCUAGGGUGU
 UGAGCAGCAUGGCCGAUGCAGUACUGGCCCGCGUUUAUAAGCAGAGCGACUUG
 GACACACUGGCCAAGGAAGCGUCAAUUCCGAUUAUCAUUGGGCUGUCAGACCU
 GUAUCAUCCCAUUCAAAUCUUGGCUGACUAUCUGACCCUGCAAGAACAUAACA
 GCUCCUGAAGGGCCUCACGUUGUCCUGGAUUGGCGACGGAAACAACAUUCUG
 CAUUCGAUCAUGAUGAGCGCUGCUAAGUUUGGCAUGCACCUCCAAGCCGCUAC
 ACCUAAGGGAUUAUGAGCCUGAUGCCAGCGUAACCAAGCUGGCCGAACAGUACG
 CGAAGGAGAAUGGCACGAAACUGCUGUUGACAAAUGACCCACUGGAGGCAGC
 UCACGGUGGCAACGUGCUGAUCACCGACACGUGGAUAUCUAUGGGACAGGAA
 GAAGAGAAGAAGAAGCGGCUGCAGGCAUUCCAAGGGUAUCAGGUCACCAUGA
 AAACGGCCAAGGUUGCUGCAUCCGACUGGACAUAUUCUGCAUUGCUUGCCCCGC
 AAACCAGAAGAAGUAGACGACGAAGUCUUUUAUUCCCCACGGUCGCUGGUGU
 UCCCCGAGGCGGAGAAUCGAAAGUGGACGAUUAUGGCCGUGAUGGUGUCCCU
 GCUGACUGAUUACUCUCCCCAACUGCAAAAGCCUAAGUUUUAAGCUCGAGCUAG
 UGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGG
 AGUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAA
 AUGUAGCCAUUCGU AUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUA
 G

>mARM567 (SEQ ID NO: 30)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAACCUGAGGAUCCUC
 CUGAACAAACGCCGCCUUUCGCAAUGGUCACAACUUUAUGGUCCGGAACUUCAG
 AUGCGGCCAGCCGCUAGCAGAACAAGGUCCAGCUGAAGGGACGGGAUCUGCUGA
 CUCUGAAGAACUUCACCGGAGAAGAGAUCAAGUACAUGCUGUGGCUGUCGGCC
 GACCUGAAGUUCAGGAUCAAGCAGAAGGGAGAAUACCUCCCGCUGCUGCAAGG
 AAAGUCCCUGGGCAUGAUUUUCGAGAAGCGCUCGACCAGAACUCGGUUGUCCA
 CCGAAACCGGGUUUGCGCUGCUGGGCGGACAUCUUGCUUCCUGACGACUCAG
 GAUAUUCACCUGGGAGUGAACGAGUCGCUGACCGACACCGCCAGAGUGCUGAG
 CUCGAUGGCCGACGCCGUGUUGGCACGCGUGUACAAGCAGUCCGAUCUGGAUA
 CCCUGGCCAAAGAAGCUUCCAUCCCGAUCAUUAACGGGCUGAGCGACCUCUAC
 CACCCCAUUCAAAUCCUGGCCGACUACCUGACUCUGCAAGAACACUACAGCUC

GCUGAAGGGGUUGACUCUGUCCUGGAUCGGCGACGGAAACAACAUCCUGCACU
 CCAUCAUGAUGUCGGCCGCAAAGUUCGGCAUGCAUUUGCAAGCCGCCACCCCA
 AAGGGCUACGAACCAGACGCGAGCGUCACCAAGCUGGCCGAACAGUACGCGAA
 GGAAAAUGGUACUAAGCUGCUGCUGACCAACGACCCAUUGGAAGCUGCCCAUG
 GUGGAAACGUGCUGAUCACCGACACCUGGAUCUCGAUGGGCCAGGAAGAGGA
 GAAGAAGAAGCGGCUGCAGGCGUUCAGGGGUUAUCAGGUCACCAUGAAAACA
 GCCAAAGUGGCAGCGUCAGACUGGACCUUCCUCCACUGUCUGCCUCGCAAGCC
 AGAGGAGGUGGACGACGAGGUGUUCUACUCCCCUCGGUCCUCUGUGUCCCCUG
 AGGCUGAGAACCGGAAGUGGACCAUUAUGGCCGUGAUGGUGUCACUCCUGAC
 UGAUUACUCCCCGCAACUGCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
 UAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAAUUGUAG
 CCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM568 (SEQ ID NO: 31)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUUAACCUGAGGAUCCUA
 UUGAACAAUGCUGCUUUUCGUAAUGGCCAUAAACUUUAUGGUUCGGAACUUUA
 GAUGCGGGCAGCCACUGCAGAACAAGGUCCAGUUGAAAGGCCGCGAUCUGUUG
 ACAUUGAAGAACUUUACCGGCGAAGAGAUUAAGUAUAUGCUGUGGCUGUCUG
 CUGACCUCAAGUUUCGAAUCAAGCAGAAGGGCGAAUAUCUCCCCCUGCUGCAA
 GGAAAGUCUCUCGGCAUGAUCUUUGAGAAGCGGAGUACCCGAACACGGCUGA
 GCACCGAAACGGGCUUCGCACUGCUGGGGGGCCAUCCCUGUUUUCUGACAACG
 CAGGACAUCCACUUGGGGGUUAAACGAAUCAUUGACUGAUACCGCCCGCGUACU
 GUCAUCCAUGGCCGACGCUGUGCUGGCUAGGGUGUACAAGCAGUCAGAUCUGG
 AUACACUGGCCAAGGAAGCUAGCAUACCAAUCAUCAUUGGACUGAGUGACCUU
 UAUCACCCGAUUCAAAUAUCUAGCCGAUUAUCUGACCCUGCAAGAGCAUUAUCU
 CUCGCUGAAAGGCCUCACGCUGUCCUGGAUCGGCGACGGCAACAACAUUCUGC
 AUAGUAUUAUGAUGUCUGCUGCCAAAUUCGGCAUGCAUCUGCAAGCUGCUAC
 GCCGAAGGGUUAUGAACCCGACGCGUCAGUUAACGAAGCUCGCUGAGCAGUAUG
 CAAAGGAGAAUGGCACAAAGCUGUUGCUUACCAACGAUCCCCUGGAAGCUGCU
 CAUGGCGGCAAUUGUGCUGAUUACUGACACCUGGAUUUCAUUGGGCCAGGAGG
 AGGAGAAGAAGAAGAGGUUACAGGCUUUUCAAGGUUACCAAGUCACGAUGAA
 AACCGCUAAGGUCGCAGCCAGCGACUGGACAUUCCUGCACUGUCUGCCAAGAA
 AGCCGGAAGAAGUGGACGACGAGGUGUUCUAUUCGCCGCGGUCUUUGGUGUU
 UCCGGAGGCCGAAAACAGGAAUUGGACCAUUAUGGCCGUGAUGGUUAUCGUUG
 CUGACGGACUACAGCCCUCAGUUGCAAAAGCCCAAGUUCUAGCUCGAGCUAGU
 GACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGA
 GUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAA
 UGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM569 (SEQ ID NO: 32)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUCUUUAACCUCCGCAUCCUC
 CUCAACAACGCCGCCUUCGGAUUGGGCAUAAACUUAUGGUCCGGAACUUCAG
 AUGCGGCCAGCCCCUGCAAAACAAGGUCCAGUUGAAGGGACGGGACCUCCUUA
 CGCUGAAGAACUUUACCGGAGAAGAGAUUAAGUACAUGCUGUGGUUGUCCGC
 UGACCUCAAGUUCGCAUUAAGCAGAAGGGAGAAUAUCUGCCGCGUCUGCAAG

GAAAGAGCCUGGGCAUGAUCUUCGAAAAGCGCUCCACUAGAACCCGGCUGUCG
 ACUGAGACUGGAUUCGCCUUGCUCGGUGGACACCCGUGCUUCCUGACGACCCA
 GGACAUCCACCUGGGAGUGAACGAGUCACUACGGAUACCGCGAGGGUGCUGU
 CCUCA AUGGCCGACGCAGUGCUCGCGCGGUGUACAAGCAGUCAGAUUCUGGAU
 ACCCUGGCCAAGGAAGCCAGCAUUCCTCAUCAACGGACUGAGCGACCUUUA
 CCACCCAAUCCAGAUCUCGCCGACUACUUAACCCUGCAAGAGCACUACAGCU
 CCCUGAAGGGACUGACUCUGUCCUGGAUCGGGGAUGGAAACAACAUCCUGCAC
 UCCAUCAUGAUGUCUGCCGCUAAGUUUGGGAUGCAUCUGCAAGCCGCAACCCC
 UAAGGGAUACGAGCCCGACGCCUCGGUGACCAAAACUUGCGGAACAGUACGCCA
 AGGAAAACGGUACCAAGCUGCUGCUGACCAACGACCCUCUGGAAGCGGCCAC
 GGAGGAAAUGUGCUGAUUACCGACACCUGGAUUUCGAUGGGCCAGGAGGAGG
 AGAAGAAGAAGAGACUGCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAAC
 CGCCAAGGUCGCCGCCAGCGACUGGACCUUCCUGCACUGUCUCCUCGGAAAC
 CGGAAGAAGUGGAUGACGAGGUGUUCUACUCCCCGCGCUCGCGUGGUGUUCGCG
 GAGGCUGAAAACAGGAAGUGGACAAUCAUGGCCGUGAUGGUGUCCUCUGUUGA
 CCGACUACUCCCCACAACUGCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM570 (SEQ ID NO: 33)

UCAACACAACAUUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUGCGCAUCCUC
 CUGAACAAACGCCGCCUCCGCAAUGGACACAACUUUAUGGUCCGCAACUCCG
 CUGUGGGCAGCCGCGUCGAGAACAAGGUCCAGCUCAAGGGGAGAGAUUCUCUGA
 CCCUGAAGAACUUCACUGGAGAGGAGAUCAAGUACAUGCUGUGGCUGUCCGCC
 GACCUGAAAUUUCGGAUUAAGCAGAAGGGCGAAUACCUCACUGCUGCAAGG
 AAAGUCUUUGGGCAUGAUCUUCGAAAAGAGAAGCACCCGGACCCGGUUGAGC
 ACCGAAACUGGGUUCGCGCUCCUCGGUGGACACCCGUGCUUCCUGACCACCCA
 AGAUAUUCAUCUGGGUGUCAACGAAAGCCUGACCGACACCGCCAGGGUGCUGU
 CAUCCAUGGCUGACGCAGUGCUCGCCCGGGUGUACAAGCAGUCAGACCUGGAC
 ACCCUCGCCAAGGAAGCUUCGAUCCCUAUCAUCAACGGACUUUCCGACCUGUA
 CCACCCCAUCCAAAUUCUGGCCGACUACCUGACUCUGCAAGAACACUAUAGCU
 CGCUGAAAGGACUACUCUGUCCUGGAUCGGGGACGGCAACAACAUUCUCCA
 UCCAUCAUGAUGUCCGUGCCAAGUUCGGAUUGCACCUCUAGCAGCGACUCC
 CAAGGGAUACGAACCUGAUGCCUCCGUGACUAAAGCUGGCAGAGCAGUACGCCA
 AGGAGAACGGUACAAAGCUGCUGCUCACGAACGACCCCCUGGAGGCGGCCAC
 GGCGGAAACGUGCUGAUUACCGAUACCUGGAUCUCAUUGGGCCAGGAAGAGG
 AGAAGAAGAAGCGGCUCACAGGCGUUUCAAGGCUACCAGGUCACCAUGAAAACC
 GCGAAGGUCGCCGCCUCCGACUGGACUUUCUUGCACUGCCUGCCGCGGAAGCC
 CGAGGAAGUGGAUGACGAAGUGUUCUACUCGCCGAGAUUCGUUGGUGUCCCU
 GAGGCCGAAAACAGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCUCUGCUGAC
 UGAUUACAGCCCACAGCUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
 UAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUAG
 CCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM571 (SEQ ID NO: 34)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAUGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
 GAAGGGUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAAAC
 CGCCAAGGUCGCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCCCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM572 (SEQ ID NO: 35)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAAUUCUCCGCAUCCUC
 CUGAACAACGCCGCGUUUCCGCAAUGGUCUAUACUUCUUGGUCCGCAACUUCG
 CUGCGGACAGCCUCUCCAAAACAAGGUCCAGCUCUAGGGGCGCGACCUCCUCA
 CACUGAAGAACUUCACUGGAGAAGAAAUCAAGUACAUGCUGUGGCUGAGCGC
 CGAUCUGAAGUUCGGGAUCAAGCAGAAGGGAGAGUACCUUCCUCUGCUGCAAG
 GGAAGUCCUUGGGAAUGAUUUUCGAGAAGCGGUCCACCCGGACAGGCUGAGC
 ACUGAAACUGGCUUCGCCUGCUGGGAGGCCACCCUUGUUUCCUGACCACUCA
 GGACAUCCACCUGGGCGUGAACGAGUCCUGACCGAUACUGCCAGAGUGCUGU
 CCUCCAUGGCCGACGCCGUGCUCGCCCGGGUGUACAAGCAGUCAGACCUCGAU
 ACGCUGGCCAAGGAAGCCUCCAUAUCCCAUUAUCAUUGGUCUGUCGGACCUCUA
 CCAUCCAAUCCAAAUCCUCGCCGACUACCUGACUCUGCAAGAACACUACAGCU
 CACUCAAGGGCCUCACCCUCUCCUGGAUCGGCGACGGAAACAACAUCCUUCAC
 UCGAUUAUGAUGUCGGCCGCGAAGUUCGGGAUGCACCUCUCCAGCUGCCACUCC
 AAAAGGCUACGAGCCGGAUGCCUCAGUGACUAAGUUGGCGGAACAGUAUGCG
 AAGGAGAACGGUACCAAGCUCCUGCUGACUAACGACCCCGCUGGAGGCCGCCCA
 CGGGGGAAACGUGCUCAUACCGAUACUUGGAUUUCCAUGGGACAGGAGGAA
 GAGAAGAAGAAGCGGUUGCAGGCAUUUCAGGGCUACCAGGUCACCAUGAAAA
 CUGCCAAAGUCGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAG
 CCUGAAGAAGUGGACGACGAGGUGUUCUACUCUCCCCGGUCCUCGUGUUCUCC
 UGAGGCCGAAAACAGGAAGUGGACCAUCAUGGCUGUGAUGGUGUCCUCCUG

ACCGACUACAGCCCUCAGCUCCAAAAACCCAAGUUUUAGCUCGAGCUAGUGAC
 UGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUC
 UCUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGU
 AGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM573 (SEQ ID NO: 36)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAACCUGAGAAUCCUC
 UUGAACAAUGCUGCUUUUCGGAAUGGCCACAACUUUAUGGUUCGGAACUCC
 GUUGCGGCCAGCCUUUACAAAACAAGGUCCAGCUGAAGGGCCGGGAUUUGCUC
 ACACUGAAGAACUUUACUGGGGAGGAGAUUAAGUAUAUGCUGUGGCUGUCCG
 CUGACCUGAAGUUUAGGAUCAAGCAGAAGGGCGAAUAUCUGCCGCUGCUGCA
 AGGGAAAAGUCUGGGCAUGAUUUUUGAAAAGCGCUCUACCCGGACCAGACUG
 UCUACGGAAACAGGCUUUGCCCUGCUGGGCGGCCACCCUGUUUUCUGACAAC
 GCAGGACAUCUACUGGGCGUGAACGAAUCACUGACCGAUACUGCUCGGGUAC
 UCAGUUCUAUGGCUGACGCAGUGCUGGCUAGGGUGUACAAGCAGAGCGACUU
 GGACACACUGGCUAAGGAGGCCAGCAUCCCCAUUAUCAUAGGCCUGUCUGAUU
 UGUACCAUCCCAUUCAAAUCCUGGCUGAUUAUCUGACACUACAAGAGCAUUAAC
 UCAAGUCUGAAGGGUUUGACUCUCUCCUGGAUCGGCGACGGCAACAACAUUUU
 ACAUUCCAUAUAUGAUGAGUGCUGCUAAGUUUGGCAUGCAUUUGCAAGCUGCU
 ACCCCAAAGGGCUAUGAACCGACGCUAGCGUAACCAAGUUGGCCGAACAGUA
 UGCUAAAGAGAAUGGCACCAAGCUGCUCUCCUGACGAAUGACCCCCUGGAAGCUG
 CUCAUGGCGGAAACGUACUUAUAACUGAUACAUGGAUUAGCAUGGGGCCAGGA
 AGAGGAGAAGAAGAAGAGACUGCAGGCCUCCAAGGCUAUCAGGUCACCAUG
 AAAACUGCCAAGGUUGCAGCUAGCGACUGGACCUUCCUGCACUGUUUGCCGAG
 GAAACCCGAGGAGGUGGACGAUGAAGUCUUUUUAUUCUCCCCGCUCUUGGUGU
 UUCCCGAGGCUGAAAAUCGAAAGUGGACGAUAAUGGCAGUGAUGGUGUCCCU
 ACUGACCGACUAUUCUCCACAACUGCAGAAGCCUAAAUUCUAGCUCGAGCUAG
 UGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGG
 AGUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAA
 AUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUA
 G

>mARM574 (SEQ ID NO: 37)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUGAGGAUCCUG
 CUGAACAAACGCUGCUUUUCGCAACGGUCAUAACUUUAUGGUUCGCAAUUUUCG
 UUGUGGCCAGCCGUGCAGAACAAGGUUCAGCUGAAGGGCAGAGAUCUGCUG
 ACUCUGAAGAACUUCACUGGGGAAGAAAUCAAGUAUAUGUUAUGGCUGUCCG
 CGGAUCUGAAAUUUCGAAUCAAGCAGAAGGGCGAAUAUCUUCUCCUGCUGCAA
 GGGAAAUCCUUGGGCAUGAUUUUUGAGAAGAGGAGCACUAGGACUAGAUUGU
 CAACAGAAACAGGCUUUGCUUUGUUGGGCGGACAUCCUGCUUUCUGACGACA
 CAGGAUAUCCACCUCGGCGUAAACGAGUCCUCACCGACACUGCUAGGGUACU
 GAGCAGCAUGGCCGACGCUGUGCUAGCCCAGGUUUACAAGCAGUCAGACCUGG
 ACACCCUUGCCAAGGAAGCUUCUAUCCAUAUAUCAACGGCCUGAGUGACCUG
 UAUCACCCUAUUCAAAACUCGCGGACUAUUUGACGCUUCAAGAACAUUACAG
 CAGCCUCAAGGGCUUAACCUUGAGUUGGAUAGGCGACGGCAACAUAUCCUGC
 AUUCCAUAUAUGAUGUCUGCCGCUAAGUUUGGCAUGCAUCUACAAGCCGCAACA

CCCAAGGGCUAUGAACCCGACGCUAGCGUGACCAAGCUGGCCGAGCAGUAUGC
 UAAGGAAAAUGGCACAAAGCUCCUUCUUACCAACGAUCCCCUGGAGGCUGCUC
 ACGGCGGCAACGUGCUGAUUACCGAUACAUGGAUUAGCAUGGGCCAGGAGGA
 GGAGAAAAAGAAGCGGCUCACAGGCUUUUCAAGGCUAUCAGGUCACCAUGAAA
 ACUGCAAAGGUCGCGUGCCUCCGACUGGACUUUCCUGCAUUGUCUACCCCGCAA
 GCCUGAGGAAGUGGACGAUGAGGUGUUCUACUCCCCACGGAGUCUGGUGUUC
 CGGAAGCAGAGAAUCGGAAGUGGACCAUCAUGGCUGUCAUGGUGUCGCUCUU
 GACUGACUAUUCUCCCCAACUGCAAAAACCCAAGUUUUAGCUCGAGCUAGUGA
 CUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGU
 CUCUAAGCUACAUAUACCAACUUAACACUUACAAAAUGUUGUCCCCCAAAUG
 UAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM575 (SEQ ID NO: 38)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGUUAUUAACCUUCGUAUCCUG
 CUAACAAUUGCUGCUUUUCGCAAUGGCCAUAAACUUUAUGGUUCGCAACUUUA
 GAUGCGGCCAGCCGCGUGCAGAACAAAGGUUCAGCUGAAGGGCCGGGACUUGCUG
 ACGCUGAAAAACUUUACCGGGGAAGAGAUUAAGUAUAUGCUGUGGCUAAGCG
 CUGAUCUGAAGUUUAGGAUCAAGCAGAAGGGCGAAUAUCUGCCACUGCUGCA
 AGGGAAGAGUCUUGGCAUGAUUUUUGAAAAGCGGUCUACCAGAACCCGGCUG
 UCGACCGAGACAGGUUUUGCUCUGCUGGGGGGCCAUCCUGUUUUCUGACAAC
 UCAGGACAUUCACCUGGGCGUGAAUGAGUCCUGACCGAUACUGCUAGGGUGU
 UGAGUAGCAUGGCCGACGCGUACUCGCGUCGAGUGUAUAAGCAGUCUGAUCU
 GGACACUCUGGCUAAGGAAGCUUCCAUUCUUAUUAACGGCUUGAGCGACC
 UGUACCACCCCAUUCAAAUCCUCGCGUAUACUUGACUUUGCAAGAACAUUAC
 AGCAGCUUGAAGGGCUUAACACUGAGCUGGAUAGGCGACGGAAACAACAUCU
 UGCAUUCCAUAUAUGAUGUCCGCCGCUAAGUUCGGGAUGCACCUCCAAGCAGCC
 ACACCCAAGGGCUAUGAACCGGAUGCUUCCGUGACAAAACUGGCUGAGCAGUA
 UGCUAAGGAGAAUGGCACGAAACUGCUGCUCACCAACGACCCAUUGGAAGCUG
 CACAUUGGUGGCAACGUACUGAUCACUGACACUUGGAUCUCAUUGGGCCAGGAG
 GAAGAGAAGAAGAAAAGGCUGCAGGCAUUUCAGGGAUACCAAGUCACUAUGA
 AAACUGCCAAGGUCGCGUGCCUCCGACUGGACAUUCUGCAUUGUCUGCCACGG
 AAGCCUGAGGAAGUCGAUGACGAAGUGUUCUAUAGCCCACGAAGCUUGGUGU
 UCCCCGAGGCUGAGAAUAGGAAGUGGACCAUUAUGGCUGUUAUGGUGUCCCU
 GCUCACCGACUAUUCUUUUAACUGCAAAAACCCAAGUUUUAGCUCGAGCUAG
 UGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGG
 AGUCUCUAAGCUACAUAUACCAACUUAACACUUACAAAAUGUUGUCCCCAAA
 AUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUA
 G

>mARM708 (SEQ ID NO: 39)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCAUUCUUUUAUUCUCCGCAUCCUCCUU
 AACAAACGCCGCGUUUAGAAACGGCCACAACUUCUUGGUCCGGAACUUCAGAUG
 UGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGACCC
 UGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCGGAC
 UUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAGGAA
 AGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCUACU

GAAACUGGGUUCGCGCUGCUCGGUGGCCACCCCUGCUUCCUGACGACCCAGGA
 CAUCCACCUCGGAGUGAACGAAUCCCUCACCGAUACCGCCCCGGGUGUUAUCGA
 GCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGACACU
 CUGGCCAAGGAGGCGUCAAUUCCCAUCAUCAACGGCCUGAGCGACCUGUACCA
 CCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGCAAGAGCACUACAGCAGCC
 UGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGGAAACAAUUAUUCUGCACUC
 CAUCAUGAUGUCCGCCGCGAAGUUCGGAAUGCAUCUGCAAGCCGCCACGCCAA
 AAGGAUACGAACCGGAUGCGUCCGUGACGAAGUUGGCGGAACAGUACGCGAA
 GGAGAACGGAACCAAGCUUCUGCUGACUAAACGACCCCCUCGAGGCUGCGCAUG
 GGGGCAACGUGCUGAUUACCGACACCUGGAUCUCCAUGGGGGCAGGAGGAAGA
 GAAGAAGAAGAGACUGCAGGCAUUCAGGGGUACCAGGUCACCAUGAAAACC
 GCAAAAGUGGCAGCUUCGGACUGGACUUCUCCUGCAUUGCCUGCCGAGGAAGCC
 GGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGGUCCUGGUGUUCCTCG
 AGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCUUGCUGACU
 GACUAUAGCCCCGACGUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUGA
 CUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCU
 AAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUAGC
 CAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM709 (SEQ ID NO: 40)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCAUGCUUUUCAACCUGAGAAUCCUCUUG
 AACAAUGCUGCUUUUCGGAAUGGCCACAACUUUAUGGUUCGGAAUCCGUU
 GCGGCCAGCCUUUACAAAACAAGGUCCAGCUGAAGGGCCGGGAUUUGCUCACA
 CUGAAGAACUUUACUGGAGAAGAGAUCAAGUACAUGCUGUGGCUGUCGGCCG
 ACCUGAAGUUCAGGAUCAAGCAGAAGGGAGAAUACCUUCCGCUGCUUCAAGG
 AAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCUA
 CUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCCUGCUUCCUGACGACCCAG
 GACAUCCACCUCGGAGUGAACGAUCCUCACCGAUACCGCCCCGGGUGUUAUC
 GAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUCGAUA
 CCUUGGCAAAGGAGGCUUCCAUUCCTCAUCAUACGGCCUGAGCGACCUGUAC
 CACCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGCAAGAGCACUACAGCAG
 CCUGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGGAAACAAUUAUUCUGCAC
 UCCAUCAUGAUGUCCGCCGCGAAGUUCGGAAUGCAUCUGCAAGCCGCCACUCC
 AAAAGGAUACGAACCGGAUGCGUCCGUGACCAAGUUGGCGGAACAGUACGCG
 AAGGAGAACGGAACCAAGCUUCUGCUGACUAAACGACCCCCUCGAGGCUGCGCA
 UGGGGGCAACGUGCUGAUUACCGACACCUGGAUCUCCAUGGGGGCAGGAGGAA
 GAGAAGAAGAAGAGACUGCAGGCAUUCAGGGGUACCAGGUCACCAUGAAAA
 CCGCAAAAGUGGCAGCUUCGGACUGGACUUUCCUGCAUUGCCUGCCGAGGAAG
 CCGGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGGUCCUGGUGUUCCT
 CGAGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCUUGCUGA
 CUGACUAUAGCCCCGACGUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM710 (SEQ ID NO: 41)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAGCAAAAGCAAUUUUCUGAAA

AUUUUCACCAUUUACGAACGAUAGCCAUGCUUUUCAACCUGAGAAUCCUCUUG
 AACAAUGCUGCUUUUCGGAUUGGCCACAACUUUAUGGUUCGGAACUUCGGUU
 GCGGCCAGCCUUUACAAAACAAGGUCCAGCUGAAGGGCCGGGAUUUGCUCACA
 CUAAAGAACUUUACUGGAGAAGAGAUCAAGUACAUGCUAUGGCUGUCGGCCG
 ACCUGAAGUUCGUAUCAAGCAGAAGGGAGAAUACCUUCCGCUGCUUCAAGGA
 AAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCUAC
 UGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCAGG
 ACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAUCG
 AGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUCGAUAC
 CUUGGCAAAGGAGGCUUCCA AUUCCAUCAUCAACGGCCUGAGCGACCUGUACC
 ACCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGCAAGAGCACUACAGCAGC
 CUGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGGAAACAAU AUUCUGCACU
 CCAUCAUGAUGUCCGCCGCGAAGUUCGGAUUGCAUCUGCAAGCCGCCACUCCA
 AAAGGAUACGAACCGGAUGCAUCCGUGACCAAGUUGGCGGAACAGUACGCGA
 AGGAGAACGGAACCAAGCUCCUGCUGACUAACGACCCGCUCGAGGCUGCGCAU
 GGGGGUAACGUGCUGAUUACGGACACCUGGAUCUCCAUGGGGGCAGGAGGAAG
 AGAAGAAGAAGAGACUGCAGGCAUUCAGGGGUACCAGGUCACCAUGAAAAC
 CGCAAAAGUGGCAGCUUCGGACUGGACUUUCCUGCAUUGCCUGCCGAGGAAGC
 CGGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGGUCCCUGGUGUUCCCC
 GAGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCUUGCUGAC
 UGACUAUAGCCCGCAGCUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
 UAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAAUGUAG
 CCAUUCGU AUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM711 (SEQ ID NO: 42)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCAUGCUUUUCAACCUGAGAAUCCUCUUG
 AACAAUGCUGCUUUUCGGAUUGGCCACAACUUUAUGGUUCGGAACUUCGGUU
 GCGGCCAGCCUUUACAAAACAAGGUCCAGCUGAAGGGCCGGGAUUUGCUCACA
 CUAAAGAACUUUACUGGAGAAGAGAUCAAGUACAUGCUAUGGCUGUCGGCCG
 ACCUGAAGUUCGUAUCAAGCAGAAGGGAGAAUACCUUCCGCUGCUUCAAGGA
 AAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCUAC
 UGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCAGG
 ACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAUCG
 AGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUCGAUAC
 CUUGGCAAAGGAGGCUUCCA AUUCCAUCAUCAACGGCCUGAGCGACCUGUACC
 ACCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGCAAGAGCACUACAGCAGC
 CUGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGGAAACAAU AUUCUGCACU
 CCAUCAUGAUGUCCGCCGCGAAGUUCGGAUUGCAUCUGCAAGCCGCCACUCCA
 AAAGGAUACGAACCGGAUGCGUCCGUGACCAAGUUGGCGGAACAGUACGCGA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCCCUCGAGGCUGCGCAU
 GGGGGCAACGUGCUGAUUACCGACACCUGGAUCUCCAUGGGGGCAGGAGGAAG
 AGAAGAAGAAGAGACUGCAGGCAUUCAGGGGUACCAGGUCACCAUGAAAAC
 CGCAAAAGUGGCAGCUUCGGACUGGACUUUCCUGCAUUGCCUGCCGAGGAAGC
 CGGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGGUCCCUGGUGUUCCCC
 GAGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCUUGCUGAC
 UGACUAUAGCCCGCAGCUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC

UAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAUUGUAG
CCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUAG

>mARM712 (SEQ ID NO: 43)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUAACCUGCGAAUCCUG
CUGAACAAACGCCGCUUUUCGGAACGGGCACAACUUUAUGGUGAGGAACUUUCG
CUGCGGACAGCCCCUCCAGAAUAAGGUCCAGCUGAAGGGCAGGGACCUGCUGA
CCCUGAAAAAUUUCACAGGGGAGGAAUCAAAGUAUAUGCUGUGGCUGUCAGC
UGAUCUGAAGUUCGGAUCAAGCAGAAGGGCGAAUAUCUGCCUCUGCUCCAGG
GCAAAAGCCUGGGGAUGAUCUUCGAAAAGCGCAGUACUCGGACCAGACUGUCA
ACCGAGACUGGAUUCGCUCUGCUGGGAGGACACCCUUGUUUUCUGACCACUCA
GGACAUUCACCUGGGAGUGAACGAGUCCUGACCGACACUGCUCGCGUCCUGA
GCUCUAUGGCCGACGCUGUGCUGGCUCGAGUCUACAAACAGUCCGACCUGGAU
ACCCUGGCCAAGGAAGCUUCUAUCCCAAUUUAUUAACGGCCUGUCAGACCUGUA
UCACCCCAUCCAGAUUCUGGGCCGAUUACCUGACCCUCCAGGAGCACUAUUCUA
GUCUGAAAGGGCUGACACUGAGUUGGAUUGGGGACGGAAACAUAUCCUGCA
CUCUAUUUAUGAUGUCAGCCGCCAAGUUUGGAAUGCACCUCAGGCUGCAACCC
CAAAAGGCUACGAACCCGAUGCCUCAGUGACAAAGCUGGCUGAACAGUACGCC
AAAGAGAACGGCACUAAGCUGCUGCUGACCAACGACCCUCUGGAGGCCGCUCA
CGGAGGCAACGUGCUGAUCACCGAUACCUGGAUUAGUAUGGGACAGGAGGAA
GAGAAGAAGAAGCGGCUCAGGCCUCCAGGGCUACCAGGUGACAAUGAAAAC
CGCUAAGGUCGCAGCCAGCGAUUGGACCUUUCUGCACUGCCUGCCCAGAAAGC
CCGAAGAGGUGGACGACGAGGUCUUCUACUCUCCAGAAAGCCUGGUGUUUCC
GAAGCUGAGAAUAGGAAGUGGACAAUUAUGGCAGUGAUGGUCAGCCUGCUGA
CUGAUUAUUCACCUCAGCUCAGAAACCAAGUUCUGAUAAACUCGAGCUAGUG
ACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAG
UCUCUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAU
GUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUAG

>mARM713 (SEQ ID NO: 44)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUAACCUGCGCAUCCUG
CUGAACAAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGCGCAACUCCG
CUGCGGCCAGCCCCUGCAGAACAAAGGUGCAGCUGAAGGGCCGCGACCUGCUGA
CCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGCC
GACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGGG
CAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCAACCCGCCUGAGCA
CCGAGACAGGCCUGGCCUGCUGGGCGGCCACCCUGCUUCCUGACCACCCAG
GACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCGUGCUGAG
CAGCAUGGCCGACGCCGUGCUGGGCCGCGUGUACAAGCAGAGCGACCUGGACA
CCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUAC
CACCCCAUCCAGAUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACAGCAG
CCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGCACA
GCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCCC
AAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCAA
GGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCACG
GCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGAG

AAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGACCGC
 CAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCCG
 AGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUUCGGAG
 GCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACCGA
 CUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAUAAACUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
 UAAGCUACAUAUACCAACUUACACUUACAAAAUGUUGUCCCCCAAAUGUAG
 CCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUAG

>mARM714 (SEQ ID NO: 45)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUCAACCUGCGAAUCCUG
 CUGAACAAACGCCGCUUUUCGGAACGGGCACAAUUUAUGGUGAGGAACUUUCG
 CUGCGGACAGCCCCUCCAGAAUAAGGUCCAGCUGAAGGGCAGGGACCUGCUGA
 CCCUGAAAAAUUUCACAGGGGAGGAAAUCAAGUAUAUGCUGUGGCUGUCAGC
 UGAUCUGAAGUUCGGAUCAAGCAGAAGGGCGAAUAUCUGCCUCUGCUCCAGG
 GCAAAAGCCUGGGGAUGAUCUUCGAAAAGCGCAGUACUCGGACCAGACUGUCA
 ACCGAGACUGGAUUCGCUCUGCUGGGAGGACACCCUUGUUUUCUGACCACUCA
 GGACAUUCACCUGGGAGUGAACGAGUCCUGACCGACACUGCUCGCGUCCUGA
 GCUCUAUGGCCGACGCUGUGCUAGCUCGAGUCUACAAACAGUCCGACCUGGAU
 ACCCUGGCCAAGGAAGCUUCUAUCCCAAUUUAUUAACGGCCUGUCAGACCUGUA
 UCACCCCAUCCAGAUUCUGGCCGAUUACCUGACCCUCCAGGAGCACUAUUCUA
 GUCUGAAAGGGCUGACACUGAGUUGGAUUGGGGACGGAAACAAUAUCCUGCA
 CUCUAUUUAUGAUGUCAGCCGCCAAGUUUGGAAUGCACCUCAGGCUGCAACCC
 CAAAAGGCUACGAACCCGAUGCCUCAGUGACAAAGCUGGCUGAACAGUACGCC
 AAAGAGAACGGCACUAAGCUGCUGCUGACCAACGACCCUCUGGAGGCCGCUCA
 CGGAGGCAACGUGCUGAUCACCGAUACCUGGAUUAGUAUGGGACAGGAGGAA
 GAGAAGAAGAAGCGGCUCAGGCCUUCAGGGCUACCAGGUGACAAUGAAAAC
 CGCUAAGGUCGCAGCCAGCGAUUGGACCUUUCUGCACUGCCUGCCCAGAAAGC
 CCGAAGAGGUGGACGACGAGGUCUUCUACUCUCCAGAAAGCCUGGUGUUUCC
 GAAGCUGAGAAUAGGAAGUGGACAAUUAUGGCAGUGAUGGUCAGCCUGCUGA
 CUGAUUAUUCACCUCAGCUCAGAAACCAAGUUCUGAUAAACUCGAGCUAGUG
 ACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAG
 UCUCUAAGCUACAUAUACCAACUUACACUUACAAAAUGUUGUCCCCCAAAU
 GUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUAG

>mARM715 (SEQ ID NO: 46)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUCAACCUGCGAAUCCUG
 CUGAACAAUGCCGCUUUUCGGAACGGGCACAAUUUCAUGGUGAGGAACUUUC
 GCUGCGGACAGCCCCUCCAGAACAAAGGUCCAGCUGAAGGGCAGGGACCUGCUG
 ACCCUGAAAAAUUUCACAGGGGAGGAAAUCAAGUACAUGCUGUGGCUGUCAG
 CCGAUCUGAAGUUCGGAUCAAGCAGAAGGGCGAAUAUCUGCCUCUGCUCCAG
 GGCAAAAGCCUGGGGAUGAUCUUCGAAAAGCGCAGUACUCGGACCAGACUGUC
 AACAGAGACUGGAUUCGCACUGCUGGGAGGACACCCAUGUUUUCUGACCACAC
 AGGACAUUCAUCUGGGAGUGAACGAGUCCUGACCGACACAGCACGCGUCCUG
 AGCUCCAUGGCUGAUGCAGUGCUGGCUCGAGUCUACAAACAGUCUGACCUGGA
 UACCCUGGCCAAGGAAGCUUCUAUCCCAAUCAUUAUUGGCCUGAGUGACCUGU

AUCACCCCAUCCAGAUUCUGGCCGAUUACCUGACCCUCCAGGAGCAUUAUUCU
 AGUCUGAAAGGGCUGACACUGAGCUGGAUUGGGGACGGAAACAAUAUCCUGC
 ACUCCAUAUUGAUGAGCGCCGCCAAGUUUGGAAUGCACCUCAGGCUGCAACC
 CAAAAGGCUACGAACCCGAUGCCUCCGUGACAAAGCUGGCAGAACAGUAUGC
 CAAAGAGAACGGCACUAAGCUGCUGCUGACCAAUGACCCUCUGGAGGCCGCUC
 ACGGAGGCAACGUGCUGAUCACUGAUACCUGGAUUAGUAUGGGACAGGAGGA
 AGAGAAGAAGAAGCGGCUCCAGGCCUCCAGGGCUACCAGGUGACAAUGAAA
 ACUGCUAAGGUCGCAGCCAGCGACUGGACCUUUCUGCAUUGCCUGCCCAGAAA
 GCCUGAAGAGGUGGACGAUGAGGUCUUCUACUCACCCAGAAGCCUGGUGUUUC
 CUGAAGCUGAGAAUAGGAAGUGGACAAUCAUGGCAGUGAUGGUCAGCCUGCU
 GACUGAUUAUUCUCCUCAGCUCCAGAAACCAAAGUUCUGAUAAUCUGAGCUAG
 UGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGG
 AGUCUCUAAGCUACAUAUACCAACUUAACUUACAAAAUGUUGUCCCCCAA
 AUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUA
 G

>mARM716 (SEQ ID NO: 47)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAACCUUCGCAUUCUC
 CUCAACAACGCCGCGUUUAGAAACGGACACAACUUCAUGGUCCGCAACUCCG
 CUGCGGACAGCCGCGUGCAGAACAAGGUCCAGCUCAAGGGUCGGGAUCUCCUGA
 CGCUGAAGAACUUUACCGGCGAAGAGAUUAAGUACAUGCUGUGGCUGUCCGCC
 GACCUUAAGUUCGGGAUCAAGCAGAAGGGCGAAUACCUUCCCCUGCUGCAAGG
 AAAGUCCCUGGGCAUGAUCUUCGAGAAGCGCAGUACCAGAACCAGACUCUCCA
 CUGAAACCGGGUUCGCGCUGCUUGGCGGCCACCCGUGUUUCCUCACUACGCAA
 GACAUCCAUCUUGGCGUGAACGAGUCCCUUACCGACACCGCCAGGGUGCUGUC
 AAGCAUGGCCGACGCCGUCCUUGCGCGCGUGUACAAGCAGUCAGACCUUGAUA
 CUCUGGCCAAGGAAGCCUCCAUCCCUAUUAUCAACGGCCUAUCCGACCUUUAC
 CACCCGAUCCAGAUCCUCGCUGACUACCUGACCCUGCAAGAACACUACAGCAG
 CCUCAAGGGACUGACUCUGUCCUGGAUCGGCGACGGGAACAACAUCCUGCACU
 CAAUCAUGAUGAGCGCAGCCAAGUUCGGCAUGCAUCUCCAAGCCGCUACACCC
 AAGGGUUAUGAACCGGACGCCUCUGUGACCAAGUUGGCAGAACAGUACGCCAA
 GGAGAACGGUACUAAGCUCCUUUUAACCAACGACCCCCUCGAAGCAGCCCAUG
 GCGGGAAUGUGCUCAUUAACGAUACCUGGAUUUCGAUGGGGCCAGGAGGAGGA
 GAAGAAGAAGCGGCUGCAGGCGUCCAGGGCUACCAGGUCACCAUGAAAACUG
 CCAAAGUGGCCGCCUCGGAUUGGACCUUUCUCCACUGCCUGCCUCGGAAGCCU
 GAGGAGGUGGACGACGAAGUGUUCUACUCCCCACGGUCCUCUGUUGUCCCCGA
 GGCCGAAAAUAGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCCUUUGACCG
 AUUACAGCCCGCAGCUUCAGAAGCCUAAAUUCUAGCUCGAGCUAGUGACUGAC
 UAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUA
 AGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAUAGCC
 AUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM717 (SEQ ID NO: 48)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUUCGCAUCCUG
 UUGAACAACGCCGCCUCCGCAAUGGUCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGACAGCCUCUCCAAAACAAGGUCCAGCUGAAGGGAAGGGACCUCUUA

CCCUCAAAAACUUUACUGGAGAGGAGAUC AAGUACAUGCUGUGGCUUAGCGCC
 GACCUUAAGUUCCGGAUCAAGCAGAAGGGAGAGUACCUC CCGCUGCUGCAAGG
 AAAGAGUCUUGGAAUGAUCUUCGAGAAGCGGUCCACCAGAACUCGCCUCUCCA
 CUGAAACCGGAUUCGCACUCCUGGGUGGACACCCGUGCUUUCUGACCACCCAA
 GACAUCCACCUCGGAGUGAACGAGAGCCUCACGGACACCGCGAGAGUGCUGUC
 AUCCAUGGCCGACGCCGUGCUUGCACGGGUCUACAAGCAGUCCGAUCUGGACA
 CUCUUGCCAAGGAAGCCUCCAUUCUUAUCAUUAACGGUCUGUCGGAUCUGUAC
 CACCCGAUUCAGAUCUUGCGGACUACCUCACACUUCAAGAACACUAUUCAAG
 CCUAAAGGGUCUGACCCUGUCCUGGAUCGGAGAUGGAAACAACAUUCUCCAUI
 CCAUCAUGAUGAGCGCUGCCAAGUUCGGAAUGCAUCUCCAAGCAGCGACUCCU
 AAGGGUUAACGAGCCGGACGCCUCAGUGACUAAGCUGGCCGAGCAGUACGCCAA
 GGAGAACGGUACCAAACUGUUGCUUACUAACGACCCGCUUGAAGCGGCCCAUG
 GAGGAAACGUGCUGAUUACCGACACCUGGAUUCGAUGGGGACAGGAAGAGGA
 GAAGAAGAAGCGGCUCCAGGCGUCCAGGGAUACCAGGUCACCAUGAAAACGG
 CCAAAGUGGCCCGCUAGCGAUUGGACCUUUCUGCACUGCCUCCCGCGCAAGCCU
 GAAGAAGUGGACGACGAAGUGUUCUACUCCCCUCGCUCUCUUGUGUCCCCGGA
 AGCCGAAAACAGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCCUCCUGACCG
 AUUACAGCCCGCAGCUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUGAC
 UAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUA
 AGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAAUGUAGCC
 AUUCGUAUCUGCUCCUAAUAAAAGAAAGUUUCUUCACAUUCUAG

>mARM718 (SEQ ID NO: 49)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACU
 CUAUUGCAGCAAUUUAAAUCAUUCUUUUAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
 CUCAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAGAACAAGGUCCAGCUCAAGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCGAAGAAAUCAAGUACAUGCUCUGGCUCUCCGCC
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUGCAAG
 GAAAGUCGCUCGGCAUGAUCUUUGAGAAGCGCUCAACCCGCACCAGGCUGUCC
 ACUGAAACCGGGUUCGCGCUGCUUGGUGGCCACCCUGCUUCCUGACCACCCA
 AGACAUUCACCUCGGAGUGAACGAUUCGCUCACUGAUACUGCCCCGGGUGCUGU
 CGUCGAUGGCCGAUGCAGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCCAUCCCUAUUAUCAACGGCCUUCUCCGACCUCUA
 CCACCCGAUUCAGAUCUUGCCGAUUAACCUACCCUGCAAGAACACUACUCGU
 CACUGAAGGGUCUGACCUUGUCCUGGAUCGGCGACGGCAACAACAUCCUCCA
 UCCAUAUGAUGUCCGCCGCCAAAUUCGGCAUGCAUCUUAAGCCGCAACCCC
 UAAGGGUUAACGAGCCGGACGCUUCCGUGACCAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCCCUAGAGGCAGCCCAC
 GGGGGCAACGUGCUUAUUAACUGACACCUGGAUCUCCAUGGGACAGGAAGAAG
 AGAAGAAGAAGCGGUUACAGGCGUCCAGGGCUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGCUGCCUCGGACUGGACCUUCCUGCAUUGCCUGCCUCGCAAGC
 CCGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGUCCCUUGUGUUCUU
 GAGGCCGAGAAUAGAAAGUGGACCAUUAUGGCCGUGAUGGUGUCCCUUCUCA
 CCGACUACUCGCCGCAACUGCAGAAACCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAGAAAGUUUCUUCACAUUCUAG

>mARM719 (SEQ ID NO: 50)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAAUUCUUCGCAUCCUC
CUCAACAACGCCGCCUUCGGAACGGUCACAACUUCAUGGUCCGGAACUCCG
CUGCGGCCAGCCGCUCCAAAACAAAGUGCAGCUUAAGGGCCGCGAUCUCCUGA
CCCUGAAGAACUUCACCGGAGAGGAAAUCAAGUACAUGCUGUGGCUCUCGGCG
GACCUGAAGUUUAGGAUUUAGCAGAAGGGGGAGUAUCUGCCGCGUCUCCAAG
GGAAGUCCCUUGGCAUGAUCUUCGAAAAGAGGUCCACCCGGACUCGGCUCAGC
ACCGAAACAGGUUUUGCACUUCUGGGGGGCCACCCGUGCUUCCUGACGACCCA
GGACAUCCAUCUGGGUGUCAACGAGAGUUUGACCGACACUGCCAGAGUGCUGU
CAUCCAUGGCGGACGCGGUGCUCGCGAGAGUGUACAAGCAGUCCGAUCUUGAC
ACCCUGGCAAAGAGGGCUUCAUCCCCGAUCAUUAACGGACUCUCGGAUCUGUA
CCACCCUAUCCAAAUCUUGGCCGACUACCUGACCCUGCAAGAACACUACAGCU
CCCUGAAGGGCCUGACUCUUUCCUGGAUUGGCGAUGGAAACAACAUUCUCCA
UCUAUUUAUGAUGUCCGCCGCCAAGUUCGGCAUGCACCUCUAAAGCCGCCACCCC
GAAGGGCUACGAACCUGACGCCUCCGUGACUAAGCUAGCCGAACAGUACGCUA
AGGAGAACGGCACUAAGCUUCUCCUUAACCAACGAUCCGCGUGGAGGGCGGCCAU
GGCGGAAAUGUGCUUAUACCCGACACCUGGAUUAGCAUGGGGGCAGGAAGAAG
AGAAGAAGAAACGGCUCCAGGCAUUCAGGGCUACCAGGUCACCAUGAAAACU
GCCAAGGUCGCCGCUAGCGACUGGACCUUCCUCCACUGUCUGCCUCGCAAGCC
UGAAGAAGUGGACGACGAGGUGUUCUACUCCCCGCGCUCCUCUGUGUUUCCUG
AGGCCGAGAACAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCAUUACUUA
GGACUACAGCCCGCAGCUGCAGAAGCCGAAGUUCUAGCUCGAGCUAGUGACUG
ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
UAAGCUACAUAUUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAAUGUAG
CCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUAG

>mARM720 (SEQ ID NO: 51)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUUAACUUGAGAAUCCUU
CUGAACAACGCCGCUUUCGCAACGGUCUAUACUUCUUGGUCCGGAACUUCAG
AUGUGGCCAGCCCCUCCAAAACAAAGUGCAGCUGAAGGGCCGGGACCUUCUUA
CGCUGAAGAAUUUACCCGGCGAAGAAAUCAAGUACAUGCUCUGGCUGUCCGCC
GAUCUUAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUCGCCGUGCUGCAAGG
GAAGUCGCGUGGGCAUGAUUUUUGAGAAGCGGUCAACUCGCACCCGCCUGUCCA
CUGAAACUGGAUUCGCACUGCUCGGUGGCCAUCCCUGCUUCCUGACCACCCAA
GACAUCCACCUCGGCGUGAACGAGUCCUGACUGACACCGCCCGGGUCUUAUC
CUCGAUGGCCGAUGCUGUGCUUGCGAGGGUGUACAAGCAGUCCGACCUCGACA
CACUCGCGAAGGAGGCCUCCAUCCCCAUCAUCAACGGCCUGUCCGACCUUUA
CACCCAAUUCAGAUCCUCGCCGAUUAACUGACCCUGCAAGAGCACUACUCGUC
GCUCAAGGGGCUUACCCUCUCGUGGAUUGGCGACGGCAACAACAUCCUUCACU
CCAUCAUGAUGUCGGCAGCGAAGUUCGGCAUGCAUCUGCAAGCCGCCACGCCU
AAGGGUUAUGAACCGGAUGCCUCAGUGACCAAGCUCGCCGAACAGUACGCGAA
AGAGAAUGGAACCAAGCUACUUCUGACCAACGACCCCCUGGAGGCCGCUACG
GCGGCAACGUCCUCAUUAACGAUACUUGGAUUUCGAUGGGACAGGAAGAGGA
AAAGAAGAAGAGACUGCAGGCGUCCAGGGAUACCAGGUCACCAUGAAAACU
GCCAAAGUGGCAGCCUCCGACUGGACCUUCCUUCACUGCCUGCCGAGGAAGCC
UGAAGAGGUGGACGACGAGGUGUUCUACUCCCCGCGCUCCUUGGUGUUUCCUG

AGGCCGAAAACCGGAAGUGGACUAUCAUGGCCGUGAUGGUGUCCCCUCCUCACC
 GACUACUCGCCGCAACUGCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUGA
 CUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCU
 AAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUUGUAGC
 CAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM721 (SEQ ID NO: 52)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGUUAUUCAACCUUAGAAUUCUC
 CUUAACAACGCCGCCUUCGGAAUGGGCAUAACUUUAUGGUCCGCAAUUUCCG
 CUGUGGACAGCCUCUGCAAAACAAGGUCCAGCUCUAGGGCCGGGAUCUGCUGA
 CUCUCAAGAACUUCACUGGGGAAGAAAUCAAGUACAUGCUCUGGCUGAGCGCC
 GACCUCAAGUUCGCAUCAAGCAGAAGGGAGAGUACCUCGCCUGCUCCAAGG
 GAAGUCCUGGGCAUGAUCUUCGAGAAGAGAUCCACCCGCACCAGACUUUCCA
 CUGAGACUGGCUUCGCCUUGCUGGGAGGCCACCCAUGCUUCCUGACGACCCAG
 GACAUUCACCUUGGCGUGAACGAGUCCUGACUGACACCGCAAGGGUGUUGUC
 CUCGAUGGCCGACGCCGUGCUUGCCCCGGGUGUACAAGCAGAGCGAUCUUGACA
 CCCUGGCUAAGGAAGCUUCCAUUCUCCAUAUCAACGGUCUGAGCGACCUGUAC
 CACCCGAUUCAGAUCCUGGCGGACUACCUAACCCUGCAAGAGCACUAUAGCUC
 CCUGAAGGGCCUCACACUUUCAUGGAUCGGCGACGGCAACAACAUCUGCUCU
 CUAUUAUGAUGAGCGCUGCCAAAUUCGGCAUGCACCUCUCAAAGCCGCCACGCCU
 AAAGGCUACGAGCCCGACGCCUCGGUGACCAAGCUUGCGGAGCAGUACGCGAA
 GGAAAACGGCACCAAGCUGCUUCUCACCAACGAUCCUCUGGAAGCGGCCCAUG
 GUGGCAACGUGCUCAUUACCGACACUUGGAUCUCCAUGGGACAGGAGGAGGA
 AAAGAAGAAGCGGCUCCAGGCGUUUCAGGGUUACCAGGUCACCAUGAAAACCG
 CCAAGGUCGCAGCCUCCGACUGGACCUUCCUUAUUGCCUUCGCGCAAGCCC
 GAAGAAGUGGACGAUGAAGUGUUUACUCACCUCGGUCACUCGUGUUCGCGG
 AAGCAGAGAACAGGAAAUGGACCAUUAUGGCGGUGAUGGUGUCCUGCUCACC
 GAUUACAGUCCGCAACUGCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACUGA
 CUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCU
 AAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUUGUAGC
 CAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM722 (SEQ ID NO: 53)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
 CUUAACAACGCCCGGUUAGAAACGGCCACAACUUCUAGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCUUCUUAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAUCCCUACCGAUACCGCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUAUCAACGGCCUUAUGAGACCUCU
 CCAUCCGAUUCAAAUCCUGGCCGAUUAACCUACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCA
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC

UAAGGGUUACGAACCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUGCUGCUGACUAACGACCCGCUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAGGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGUGGCCUCCGACUGGACCUUCCUGCACUGGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCUCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUUCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM723 (SEQ ID NO: 54)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUUAAGGGCCGGGAUCUCCUCA
 CCCUUA AAAACUUCACCGGCCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACCUUAAGUUCGCAUUAAGCAGAAGGGGGAUACCUUCCGCGUGCUUCAAGG
 AAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCUACCAGGACCAGGCUUUCUA
 CUGAAACUGGGUUCGCGCUUCUCGGCGGUAUCCUGCUUCCUCACGACCCAA
 GACAUCCACCUCGGAGUGAACGAUCCCUACGGAUACUGCCCGCGUGCUUUC
 GAGCAUGGCAGACGCCGUGCUCGCCCCGGGUGUACAAACAGUCCGAUCUCGACA
 CUCUCGCCAAGGAGGCGUCAAUUCCUUAUUAUCAACGGUCUUAUGUGACCUUAC
 CACCCGAUCCAGAUCCUCGCCGAUUAACCUACACUCCAAGAACACUACAGCUC
 CCUUAAGGGUCUUACCCUCUCCUGGAUCGGCGACGGCAACAACAUUCUCCACU
 CCAUCAUGAUGUCCGCCGCAAAGUUCGGCAUGCAUCUUAAGCCGCCACCCCG
 AAGGGCUACGAGCCUGAUGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUAA
 GGAGAACGGAACCAAGCUUCUUCUACUAACGACCCACUCGAAGCAGCCCAUG
 GGGGCAACGUGCUUAUCACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAGAG
 AAGAAGAAGCGGCUCACAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAACCGC
 CAAGGUCGUGCCUCCGACUGGACCUUUCUCCACUGCCUCCUCCUGCAAACCUG
 AAGAAGUGGACGACGAGGUGUUCUACUCGCCCCGGAGCCUCGUGUUCUCCGAG
 GCCGAGAAUAGAAAGUGGACCAUUAUGGCCGUGAUGGUGUCACUCCUACCCGA
 CUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACUGACU
 AGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAA
 GCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAUGUAGCCA
 UUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM724 (SEQ ID NO: 55)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGACUAACUUCAUGGUCCGGAACUUCAG
 AUGUGGACAGCCGCUUCAAACAAGGUCCAGCUGAAGGGUCGGGAUCUUCUG
 ACCCUGAAGAACUUUACCGGAGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGC
 GGACUUGAAGUUCGCAUUAAGCAGAAGGGAGAAUACCUCCCGCUGCUUCAAG
 GAAAGAGCCUCGGAAUGAUUUUUGAGAAGCGCUCUACCAGGACCCGCCUUCU
 ACUGAAACUGGAUUCGCGCUGCUGGGUGGACACCCUGCUUCCUGACGACCCA

GGACAUCCACCUCGGAGUGAACGAAUCCCUCACUGAUACCGCCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUCAUACCGGACUUAGUGACCUCUA
 CCAUCCGAUUCAAAUCCUGGCCGACUACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGAGAUGGAAACAACAUUCUCCAC
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGAUUGCAUCUUAAGCCGCCACGCC
 UAAGGGUUAACGAACCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGUACCAAGCUUCUCCUGACCAACGACCCACUAGAAGCAGCCCAC
 GGUGGAAACGUGCUUAUUACUGACACUUGGAUCUCCAUGGGACAGGAGGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAAC
 CGCCAAGGUCGCUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCGCCGAGCCUCGUGUUCGCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAAUGUA
 GCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM725 (SEQ ID NO: 56)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAACCUCCGCAUUCUC
 CUCAACAACGCUGCCUUCGGAUUGGACAUAACUUCUAGGUCCGGAACUUCAG
 AUGCGGACAGCCGCUUCAGAACAAGGUCCAGCUUAAGGGGAGAGAUCUCCUUA
 CCCUCAAAAACUUCACUGGCGAAGAAUACAAGUACAUGCUCUGGCCUUAUGUGCG
 GAUCUCAAGUUCGCAUCAAGCAGAAGGGAGAAUACCUCCCGCUCCUUAAGG
 AAAGAGCCUCGGCAUGAUUUUUGAGAAGAGGUCCACCAGAACUCGCCUUUCAA
 CCGAGACUGGGUUCGCCUGCUUGGCGGUCACCCUGCUUCCUCACUACCCAA
 GACAUCCACCUCGGCGUGAACGAGAGCCUUAACCGACACCGCCCGCGUGCUCUC
 CUCAAUGGCCGACGCUUGUGCUCGCCCGGGUGUACAAGCAGUCCGACCUUGAUA
 CUCUCGCCAAGGAGGCCUCCAUCCCAAUUAUCAACGGGCUCUCUGAUCUCUAC
 CACCCUAUCCAAAUCCUCGCGGACUACCUCACCCUCCAAGAGCACUAUAGCUC
 GCUCAAGGGCCUCACCCUUUCCUGGAUUGGCGACGGCAACAACAUUCUUCACU
 CGAUCAUGAUGUCCGCCGCCAAGUUCGGCAUGCAUCUCCAAGCCGCGACCCCC
 AAGGGCUACGAGCCUGACGCAUCCGUGACCAAGCUCGCCGAGCAGUACGCGAA
 GGAAAUGGCACCAAGCUUCUUCUACCAACGACCCCCUUGAGGCCGCUCAUG
 GCGGCAACGUGCUCAUCACUGACACUUGGAUCAGCAUGGGGCCAGGAGGAGGAA
 AAGAAGAAGCGCCUUCAGGCAUUCAGGGUUAACAGGUCACCAUGAAAACCGC
 CAAAGUGGCCGCCUCCGACUGGACCUUUCUUCACUGUCUCCCGCGGAAGCCUG
 AAGAAGUGGAUGACGAAGUGUUUACUCCCCUCGGUCACUCGUGUUCGGGAA
 GCAGAAAACAGGAAGUGGACCAUUAUGGCGGUCUAGGUGUCCCUCCUACCGA
 CUACAGCCCGCAGCUUCAGAAACCCAAGUUCUAGCUCGAGCUAGUGACUGACU
 AGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAA
 GCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAAUGUAGCCA
 UUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM726 (SEQ ID NO: 57)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC

CUUAACAACGCAGCGUUUAGAAACGGUCACAACUUCAUGGUCCGGAACUUCGG
 CUGUGGACAGCCGCUUCAAACAAGGUCCAGCUGAAGGGUCGGGACCUUCUGA
 CCCUGAAGAACUUUACUGGAGAAGAGAUCAAGUACAUGCUUUGGCUGUCCGC
 GGACUUGAAGUUCGCAUUAAGCAGAAGGGAGAAUACCUUCCGCUGCUCCAAG
 GAAAGAGCCUGGGAAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGAUUCGCGCUGCUGGGUGGUCACCCUUGCUUCCUGACGACCCA
 GGACAUUCACCUCGGAGUGAACGAGUCCCUACUGAUACCGCCAGAGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCUAGGGUGUACAAACAGUCCGAUCUGGAC
 ACCCUGGCCAAGGAGGCAUCAAUUCCUAUUAUCAACGGACUUAGUGACCUCUA
 CCAUCCGAUUCAAAUCCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGAGAUGGAAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCGGCCAAGUUCGGAAUGCAUCUCCAAGCCGCCACGCC
 GAAAGGAUACGAGCCGGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCGCUAGAAGCCGCCAC
 GGUGGAAACGUGCUUAUUAACUGACACCUGGAUCUCCAUGGGACAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAAC
 CGCCAAGGUCGCCGCCUCCGACUGGACCUUCCUUCACUGCCUGCCUCGGAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCGCGGAGCCUCGUGUUCUU
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUCCUCAC
 CGACUACAGCCCGCAGCUUCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
 UAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAAUGUAG
 CCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM727 (SEQ ID NO: 58)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUUCUC
 CUCAACAACGCAGCCUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAGAACAAGGUCCAGCUCUAGGGCCGGGACCUCCUCA
 CCCUCAAAAACUUUACCGGCCAAGAGAUCAAGUACAUGCUCUGGCUUUCGGCC
 GACCUUAAGUUCGCAUCAAGCAGAAGGGGGAUACCUUCCGCUGCUUCAAGG
 AAAGUCCCUCCGGAUGAUCUUUGAAAAGCGCUCGACCAGGACCCGCCUUUCCA
 CUGAAACCGGGUUCGCGCUUCUCGGUGGCCACCCUGCUUCCUCACCACCCAA
 GACAUUCACCUCGGAGUGAACGAAUCCCUUACCGAUACCGCAAGAGUGCUUUC
 GUCGAUGGCCGAUGCCGUGCUUGCGCGGGUGUACAAGCAGUCAGAUCUCGACA
 CUCUCGCCAAGGAGGCGUCCAUUCCUAUUAUCAACGGCCUUUCCGACCUUAC
 CACCCGAUUCAGAUCUCCGCGCAUUAACCUCACCCUGCAAGAGCACUACUCGUC
 ACUCAAGGGUCUUACCCUCUCCUGGAUCGGCGACGGAAACAACAUCCUCCAUI
 CGAUCAUGAUGUCCGCCGCCAAAUUCGGCAUGCACCUCUCCAAGCCGCGACCCCG
 AAGGGUACGAGCCCGACGCUUCCGUGACCAAGCUCGCCGAACAGUACGCUAA
 GGAAAACGGCACCAAGCUCCUCCUCACUAACGACCCUCUCGAAGCAGCCCAUG
 GGGGCAACGUGCUCAUUAACUGACACUUGGAUCUCGAUGGGCCAGGAAGAGGA
 GAAAAAGAAGCGGCUUCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAACC
 GCCAAGGUCGCGUCCUGGACUGGACCUUCCUUCACUGCCUUCGCGCAAGCC
 UGAAGAGGUGGACGAUGAGGUGUUCUACUCCCCACGGUCCCUUGUGUUCCCCG
 AGGCCGAGAAUAGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCGCUCCUCACU
 GACUACUCCCCGCAACUUCAGAAGCCUAAGUUCUAGCUCGAGCUAGUGACUGA
 CUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCU

AAGCUACAUAUACCAACUACACUACAAAUGUUGUCCCCAAAUGUAGC
CAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM728 (SEQ ID NO: 59)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUUAAUCUGAGAAUACU
UCUAAACAACGCCGCCUUCGGAUUGGCCAUAACUUUAUGGUUCGGAUUUCC
GCUGCGGCCAGCCGUGCAGAACAAAGGUCCAGCUGAAGGGAAGAGACUUGCUG
ACCCUCAAGAACUUCACCGGAGAAGAAAUCAAGUAUAUGCUGUGGCUGUCCGC
CGACCUGAAAUUCGCAUCAAGCAGAAGGGCGAAUAUCUGCCGCUGUUGCAAG
GGAAGUCCCUGGGGAUGAUCUUCGAGAAGAGGUCCACCAGAACACGGCUUUA
ACCGAAACCGGGUUUGCAGCUGCGUGGGUGGACACCCUGUUUUCUGACCACUCA
AGAUAUCCACCUGGGCGUGAACGAGUCCCUUACCGACACUGCUAGGGUGUUGU
CCAGCAUGGCCGAUGCCGUCCUGGCUCGCGUGUACAAGCAGUCCGACCUGGAU
ACCCUGGCAAAGGAAGCGUCCAUUCCCAUUAUCAACGGGCUGUCCGACCUGUA
CCAUCCGAUUCAAAUCUGGGCGGACUACCUGACUCUGCAAGAGCAUACAGCA
GCUUGAAGGGGCUUACUCUCUCUGUGGAUCGGCGACGGGAACAACAUCUGCAC
UCCAUCAUGAUGUCCGCCGCCAAGUUCGGGAUGCAUUUGCAAGCUGCGACCCC
GAAAGGUUACGAGCCC GAUGCUAGCGUAACUAAGCUUGCCGAACAGUACGCCA
AAGAGAAUGGUACAAAACUGCUUCUGACUAACGACCCGCUGGAAGCAGCCCAC
GGCGGGAACGUGCUGAUAAACGACACCUGGAUUUCAUUGGGGCAGGAGGAAG
AGAAGAAGAAGCGACUGCAGGCGUCCAAAGGCUAUCAGGUUACCAUGAAAAC
CGCCAAAGUGGCAGCCAGCGAUUGGACUUUCCUGCACUGUCUGCCGCGGAAGC
CCGAGGAAGUUGAUGACGAAGUAUUCUACUACCCCGGAGCCUCGUGUUCCCC
GAGGCCGAAAACCGGAAGUGGACUAUUUUGGCCGUGAUGGUGUCGUGUUGA
CCGACUACAGCCCGCAACUGCAGAAGCCGAAGUUUAGCUCGAGCUAGUGACU
GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
CUAAGCUACAUAUACCAACUACACUACAAAUGUUGUCCCCAAAUGUA
GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM729 (SEQ ID NO: 60)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAACCUGAGGAUCCUU
UUGAACAAACGCCGCCUUCGCAACGGCCACAACUUUAUGGUCCGCAAUUUCCG
CUGCGGGCAGCCGUGCAGAACAAAGGUCCAGCUGAAGGGCCGGGAUCUGCUGA
CCCUGAAGAACUUCACCGGGGAGGAAAUCAAGUACAUGCUUUGGCUCUCCGCC
GAUCUGAAGUUCAGAAUCAAGCAGAAGGGAGAGUACCUCCCGUUGCUGCAAG
GAAAGUCACUCGGAUUGAUUUUCGAAAAGAGAAGCACUAGGACCCGCCUCUCA
ACUGAAACCGGGUUCGCGCUGCUCGGGGGCCAUCCGUGUUUCCUGACUACCCA
AGACAUCCACCUGGGAGUGAACGAGUCGUGACCGACACCGCACGCGUGCUGU
CAUCCAUGGCGGACGCAGUGCUUGCCCGGGUGUACAAGCAGUCGGACCUGGAC
ACUCUUGCCAAGGAGGCAUCAAUCCCCAUCAUUAACGGACUGUCCGAUCUCUA
CCACCCGAUUCAGAUCCUGGCUGACUACCUAACCCUGCAAGAGCACUACUCAA
GCCUGAAGGGGCUGACCCUGUCGUGGAUCGGGGACGGCAACAACAUCUGCAC
UCCAUCAUGAUGUCGGCGGCUAAGUUCGGGAUGCAUUUGCAAGCGGCAACUCC
GAAGGGUUAUGAACCCGACGCCUCCGUGACCAAGCUGGCCGAACAGUACGCCA
AGGAAAACGGAACCAAGUUGCUGCUGACUAAUGAUCCCCUGGAGGGCGGCCAC
GGGGGGAACGUGCUGAUAAACCGAUACCUGGAUCUCCAUGGGGCAGGAAGAAG

AGAAGAAAAAGCGGCUGCAGGCAUUECCAGGGAUACCAGGUCACCAUGAAAACC
 GCAAAAGUGGCAGCCAGCGACUGGACUUUCCUCCAUGGCCUGCCGCGAAAGCC
 GGAGGAGGUCGAUGACGAGGUGUUCUACUCCCCGCGGUCGCUUGGUGUCCCCG
 AGGCGGAAAACCGGAAGUGGACCAUUAUGGCCGUGAUGGUGUCACUCCUGAC
 UGACUACAGCCCGCAACUGCAGAAGCCGAAGUUCUAGCUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
 UAAGCUACAUAUACCAACUUACACUUACAAAAUGUUGUCCCCCAAAAUGUAG
 CCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUAG

>mARM1787 (SEQ ID NO: 61)

CUUAAGGGGGCGCUGCCUACGGAGGUGGCAGCCAUCUCCUUCUCGGCAUCAAG
 CUUACCAUGGUGCCCCAGGCCUGCUCUUGGUCCCCGUGCUGGUGUCCCCCU
 CUGCUUCGGCAAGUUCCCCAUUACACCAUCCCCGACAAGCUGGGGGCCGUGGA
 GCCCCAUCGACAUCCACCACCUGUCCUGCCCCAACAAACCUCGUGGUCGAGGAC
 GAGGGCUGCACCAACCUGAGCGGGUUCUCCUACAUGCUUUUCAUUCUCCGCAU
 CCUCCUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACU
 UCAGAUGUGGCCAGCCGCUUCAAAACAAGGUCCAGCUGAAGGGGCCGGGAUCU
 CUGACCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUC
 CGCGGACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGUGCUUC
 AAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCACCAAGGACCCGCCU
 UCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGAC
 CCAGGACAUCACCUCGGAGUGAACGAAUCCCUCACCGAUACCGCCCGGGUGU
 UAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUG
 GACACUCUGGCCAAGGAGGCGUCAAUUCCUUAUUAUCAACGGCCUAGUGACCU
 CUACCAUCCGAUUCAGAUCCUGGCCGAUUAACCUCACCCUGCAAGAACACUACA
 GCUCCCUGAAGGGUUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUC
 CAUUCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCAC
 GCCGAAGGGUACGAGCCCAGCGCUUCCGUGACUAAGCUCGCCGAGCAGUACG
 CUAAGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCC
 CACGGGGGCAACGUGCUUAUUAACUGACACCUGGAUCUCCAUGGGCCAGGAAGA
 AGAGAAAAAGAAAGCGGCUGCAGGCGUCCAGGGAUUAUCAGGUCACCAUGAAA
 ACCGCCAAGGUCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAA
 GCCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUCC
 CCGAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUC
 ACCGACUACAGCCCGCAGCUUCAGAAAGCCCAAGUUCUAGAUAAUGUGAAUGCAA
 GGCUGGCCGGAAGCCCUUGCCUGAAAGCAAGAUUUCAGCCUGGAAGAGGGCAA
 AGUGGACGGGAGUGGACAGGAGUGGAUGCGAUAGAUGUGGUUUGAAGCUGA
 UGGGUGCCAGCCUGCAUUGCUGAGUCAAUCAAUAAAGAGCUUUCUUUUGACC
 CAUUCUAGAUCUAG

>mARM1788 (SEQ ID NO: 62)

AGGAAACUUAAGAUUAUUAUCAUAAAACAAAAAGCCGCCAAUGCUGUUAAC
 CUGCGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUAUGGU
 GCGCAACUUCGCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCC
 GCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUG
 UGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCC
 CCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCA
 CCCGCCUGAGCACCGAGACAGGCCUGGCCUGCUGGGCGGCCACCCUGCUUC
 CUGACCACCCAGGACAUCACCUGGGCGUGAACGAGAGCCUGACCGACACCGC
 CCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGA

GCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUG
 AGCGACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGA
 GCACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACA
 ACAUCCUGCAGCAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAG
 GCCGCCACCCCAAGGGCUACGAGCCCAGGCCAGCGUGACCAAGCUGGCCGA
 GCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGG
 AGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGC
 CAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGAC
 CAUGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGC
 CCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUG
 GUGUCCCCCGAGGCCGAGAACCGCCAAGUGGACCAUCAUGGCCGUGAUGGUGAG
 CCUGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCCAAGUUCUGAACGCCGA
 AGCCUGCAGCCAUGCGACCCCCACGCCACCCCGUGCCUCCUGCCUCCGCGCAGCC
 UGCAGCGGGAGACCCUGUCCCCGCCCCAGCCGUCCUCCUGGGGUGGACCCUAG
 UUUAAUAAAGAUUCACCAAGUUUCACGCAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>mARM1789 (SEQ ID NO: 63)

CUUAAGGGGGCGCUGCCUACGGAGGUGGCAGCCAUCUCCUUCUCGGCAUCAAG
 CUUACCAUGGUGCCCCAGGCCUGCUCUUGGUCCCGCUGCUGGUGUCCCCCU
 CUGCUUCGGCAAGUUCCCCAUCUACACCAUCCCCGACAAGCUGGGGCCGUGGA
 GCCCCAUCGACAUCCACCACCUGUCCUGCCCCAACCAACCUCGUGGUCGAGGAC
 GAGGGCUGCACCAACCUGAGCGGGUUCUCCUACAUGCUGUUAACCUGCGCAU
 CCUGCUGAACAAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGCGCAACU
 UCCGCUGCGGCCAGCCCCUGCAGAACAAAGGUGCAGCUGAAGGGCCGCGACCUG
 CUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAG
 CGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGC
 AGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGACCCGCCUG
 AGCACCGAGACAGGCCUGGCCUGCUGGGCGGCCACCCUGCUUCCUGACCAC
 CCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCGUGC
 UGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCGACCUG
 GACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCU
 GUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGCACUACA
 GCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUG
 CACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCAC
 CCCCAGGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGAGCAGUACG
 CCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCC
 CACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGA
 GGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGA
 CCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAG
 CCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCC
 CGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGA
 CCGACUACAGCCCCCAGCUGCAGAAGCCCCAAGUUCUGAAUAAGUGAUGCAAGG
 CUGGCCGGAAGCCCUUGCCUGAAAGCAAGAUUUCAGCCUGGAAGAGGGCAAAG
 UGGACGGGAGUGGACAGGAGUGGAUGCGAUAAGAUGUGGUUUGAAGCUGAUG
 GGUGCCAGCCUGCAUUGCUGAGUCAAUCAAUAAGAGCUUUCUUUUGACCCA
 UUCUAGAUCUAG

>mARM1790 (SEQ ID NO: 64)

AGGAAACUUAAGAUUAUUACAUCAAAACAAAAAGCCGCCAAUGCUUUUCAAU
 CUCCGCAUCCUCCUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGU
 CCGGAACUUCAGAUUGGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCC
 GGGAUUCUUCUGACCCUGAAGAACUUUACUGGGCGAAGAGAUCAAGUACAUGCU
 CUGGCUCUCCGCGGACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUC
 CGCUGCUUCAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGG
 ACCCGCCUUUCUACUGAAACUGGGGUUCGCGCUGCUCGGUGGCCACCCUGCUU
 CCUGACGACCCAGGACAUCCACCUCGGAGUGAACGAAUCCCUCACCGAUACCG
 CCCGGGUGUUAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAG
 UCCGAUCUGGACACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCU
 UAGUGACCUCUACCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAG
 AACACUACAGCUCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAAC
 AACAUUCUCCAUCCAUCUAGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUA
 AGCCGCCACGCCGAAGGGUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCG
 AGCAGUACGCUAAGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUA
 GAAGCAGCCCACGGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGG
 CCAGGAAGAAGAGAAAAAGAAGCGGCUGCAGGCGUCCAGGGAUUUCAGGUC
 ACCAUGAAAACCGCCAAGGUCGUGCCUCCGACUGGACCUUCCUGCACUGCCU
 GCCUCGCAAGCCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCC
 UCGUGUUCCCCGAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGU
 GUCACUGCUCACCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGACGC
 CGAAGCCUGCAGCCAUGCGACCCACGCCACCCCGUGCCUCCUGCCUCCGCGCA
 GCCUGCAGCGGGAGACCCUGUCCCCGCCCCAGCCGUCCUCCUGGGGUGGACCC
 UAGUUUAAUAAAGAUUCACCAAGUUUCACGCAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>mARM1791 (SEQ ID NO: 65)

CUUAAGGGGGCGCUGCCUACGGAGGUGGCAGCCAUCUCCUUCUCGGCAUCAAG
 CUUACCAUGGUGCCCCAGGCCUGCUCUUGGUCCCGCUGCUGGUGUUCUUUU
 CUGCUUCGGCAAGUUCUUUACUACACCAUCCCCGACAAGCUGGGGGCCGUGGA
 GCCCCAUCGACAUCCACCACCUGUCCUGCCCCAACAAACCUCGUGGUCGAGGAC
 GAGGGCUGCACCAACCUGAGCGGGUUCUCCUACAUAGCUUUUCAACCUGAGAAU
 CCUCUUGAACAAUGCUGCUUUUCGGAAUGGCCACAACUUUAUGGUUCGGAACU
 UCCGUUGCGGCCAGCCUUUACAAAACAAGGUCCAGCUGAAGGGCCGGGAUUUG
 CUCACACUAAAGAACUUUACUGGAGAAGAGAUCAAGUACAUGCUAUGGCUGU
 CGGCCGACCUGAAGUUCGUAUCAAGCAGAAGGGAGAAUACCUUCCGCUGCUU
 CAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCU
 UUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGA
 CCCAGGACAUCCACCUCGGAGUGAACGAAUCCCUCACCGAUACCGCCCGGGUG
 UUAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCU
 CGAUACCUUGGCAAAGGAGGCUUCCAUUCUCCAUCAUCAACGGCCUGAGCGACC
 UGUACCACCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGCAAGAGCACUAC
 AGCAGCCUGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGGAAACAAUAUUC
 UGCACUCCAUCAUGAUGUCCGCCGCGAAGUUCGGAAUGCAUCUGCAAGCCGCC
 ACUCCAAAAGGAUACGAACCGGAUGCAUCCGUGACCAAGUUGGCGGAACAGUA
 CGCGAAGGAGAACGGAACCAAGCUCCUGCUGACUAACGACCCGCUUGAGGCUG
 CGCAUGGGGGUAACGUGCUGAUUACGGACACCUGGAUCUCCAUGGGGGCAGGA
 GGAAGAGAGAAGAAGAGACUGCAGGCAUUCAGGGGUACCAGGUCACCAUG
 AAAACCGCAAAAGUGGCAGCUUCGGACUGGACUUUCCUGCAUUGCCUGCCGAG

GAAGCCGGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGGUCCCUGGUGU
 UCCCCGAGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAUGGUGUCCUUG
 CUGACUGACUAUAGCCCCGAGCUGCAGAAGCCUAAGUUCUAGAUAAAGUGAUGC
 AAGGCUGGCCGGAAGCCCUUGCCUGAAAGCAAGAUUUCAGCCUGGAAGAGGGC
 AAAGUGGACGGGAGUGGACAGGAGUGGAUGCGAUAAAGAUGUGGUUUGAAGCU
 GAUGGGUGCCAGCCCUGCAUUGCUGAGUCAAUCAAUAAAGAGCUUUCUUUUG
 ACCCAUUCUAGAUCUAG

>mARM1792 (SEQ ID NO: 66)

UGAGUGUCGUACAGCCUCCAGGCCCCCCCUCCCGGGAGAGCCAUAUGUGGUCU
 GCGGAACCGGUGAGUACACCGGAUUGCCGGGAAGACUGGGUCCUUUCUUGG
 AUAAACCCACUCUAUGCCCCGGCCAUUUGGGCGUGCCCCCGCAAGACUGCUAGC
 CGAGUAGUGUUGGGUUGCGAUGCUGUUAACCUGCGCAUCCUGCUGAACAAACG
 CCGCCUUCCGCAACGGCCACAACUUCUUAUGGUGCGCAACUUCCGCUGCGGCCAG
 CCCCUGCAGAACAAAGGUGCAGCUGAAGGGCCGCGACCUGCUGACCCUGAAGAA
 CUUCACCGGCGAGGAGAUAAGUACAUGCUGUGGCUGAGCGCCGACCUGAAGU
 UCCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGGGCAAGAGCCUG
 GGCAUGAUCUUCGAGAAGCGCAGCACCCGCAACCCGCCUGAGCACCGAGACAGG
 CCUGGGCCCUGCUGGGCGGGCCACCCUGCUUCCUGACCACCCAGGACAUCACCUC
 GGGCGUGAACGAGAGCCUGACCAGACACCGCCCGCGUGCUGAGCAGCAUGGCCG
 ACGCCGUGCUGGGCCCGCGUGUACAAGCAGAGCGACCUGGACACCCUGGCCAAG
 GAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUACCACCCCAUCCA
 GAUCCUGGGCCGACUACCUGACCCUGCAGGAGCACUACAGCAGCCUGAAGGGCC
 UGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCCUGCACAGCAUCAUGAUG
 AGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCCAAGGGCUACGA
 GCCCGACGCCAGCGUGACCAAGCUGGGCCGAGCAGUACGCCAAGGAGAACGGCA
 CCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCACGGCGGCCAACGUG
 CUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGAGAAGAAGAAGC
 GCCUGCAGGCCUUCCAGGGCUACCAGGUGACCAUGAAGACCGCCAAGGUGGCC
 GCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCCAGGAGGUGGA
 CGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUUCCCCGAGGGCCGAGAACC
 GCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACCGACUACAGCCCC
 CAGCUGCAGAAGCCCCAAGUUCUGAAUAAGUGAUAGAGCGGCCAAACCCUAGCUA
 CACUCCAUAAGCUAGUUUCUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU
 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU
 GGCUCCAUCUUAAGCCUAGUCACGGCUAGCUGUGAAAGGUCCGUGAGCCGCAU
 GACUGCAGAGAGUGCCGUAACUGGGCCUCUCUGCAGAUCAUGUUCUAG

>mARM1793 (SEQ ID NO: 67)

AGGAAACUUAAGAUUAUUAACAUCAAAACAAAAAGCCGCCAAUGCUUUUCAAU
 CUCCGCAUCCUCCUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGU
 CCGGAACUUCAGAUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCC
 GGGAUUCUUCUGACCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGC
 CUGGCUCUCCGCGGACUUGAAGUUCGCAUUAAGCAGAAGGGGGAUACCUUC
 CGCUGCUUCAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGG
 ACCCGCCUUUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUU
 CCUGACGACCCAGGACAUCCACCUCGGAGUGAACGAAUCCCUCACCGAUACCG
 CCCGGGUGUUUAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAG
 UCCGAUCUGGACACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCU
 UAGUGACCUCUACCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAG

AACACUACAGCUCCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAAC
 AACAUUCUCCAUUCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUCA
 AGCCGCCACGCCGAAGGGUUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCG
 AGCAGUACGCUAAGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUA
 GAAGCAGCCCACGGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGG
 CCAGGAAGAAGAGAAAAAGAGCGGCGUGCAGGCGUUCAGGGAUUUCAGGUC
 ACCAUGAAAACCGCCAAGGUCGCGUCCGCCGACUGGACCUUCCUGCACUGCCU
 GCCUCGCAAGCCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCC
 UCGUGUUCCTCCGAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGU
 GUCACUGCUCACCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGGCUG
 GAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGGCCUCCCAACGGGCCCUCCUCC
 CCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAGCAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAA

>mARM1794 (SEQ ID NO: 68)

AGGAAACUUAAGAUUAUUACAUCAAAAACAAAAAGCCGCCAAUGCUGUUAAC
 CUGCGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUAUGGU
 GCGCAACUUCGCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCC
 GCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUG
 UGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCC
 CCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCA
 CCCGCCUGAGCACCGAGACAGGCCUGGCCUUGCUGGGCGGCCACCCUUGCUUC
 CUGACCACCCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGC
 CCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGA
 GCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUG
 AGCGACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGA
 GCACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACA
 ACAUCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAG
 GCCGCCACCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGA
 GCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGG
 AGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGC
 CAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGAC
 CAUGAAGACCGCCAAGGUGGGCCGACGACUGGACCUUCCUGCACUGCCUGC
 CCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUG
 GUGUUCCTCCGAGGCCGAGAACC GCAAGUGGACCAUCAUGGCCGUGAUGGUGAG
 CCUGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGCUGGAG
 CCUCGGUAGCCGUUCCUCCUGCCCGCUGGGGCCUCCCAACGGGCCCUCCUCCCCU
 CCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAGCAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAA

>mARM1795 (SEQ ID NO: 69)

AGGAAACUUAAGAUUAUUACAUCAAAAACAAAAAGCCGCCAAUGCUGUUAAC
 CUGAGAAUCCUCUUGAACA AUGCUGCUUUUCGGAUUGGCCACAACUUAUGG
 UUCGGAACUUCGUGCGGCCAGCCUUUACAAAACAAGGUCCAGCUGAAGGGC
 CGGGAUUUGCUCACACUAAAGAACUUUACUGGAGAAGAGAUCAAGUACAUGC
 UAUGGCUGUCGGCCGACCUGAAGUUCGUAUCAAGCAGAAGGGAGAAUACCU

UCCGCUGCUUCAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUC AACCA
 GGACCCGCCUUUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUCGC
 UCCUGACGACCCAGGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUAC
 CGCCCGGGUGUUUUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAAC
 AGUCCGAUCUCGAUACCUUGGCAAAGGAGGCUUCCAUUCCCAUCAUCAACGGC
 CUGAGCGACCUGUACCACCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGCA
 AGAGCACUACAGCAGCCUGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGGA
 AACAAUUAUUCUGCACUCCAUC AUGAUGUCCGCCGCGAAGUUCGGA AUGCAUCU
 GCAAGCCGCCACUCCAAAAGGAUACGAACCGGAUGCAUCCGUGACCAAGUUGG
 CGGAACAGUACGCGAAGGAGAACGGAACCAAGCUCCUGCUGACUAACGACCCG
 CUCGAGGCUGCGCAUGGGGGUAACGUGCUGAUUACGGACACCUGGAUCUCCAU
 GGGGCAGGAGGAAGAGAAGAAGAAGAGACUGCAGGCAUUCCAGGGGUACCAG
 GUCACCAUGAAAACCGCAAAAGUGGCAGCUUCGGACUGGACUUUCCUGCAUUG
 CCUGCCGAGGAAGCCGGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGGU
 CCCUGGUGUUCUCCCGAGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAUG
 GUGUCCUUGCUGACUGACUAUAGCCCGCAGCUGCAGAAGCCUAAGUUCUAGGC
 UGGAGCCUCGGUAGCCGUUCCUCCUGCCC GCUGGGCCUCCCAACGGGCCCUCC
 UCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAG
 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAA

>mARM1796 (SEQ ID NO: 70)

AGGAAACUUAAGAAUUAUUGGUUAAAGAAGUAUAUUAGUGCUAAUUUCCUC
 CGUUUGUCCUAGCUUUUCUCUUCUGUCAACCCACACGCCUUUGGCACAAUGC
 UUUUCAAUUCUCCGCAUCCUCCUUAACAACGCCGCGUUUAGAAACGGCCACAAC
 UUCAUGGUCCGGAACUUCAGAUGUGGCCAGCCGCUUCAAACAAGGUCCAGCU
 GAAGGGCCGGGAUCUUCUGACCCUGAAGAACUUUACUGGCGAAGAGAUCAAG
 UACAUGCUCUGGCUCUCCGCGGACUUGAAGUCCGCAUUAAGCAGAAGGGGGA
 AUACCUUCCGUGCUUCAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCU
 CAACCAGGACCCGCCUUUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCAC
 CCCUGCUUCCUGACGACCCAGGACAUCCACCUCGGAGUGAACGAAUCCUCAC
 CGAUACCGCCCCGGGUGUUUUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGU
 ACAAACAGUCCGAUCUGGACACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUUC
 AACGGCCUUAGUGACCUCUACCAUCCGAUUCAGAUCUGGCCGAUUACCUCAC
 CCUGCAAGAACACUACAGCUCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCG
 ACGGCAACAACAUUCUCCAUCUCCAUC AUGAUGUCCGCCGCAAAAUUCGGCAUG
 CAUCUUCAAGCCGCCACGCCGAAGGGUUACGAGCCCGACGCUUCCGUGACUAA
 GCUCGCCGAGCAGUACGCUAAGGAGAACGGAACCAAGCUUCUGCUGACUAACG
 ACCCACUAGAAGCAGCCCACGGGGGCAACGUGCUUAUUACUGACACCUGGAUC
 UCCAUGGGCCAGGAAGAAGAGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAU
 AUCAGGUCACCAUGAAAACCGCCAAGGUCGCGUCCUCCGACUGGACCUUCCUG
 CACUGCCUGCCUCGCAAGCCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCC
 ACGGAGCCUCGUGUUCUCCCGAGGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCG
 UGAUGGUGUCACUGCUCACCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUC
 UAGCUCGAGACACAUCACAACCACAACCUUCUCAGGCUACCCUGAGAAAAAAA
 GACAUGAAGACUCAGGACUCAUCUUUUCUGUUGGUGUAAAAUCAACACCCUA
 AGGAACACAAAUUUCUUUAAACAUUUGACUUCUUGUCUCUGUGCUGCAAUA
 AUAAAAAUGGAAAGAAUCUAUCUAG

>mARM1797 (SEQ ID NO: 71)

AGGAAACUUAAGAAUUAUUGGUUAAAGAAGUAUAUUAGUGCUAAUUUCCCUC
CGUUUGUCCUAGCUUUUCUCUUCUGUCAACCCACACGCCUUUGGCACAAUGC
UGUUCAACCUGCGCAUCCUGCUGAACAACGCCGCCUUCCGCAACGGCCACAAC
UUCAUGGUGCGCAACUUCCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCU
GAAGGGCCGCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUAAGU
ACAUGCUGUGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAG
UACCUGCCCCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAG
CACCCGCACCCGCCUGAGCACCAGACAGGCCUGGCCUGCUGGGCGGCCACCC
CUGCUUCCUGACCACCCAGGACAUCACCUGGGCGUGAACGAGAGCCUGACCG
ACACCGCCCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUAC
AAGCAGAGCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAA
CGGCCUGAGCGACCUGUACCACCCAUCCAGAUCUGGCCGACUACCUGACCC
UGCAGGAGCACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGAC
GGCAACAACAUCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCA
CCUGCAGGCCGCCACCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGC
UGGCCGAGCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGAC
CCCCUGGAGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAG
CAUGGGCCAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACC
AGGUGACCAUGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCAC
UGCCUGCCCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCG
CAGCCUGGUGUUCGCCGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGA
UGGUGAGCCUGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGA
CUCGAGACACAUCACAACCAACCUUCUCAGGCUACCCUGAGAAAAAAGAC
AUGAAGACUCAGGACUCAUCUUUUCUGUUGGUGUAAAAUCAACACCCUAAGG
AACACAAAUUUCUUUAAACAUUUGACUUCUUGUCUCUGUGCUGCAAUUAUA
AAAAUGGAAAGAAUCUAUCUAG

>mARM1798 (SEQ ID NO: 72)

AGGAAACUUAAGAAUUAUUGGUUAAAGAAGUAUAUUAGUGCUAAUUUCCCUC
CGUUUGUCCUAGCUUUUCUCUUCUGUCAACCCACACGCCUUUGGCACAAUGC
UUUUCAACCUGAGAAUCCUCUUGAACA AUGCUGCUUUUCGGA AUGGCCACAAC
UUUAUGGUUCGGAACUUCCGUUGCGGCCAGCCUUUACAAAACAAGGUCCAGCU
GAAGGGCCGGGAUUUGCUCACACUAAAGAACUUUACUGGAGAAGAGAUCAAG
UACAUGCUAUGGCUGUCGGCCGACCUGAAGUUCGUAUCAAGCAGAAGGGAG
AAUACCUUCCGUGCUUCAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGC
UCAACCAGGACCCGCCUUUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCA
CCCCUGCUUCCUGACGACCCAGGACAUCACCUCGGAGUGAACGAAUCCCUCA
CCGAUACCGCCCCGGGUGUUAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUG
UACAAACAGUCCGAUCUCGAUACCUUGGCAAGGAGGCUUCCA UUCCCAUCAU
CAACGGCCUGAGCGACCUGUACCACCCAAUCCAAA UCCUGGCUGACUACCUGA
CCCUGCAAGAGCACUACAGCAGCCUGAAGGGUUCUGACCCUGUCAUGGAUUGGC
GAUGGAAACAAUAUUCUGCACUCCAUCAUGAUGUCCGCCGCGAAGUUCGGAU
GCAUCUGCAAGCCGCCACUCCAAAAGGAUACGAACCGGAUGCAUCCGUGACCA
AGUUGGCGGAACAGUACGCGAAGGAGAACGGAACCAAGCUCCUGCUGACUAA
GACCCGCUCGAGGCUGCGCAUGGGGGUAACGUGCUGAUUACGGACACCUGGAU
CUCCAUGGGGCAGGAGGAAGAGAAGAAGAAGAGACUGCAGGCAUCCAGGGG
UACCAGGUCACCAUGAAAACCGCAAAAGUGGCAGCUUCGGACUGGACUUCCU
GCAUUGCCUGCCGAGGAAGCCGGAGGAAGUCGACGACGAAGUGUUCUACUCGC
CUCGGUCCUGGUGUUCGCCGAGGCCGAAAACCGGAAGUGGACCAUCAUGGCC

GUGAUGGUGUCCUUGCUGACUGACUAUAGCCCGCAGCUGCAGAAGCCUAAGUU
 CUAGCUCGAGACACAUCACAACCACAACCUUCUCAGGCUACCCUGAGAAAAAA
 AGACAUGAAGACUCAGGACUCAUCUUUUCUGUUGGUGUAAAAUCAACACCCU
 AAGGAACACAAAUUUCUUUAAACAUUUGACUUCUUGUCUCUGUGCUGCAAUU
 AAUAAAAAUGGAAAGAAUCUAUCUAG

>mARM1799 (SEQ ID NO: 73)

AUUUUUACAUCAAAACAAAAGCCGCCACCAUGCUGUUAACCUGCGCAUCCU
 GCUGAACAAACGCCGCCUUCGCAACGGCCACAACUUCAUGGUGCGCAACUUC
 GCUGCGGCCAGCCCCUGCAGAACAAAGGUGCAGCUGAAGGGCCGCGACCUGCUG
 ACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGC
 CGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGG
 GCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCAACCCGCCUGAGC
 ACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUCCUGACCACCCA
 GGACAUCCACCUGGGCGUGAACGAGAGCCUGACCAGACACCGCCCGCGUGCUGA
 GCAGCAUGGCCGACGCCGUGCUGGGCCCGCGUGUACAAGCAGAGCGACCUGGAC
 ACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUA
 CCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGCACUACAGCA
 GCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGCAC
 AGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCC
 CAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCA
 AGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCAC
 GGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGA
 GAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGACCG
 CCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCC
 GAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCCGA
 GGCCGAGAACCAGCAAGUGGACCAUCAUGGCCCGUGAUGGUGAGCCUGCUGACCG
 ACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGUAAUGAGCU
 GGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCUCCCAACGGGCCCUCU
 CCCCUCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAUC
 UAG

>mARM1800 (SEQ ID NO: 74)

AGGAAACUUAAGAAUUAUUGGUUAAAGAAGUAUAUUAGUGCUAAUUUCCCUC
 CGUUUGUCCUAGCUUUUCUCUUCUGUCAACCCACACGCCUUUGGCACAAUGC
 UGUUCAACCUGCGCAUCCUGCUGAACAAACGCCGCCUUCGCAACGGCCACAAC
 UUCAUGGUGCGCAACUUCGCGUGCGGCCAGCCCCUGCAGAACAAAGGUGCAGCU
 GAAGGGCCGCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGU
 ACAUGCUGUGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAG
 UACCUGCCCCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAG
 CACCCGCACCCGCCUGAGCACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCC
 CUGCUUCCUGACCAACCAGGACAUCACCCUGGGCGUGAACGAGAGCCUGACCG
 ACACCGCCCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGGCCCGCGUGUAC
 AAGCAGAGCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAA
 CGGCCUGAGCGACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCC
 UGCAGGAGCACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGAC
 GGCAACAACAUCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCA
 CCUGCAGGCCGCCACCCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGC
 UGGCCGAGCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGAC
 CCCCUGGAGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAG

CAUGGGCCAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCCAGGGCUACC
 AGGUGACCAUGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCAC
 UGCCUGCCCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCG
 CAGCCUGGUGUUCCCCGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGA
 UGGUGAGCCUGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGA
 CUCGAGACACAUCACAACCACAACCUUCUCAGGCUACCCUGAGAAAAAAGAC
 AUGAAGACUCAGGACUCAUCUUUUCUGUUGGUGUAAAAUCAACACCCUAAGG
 AACACAAAUUUCUUUAAACAUUUGACUUCUUGUCUCUGUGCUGCAAUUAUA
 AAAAAUGGAAAGAAUCUAUCUAG

>mARM1801 (SEQ ID NO: 75)

AGGAAACUUAAGAUUAUUACAUCAAAAACAAAAAGCCGCCAAUGCUGUUAAC
 CUGCGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUAUGGU
 GCGCAACUUCCGCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCC
 GCGACCUGCUGACCCUGAAGAACUUCACCGGCCGAGGAGAUCAAGUACAUGCUG
 UGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCC
 CCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCA
 CCCGCCUGAGCACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUC
 CUGACCACCCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGC
 CCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGA
 GCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUG
 AGCGACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGA
 GCACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACA
 ACAUCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAG
 GCCGCCACCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGA
 GCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGG
 AGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGC
 CAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGAC
 CAUGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGC
 CCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUG
 GUGUUCCTCCGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAG
 CCUGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAACGCCGA
 AGCCUGCAGCCAUGCGACCCCCACGCCACCCCGUGCCUCCUGCCUCCGCGCAGCC
 UGCAGCGGGAGACCCUGUCCCCCGCCCCAGCCGUCCUCCUGGGGUGGACCCUAG
 UUUAAUAAAGAUUCACCAAGUUACGCAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>mARM1802 (SEQ ID NO: 76)

CUUAAGGGGGCGCUGCCUACGGAGGUGGCAGCCAUCUCCUUCUCGGCAUCAAG
 CUUACCAUGGUGCCCCAGGCCUGCUCUUGGUUCCCGCUGCUGGUGUUCCTCCU
 CUGCUUCGGCAAGUUCCTCAUCUACACCAUCCCCGACAAGCUGGGGGCCGUGGA
 GCCCCAUCGACAUCCACCACCUGUCCUGCCCCAACAACCUCGUGGUCGAGGAC
 GAGGGCUGCACCAACCUGAGCGGGUUCUCCUACAUGCUGUUAACCUGCGCAU
 CCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGCGCAACU
 UCCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCCGCGACCUG
 CUGACCCUGAAGAACUUCACCGGCCGAGGAGAUCAAGUACAUGCUGUGGCUGAG
 CGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGC
 AGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUG
 AGCACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUCCUGACCAC

CCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCCGCGUGC
 UGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCGACCUG
 GACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCU
 GUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGCACUACA
 GCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUG
 CACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCAC
 CCCC AAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACG
 CCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCC
 CACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGA
 GGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGA
 CCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAG
 CCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCC
 CGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGA
 CCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAAUAAGUGAAUGCAAG
 GCUGGCCGGAAGCCCUUGCCUGAAAGCAAGAUUUCAGCCUGGAAGAGGGGCAA
 GUGGACGGGAGUGGACAGGAGUGGAUGCGAUAAAGAUUGGUUUGAAGCUGAU
 GGGUGCCAGCCUGCAUUGCUGAGUCAAUCAAUAAAGAGCUUUCUUUUGACCC
 AUUCUAGAUCUAG

>mARM1803 (SEQ ID NO: 77)

UCAACACAACAUAUACAAAACAAACGAUUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGGGCGUCUUAACCUGCGGAUC
 CUGCUGAACAACGCCGCCUUCGGAACGGCCACAACUUAUGGUCCGCAACUU
 CAGAU GCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCCGGGACCUGC
 UGACCCUGAAGAACUUCACCGGCGAAGAGAUCAAGUACAUGCUGUGGCUGAGC
 GCCGACCUGAAGUUCGGAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCA
 AGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGGAGCACCCGGACCCGGCUGA
 GCACCGAGACAGGCUUUGCCCUGCUGGGAGGCCACCCUGCUUUCUGACCACC
 CAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCAGAGUGCU
 GAGCAGCAUGGCCGACGCCGUGCUGGCCCGGGUGUACAAGCAGAGCGACCUGG
 ACACCCUGGCCAAAGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUG
 UACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAACACUACAG
 CUCCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGC
 ACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCAUCUGCAGGCCGCCACC
 CCCAAGGGCUACGAGCCUGAUGCCAGCGUGACCAAGCUGGCCGAGCAGUACGC
 CAAAGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAAGCCGCC
 ACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAAGAG
 GAAAAGAAGAAGCGGCUGCAGGCCUUCAGGGCUACCAGGUCACAAUGAAGAC
 CGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGC
 CCGAAGAGGUGGACGACGAGGUGUUCUACAGCCCCCGGUCCCUGGUGUCCCC
 GAGGCCGAGAACCGGAAGUGGACCAUUAUGGCCGUGAUGGUGUCCCUGCUGAC
 CGACUACUCCCCCAGCUGCAGAAGCCCAAGUUCUAGAUAAAGUGAACUCGAGC
 UAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAA
 UGGAGUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCC
 AAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUU
 CUAG

>mARM1804 (SEQ ID NO: 78)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGGGCGUCUUAACCUGCGGAUC
CUGCUGAACAACGCCGCCUUCGGAACGGCCACAACUUAUGGUCCGCAACUU
CAGAUGCGGCCAGCCCCUGCAGAACAGGGUGCAGCUGAAGGGCCGGGACCUGC
UGACCCUGAAGAACUUCACCGGC GAAGAGAUCAGGUACAUGCUGUGGCUGAGC
GCCGACCUGAAGUUCGGAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCA
AGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGGAGCACCCGGACCCGGCUGA
GCACCGAGACAGGCUUUGCCCUGCUGGGAGGCCACCCUGCUUUCUGACCACC
CAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCAGAGUGCU
GAGCAGCAUGGCCGACGCCGUGCUGGCCCCGGGUGUACAAGCAGAGCGACCUGG
ACACCCUGGCCAAAGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUG
UACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAACACUACAG
CUCCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGC
ACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCAUCUGCAGGCCGCCACC
CCCAAGGGCUACGAGCCUGAUGCCAGCGUGACCAAGCUGGCCGAGCAGUACGC
CAAAGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAAGCCGCC
ACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAAGAG
GAAAAGAAGAAGCGGCUGCAGGCCUUCAGGGCUACCAGGUCACAAUGAAGAC
CGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGC
CCGAAGAGGUGGACGACGAGGUGUUCUACAGCCCCGGUCCUGGUGUUCGCC
GAGGCCGAGAACC GGAAGUGGACCAUUAUGGCCGUGAUGGUGUCCUGCUGAC
CGACUACUCCCCCAGCUGCAGAAGCCCAAGUUCUAGAUAAUGUGAACUCGAGC
UAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAA
UGGAGUCUCUAAGCUACAUAUAACCAACUUACACUUACAAA AUGUUGUCCCC
AAA AUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
CUAG

>mARM1805 (SEQ ID NO: 79)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGGUCUUAACCUGCGGAUC
CUGCUGAACAACGCCGCCUUCGGAACGGCCACAACUUAUGGUCCGCAACUU
CAGAUGCGGCCAGCCCCUGCAGAACAGGGUGCAGCUGAAGGGCCGGGACCUGC
UGACCCUGAAGAACUUCACCGGC GAAGAGAUCAGGUACAUGCUGUGGCUGAGC
GCCGACCUGAAGUUCGGAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCA
AGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGGAGCACCCGGACCCGGCUGA
GCACCGAGACAGGCUUUGCCCUGCUGGGAGGCCACCCUGCUUUCUGACCACC
CAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCAGAGUGCU
GAGCAGCAUGGCCGACGCCGUGCUGGCCCCGGGUGUACAAGCAGAGCGACCUGG
ACACCCUGGCCAAAGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUG
UACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAACACUACAG
CUCCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGC
ACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCAUCUGCAGGCCGCCACC
CCCAAGGGCUACGAGCCUGAUGCCAGCGUGACCAAGCUGGCCGAGCAGUACGC
CAAAGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAAGCCGCC
ACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAAGAG
GAAAAGAAGAAGCGGCUGCAGGCCUUCAGGGCUACCAGGUCACAAUGAAGAC
CGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGC
CCGAAGAGGUGGACGACGAGGUGUUCUACAGCCCCGGUCCUGGUGUUCGCC

GAGGCCGAGAACCGGAAGUGGACCAUUAUGGCCGUGAUGGUGUCCCUGCUGAC
 CGACUACUCCCCCAGCUGCAGAAGCCCAAGUUCUAGAUAAAGUGAACUCGAGC
 UAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAA
 UGGAGUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCC
 AAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUU
 CUAG

>mARM1806 (SEQ ID NO: 80)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUAACCUGAGGAUCCUG
 CUGAACAAACGCAGCUUUCAGGAACGGCCACAACUUCAUGGUGAGGAACUCCG
 GUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCAGGGACCUGCUGA
 CCCUGAAGAACUUCACCGGAGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGCA
 GACCUGAAGUUCAGGAUCAAGCAGAAGGGAGAGUACCUGCCCCUGCUGCAGGG
 GAAGUCCCUGGGCAUGAUCUUCGAGAAGAGGAGUACCAGGACCAGGCUGAGC
 ACCGAAACCGGCUUCGCCCUGCUGGGAGGACACCCCUGCUUCCUGACCACCCA
 GGACAUCCACCUGGGCGUGAACGAGAGUCUGACCGACACCGCCAGGGUGCUGU
 CUAGCAUGGCCGACGCCGUGCUGGCCAGGGUGUACAAGCAGUCAGACCUGGAC
 ACCCUGGCUAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUA
 CCACCCCAUCCAGAUCUCCUGGCUGACUACCUGACCCUGCAGGAGCACUACAGCU
 CUCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGGAACAACAUCCUGCAC
 AGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCUACCCC
 CAAGGGUUAACGAGCCCAGCGCCAGCGUGACCAAGCUGGCAGAGCAGUACGCCA
 AGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGGCCGCCAC
 GGAGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGACAGGAGGAGG
 AGAAGAAGAAGCGGCUGCAGGCUUUCAGGGUUAACCAGGUGACCAUGAAGAC
 CGCCAAGGUGGCUGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCAGGAAGC
 CCGAGGAGGUGGACGACGAGGUGUUCUACUCUCCAGGAGCCUGGUGUCCCC
 GAGGCCGAGAACAGGAAGUGGACCAUCAUGGCUGUGAUGGUGUCCCUGCUGA
 CCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAAUAAGUGAACUCGAG
 CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
 AUGGAGUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCC
 CAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
 UCUAG

>mARM1808 (SEQ ID NO: 81)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUAACCUGAGGAUCCUG
 CUGAACAAACGCAGCUUUCAGGAACGGCCACAACUUCAUGGUGAGGAACUCCG
 GUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCAGGGACCUGCUGA
 CCCUGAAGAACUUCACCGGAGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGCA
 GACCUGAAGUUCAGGAUCAAGCAGAAGGGAGAGUACCUGCCCCUGCUGCAGGG
 GAAGUCCCUGGGCAUGAUCUUCGAGAAGAGGAGUACCAGGACCAGGCUGAGC
 ACCGAAACCGGCUUCGCCCUGCUGGGAGGACACCCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAU
 CAAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCUAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUA
 CCACCCCAUCCAGAUCUCCUGGCUGACUACCUGACCCUGCAGGAGCACUACAGCU

CUCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGGAACAACAUCCUGCAC
 UCCAUCAUGAUGUCCGCCGCGAAGUUCGGAUUGCAUCUGCAAGCCGCCACGCC
 AAAAGGAUACGAACCGGAUGCGCCCGUGACAAAGUUGGCGGAACAGUACGCU
 AAGGAGAACGGAACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCA
 CGGAGGCAACGUGCUGAUCACCGACACCUUGGAUCAGCAUGGGACAGGAGGAGG
 AGAAGAAGAAGCGGCUGCAGGCUUUCAGGGUUAACAGGUGACCAUGAAGAC
 CGCCAAGGUGGCUGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCAGGAAGC
 CCGAGGAGGUGGACGACGAGGUGUUCUACUCUCCCAGGAGCCUGGUGUUCGCC
 GAGGCCGAGAACAGGAAGUGGACCAUCAUGGCUGUGAUGGUGUCCUGCUGA
 CCGACUACAGCCCCAGCUGCAGAAGCCCAAGUUCUGAAUAAGUGAACUCGAG
 CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
 AUGGAGUCUCUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCC
 CAAAUGUAGCCAUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
 UCUAG

>mARM1809 (SEQ ID NO: 82)

UCAACACAACAUUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUAACCUGCGCAUCCUG
 CUGAACAAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGCGCAACUCCG
 CUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCCGCGACCUGCUGA
 CCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGCC
 GACCUGAAGUCCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGGG
 CAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCAACCCGCCUGAGCA
 CCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUCCUGACCACCCAG
 GACAUCCACCUGGGCGUGAACGAGAGCCUGACCAGACACCGCCCGCGUGCUGAG
 CAGCAUGGCCGACGCCGUGCUGGGCCCGGUGUACAAGCAGAGCGACCUGGACA
 CCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUAC
 CACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGCACUACAGCAG
 CCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGCACA
 GCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGGCCGCCACCCCC
 AAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCAA
 GGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGGCCGCCACG
 GCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGAG
 AAGAAGAAGCGCCUGCAGGCCUCCAGGGCUACCAGGUGACCAUGAAGACCGC
 CAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCCG
 AGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUUCGCCGAG
 GCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACCGA
 CUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAAUAAGUGAACUCGAGCUAG
 UGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGG
 AGUCUCUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAA
 AUGUAGCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUA
 GAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>mARM1816 (SEQ ID NO: 83)

AGGAAACUUAAGUCAACACAACAUUACAAAACAAACGAAUCUCAAGCAAUC
 AAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAG
 CAAUUUUCUGAAAAUUUUCACCAUUUACGAACGAUAGCCAUGCUGUUAACCU
 GCGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGC

GCAACUUCCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCCGC
 GACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUG
 GCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCC
 UGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACC CGCACC
 CGCCUGAGCACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCU
 GACCACCCAGGACAUCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCC
 GCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGGCCCGCGUGUACAAGCAGAGC
 GACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAG
 CGACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGC
 ACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAAC
 AUCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGC
 CGCCACCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGAGC
 AGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAG
 GCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCA
 GGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCA
 UGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCC
 CGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGU
 GUUCCCCGAGGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCC
 UGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGACUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUAACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1822 (SEQ ID NO: 84)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAACUUGAGAAUCCUG
 CUGAACAACGCCGCCUUUCGCAACGGUCACAAUUUUUAUGGUCAGAAACUUCAG
 AUGCGGACAGCCCCUCCAAAACAAGGUCCAGCUGAAGGGCCGCGAUCUCCUCA
 CCCUGAAGAACUUCACGGGGGAGGAGAUCAAGUACAUGCUGUGGCUCUCCGCU
 GACCUGAAGUUCAGGAUCAAGCAGAAGGGAGAAUAUCUGCCGCGUGCUGCAAG
 GGAAGUCCCUGGGGAUGAUUUUCGAGAAGCGGAGCACCCGGACUCGGCUCUCC
 ACUGAAACUGGUUUCGCCUUCUGGGCGGUCACCCUGCUUCCUGACCACUCA
 AGACAUUCACCUCGGAGUGAACGAGUCCUUGACUGACACCGCCCGGGUGCUGU
 CGAGCAUGGCAGACGCCGUGCUAGCCCGCGUGUACAAGCAGUCAGACCUCGAU
 ACCUGGCCAAGGAGGCUUCGAUCCCGAUCAUCAACGGGUUGUCCGACCUGUA
 CCACCCGAUUCAGAUUCUCGCCGACUACCUCACCCUGCAAGAGCAUUACAGCU
 CCCUGAAGGGGCUUACCCUGUCCUGGAUUGGCGACGGAAACAACAUCCUGCAC
 UCCAUUAUGAUGUCGGCGGCCAAGUUCGGCAUGCACCUCCAAGCCGCGACCCC
 UAAGGGUUAACGAACCAGACGCGUCAGUGACUAAGCUGGCCGAACAGUACGCAA
 AGGAAAAUGGCACGAAGCUGCUCCUGACCAACGAUCCGUUGGAAGCCGCCCAU
 GGCGGAAAUGUGCUCAUACCGACACCUGGAUCUCGAUGGGACAGGAGGAAG
 AGAAGAAGAAGCGGCUGCAGGCGUUCAGGGCUACCAGGUCACCAUGAAAACU
 GCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUUCGCGCAAGCC
 UGAGGAGGUGGACGAUGAAGUGUUCUACUCUCCACGGUCCUGGUGUCCCCG
 AGGCGGAGAACCGCAAAUGGACCAUCAUGGCUGUGAUGGUCAGCCUGCUGACC
 GAUUACAGCCCUCAGUUGCAAAAGCCGAAGUUUUGAUAAACUCGAGCUAGUGA
 CUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGU
 CUCUAAGCUACAUAUAACCAACUACACUUAACAAAUGUUGUCCCCCAAAUG
 UAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1823 (SEQ ID NO: 85)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGUUAACCUCCGCAUCCUC
CUCAACAACGCCGCAUUCAGAAACGGGCACAACUUAUGGUCAGAAACUCCG
CUGCGGGCAACCCCUACAAAACAAGGUCCAGCUCAAGGGGCGGGACCUCCUGA
CCCUGAAGAACUUCACCGGCGAAGAGAUCAAGUACAUGCUGUGGCUCUCCGCC
GACCUGAAGUCCGCAUCAAGCAGAAGGGAGAGUACCUCCCGCUGCUGCAAGG
GAAGUCGCUGGGGAUGAUCUUCGAGAAGCGGUCAACCAGAACCCGGCUGUCA
CCGAAACCGGGUUCGCACUGCUGGGGGGACACCCGUGCUUCCUGACCACCCAA
GACAUCCACCUGGGAGUGAACGAAUCGCUGACCGACACCGCCCCGCGUGCUGAG
CUCAAUGGCGGACGCCGUGCUGGCCCCGCGUGUACAAGCAGUCCGACCUGGACA
CCCUGGCCAAGGAAGCGUCCAUCCCGAUCAUCAACGGACUGUCCGACCUGUAC
CACCCGAUCCAGAUCUCCUGGCAGACUACCUGACCCUGCAAGAACACUACAGCUC
CCUGAAGGGCCUGACCCUGUCAUGGAUCGGGGACGGGAACAACAUCUGCACU
CCAUAUAUGAUGUCAGCCGCCAAGUUCGGAAUGCACCUCCAAGCCGCAACCCCG
AAGGGCUACGAACCGGACGCAUCAGUGACCAAACUGGCCGAGCAGUACGCCAA
GGAAAACGGCACCAAGCUCCUGCUGACCAACGACCCGCGUGGAGGCGGCACACG
GGGGGAACGUGCUGAUCACCGACACCUGGAUCUCCAUGGGACAGGAGGAGGA
AAAGAAGAAGCGGCUGCAGGCGUCCAGGGGUACCAGGUCACCAUGAAAACCG
CGAAGGUCGCGGCAUCAGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGCCG
GAAGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUCCCCGA
GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
ACUACUCGCCGACGUCGAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
CUAAGCUACAUAUAACCAACUACACUUAACAAAUGUUGUCCCCCAAAAUGUA
GCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAGAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>mARM1840 (SEQ ID NO: 86)

CUCCCCUCCCCCCCCCUAACGUUACUGGCCGAAGCCGCUUGGAAUAAGGCCGG
UGUGCGUUUGUCUAUAUGUUAUUUCCACCAUAUUGCCGUCUUUUGGCAAUG
UGAGGGCCCCGAAACCUGGCCUGUCUUCUUGACGAGCAUCCUAGGGGUCUU
UCCCCUCUCGCCAAAGGAAUGCAAGGUCUGUUGAAGUGUCGUGAAGGAAGCAG
UCCUCUGGAAGCUUCUUGAAGACAAACAACGUCUGUAGCGACCCUUGCAGG
CAGCGGAACCCCCCACCUGGCGACAGGUGCCUCUGCGGCCAAAAGCCACGUGU
AUAAGAUACACCUGCAAAGGCGGCACAACCCAGUGCCACGUUGUGAGUUGGA
UAGUUGUGGAAAGAGUCAAAUGGCUCUCCUCAAGCGUAUUAACAAGGGGCU
GAAGGAUGCCCAGAAGGUACCCCAUUGUAUGGGAUCUGAUCUGGGGCCUCGG
UGCACAUGCUUUACGUGUGUUUAGUCGAGGUUAAAAACGUCUAGGCCCCCCG
AACCACGGGGACGUGGUUUUCCUUUGAAAAACACGAUGAUAAUAUGCUUUUC
AAUCUCCGCAUCCUCCUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAU
GGUCCGGAACUUCAGAUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGG
GCCGGGAUCUUCUGACCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACA
GCUCUGGCUCUCCGCGGACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACC
UCCGCGUCUUAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACC
AGGACCCGCCUUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUG
CUUCCUGACGACCCAGGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUA

CCGCCCCGGGUGUUAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAA
 CAGUCCGAUCUGGACACUCUGGCCAAGGAGGCGUCAAUUCCUAUUAUCAACGG
 CCUUAGUGACCUCUACCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGC
 AAGAACACUACAGCUCCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGC
 AACAACAUUCUCCAUUCCAUCGAUGUCCGCCGCAAAAUUCGGCAUGCAUCU
 UCAAGCCGCCACGCCGAAGGGUUAACGAGCCGACGCUUCCGUGACUAAGCUCG
 CCGAGCAGUACGCUAAGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCA
 CUAGAAGCAGCCCACGGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAU
 GGGCCAGGAAGAAGAGAAAAAGAAGCGGCUGCAGGCGUCCAGGGAUUAUCAG
 GUCACCAUGAAAACCGCCAAGGUCGUGCCUCCGACUGGACCUUCCUGCACUG
 CCUGCCUCGCAAGCCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGA
 GCCUCGUGUCCCCGAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUG
 GUGUCACUGCUCACCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUGAAU
 AAGUAGAUAGUGCAGUCACUGGCACAACGCGUUGCCCGGUAAGCCAAUCGGGU
 AUACACGGUCGUAUACUGCAGACAGGGUUCUUCUACUUUGCAAGAUAGUCU
 AGAGUAGUAAAAUAAAUAGUAUAAGUCUAG

>mARM1841 (SEQ ID NO: 87)

CUCCCCCCCCCCCCCUAACGUUACUGGCCGAAGCCGCUUGGAAUAAGGCCGG
 UGUGCGUUUGUCUAUAUGUUAUUUCCACCAUAUUGCCGUCUUUUGGCAUUG
 UGAGGGCCCGGAAACCUGGCCUGUCUUCUUGACGAGCAUCCUAGGGGUCUU
 UCCCCUCUCGCCAAAGGAAUGCAAGGUCUGUUGAAUGUCGUGAAGGAAGCAG
 UCCUCUGGAAGCUUCUUGAAGACAAACAACGUCUGUAGCGACCCUUUGCAGG
 CAGCGGAACCCCCACCUGGCCGACAGGUGCCUCUGCGGCCAAAAGCCACGUGU
 AUAAGAUACACCUGCAAAGGCGGCACAACCCAGUGCCACGUUGUGAGUUGGA
 UAGUUGUGGAAAGAGUCAAAUGGCUCUCCUCAAGCGUAUUAACAAGGGGCU
 GAAGGAUGCCCAGAAGGUACCCCAUUGUAUGGGAUCUGAUCUGGGGCCUCGG
 UGCACAUGCUUUACGUGUGUUUAGUCGAGGUUAAAAACGUCUAGGCCCCCCC
 AACCACGGGGACGUGGUUUUCCUUUGAAAAACACGAUGAUAAUAUGCUUUUC
 AACCUGAGAAUCCUCUUGAACAUAUGCUGCUUUUCGGAUUGGCCACAACUUUAU
 GGUUCGGAACUUCGUGUGCGGCCAGCCUUUACAAAACAAGGUCCAGCUGAAGG
 GCCGGGAUUUGCUCACACUAAAGAACUUUACUGGAGAAGAGAUCAAGUACAU
 GCUAUGGCUGUCGGCCGACCUGAAGUUCGUAUCAAGCAGAAGGGAGAAUACC
 UCCGCGUGCUUCAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACC
 AGGACCCGCCUUUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUG
 CUUCCUGACGACCCAGGACAUCACCUCGGAGUGAACGAAUCCCUCACCGAUA
 CCGCCCCGGGUGUUAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAA
 CAGUCCGAUCUCGAUACCUUGGCAAAGGAGGCUUCCAUUCCCAUCAUCAACGG
 CCUGAGCGACCUGUACCACCCAAUCCAAAUCCUGGCUGACUACCUGACCCUGC
 AAGAGCACUACAGCAGCCUGAAGGGUCUGACCCUGUCAUGGAUUGGCGAUGG
 AAACAAUAUUCUGCACUCCAUCAUGAUGUCCGCCGCGAAGUUCGGAAUGCAUC
 UGCAAGCCGCCACUCCAAAAGGAUACGAACCGGAUGCAUCCGUGACCAAGUUG
 GCGGAACAGUACGCGAAGGAGAACGGAACCAAGCUCCUGCUGACUAACGACCC
 GCUCGAGGCUGCGCAUGGGGGUAACGUGCUGAUUACGGACACCUGGAUCUCCA
 UGGGGCAGGAGGAAGAGAAGAAGAAGAGACUGCAGGCAUUCAGGGGUACCA
 GGUCACCAUGAAAACCGCAAAAGUGGCAGCUUCGGACUGGACUUUCCUGCAUU
 GCCUGCCGAGGAAGCCGGAGGAAGUCGACGACGAAGUGUUCUACUCGCCUCGG
 UCCUGGUGUCCCCGAGGCCGAAAACCGGAAGUGGACCAUCAUGGCCGUGAU
 GGUGUCCUUGCUGACUGACUAUAGCCCGCAGCUGCAGAAGCCUAAGUUCUGAA
 UAAGUAGAUAGUGCAGUCACUGGCACAACGCGUUGCCCGGUAAGCCAAUCGGG

UAUACACGGUCGUCAUACUGCAGACAGGGUUCUUCUACUUUGCAAGAUAGUC
UAGAGUAGUAAAAUAAUAGUAUAAGUCUAG

>mARM1842 (SEQ ID NO: 88)

CUCCCCCCCCCCCCUAACGUUACUGGCCGAAGCCGCUUGGAAUAAGGCCGG
UGUGCGUUUGUCUAUAUGUUAUUUCCACCAUAUUGCCGUCUUUUGGCAAUG
UGAGGGCCCGGAAACCUGGCCUGUCUUCUUGACGAGCAUCCUAGGGGUCUU
UCCCCUCUCGCCAAAGGAAUGCAAGGUCUGUUGAAUGUCGUGAAGGAAGCAG
UCCUCUGGAAGCUUCUUGAAGACAAACAACGUCUGUAGCGACCCUUUGCAGG
CAGCGGAACCCCCACCUGGCGACAGGUGCCUCUGCGGCCAAAAGCCACGUGU
AUAAGAUACACCUGCAAAGGCGGCACAACCCAGUGCCACGUUGUGAGUUGGA
UAGUUGUGGAAAGAGUCAAAUGGCUCUCCUCAAGCGUAUUAACAAGGGGCU
GAAGGAUGCCCAGAAGGUACCCCAUUGUAUGGGAUCUGAUCUGGGGCCUCGG
UGCACAUGCUUUACGUGUGUUUAGUCGAGGUUAAAAACGUCUAGGCCCCCCG
AACCACGGGGACGUGGUUUUCCUUUGAAAAACACGAUGAUAAUAUGCUGUUC
AACCUGCGCAUCCUGCUGAACAACGCCGCCUCCGCAACGGCCACAACUUCAU
GGUGCGCAACUCCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGG
GCCGCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUG
CUGUGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCU
GCCCCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCC
GCACCCGCCUGAGCACCGAGACAGGCCUGGCCUGCUGGGCGGCCACCCUGC
UCCUGACACCCAGGACAUCACCCUGGGCGUGAACGAGAGCCUGACCGACAC
CGCCCGCUGCUGAGCAGCAUGGCCGACGCCGUGCUGGGCCGCGUGUACAAGC
AGAGCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGC
CUGAGCGACCUGUACCACCCAUCCAGAUCUGGCCGACUACCUGACCCUGCA
GGAGCACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCA
ACAACAUCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUG
CAGGCCGCCACCCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGC
CGAGCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCC
UGGAGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUG
GGCCAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUCCAGGGCUACCAGGU
GACCAUGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCC
UGCCCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGC
CUGGUGUCCCCGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGU
GAGCCUGCUGACCGACUACAGCCCCAGCUGCAGAAGCCCAAGUUCUGAAUAA
GUAGAUAGUGCAGUCACUGGCACAACGCGUUGCCCGGUAAGCCAAUCGGGUAU
ACACGGUCGUCAUACUGCAGACAGGGUUCUUCUACUUUGCAAGAUAGUCUAG
AGUAGUAAAAUAAUAGUAUAAGUCUAG

>mARM1843 (SEQ ID NO: 89)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
CCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUUAU

CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAAC
 CGCCAAGGUCGCUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCGCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1844 (SEQ ID NO: 90)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUUCGCAUUUAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAAC
 CGCCAAGGUCGCUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCGCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1845 (SEQ ID NO: 91)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG

AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUCAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCGCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1846 (SEQ ID NO: 92)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUCAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCGCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1847 (SEQ ID NO: 93)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUUUCAUUCUCCGCAUCCUC
CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
CCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
GGACAUCCACCUCGGAGUGAACGAUCCUCACCGAUACCGCCCCGGGUGUUAU
CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
CCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUACAGCU
CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
GAAGGGUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
CGCCAAGGUCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUCCCC
GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
CUAAGCUACAUAUAACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
GCCAUUCGUAUCUGCUCCUAAUAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1882 (SEQ ID NO: 94)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGGUGUUAACCUCUCCGCAUCCUC
CUCAACAACGCCGCAUUCAGAAACGGGCACAACUUCAUGGUCAGAAACUUCG
CUGCGGGCAACCCCUACAAAACAAGGUCCAGCUCAAGGGGCGGGACCUCUGA
CCCUGAAGAACUUCACCGGCGAAGAGAUCAAGUACAUGCUGUGGCUCUCCGCC
GACCUGAAGUCCGCAUCAAGCAGAAGGGAGAGUACCUCCCGCUGCUGCAAGG
GAAGUCGUGGGGAUGAUCUUCGAGAAGCGGUCAACCAGAACCCGGCUGUCA
CCGAAACCGGGUUCGCACUGCUGGGGGGACACCCGUGCUUCCUGACCACCCAA
GACAUCCACCUGGGAGUGAACGAUUCGCUGACCGACACCGCCCGCGUGCUGAG
CUCAAUGGCGGACGCCGUGCUGGCCCCGCGUGUACAAGCAGUCCGACCUGGACA
CCUGGCCAAGGAAGCGUCCAUCCCGAUCAUCAACGGACUGUCCGACCUGUAC
CACCCGAUCCAGAUCUGGCAGACUACCUGACCCUGCAAGAACACUACAGCUC
CCUGAAGGGCCUGACCCUGUCAUGGAUCGGGGACGGGAACAACAUCCUGCACU
CCAUAUAUGAUGUCAGCCGCCAAGUUCGGAAUGCACCUCOAAGCCGCAACCCCG
AAGGGCUACGAACCGGACGCAUCAGUGACCAAAACUGGCCGAGCAGUACGCCAA
GGAAAACGGCACCAAGCUCCUGCUGACCAACGACCCCGCUGGAGGGCCGCACACG
GGGGGAACGUGCUGAUCACCGACACCUGGAUCUCCAUGGGACAGGAGGAGGA
AAAGAAGAAGCGGCUGCAGGCGUUCAGGGGUACCAGGUCACCAUGAAAACCG
CGAAGGUCGCGGCAUCAGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGCCG

GAAGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUUCCTCGA
 GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
 ACUACUCGCCGCGAGCUGCAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1883 (SEQ ID NO: 95)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGGUGUUAACCUCCGCAUCCUC
 CUCAACAACGCCGCAUUCAGAAACGGGCACAACUUAUGGUCAGAAACUCCG
 CUGCGGGCAACCCCUACAAAACCGGGUCCAGCUCUAGGGGCGGGACCUCUGA
 CCCUGAAGAACUUCACCGGCGAAGAGAUCAAGUACAUGCUGUGGCUCUCCGCC
 GACCUGAAGUUCGCAUCAAGCAGAAGGGAGAGUACCUCCTCGCUGCUGCAAGG
 GAAGUCGCUGGGGAUGAUCUUCGAGAAGCGGUCAACCAGAACCCGGCUGUCA
 CCGAAACCGGGUUCGCACUGCUGGGGGGACACCCGUGCUUCCUGACCACCCAA
 GACAUCCACCUGGGAGUGAACGAAUCGCUGACCGACACCGCCCGCGUGCUGAG
 CUCAAUGGCGGACGCCGUGCUGGGCCCGGUGUACAAGCAGUCCGACCUGGACA
 CCCUGGCCAAGGAAGCGUCCAUCCGAUCAUCAACGGACUGUCCGACCUGUAC
 CACCCGAUCCAGAUCCUGGCAGACUACCUGACCCUGCAAGAACACUACAGCUC
 CCUGAAGGGCCUGACCCUGUCAUGGAUCGGGGACGGGAACAACAUCCUGCACU
 CCAUAAUGAUGUCAGCCGCCAAGUUCGGAAUGCACCUCCAAGCCGCAACCCCG
 AAGGGCUACGAACCGGACGCAUCAGUGACCAAACUGGCCGAGCAGUACGCCAA
 GGAAAACGGCACCAAGCUCCUGCUGACCAACGACCCCGCUGGAGGCGGCACACG
 GGGGGAACGUGCUGAUCACCGACACCUGGAUCUCCAUGGGACAGGAGGAGGA
 AAAGAAGAAGCGGCUGCAGGCGUCCAGGGGUACCAGGUCACCAUGAAAACCG
 CGAAGGUCGCGGCAUCAGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGCCG
 GAAGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUUCCTCGA
 GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
 ACUACUCGCCGCGAGCUGCAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUUAACACUUAACAAAUGUUGUCCCCCAAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1884 (SEQ ID NO: 96)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGGUGUUAACCUCCGCAUCCUC
 CUCAACAACGCCGCAUUCAGAAACGGGCACAACUUAUGGUCAGAAACUCCG
 CUGCGGGCAACCCCUACAAAACCGGGUCCAGCUCUAGGGGCGGGACCUCUGA
 CCCUGAAGAACUUCACCGGCGAAGAGAUCCGGUACAUGCUGUGGCUCUCCGCC
 GACCUGAAGUUCGCAUCAAGCAGAAGGGAGAGUACCUCCTCGCUGCUGCAAGG
 GAAGUCGCUGGGGAUGAUCUUCGAGAAGCGGUCAACCAGAACCCGGCUGUCA
 CCGAAACCGGGUUCGCACUGCUGGGGGGACACCCGUGCUUCCUGACCACCCAA
 GACAUCCACCUGGGAGUGAACGAAUCGCUGACCGACACCGCCCGCGUGCUGAG
 CUCAAUGGCGGACGCCGUGCUGGGCCCGGUGUACAAGCAGUCCGACCUGGACA
 CCCUGGCCAAGGAAGCGUCCAUCCGAUCAUCAACGGACUGUCCGACCUGUAC
 CACCCGAUCCAGAUCCUGGCAGACUACCUGACCCUGCAAGAACACUACAGCUC
 CCUGAAGGGCCUGACCCUGUCAUGGAUCGGGGACGGGAACAACAUCUGCACU

CCAUA AUGAUGUCAGCCGCCAAGUUCGGAAUGCACCUC AAGCCGCAACCCCG
 AAGGGCUACGAACCGGACGCAUCAGUGACCAAACUGGCCGAGCAGUACGCCAA
 GGAAAACGGCACCAAGCUCCUGCUGACCAACGACCCGCUGGAGGCCGCACACG
 GGGGGAACGUGCUGAUCACCGACACCUGGAUCUCCAUGGGACAGGAGGAGGA
 AAAGAAGAAGCGGCGCAGGCGUCCAGGGGUACCAGGUCACCAUGAAAACCG
 CGAAGGUCGCGGCAUCAGACUGGACCUUCCUGCAGCUGCCUGCCCCGGAAGCCG
 GAAGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUCCCCGA
 GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
 ACUACUCGCCGCAGCUGCAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1885 (SEQ ID NO: 97)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGGUCAACCUCGCAUCCUC
 CUCAACAACGCCGCAUUCAGAAACGGGCACAACUUCAUGGUCAGAAACUCCG
 CUGCGGGCAACCCCUACAAAACAAGGUCCAGCUCAAGGGGCGGGACCUCUGA
 CCCUGAAGAACUUCACCGGCGAAGAGAUCAAGUACAUGCUGUGGCUCUCCGCC
 GACCUGAAGUUCGCAUCAAGCAGAAGGGAGAGUACCUCGCGUCUGCAAGG
 GAAGUCGCUGGGGAUGAUCUUCGAGAAGCGGUCAACCAGAACCCGGCUGUCA
 CCGAAACCGGGUUCGCACUGCUGGGGGGACACCCGUGCUUCCUGACCACCCAA
 GACAUCCACCUGGGAGUGAACGAAUCGCUGACCGACACCGCCCGCGUGCUGAG
 CUCAAUGGCGGACGCCGUGCUGGCCCCGCGUGUACAAGCAGUCCGACCUGGACA
 CCCUGGCCAAGGAAGCGUCCAUCCGAUCAUACACGACUGUCCGACCUGUAC
 CACCCGAUCCAGAUCCUGGCAGACUACCUGACCCUGCAAGAACACUACAGCUC
 CCUGAAGGGCCUGACCCUGUCAUGGAUCGGGGACGGGAACAACAUCCUGCACU
 CCAUAAUGAUGUCAGCCGCCAAGUUCGGAAUGCACCUC AAGCCGCAACCCCG
 AAGGGCUACGAACCGGACGCAUCAGUGACCAAACUGGCCGAGCAGUACGCCAA
 GGAAAACGGCACCAAGCUCCUGCUGACCAACGACCCGCUGGAGGCCGCACACG
 GGGGGAACGUGCUGAUCACCGACACCUGGAUCUCCAUGGGACAGGAGGAGGA
 AAAGAAGAAGCGGCGCAGGCGUCCAGGGGUACCAGGUCACCAUGAAAACCG
 CGAAGGUCGCGGCAUCAGACUGGACCUUCCUGCAGCUGCCUGCCCCGGAAGCCG
 GAAGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUCCCCGA
 GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
 ACUACUCGCCGCAGCUGCAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1886 (SEQ ID NO: 98)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGGUCAACCUCGCAUCCUC
 CUCAACAACGCCGCAUUCAGAAACGGGCACAACUUCAUGGUCAGAAACUCCG
 CUGCGGGCAACCCCUACAAAACCGGGUCCAGCUCAAGGGGCGGGACCUCUGA
 CCCUGAAGAACUUCACCGGCGAAGAGAUCAAGUACAUGCUGUGGCUCUCCGCC
 GACCUGAAGUUCGCAUCAAGCAGAAGGGAGAGUACCUCGCGUCUGCAAGG
 GAAGUCGCUGGGGAUGAUCUUCGAGAAGCGGUCAACCAGAACCCGGCUGUCA
 AAGGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUCCCCGA
 GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
 ACUACUCGCCGCAGCUGCAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAGAAAGUUUCUUCACAUUCUAG

CCGAAACCGGGUUCGCACUGCUGGGGGGACACCCGUGCUUCCUGACCACCCAA
 GACAUCCACCUGGGAGUGAACGAAUCGCUGACCGACACCGCCCGCGUGCUGAG
 CUCAAUGGCGGACGCCGUGCUGGCCCCGCGUGUACAAGCAGUCCGACCUGGACA
 CCCUGGCCAAGGAAGCGUCCAUCCCGAUAUCAACGGACUGUCCGACCUGUAC
 CACCCGAUCCAGAUCUCCUGGCAGACUACCUGACCCUGCAAGAACACUACAGCUC
 CCUGAAGGGCCUGACCCUGUCAUGGAUCGGGGACGGGAACAACAUCCUGCACU
 CCAUAAUGAUGUCAGCCGCCAAGUUCGGAAUGCACCUGCAAGCCGCAACCCCG
 AAGGGCUACGAACCGGACGCAUCAGUGACCAAACUGGCCGAGCAGUACGCCAA
 GGAAAACGGCACCAAGCUCCUGCUGACCAACGACCCGCGUGGAGGCCGCACACG
 GGGGGAACGUGCUGAUCACCGACACCUGGAUCUCCAUGGGACAGGAGGAGGA
 AAAGAAGAAGCGGCUGCAGGCGUCCAGGGGUACCAGGUCACCAUGAAAACCG
 CGAAGGUCGCGGCAUCAGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGCCG
 GAAGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUCCCCGA
 GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
 ACUACUCGCCGCAGCUGCAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAGAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>mARM1887 (SEQ ID NO: 99)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGGUCAACCUCGCAUCCUC
 CUCAACAACGCCGCAUUCAGAAACGGGCACAACUUCAUGGUCAGAAACUCCG
 CUGCGGGCAACCCCUACAAAACCGGGUCCAGCUCUAAAGGGCGGGACCUCUGA
 CCCUGAAGAACUUCACCGGCGAAGAGAUCCGGUACAUGCUGUGGCUCUCCGCC
 GACCUGAAGUUCGCAUCAAGCAGAAGGGAGAGUACCUCGCGUGCUGCAAGG
 GAAGUCGCUGGGGAUGAUCUUCGAGAAGCGGUCAACCAGAACCCGGCUGUCA
 CCGAAACCGGGUUCGCACUGCUGGGGGGACACCCGUGCUUCCUGACCACCCAA
 GACAUCCACCUGGGAGUGAACGAAUCGCUGACCGACACCGCCCGCGUGCUGAG
 CUCAAUGGCGGACGCCGUGCUGGCCCCGCGUGUACAAGCAGUCCGACCUGGACA
 CCCUGGCCAAGGAAGCGUCCAUCCCGAUAUCAACGGACUGUCCGACCUGUAC
 CACCCGAUCCAGAUCUCCUGGCAGACUACCUGACCCUGCAAGAACACUACAGCUC
 CCUGAAGGGCCUGACCCUGUCAUGGAUCGGGGACGGGAACAACAUCCUGCACU
 CCAUAAUGAUGUCAGCCGCCAAGUUCGGAAUGCACCUGCAAGCCGCAACCCCG
 AAGGGCUACGAACCGGACGCAUCAGUGACCAAACUGGCCGAGCAGUACGCCAA
 GGAAAACGGCACCAAGCUCCUGCUGACCAACGACCCGCGUGGAGGCCGCACACG
 GGGGGAACGUGCUGAUCACCGACACCUGGAUCUCCAUGGGACAGGAGGAGGA
 AAAGAAGAAGCGGCUGCAGGCGUCCAGGGGUACCAGGUCACCAUGAAAACCG
 CGAAGGUCGCGGCAUCAGACUGGACCUUCCUGCACUGCCUGCCCCGGAAGCCG
 GAAGAGGUGGACGACGAGGUGUUCUACUCGCCGCGCUCGCUGGUGUCCCCGA
 GGCGGAGAACAGGAAGUGGACCAUCAUGGCGGUGAUGGUCAGCCUCCUGACCG
 ACUACUCGCCGCAGCUGCAGAAGCCGAAGUUCUGAUAAACUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1888 (SEQ ID NO: 100)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGGUCAACCUGCGCAUCCUG
CUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGGUGCGCAACUCCG
CUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCCGCGACCUGCUGA
CCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGCC
GACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGGG
CAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUGAGCA
CCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCUGACCACCCAG
GACAUCCACCUGGGCGUGAACGAGAGCCUGACCAGACACCGCCCCGCGUGCUGAG
CAGCAUGGCCGACGCCGUGCUGGCCCCGCGUGUACAAGCAGAGCGACCUGGACA
CCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUAC
CACCCCAUCCAGAUAUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACAGCAG
CCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCCUGCACA
GCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCCC
AAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCAA
GGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGGCCGCCACG
GCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGAG
AAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGACCGC
CAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCCG
AGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCCGAG
GCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACCGA
CUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAUAAUCGAGCUAGUGACUG
ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
UAAGCUACAUAUAACCAACUUACACUUACAAAAUGUUGUCCCCCAAAUGUAG
CCAUUCGUUAUCUGCUCUAAUAAAAAGAAAGUUUCUUCACAUUCUAGAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>mARM1889 (SEQ ID NO: 101)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUGGUCAACCUGCGCAUCCUG
CUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGGUGCGCAACUCCG
CUGCGGCCAGCCCCUGCAGAACC GGUGCAGCUGAAGGGCCGCGACCUGCUGA
CCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGCC
GACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGGG
CAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUGAGCA
CCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCUGACCACCCAG
GACAUCCACCUGGGCGUGAACGAGAGCCUGACCAGACACCGCCCCGCGUGCUGAG
CAGCAUGGCCGACGCCGUGCUGGCCCCGCGUGUACAAGCAGAGCGACCUGGACA
CCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUAC
CACCCCAUCCAGAUAUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACAGCAG
CCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCCUGCACA
GCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCCC
AAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCAA
GGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGGCCGCCACG
GCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGAG
AAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGACCGC
CAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCCG

AGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUUCCCCGAG
 GCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACCGA
 CUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAUAAACUCGAGCUAGUGACUG
 ACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUC
 UAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAAUGUAG
 CCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUUCUAG

>mARM1890 (SEQ ID NO: 102)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUGUCAAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAAUUAUCAACGGCCUUAGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUCAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCAC
 GGGGGCAACGUGCUUAAUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCUCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCU
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUCUUCUAG

>mARM1891 (SEQ ID NO: 103)

UCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGCUUGUCAAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAACCGGGUCCAGCUGAAGGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAAUUAUCAACGGCCUUAGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUCUCCAU

UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUCAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCAC
 GGGGGCAACGUGCUUAUUAACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUUCAGGUCACCAUGAAAAAC
 CGCCAAGGUCGUGGCCUCCGACUGGACCUUCCUGCACUGGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCGCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGACU
 GACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCU
 CUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGUA
 GCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1898 (SEQ ID NO: 104)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUUUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGGGCCUUGUCAUUCUCCGCAUC
 CUCCUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCUUGGUCCGGAACUU
 CAGAUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUCUUC
 UGACCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCC
 GCGGACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCA
 AGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCACCAAGGACCCGCCUUU
 CUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACC
 CAGGACAUCCACCUCGGAGUGAACGAUCCCUACCGAUACCGCCCGGGUGUU
 AUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGG
 ACACUCUGGCCAAGGAGGCGUCAAUUCCUAUUAUCAACGGCCUAGUGACCUC
 UACCAUCCGAUUCAGAUCUCCUGGCCGAUUAACCUACCCUGCAAGAACACUACAG
 CUCCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCC
 AUUCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACG
 CCGAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGC
 UAAGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCC
 ACGGGGGCAACGUGCUUAUUAACUGACACCUGGAUCUCCAUGGGCCAGGAAGAA
 GAGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUUCAGGUCACCAUGAAAA
 CCGCCAAGGUCGUGGCCUCCGACUGGACCUUCCUGCACUGGCCUGCCUCGCAAG
 CCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUCCC
 CGAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUC
 ACCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGAC
 UGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUC
 UCUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGU
 AGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1899 (SEQ ID NO: 105)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUUUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGGGCCUUGUCAUUCUCCGCAUC
 CUCCUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCUUGGUCCGGAACUU
 CAGAUGUGGCCAGCCGCUUCAAACCGGGUCCAGCUGAAGGGCCGGGAUCUUC
 UGACCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCC
 GCGGACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCA
 AGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCACCAAGGACCCGCCUUU

CUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCCUGCUUCCUGACGACC
 CAGGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUU
 AUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGG
 ACACUCUGGCCAAGGAGGCGUCAAUUCCUAUUAUCAACGGCCUAGUGACCUC
 UACCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUACAG
 CUCCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCC
 AUUCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACG
 CCGAAGGGUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGC
 UAAGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCC
 ACGGGGGCAACGUGCUUAUACUGACACCUGGAUCUCCAUGGGGCCAGGAAGAA
 GAGAAAAAGAAGCGGCUGCAGGCGUCCAGGGGAUAUCAGGUCACCAUGAAAA
 CCGCCAAGGUCGCGUCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAG
 CCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUCCCC
 CGAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUC
 ACCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUGAC
 UGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUC
 UCUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAUGU
 AGCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAGAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAA

>mARM1900 (SEQ ID NO: 106)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGGGCGGACUUGUCAAUUCUCCGC
 AUCCUCCUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCUUGGUCCGGAA
 CUUCAGAUGUGGCCAGCCGCUUCAAACAAGGUCCAGCUGAAGGGCCGGGAUC
 UUCUGACCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUC
 UCCGCGGACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCUGCU
 UCAAGGAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCC
 UUUCUACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCCUGCUUCCUGACG
 ACCCAGGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGU
 GUUAUCGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUC
 UGGACACUCUGGCCAAGGAGGCGUCAAUUCCUAUUAUCAACGGCCUAGUGAC
 CUCUACCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUA
 CAGCUCCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUC
 UCAUUCUUAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCC
 ACGCCGAAGGGUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUA
 CGCUAAGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAG
 CCCACGGGGGCAACGUGCUUAUACUGACACCUGGAUCUCCAUGGGGCCAGGAA
 GAAGAGAAAAAGAAGCGGCUGCAGGCGUCCAGGGGAUAUCAGGUCACCAUGA
 AAACCGCCAAGGUCGCGUCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGC
 AAGCCUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUU
 CCCCAGGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGC
 UCACCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGCUCGAGCUAGUG
 ACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAG
 UCUCUAAGCUACAUAUACCAACUACACUUAACAAAUGUUGUCCCCCAAAU
 GUAGCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAG

>mARM1903 (SEQ ID NO: 107)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCAUGGCCUUUUAUAUCUCCGCAUCCUC
CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
AUGUGGCCAGCCGCUUCAAGGCAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
CCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
GACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCCGGGUGUUAU
CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
CCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
GAAGGGUUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
CGCCAAGGUCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUCCCC
GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCA
CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGAUAAUGUGAACUCGAG
CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
AUGGAGUCUCUAAGCUACAUAUACCAACUUAACUUAACAAAUGUUGUCCCC
CAAAAUGUAGCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
UCUAG

>mARM1904 (SEQ ID NO: 108)

UCAACACAACAUUAUACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAAGCAAUUUUCUGAAA
AUUUUCACCAUUUACGAACGAUAGCCAUGGCCUUUUAUAUCUCCGCAUCCUC
CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
AUGUGGCCAGCCGCUUCAAGGCCGGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
CCCUGAAGAACUUUACUGGCGAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
GACUUGAAGUUCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCCGGGUGUUAU
CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
CCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
GAAGGGUUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
CGCCAAGGUCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC

CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUC^{CCCC}
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCU
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGAUAAAGUGAACUCGAG
 CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
 AUGGAGUCUCUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCC
 CAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
 UCUAG

>mARM1905 (SEQ ID NO: 109)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCAUGGCCCUUUUCAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCUUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAGGCCGGGUCCAGCUGAAGGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCCAAGAGAUCAAGGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUAUCAACGGCCUAGUGACCUCUA
 CCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUCAAGCCGCCACGCC
 GAAGGGUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUC^{CCCC}
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCU
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGAUAAAGUGAACUCGAG
 CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
 AUGGAGUCUCUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCC
 CAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
 UCUAG

>mARM1906 (SEQ ID NO: 110)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCAUGGCCCUUGUCAUUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCUUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAGGCAGGGUCCAGCUGAAGGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCCAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUAUCAACGGCCUAGUGACCUCUA

CCAUCCGAUUCAGAUCCUGGCCGAUUACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGCUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUGCCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUC
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAAGUGAAUAGACUCGAG
 CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
 AUGGAGUCUCUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCC
 CAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
 UCUAG

>mARM1907 (SEQ ID NO: 111)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUCUUUUAAAGCAAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCAUGGCCUUUUCAAUCUCCGCAUCCUC
 CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
 AUGUGGCCAGCCGCUUCAAGUCAAGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
 CCCUGAAGAACUUUACUGGCCAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
 GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCUUGCUUCAAG
 GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
 ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
 GGACAUCCACCUCGGAGUGAACGAAUCCUCACCGAUACCGCCCCGGGUGUUAU
 CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
 ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAUGUGACCUCU
 CCAUCCGAUUCAGAUCUGGCCGAUUACCUCACCCUGCAAGAACACUACAGCU
 CCCUGAAGGGUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
 UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
 GAAGGGUUAACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
 AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
 GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
 AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGGAUAUCAGGUCACCAUGAAAAC
 CGCCAAGGUCGCUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
 CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUGCCC
 GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUC
 CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGAUAAAGUGAACUCGAG
 CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
 AUGGAGUCUCUAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCC
 CAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
 UCUAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAA

>mARM1908 (SEQ ID NO: 112)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUCUUUUAAAGCAAAAGCAAUUUUCUGAAA

AUUUUCACCAUUUACGAACGAUAGCCAUGGCCCUUUUCAAUCUCCGCAUCCUC
CUUAACAACGCCGCGUUUAGAAACGGCCACAACUUCAUGGUCCGGAACUUCAG
AUGUGGCCAGCCGCUUCAAGUCAGGGUCCAGCUGAAGGGCCGGGAUCUUCUGA
CCCUGAAGAACUUUACUGGCCAAGAGAUCAAGUACAUGCUCUGGCUCUCCGCG
GACUUGAAGUCCGCAUUAAGCAGAAGGGGGAAUACCUUCCGCGUGCUUCAAG
GAAAGAGCCUCGGCAUGAUCUUUGAGAAGCGCUCAACCAGGACCCGCCUUUCU
ACUGAAACUGGGUUCGCGCUGCUCGGUGGCCACCCUGCUUCCUGACGACCCA
GGACAUCCACCUCGGAGUGAACGAUCCUCACCGAUACCGCCCCGGGUGUUAU
CGAGCAUGGCAGAUGCCGUGCUGGCCAGGGUGUACAAACAGUCCGAUCUGGAC
ACUCUGGCCAAGGAGGCGUCAAUUCCUAUUUAUCAACGGCCUUAGUGACCUCUA
CCAUCCGAUUCAGAUCUGGCCGAUUAACCUCACCCUGCAAGAACACUACAGCU
CCCUGAAGGGUUCUGACAUUGUCCUGGAUCGGCGACGGCAACAACAUUCUCCAU
UCCAUCAUGAUGUCCGCCGCAAAAUUCGGCAUGCAUCUUAAGCCGCCACGCC
GAAGGGUACGAGCCCGACGCUUCCGUGACUAAGCUCGCCGAGCAGUACGCUA
AGGAGAACGGAACCAAGCUUCUGCUGACUAACGACCCACUAGAAGCAGCCCAC
GGGGGCAACGUGCUUAUUACUGACACCUGGAUCUCCAUGGGCCAGGAAGAAG
AGAAAAAGAAGCGGCUGCAGGCGUUCAGGGAUUACAGGUCACCAUGAAAAC
CGCCAAGGUCGCGUGCCUCCGACUGGACCUUCCUGCACUGCCUGCCUCGCAAGC
CUGAAGAAGUGGACGACGAGGUGUUCUACUCGCCACGGAGCCUCGUGUUCGCC
GAGGCCGAGAAUAGAAAGUGGACCAUCAUGGCCGUGAUGGUGUCACUGCUCU
CCGACUACAGCCCGCAGCUUCAGAAGCCCAAGUUCUAGAUAAAGUGAACUCGAG
CUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGA
AUGGAGUCUCUAAAGCUACAUAUACCAACUACACUACAAAAUGUUGUCCCC
CAAAUGUAGCCAUUCGUUUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAU
UCUAG

>mARM1915 (SEQ ID NO: 113)

GGCAGAAAAAUUUGCUACAUUGUUUCACAAACUUCAAAUAUUUAUUCAUUUUAU
UUAGAUCUAUUUAUUAUCAAAAACAAAAGCCGCCACCAUGCUGUUAACCUG
CGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGGUGCG
CAACUUCCGCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCCGCG
ACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGG
CUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCU
GCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCC
GCCUGAGCACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUCCUG
ACCACCCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCG
CGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCG
ACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGC
GACCUGUACCACCCCAUCCAGAUCUUGGCCGACUACCUGACCCUGCAGGAGCA
CUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACA
UCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCC
GCCACCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCA
GUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGG
CCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAG
GAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAU
GAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCC
GCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUG
UCCCCCGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCU
GCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGU
AAUGAGCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCUCCCAACGG

GCCCUCCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAG
UGGGCAUCUAG

>mARM1916 (SEQ ID NO: 114)

GGCAGAAAAAUUUGCUACAUGUUUCACAAACUUCAAAUAUUUAUUCAUUUUAU
UUAGAUCUAUUUAUACAUCAAAACAAAAAGCCGCCACCAUGGGAGUAUUCAA
CCUGCGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGG
UGCGCAACUUCGCGUGCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGC
CGCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCU
GUGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGC
CCCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGC
ACCCGCCUGAGCACCGAGACAGGCUUUCGCCUGCUGGGCGGCCACCCUGCUU
CCUGACCACCCAGGACAUCACCUGGGCGUGAACGAGAGCCUGACCGACACCG
CCCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAG
AGCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCU
GAGCGACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGG
AGCACUACAGCAGCCUGAAGGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAAC
AACAUCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCA
GGCCGCCACCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCG
AGCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUG
GAGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGG
CCAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGA
CCAUGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUG
CCCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCU
GGUGUUCGCCGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGA
GCCUGCUGACCGACUACAGCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUUC
UAGUAAUGAGCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGGCCUCCCA
ACGGGCCCUCCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUC
UGAGUGGGCAUCUAG

>mARM1917 (SEQ ID NO: 115)

GGCAGAAAAAUUUGCUACAUGUUUCACAAACUUCAAAUAUUUAUUCAUUUUAU
UUAGAUCUAUUUAUACAUCAAAACAAAAAGCCGCCACCAUGGGAGUAUUCAA
CCUGCGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGG
UGCGCAACUUCGCGUGCGGCCAGCCCCUGCAGAACCAGGUGCAGCUGAAGGGC
CGCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCCGGUACAUGCU
GUGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGC
CCCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGC
ACCCGCCUGAGCACCGAGACAGGCUUUCGCCUGCUGGGCGGCCACCCUGCUU
CCUGACCACCCAGGACAUCACCUGGGCGUGAACGAGAGCCUGACCGACACCG
CCCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAG
AGCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCU
GAGCGACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGG
AGCACUACAGCAGCCUGAAGGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAAC
AACAUCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCA
GGCCGCCACCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCG
AGCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUG
GAGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGG
CCAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGA
CCAUGAAGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUG

CCCCGCAAGCCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCU
GGUGUUCCCCGAGGCCGAGAACC GCAAGUGGACCAUCAUGGCCGUGAUGGUGA
GCCUGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCCAAGUUCUGAGGUCUC
UAGUAAUGAGCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCCGUGGGGCCUCCCA
ACGGGGCCCUCCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUC
UGAGUGGGCAUCUAG

>mARM1918 (SEQ ID NO: 116)

GGCAGAAAAAUUUGCUACAUAUUGUUUCACAAACUUCAAAUAUUAUUCAUUUUAU
UUAGAUCUAUUAUUAUCAAAAACAAAAAGCCGCCACCAUGCUGGUAUUCAAC
CUGCGCAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUC AUGGU
GCGCAACUUCCGCU GCGGCCAGCCCCUGCAGAACC GGGUGCAGCUGAAGGGCC
GCGACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCCGGUACAUGCUG
UGGCUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCC
CCUGCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCA
CCCGCCUGAGCACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUC
CUGACCACCCAGGACAUCACCUUGGGCGUGAACGAGAGCCUGACCGACACCGC
CCGCGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGA
GCGACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUG
AGCGACCUGUACCACCCCAUCCAGAUCUUGGCCGACUACCUGACCCUGCAGGA
GCACUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACA
ACAUCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAG
GCCGCCACCCCAAGGGCUACGAGCCC GACGCCAGCGUGACCAAGCUGGGCCGA
GCAGUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGG
AGGCCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGC
CAGGAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUC CAGGGCUACCAGGUGAC
CAUGAAGACCGCCAAGGUGGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGC
CCCGCAAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUG
GUGUUCCCCGAGGCCGAGAACC GCAAGUGGACCAUCAUGGCCGUGAUGGUGAG
CCUGCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCCAAGUUCUGAGGUCUCU
AGUAAUGAGCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCCGUGGGGCCUCCCA
CGGGCCCUCCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCU
GAGUGGGCAUCUAG

>mARM1919 (SEQ ID NO: 117)

AUUAAUUAUCAAAAACAAAAAGCCGCCACCAUGGGAGUAUUCAACCUGCGCAU
CCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGGUGCGCAACU
UCCGCU GCGGCCAGCCCCUGCAGAACAAGGUGCAGCUGAAGGGCCGCGACCUG
CUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAG
CGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGC
AGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUG
AGCACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUCCUGACCAC
CCAGGACAUCACCUUGGGCGUGAACGAGAGCCUGACCGACACCGCCCCGCGUGC
UGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCGACCUG
GACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCU
GUACCACCCCAUCCAGAUCUUGGCCGACUACCUGACCCUGCAGGAGCACUACA
GCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUG
CACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCAC
CCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGAGCAGUACG
CCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCC

CACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGA
GGAGAAGAAGAAGCGCCUUCAGGCCUACCAGGUGACCAUGAAGA
CCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAG
CCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCC
CGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGA
CCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGUAAUGA
GCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCUCCCAACGGGCCCCU
CCUCCCCUCCUUGCACCGGCCCCUCCUGGUCUUUGAAUAAAGUCUGAGUGGGC
AUCUAG

>mARM1920 (SEQ ID NO: 118)

AUUUUUACAUCAAAACAAAAGCCGCCACCAUGGGAGUAUUAACCUGCGCAU
CCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGCGCAACU
UCCGCUGCGGCCAGCCCCUGCAGAACCAGGUGCAGCUGAAGGGCCGCGACCUG
CUGACCCUGAAGAACUUCACCGGCGAGGAGAUCCGGUACAUGCUGUGGCUGAG
CGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGC
AGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUG
AGCACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCUGACCAC
CCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCGUGC
UGAGCAGCAUGGCCGACGCCGUGCUGGGCCCGCGUGUACAAGCAGAGCGACCUG
GACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCU
GUACCACCCCAUCCAGAUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACA
GCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUCCUG
CACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCAC
CCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGAGCAGUACG
CCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCC
CACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGA
GGAGAAGAAGAAGCGCCUUCAGGCCUACCAGGUGACCAUGAAGA
CCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAG
CCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCC
CGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGA
CCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGUAAUGA
GCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCUCCCAACGGGCCCCU
CCUCCCCUCCUUGCACCGGCCCCUCCUGGUCUUUGAAUAAAGUCUGAGUGGGC
AUCUAG

>mARM1921 (SEQ ID NO: 119)

AUUUUUACAUCAAAACAAAAGCCGCCACCAUGCUGGUUAUUAACCUGCGCAU
CCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGCGCAACU
UCCGCUGCGGCCAGCCCCUGCAGAACCAGGUGCAGCUGAAGGGCCGCGACCUG
CUGACCCUGAAGAACUUCACCGGCGAGGAGAUCCGGUACAUGCUGUGGCUGAG
CGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGC
AGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUG
AGCACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCUGACCAC
CCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCGUGC
UGAGCAGCAUGGCCGACGCCGUGCUGGGCCCGCGUGUACAAGCAGAGCGACCUG
GACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCU
GUACCACCCCAUCCAGAUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACA
GCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUCCUG
CACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCAC

CCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACG
 CCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCC
 CACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGA
 GGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGA
 CCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGGCCUGCCCCGCAAG
 CCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCC
 CGAGGCCGAGAACCAGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGA
 CCGACUACAGCCCCCAGCUGCAGAAGCCCCAAGUUCUGAGGUCUCUAGUAAUGA
 GCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCUCCCAACGGGCCCCU
 CCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGC
 AUCUAG

>mARM1925 (SEQ ID NO: 120)

UCAACACAACAUUAACAAAACAAACGAAUCUCAAGCAAUCAAGCAUUCUACUU
 CUAUUGCAGCAAUUUAAAUCAUUUCUUUAAAAGCAAAGCAAUUUUCUGAAA
 AUUUUCACCAUUUACGAACGAUAGCCACCAUGUUGUUAACUUGAGGAUCUU
 GUUGAACAAACGCCGCCUUCAGGAACGGACACAACUUC AUGGUAAGGAACUUC
 GGUGCGGACAGCCCUUGCAGAACAAAGUACAGUUGAAAGGAAGGGACUUGUU
 GACAUUGAAAAACUUCACAGGAGAAGAAAUCAAAUAUGUUGUGGUUGUCG
 GCCGACUUGAAAUCAGGAUCAAAACAGAAAGGAGAAUACUUGCCCUUGUUGC
 AGGGAAAAUCGUUGGGAAUGAUCUUCGAAAAAAGGUCGACAAGGACAAGGUU
 GUCGACAGAAACAGGAUUCGCCUUGUUGGGAGGACACCCUGCUUCUUGACAA
 CACAGGACAUCCACUUGGGAGUAAACGAAUCGUUGACAGACACAGCCAGGGUA
 UUGUCGUCGAUGGCCGACGCCGUUUGGCCAGGGUAUACAAACAGUCGGACUU
 GGACACAUUGGCCAAAGAAGCCUCGAUCCCCAUCAUCAACGGAUUGUCGGACU
 UGUACCACCCCAUCCAGAUUCUUGGCCGACUACUUGACAUUGCAGGAACACUAC
 UCGUCGUUGAAAGGAUUGACAUUGUCGUGGAUCGGAGACGGAAACAACAUCU
 UGCACUCGAUCAUGAUGUCGGCCGCCAAAUUCGGAUUGCACUUGCAGGCCGCC
 ACACCCAAAGGAUACGAACCCGACGCCUCGGUAACAAAUAUGGCCGAACAGUA
 CGCCAAAGAAAACGGAACAAAUAUGUUGUUGACAAACGACCCCUUGGAAGCCG
 CCCACGGAGGAAACGUAUUGAUCACAGACACAUGGAUCUCGAUGGGACAGGA
 AGAAGAAAAAAGGUUGCAGGCCUUCAGGGAUACCAGGUAACA AUG
 AAAACAGCCAAAGUAGCCGCCUCGGACUGGACAUCUUGCACUGCUUGCCCAG
 GAAACCCGAAGAAGUAGACGACGAAGUAUUCUACUCGCCAGGUCGUUGGUA
 UCCCCGAAGCCGAAAACAGGAAUGGACAAUCAUGGCCGUA AUGGUAUCGU
 UGUUGACAGACUACUCGCCCCAGUUGCAGAAACCCAAAUAUGAAUAGUGAAC
 UCGAGCUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAAGAACA
 CCCGAAUGGAGUCUCUAAGCUACAUAUAACCAACUUAACAUUACAAAAUGUUG
 UCCCCAAA AUGUAGCCAUUCGUUUCUGCUCCUAAUAAAAAGAAUGUUCUUC
 ACAUUCUAG

>mARM1926 (SEQ ID NO: 121)

AUUUUACAUCAAAACAAAAGCCGCCACCAUGCUGUUAACCUGCGCAUCCU
 GCUGAACAAACGCCGCCUUCGCAACGGCCACAACUUC AUGGUGCGCAACUUC
 GCUGCGGCCAGCCCCUGCAGGGCAAGGUGCAGCUGAAGGGCCGCGACCUGCUG
 ACCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGC
 CGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGG
 GCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUGAGC
 ACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUCCUGACCACCCA
 GGACAUCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCGUGCUGA

GCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCGACCUGGAC
 ACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUA
 CCACCCCAUCCAGAUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACAGCA
 GCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGCAC
 AGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCC
 CAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCA
 AGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCAC
 GGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGA
 GAAGAAGAAGCGCCUGCAGGCCUCCAGGGCUACCAGGUGACCAUGAAGACCG
 CCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCC
 GAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCCGA
 GGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACCG
 ACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGUAAUGAGCU
 GGAGCCUCGGUAGCCGUUCCUCCUGCCCCGCUGGGCCUCCCAACGGGGCCUCCU
 CCCCUCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAUC
 UAG

>mARM1927 (SEQ ID NO: 122)

AUUUUUACAUCAAAACAAAAGCCGCCACCAUGCUGUUAACCUGCGCAUCCU
 GCUGAACAACGCCGCCUUCCGCAACGGCCACAACUUAUGGUGCGCAACUUC
 GCUGCGGCCAGCCCCUGCAGGGCCGGGUGCAGCUGAAGGGCCGCGACCUGCUG
 ACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAGCGC
 CGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGG
 GCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCAACCCGCCUGAGC
 ACCGAGACAGGCUUCGCCUGCUGGGCGGCCACCCUGCUUCCUGACCACCCA
 GGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCGUGCUGA
 GCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCGACCUGGAC
 ACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUA
 CCACCCCAUCCAGAUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACAGCA
 GCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUGCAC
 AGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCC
 CAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCA
 AGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCAC
 GGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGA
 GAAGAAGAAGCGCCUGCAGGCCUCCAGGGCUACCAGGUGACCAUGAAGACCG
 CCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCC
 GAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCCGA
 GGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACCG
 ACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGUAAUGAGCU
 GGAGCCUCGGUAGCCGUUCCUCCUGCCCCGCUGGGCCUCCCAACGGGGCCUCCU
 CCCCUCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAUC
 UAG

>mARM1928 (SEQ ID NO: 123)

AUUUUUACAUCAAAACAAAAGCCGCCACCAUGCUGUUAACCUGCGCAUCCU
 GCUGAACAACGCCGCCUUCCGCAACGGCCACAACUUAUGGUGCGCAACUUC
 GCUGCGGCCAGCCCCUGCAGGGCCGGGUGCAGCUGAAGGGCCGCGACCUGCUG
 ACCCUGAAGAACUUCACCGGCGAGGAGAUCCGGUACAUGCUGUGGCUGAGCGC
 CGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGCAGG
 GCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCAACCCGCCUGAGC

ACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCCUGCUUCCUGACCACCCA
 GGACAUCCACCUGGGCGUGAACGAGAGCCUGACCACACCGCCCGCGUGCUGA
 GCAGCAUGGCCGACGCCGUGCUGGGCCGCGUGUACAAGCAGAGCGACCUGGAC
 ACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCUGUA
 CCACCCCAUCCAGAUCUGGGCCGACUACCUGACCCUGCAGGAGCACUACAGCA
 GCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCCUGCAC
 AGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCCC
 CAAGGGCUACGAGCCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCCA
 AGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCAC
 GGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGAGGAGGA
 GAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGACCG
 CCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCCC
 GAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUCCCCGA
 GGCCGAGAACCGCAAGUGGACCAUCAUGGCCCGUGAUGGUGAGCCUGCUGACCG
 ACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGUAAUGAGCU
 GGAGCCUCGGUAGCCGUUCCUCCUGCCCCGUGGGCCUCCCAACGGGCCCCUCCU
 CCCCUCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAUC
 UAG

>mARM1929 (SEQ ID NO: 124)

GGCAGAAAAAUUUGCUACAUAUUGUUUCACAAACUUCAAAUAUUAUUAUUAU
 UUAGAUCUAUUAUUAUACAUAACAAAAAGCCGCCACCAUGCUGUUAACCUG
 CGCAUCCUGCUGAACAAACGCCGCCUUCGCAACGGCCACAACUUAUGGUGCG
 CAACUUCCGCUUGCGGCCAGCCCCUGCAGGGCAAGGUGCAGCUGAAGGGCCGCG
 ACCUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGG
 CUGAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCU
 GCUGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCC
 GCCUGAGCACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCCUGCUUCCUG
 ACCACCCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCG
 CGUGCUGAGCAGCAUGGCCGACGCCGUGCUGGGCCGCGUGUACAAGCAGAGCG
 ACCUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGC
 GACCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGCA
 CUACAGCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACA
 UCCUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCC
 GCCACCCCCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGAGCA
 GUACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGG
 CCGCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAG
 GAGGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAU
 GAAGACCGCCAAGGUGGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCC
 GCAAGCCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUG
 UCCCCCGAGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCU
 GCUGACCGACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGU
 AAUGAGCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCCGUGGGCCUCCCAACGG
 GCCCUCCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAG
 UGGGCAUCUAG

AT1G67090> (SEQ ID NO: 125)

CACAAAGAGUAAAGAAGAACA

AT1G35720> (SEQ ID NO: 126)
AACACUAAAAGUAGAAGAAAA

AT5G45900> (SEQ ID NO: 127)
CUCAGAAAGAUAGAUCAGCC

>pARM563 (SEQ ID NO: 128)
ATGCTGTTTAATCTGAGGATCCTGTTAAACAATGCAGCTTTTAGAAATGGTCACA
ACTTCATGGTTCGAAATTTTCGGTGTGGACAACCACTACAAAATAAAGTGCAGCT
GAAGGGCCGTGACCTTCTCACTCTAAAAAACTTTACCGGAGAAGAAATTAATA
TATGCTATGGCTATCAGCAGATCTGAAATTTAGGATAAAACAGAAAGGAGAGTA
TTTGCCTTTATTGCAAGGGAAGTCCTTAGGCATGATTTTGTAGAAAAGAAGTACT
CGAACAAGATTGTCTACAGAAACAGGCTTTGCACTTCTGGGAGGACATCCTTGTT
TTCTTACCACACAAGATATTCATTTGGGTGTGAATGAAAGTCTCACGGACACGGC
CCGTGTATTGTCTAGCATGGCAGATGCAGTATTGGCTCGAGTGTATAACAATCA
GATTTGGACACCCTGGCTAAAGAAGCATCCATCCCAATTATCAATGGGCTGTCAG
ATTTGTACCATCCTATCCAGATCCTGGCTGATTACCTCACGCTCCAGGAACACTA
TAGCTCTCTGAAAGGTCTTACCCTCAGCTGGATCGGGGATGGGAACAATATCCTG
CACTCCATCATGATGAGCGCAGCGAAATTCGGAATGCACCTTCAGGCAGCTACTC
CAAAGGGTTATGAGCCGGATGCTAGTGTAAACCAAGTTGGCAGAGCAGTATGCCA
AAGAGAATGGTACCAAGCTGTTGCTGACAAATGATCCATTGGAAGCAGCGCATG
GAGGCAATGTATTAATTACAGACACTTGGATAAGCATGGGACAAGAAGAGGAGA
AGAAAAAGCGGCTCCAGGCTTTCCAAGGTTACCAGGTTACAATGAAGACTGCTA
AAGTTGCTGCCTCTGACTGGACATTTTTACACTGCTTGCCCAGAAAGCCAGAAGA
AGTGGATGATGAAGTCTTTTATTCTCCTCGATCACTAGTGTTCACAGAGGCAGAA
AACAGAAAGTGGACAATCATGGCTGTCATGGTGTCCCTGCTGACAGATTACTCAC
CTCAGCTCCAGAAGCCTAAATTTGA

>pARM564 (SEQ ID NO: 129)
ATGCTCTTTAATCTGCGCATCTTACTGAACAACGCCGCATTCCGGAACGGTCACA
ACTTCATGGTCCGCAATTTCCGCTGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
GAAGGGACGGGATCTGCTGACACTGAAGAACTTACCGGAGAAGAGATCAAGTA
CATGCTGTGGCTCAGCGCAGACTTGAAGTTCCGGATCAAGCAGAAGGGAGAATA
CTTGCCCCTGCTGCAAGGAAAGTCGCTGGGAATGATTTTGTAGAAGCGGTCAACT
CGCACCAAGACTCTCCACCGAACTGGTTTCGCACTGCTTGGCGGGCACCTTGCT
TCCTGACGACTCAGGACATCCACCTCGGCGTGAACGAATCGCTAACCGATACCG
CCAGAGTGCTTTCTTCCATGGCCGACGCGGTGCTGGCCAGGGTGTACAAGCAGTC
CGACCTCGATACCTTGGCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAGC
GACCTGTACCACCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCACT
ACAGCAGCCTGAAGGGTCTGACCCTGTCATGGATTGGCGATGGAAACAATATTC
TGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCGCCAC
TCCAAAAGGATACGAACCGGATGCGTCCGTGACCAAGTTGGCGGAACAGTACGC
GAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCCCTCGAGGCTGCGCA
TGGGGGCAACGTGCTGATTACCGACACCTGGATCTCCATGGGGCAGGAGGAAGA
GAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAACCG
CAAAAGTGGCAGCTTCGGACTGGACTTTCTCTGCATTGCCTGCCGAGGAAGCCGG
AGGAAGTCGACGACGAAGTGTTCTACTCGCCTCGGTCCCTGGTGTTCCTCGAGGC
CGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGCTGACTGACTAT
AGCCCGCAGCTGCAGAAGCCTAAGTTCTAG

>pARM565 (SEQ ID NO: 130)

ATGCTGTTTAACCTACGTATTTTGCTCAACAATGCAGCCTTTAGAAACGGACATA
 ACTTTATGGTTCGAAACTTTCGCTGCGGGCAGCCACTGCAGAACAAGGTCCAGCT
 GAAAGGGAGAGATTTGCTCACGCTGAAGAACTTTACTGGCGAAGAAATCAAGTA
 TATGCTGTGGTTGTCCGCGGACCTCAAGTTTCGGATTAAGCAGAAAGGGGAGTAT
 CTGCCACTGCTGCAAGGAAAGAGCCTCGGCATGATCTTCGAGAAGCGGAGCACT
 CGGACCAGGCTGAGTACCGAAACTGGCTTCGCATTGTTGGGTGGACATCCATGTT
 TTCTGACAACGCAGGACATTCATCTGGGCGTGAACGAGAGTCTGACGGACACAG
 CTCGCGTTCTGTCCTCTATGGCTGATGCGGTGTTGGCCCGGGTCTATAAGCAGTC
 CGATTTGGACACCTTGGCTAAGGAAGCTAGCATACCGATTATCAATGGGCTGTCC
 GACCTGTATCACCTATTCAAATCCTGGCCGACTACCTCACACTGCAAGAACACT
 ATAGCTCATTGAAGGGACTGACCCTGAGCTGGATAGGGGACGGAAACAACATCC
 TACATAGCATTATGATGTCCGCTGCCAAGTTTGGCATGCATCTTCAAGCCGCCAC
 GCCAAAGGGTTATGAGCCCGACGCGTCAGTGACAAAGCTGGCCGAGCAGTACGC
 TAAGGAGAATGGTACCAAATTACTGCTGACTAATGATCCACTGGAGGCTGCACA
 TGGCGGCAATGTACTGATCACCGACACATGGATCTCGATGGGCCAGGAGGAAGA
 AAAGAAGAAGAGGCTTCAGGCCTTCCAAGGCTACCAGGTCACCATGAAAACAGC
 TAAGGTTGCAGCATCTGATTGGACCTTTCTGCACTGTCTGCCAAGGAAGCCCGAA
 GAGGTGGACGATGAAGTATTCTATAGCCACGGAGTTTGGTGTTCCCTGAGGCTG
 AAAATAGGAAGTGGACAATTATGGCCGTAAATGGTGTCCCTGTTAACCGACTACTC
 TCCGCAACTGCAGAAACCTAAGTTTTAG

>pARM566 (SEQ ID NO: 131)

ATGCTGTTTAACCTTAAGGATCCTGCTGAACAACGCCGCTTTTCGTAACGGTCATA
 ACTTTATGGTCCGGAACCTTAGATGTGGCCAGCCGCTGCAGAACAAGGTTTCAGCT
 GAAGGGGAGGGATCTGCTGACCTTGAAGAACTTTACCGGCGAAGAGATCAAGTA
 CATGTTGTGGCTGAGCGCCGATCTGAAGTTTAGGATTAAGCAGAAAGGGGGAGTA
 TTTGCCACTGCTGCAAGGAAAATCCTTGGGGATGATCTTCGAGAAGCGCTCCACT
 AGAACCCGGCTAAGCACAGAAACCGGCTTCGCACCTTCTGGGTGGACATCCCTGTT
 TTCTGACGACGCAGGATATACACCTGGGCGTGAATGAGAGTCTGACGGACACAG
 CTAGGGTGTTGAGCAGCATGGCCGATGCAGTACTGGCCCGCGTTTATAAGCAGA
 GCGACTTGGACACACTGGCCAAGGAAGCGTCAATTCCGATTATCAATGGGCTGT
 CAGACCTGTATCATCCCATTCAAATCTTGGCTGACTATCTGACCCTGCAAGAACA
 TTACAGCTCCCTGAAGGGCCTCACGTTGTCCTGGATTGGCGACGGAAACAACATT
 CTGCATTTCGATCATGATGAGCGCTGCTAAGTTTGGCATGCACCTCCAAGCCGCTA
 CACCTAAGGGATATGAGCCTGATGCCAGCGTAACCAAGCTGGCCGAACAGTACG
 CGAAGGAGAATGGCACGAAACTGCTGTTGACAAATGACCCACTGGAGGCAGCTC
 ACGGTGGCAACGTGCTGATCACCGACACGTGGATATCTATGGGACAGGAAGAAG
 AGAAGAAGAAGCGGCTGCAGGCATTCCAAGGGTATCAGGTCACCATGAAAACG
 GCCAAGGTTGCTGCATCCGACTGGACATTTCTGCATTGCTTGCCCCGCAAACCAG
 AAGAAGTAGACGACGAAGTCTTTTATTCCCCACGGTCGCTGGTGTTCCCCGAGGC
 GGAGAATCGAAAGTGGACGATTATGGCCGTGATGGTGTCCCTGCTGACTGATTA
 CTCTCCCCAACTGCAAAAGCCTAAGTTTTAG

>pARM567 (SEQ ID NO: 132)

ATGCTTTTCAACCTGAGGATCCTCCTGAACAACGCCGCTTTTCGCAATGGTCAACA
 ACTTTATGGTCCGGAACCTTCAGATGCGGCCAGCCGCTGCAGAACAAGGTCCAGC
 TGAAGGGACGGGATCTGCTGACTCTGAAGAACTTCACCGGAGAAGAGATCAAGT
 ACATGCTGTGGCTGTCGGCCGACCTGAAGTTCAGGATCAAGCAGAAGGGAGAAT
 ACCTCCCGCTGCTGCAAGGAAAGTCCCTGGGCATGATTTTCGAGAAGCGCTCGAC

CAGAACTCGGTTGTCCACCGAAACCGGGTTTGCCTGCTGGGCGGACATCCTTGC
 TTCCTGACGACTCAGGATATTACCTGGGAGTGAACGAGTCGCTGACCGACACC
 GCCAGAGTGCTGAGCTCGATGGCCGACGCCGTGTTGGCACGCGTGTACAAGCAG
 TCCGATCTGGATAACCCTGGCCAAAGAAGCTTCCATCCCGATCATTAAACGGGCTGA
 GCGACCTCTACCACCCCATTCAAATCCTGGCCGACTACCTGACTCTGCAAGAACA
 CTACAGCTCGCTGAAGGGGTTGACTCTGTCCTGGATCGGCGACGGAAACAACAT
 CCTGCACTCCATCATGATGTCGGCCGCAAAGTTCGGCATGCATTTGCAAGCCGCC
 ACCCCAAAGGGCTACGAACCAGACGCGAGCGTCACCAAGCTGGCCGAACAGTAC
 GCGAAGGAAAATGGTACTAAGCTGCTGCTGACCAACGACCCATTGGAAGCTGCC
 CATGGTGGAAACGTGCTGATCACCGACACCTGGATCTCGATGGGCCAGGAAGAG
 GAGAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTATCAGGTCACCATGAAAAC
 AGCCAAAGTGGCAGCGTCAGACTGGACCTTCCTCCACTGTCTGCCTCGCAAGCCA
 GAGGAGGTGGACGACGAGGTGTTCTACTCCCCTCGGTCCCTCGTGTTCCTGAGG
 CTGAGAACCGGAAGTGGACCATTATGGCCGTGATGGTGTCACTCCTGACTGATTA
 CTCCCCGCAACTGCAGAAGCCCAAGTTCTAG

>pARM568 (SEQ ID NO: 133)

ATGCTGTTTAACCTGAGGATCCTATTGAACAATGCTGCTTTTCGTAATGGCCATA
 ACTTTATGGTTCGGAACCTTAGATGCGGGCAGCCACTGCAGAACAAGGTCCAGTT
 GAAAGGCCGCGATCTGTTGACATTGAAGAACCTTACCGGCGAAGAGATTAAGTA
 TATGCTGTGGCTGTCTGCTGACCTCAAGTTTCGAATCAAGCAGAAGGGCGAATAT
 CTCCCCCTGCTGCAAGGAAAGTCTCTCGGCATGATCTTTGAGAAGCGGAGTACCC
 GAACACGGCTGAGCACCGAAACGGGCTTCGCACTGCTGGGGGGCCATCCCTGTT
 TTCTGACAACGCAGGACATCCACTTGGGGGTTAACGAATCATTGACTGATACCGC
 CCGCGTACTGTCATCCATGGCCGACGCTGTGCTGGCTAGGGTGTACAAGCAGTCA
 GATCTGGATACACTGGCCAAGGAAGCTAGCATACCAATCATCAATGGACTGAGT
 GACCTTTATCACCCGATTCAAATACTAGCCGATTATCTGACCCTGCAAGAGCATT
 ACTCCTCGCTGAAAGGCCTCACGCTGTCTGGATCGGCGACGGCAACAACATTCT
 GCATAGTATTATGATGTCTGCTGCCAAATTCGGCATGCATCTGCAAGCTGCTACG
 CCGAAGGGTTATGAACCCGACGCGTCAGTTACGAAGCTCGCTGAGCAGTATGCA
 AAGGAGAATGGCACAAAGCTGTTGCTTACCAACGATCCCCTGGAAGCTGCTCAT
 GGCGGCAATGTGCTGATTACTGACACCTGGATTTCATATGGGCCAGGAGGAGGAG
 AAGAAGAAGAGGTTACAGGCTTTTCAAGGTTACCAAGTCACGATGAAAACCGCT
 AAGGTCGACGCCAGCGACTGGACATTCCTGCACTGTCTGCCAAGAAAGCCGGAA
 GAAGTGGACGACGAGGTGTTCTATTCCCCGCGGTCTTTGGTGTTCGCGAGGCGG
 AAAACAGGAAATGGACCATTATGGCCGTGATGGTATCGTTGCTGACGGACTACA
 GCCCTCAGTTGCAAAAGCCCAAGTTCTAG

>pARM569 (SEQ ID NO: 134)

ATGCTCTTTAACCTCCGCATCCTCCTCAACAACGCCGCCTTCCGGAATGGGCATA
 ACTTCATGGTCCGGAACCTCAGATGCGGCCAGCCCCTGCAAAACAAGGTCCAGTT
 GAAGGGACGGGACCTCCTTACGCTGAAGAACCTTACCGGAGAAGAGATTAAGTA
 CATGCTGTGGTTGTCCGCTGACCTCAAGTTCCGCATTAAGCAGAAGGGAGAATAT
 CTGCCGCTGCTGCAAGGAAAGAGCCTGGGCATGATCTTCGAAAAGCGCTCCACT
 AGAACCCGGCTGTGCACTGAGACTGGATTTCGCCTTGCTCGGTGGACACCCGTGCT
 TCCTGACGACCCAGGACATCCACCTGGGAGTGAACGAGTCACTTACGGATACCG
 CGAGGGTGTGTCCTCAATGGCCGACGCAGTGCTCGCGCGCGTGTACAAGCAGT
 CAGATCTGGATACCCTGGCCAAGGAAGCCAGCATTCCCATCATCAACGGACTGA
 GCGACCTTTACCACCAATCCAGATCCTCGCCGACTACTTAACCCTGCAAGAGCA
 CTACAGCTCCCTGAAGGGACTGACTCTGTCCTGGATCGGGGATGGAAACAACAT
 CCTGCACTCCATCATGATGTCTGCCGCTAAGTTTGGGATGCATCTGCAAGCCGCA

ACCCCTAAGGGATACGAGCCCGACGCCTCGGTGACCAACTTGCGGAACAGTAC
 GCCAAGGAAAACGGTACCAAGCTGCTGCTGACCAACGACCCTCTGGAAGCGGCC
 CACGGAGGAAATGTGCTGATTACCGACACCTGGATTTTCGATGGGCCAGGAGGAG
 GAGAAGAAGAAGAGACTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAAC
 CGCCAAGGTCGCCGCCAGCGACTGGACCTTCTGCACTGTCTCCCTCGGAAACCG
 GAAGAAGTGGATGACGAGGTGTTCTACTCCCCGCGCTCGCTGGTGTTCGCGGAG
 GCTGAAAACAGGAAGTGGACAATCATGGCCGTGATGGTGTCCCTGTTGACCGAC
 TACTCCCCACAACCTGCAGAAGCCCAAGTTCTAG

>pARM570 (SEQ ID NO: 135)

ATGCTTTTCAATCTGCGCATCCTCCTGAACAACGCCGCCTTCCGCAATGGACACA
 ACTTTATGGTCCGCAACTTCCGCTGTGGGCAGCCGCTGCAGAACAAAGGTCCAGCT
 CAAGGGGAGAGATCTCCTGACCCTGAAGAACTTCACTGGAGAGGAGATCAAGTA
 CATGCTGTGGCTGTCCGCCGACCTGAAATTTCCGATTAAGCAGAAGGGCGAATA
 CCTCCCCTGCTGCAAGGAAAGTCTTTGGGCATGATCTTCGAAAAGAGAAGCAC
 CCGGACCCGGTTGAGCACCGAACTGGGTTTCGCGCTCCTCGGTGGACACCCGTG
 CTTCCTGACCACCCAAGATATTCATCTGGGTGTCAACGAAAGCCTGACCGACACC
 GCCAGGGTGCTGTTCATCCATGGCTGACGCAGTGCTCGCCCGGGTGTACAAGCAG
 TCAGACCTGGACACCCTCGCCAAGGAAGCTTCGATCCCTATCATCAACGGACTTT
 CCGACCTGTACCACCCCATCCAAATTCTGGCCGACTACCTGACTCTGCAAGAACA
 CTATAGCTCGCTGAAAGGACTTACTCTGTCCTGGATCGGGGACGGCAACAACATT
 CTCCATTCCATCATGATGTCCGCTGCCAAGTTCGGAATGCACCTTCAAGCAGCGA
 CTCCCAAGGGATACGAACCTGATGCCTCCGTGACTAAGCTGGCAGAGCAGTACG
 CCAAGGAGAACGGTACAAAGCTGCTGCTCACGAACGACCCCTGGAGGGCGGCC
 ACGGCGGAAACGTGCTGATTACCGATACCTGGATCTCAATGGGCCAGGAAGAGG
 AGAAGAAGAAGCGGCTCCAGGCGTTTCAAGGCTACCAGGTCACCATGAAAACCG
 CGAAGGTGCGCCGCTCCGACTGGACTTTCTTGCCTGCTGCGCGGAAGCCCGA
 GGAAGTGGATGACGAAGTGTCTACTCGCCGAGATCGTTGGTGTTCCTGAGGCC
 GAAAACAGGAAGTGGACCATCATGGCCGTGATGGTGTCCCTGCTGACTGATTAC
 AGCCACAGCTGCAGAAGCCTAAGTTCTAG

>pARM571 (SEQ ID NO: 136)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACAAGGTCCAGCT
 GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGAATA
 CTTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCCTTTCTACTGAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTTGATCGGCGACGGCAACAACATTC
 TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC

GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
AGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM572 (SEQ ID NO: 137)

ATGCTTTTCAACCTGAGAATCCTCCTGAACAACGCCGCCTTCCGCAATGGTCATA
ACTTCATGGTCCGCAACTTTCGCTGCGGACAGCCTCTCCAAAACAAGGTCCAGCT
CAAGGGGCGCGACCTCCTCACACTGAAGAACTTCACTGGAGAAGAAATCAAGTA
CATGCTGTGGCTGAGCGCCGATCTGAAGTTCCGGATCAAGCAGAAGGGAGAGTA
CCTTCCTCTGCTGCAAGGGAAGTCCTTGGGAATGATTTTCGAGAAGCGGTCCACC
CGGACCAGGCTGAGCACTGAACTGGCTTCGCCCTGCTGGGAGGCCACCCTTGTT
TCCTGACCACTCAGGACATCCACCTGGGCGTGAACGAGTCCCTGACCGATACTGC
CAGAGTGCTGTCTCCATGGCCGACGCCGTGCTCGCCCGGGTGTACAAGCAGTCA
GACCTCGATACGCTGGCCAAGGAAGCCTCCATTCCCATTATCAATGGTCTGTCCG
ACCTCTACCATCCAATCCAAATCCTCGCCGACTACCTGACTCTGCAAGAACACTA
CAGCTCACTCAAGGGCCTCACCTCTCCTGGATCGGCGACGGAAACAACATCCTT
CACTCGATTATGATGTCCGCCGCGAAGTTCGGGATGCACCTCCAAGCTGCCACTC
CAAAAGGCTACGAGCCGGATGCCTCAGTACTAAGTTGGCGGAACAGTATGCGA
AGGAGAACGGTACCAAGCTCCTGCTGACTAACGACCCGCTGGAGGCCGCCACG
GGGGAACGTGCTCATCACCGATACTTGGATTTCCATGGGACAGGAGGAAGAGA
AGAAGAAGCGGTTGCAGGCATTTACGGGCTACCAGGTCACCATGAAAACCTGCCA
AAGTCGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCAAGCCTGAAG
AAGTGGACGACGAGGTGTTCTACTCTCCCCGGTCCCTCGTGTTCCCTGAGGCCGA
AAACAGGAAGTGGACCATCATGGCTGTGATGGTGTCCCTCCTGACCGACTACAG
CCCTCAGCTCCAAAAACCCAAGTTTTAG

>pARM573 (SEQ ID NO: 138)

ATGCTTTTCAACCTGAGAATCCTCCTGAACAATGCTGCTTTTCGGAATGGCCACA
ACTTTATGGTTCGGAACCTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
GAAGGGCCGGGATTTGCTCACACTGAAGAACTTTACTGGGGAGGAGATTAAGTA
TATGCTGTGGCTGTCCGCTGACCTGAAGTTTAGGATCAAGCAGAAGGGCGAATA
TCTGCCGCTGCTGCAAGGGAAAAGTCTGGGCATGATTTTTGAAAAGCGCTCTACC
CGGACCAGACTGTCTACGGAAACAGGCTTTGCCCTGCTGGGCGGCCACCCCTGTT
TTCTGACAACGCAGGACATCCATCTGGGCGTGAACGAATCACTGACCGATACTG
CTCGGGTACTCAGTTCTATGGCTGACGCAGTGCTGGCTAGGGTGTACAAGCAGA
GCGACTTGGACACACTGGCTAAGGAGGCCAGCATCCCCATTATCAATGGCCTGTC
TGATTTGTACCATCCATTCAAATCCTGGCTGATTATCTGACACTACAAGAGCAT
TACTCAAGTCTGAAGGGTTTGA CTCTCCTGGATCGGCGACGGCAACAACATTT
TACATTCCATTATGATGAGTGCTGCTAAGTTTGGCATGCATTTGCAAGCTGCTAC
CCCAAAGGGCTATGAACCTGACGCTAGCGTAACCAAGTTGGCCGAACAGTATGC
TAAAGAGAATGGCACCAAGCTGCTCCTGACGAATGACCCCTGGAAGCTGCTCA
TGGCGGAAACGTACTTATAACTGATACATGGATTAGCATGGGCCAGGAAGAGGA
GAAGAAGAAGAGACTGCAGGCCTTCCAAGGCTATCAGGTCACCATGAAAACCTGC
CAAGGTTGCAGCTAGCGACTGGACCTTCCTGCACTGTTTGCCGAGGAACCCGA
GGAGGTGGACGATGAAGTCTTTTATTCTCCCCGCTCCTTGGTGTTCCTGAGGCT
GAAAATCGAAAGTGGACGATAATGGCAGTGATGGTGTCCCTACTGACCGACTAT
TCTCCACAACCTGCAGAAGCCTAAATTCTAG

>pARM574 (SEQ ID NO: 139)

ATGCTTTTCAATCTGAGGATCCTGCTGAACAACGCTGCTTTTCGCAACGGTCATA
ACTTTATGGTTCGCAATTTTCGTTGTGGCCAGCCGCTGCAGAACAAAGGTTACAGT

GAAGGGCAGAGATCTGCTGACTCTGAAGAACTTCACTGGGGAAGAAATCAAGTA
TATGTTATGGCTGTCCGCGGATCTGAAATTTTGAATCAAGCAGAAGGGCGAATAT
CTTCCCCTGCTGCAAGGGAAATCCTTGGGCATGATTTTTGAGAAGAGGAGCACTA
GGACTAGATTGTCAACAGAAACAGGCTTTGCTTTGTTGGGCGGACATCCCTGCTT
TCTGACGACACAGGATATCCACCTCGGCGTAAACGAGTCCCTCACCGACACTGCT
AGGGTACTGAGCAGCATGGCCGACGCTGTGCTAGCCCGGGTTTACAAGCAGTCA
GACCTGGACACCCTTGCCAAGGAAGCTTCTATTCCAATTATCAACGGCCTGAGTG
ACCTGTATCACCTATTCAAATACTCGCCGACTATTTGACGCTTCAAGAACATTA
CAGCAGCCTCAAGGGCTTAACCTTGAGTTGGATAGGCGACGGCAACAATATCCT
GCATTCCATTATGATGTCTGCCGCTAAGTTTGGCATGCATCTACAAGCCGCAACA
CCCAAGGGCTATGAACCCGACGCTAGCGTGACCAAGCTGGCCGAGCAGTATGCT
AAGGAAAATGGCACAAAGCTCCTTCTTACCAACGATCCCCTGGAGGCTGCTCAC
GGCGGCAACGTGCTGATTACCGATACATGGATTAGCATGGGCCAGGAGGAGGAG
AAAAAGAAGCGGCTCCAGGCTTTTCAAGGCTATCAGGTCACCATGAAAACCTGCA
AAGGTCGCTGCCTCCGACTGGACTTTCCTGCATTGTCTACCCCGCAAGCCTGAGG
AAGTGGACGATGAGGTGTTCTACTCCCCACGGAGTCTGGTGTTCCTCGGAAGCAG
AGAATCGGAAGTGGACCATCATGGCTGTCATGGTGTGCTCTTGACTGACTATTC
TCCCCAACTGCAAAAACCCAAGTTTTAG

>pARM575 (SEQ ID NO: 140)

ATGCTTTTCAATCTGAGGATCCTGCTGAACAACGCTGCTTTTCGCAACGGTCATA
ACTTTATGGTTTCGCAATTTTCGTTGTGGCCAGCCGCTGCAGAACAAAGGTTCAAGT
GAAGGGCAGAGATCTGCTGACTCTGAAGAACTTCACTGGGGAAGAAATCAAGTA
TATGTTATGGCTGTCCGCGGATCTGAAATTTTGAATCAAGCAGAAGGGCGAATAT
CTTCCCCTGCTGCAAGGGAAATCCTTGGGCATGATTTTTGAGAAGAGGAGCACTA
GGACTAGATTGTCAACAGAAACAGGCTTTGCTTTGTTGGGCGGACATCCCTGCTT
TCTGACGACACAGGATATCCACCTCGGCGTAAACGAGTCCCTCACCGACACTGCT
AGGGTACTGAGCAGCATGGCCGACGCTGTGCTAGCCCGGGTTTACAAGCAGTCA
GACCTGGACACCCTTGCCAAGGAAGCTTCTATTCCAATTATCAACGGCCTGAGTG
ACCTGTATCACCTATTCAAATACTCGCCGACTATTTGACGCTTCAAGAACATTA
CAGCAGCCTCAAGGGCTTAACCTTGAGTTGGATAGGCGACGGCAACAATATCCT
GCATTCCATTATGATGTCTGCCGCTAAGTTTGGCATGCATCTACAAGCCGCAACA
CCCAAGGGCTATGAACCCGACGCTAGCGTGACCAAGCTGGCCGAGCAGTATGCT
AAGGAAAATGGCACAAAGCTCCTTCTTACCAACGATCCCCTGGAGGCTGCTCAC
GGCGGCAACGTGCTGATTACCGATACATGGATTAGCATGGGCCAGGAGGAGGAG
AAAAAGAAGCGGCTCCAGGCTTTTCAAGGCTATCAGGTCACCATGAAAACCTGCA
AAGGTCGCTGCCTCCGACTGGACTTTCCTGCATTGTCTACCCCGCAAGCCTGAGG
AAGTGGACGATGAGGTGTTCTACTCCCCACGGAGTCTGGTGTTCCTCGGAAGCAG
AGAATCGGAAGTGGACCATCATGGCTGTCATGGTGTGCTCTTGACTGACTATTC
TCCCCAACTGCAAAAACCCAAGTTTTAG

>pARM708 (SEQ ID NO: 141)

ATGCTTTTTAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT

CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCCATCATCAACGGCCTGA
 GCGACCTGTACCACCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCA
 CTACAGCAGCCTGAAGGGTCTGACCCTGTCTATGGATTGGCGATGGAAACAATAT
 TCTGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCGCC
 ACGCCAAAAGGATACGAACCGGATGCGTCCGTGACGAAGTTGGCGGAACAGTAC
 GCGAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCCCCTCGAGGCTGCG
 CATGGGGGCAACGTGCTGATTACCGACACCTGGATCTCCATGGGGCAGGAGGAA
 GAGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAAC
 CGCAAAGTGGCAGCTTCGGACTGGACTTTCTCTGCATTGCCTGCCGAGGAAGCC
 GGAGGAAGTCGACGACGAAGTGTTCTACTCGCCTCGGTCCCTGGTGTTCCTCGAG
 GCCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGCTGACTGAC
 TATAGCCCGCAGCTGCAGAAGCCTAAGTTCTAG

>pARM709 (SEQ ID NO: 142)

ATGCTTTTCAACCTGAGAATCCTCTTGAACAATGCTGCTTTTCGGAATGGCCACA
 ACTTTATGGTTCGGAACCTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
 GAAGGGCCGGGATTTGCTCACACTGAAGAACTTTACTGGAGAAGAGATCAAGTA
 CATGCTGTGGCTGTGCGCCGACCTGAAGTTCAGGATCAAGCAGAAGGGAGAATA
 CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCATAACG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTCGATACCTTGGCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAG
 CGACCTGTACCACCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCAC
 TACAGCAGCCTGAAGGGTCTGACCCTGTCTATGGATTGGCGATGGAAACAATATT
 CTGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCGCCA
 CTCCAAAAGGATACGAACCGGATGCGTCCGTGACCAAGTTGGCGGAACAGTACG
 CGAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCCCCTCGAGGCTGCGC
 ATGGGGGCAACGTGCTGATTACCGACACCTGGATCTCCATGGGGCAGGAGGAAG
 AGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAACC
 GCAAAGTGGCAGCTTCGGACTGGACTTTCTCTGCATTGCCTGCCGAGGAAGCCG
 GAGGAAGTCGACGACGAAGTGTTCTACTCGCCTCGGTCCCTGGTGTTCCTCGAGG
 CCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGCTGACTGACT
 ATAGCCCGCAGCTGCAGAAGCCTAAGTTCTAG

>pARM710 (SEQ ID NO: 143)

ATGCTTTTCAACCTGAGAATCCTCTTGAACAATGCTGCTTTTCGGAATGGCCACA
 ACTTTATGGTTCGGAACCTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
 GAAGGGCCGGGATTTGCTCACACTAAAGAACTTTACTGGAGAAGAGATCAAGTA
 CATGCTATGGCTGTGCGCCGACCTGAAGTTCGATCAAGCAGAAGGGAGAATA
 CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCATAACG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTCGATACCTTGGCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAG
 CGACCTGTACCACCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCAC
 TACAGCAGCCTGAAGGGTCTGACCCTGTCTATGGATTGGCGATGGAAACAATATT
 CTGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCGCCA
 CTCCAAAAGGATACGAACCGGATGCATCCGTGACCAAGTTGGCGGAACAGTACG
 CGAAGGAGAACGGAACCAAGCTCCTGCTGACTAACGACCCGCTCGAGGCTGCGC

ATGGGGGTAAACGTGCTGATTACGGACACCTGGATCTCCATGGGGCAGGAGGAAG
AGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAACC
GCAAAAGTGGCAGCTTCGGACTGGACTTTCCTGCATTGCCTGCCGAGGAAGCCG
GAGGAAGTCGACGACGAAGTGTCTACTCGCCTCGGTCCCTGGTGTTCCTCCGAGG
CCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGCTGACTGACT
ATAGCCCGCAGCTGCAGAAGCCTAAGTTCTAG

>pARM711 (SEQ ID NO: 144)

ATGCTTTTCAACCTGAGAATCCTCTTGAACAATGCTGCTTTTCGGAATGGCCACA
ACTTTATGGTTCGGAACCTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
GAAGGGCCGGGATTTGCTCACACTAAAGAACTTTACTGGAGAAGAGATCAAGTA
CATGCTATGGCTGTCGGCCGACCTGAAGTTCGTATCAAGCAGAAGGGAGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCATAACG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTCGATACCTTGCCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAG
CGACCTGTACCACCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCAC
TACAGCAGCCTGAAGGGTCTGACCCTGTATGGATTGGCGATGGAAACAATATT
CTGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCGCCA
CTCCAAAAGGATACGAACCGGATGCGTCCGTGACCAAGTTGGCGGAACAGTACG
CGAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCCTCGAGGCTGCGC
ATGGGGGCAACGTGCTGATTACCGACACCTGGATCTCCATGGGGCAGGAGGAAG
AGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAACC
GCAAAAGTGGCAGCTTCGGACTGGACTTTCCTGCATTGCCTGCCGAGGAAGCCG
GAGGAAGTCGACGACGAAGTGTCTACTCGCCTCGGTCCCTGGTGTTCCTCCGAGG
CCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGCTGACTGACT
ATAGCCCGCAGCTGCAGAAGCCTAAGTTCTAG

>pARM712 (SEQ ID NO: 145)

ATGCTGTTCAACCTGCGAATCCTGCTGAACAACGCCGCTTTTCGGAACGGGCACA
ACTTTATGGTGAGGAACCTTCGCTGCGGACAGCCCTCCAGAATAAGGTCCAGCT
GAAGGGCAGGGACCTGCTGACCCTGAAAAATTTACAGGGGAGGAAATCAAGTA
TATGCTGTGGCTGTCAGCTGATCTGAAGTTCGGATCAAGCAGAAGGGCGAATA
TCTGCCTCTGCTCCAGGGCAAAAGCCTGGGGATGATCTTCGAAAAGCGCAGTACT
CGGACCAGACTGTCAACCGAGACTGGATTGCTCTGCTGGGAGGACACCCTTGTT
TTCTGACCACTCAGGACATTCACCTGGGAGTGAACGAGTCCCTGACCGACACTGC
TCGCGTCTGAGCTCTATGGCCGACGCTGTGCTGGCTCGAGTCTACAAACAGTCC
GACCTGGATACCCTGGCCAAGGAAGCTTCTATCCCAATTATTAACGGCCTGTCAG
ACCTGTATCACCCCATCCAGATTCTGGCCGATTACCTGACCCTCCAGGAGCACTA
TTCTAGTCTGAAAGGGCTGACACTGAGTTGGATTGGGGACGGAAACAATATCCT
GCACTCTATTATGATGTCAGCCGCCAAGTTTGAATGCACCTCCAGGCTGCAACC
CCAAAAGGCTACGAACCCGATGCCTCAGTGACAAAGCTGGCTGAACAGTACGCC
AAAGAGAACGGCACTAAGCTGCTGCTGACCAACGACCCTCTGGAGGCGCTCAC
GGAGGCAACGTGCTGATCACCGATACCTGGATTAGTATGGGACAGGAGGAAGAG
AAGAAGAAGCGGCTCCAGGCCTTCCAGGGCTACCAGGTGACAATGAAAACCGCT
AAGGTCGACGCCAGCGATTGGACCTTTCTGCACTGCCTGCCAGAAAGCCCGAA
GAGGTGGACGACGAGGTCTTCTACTCTCCAGAAGCCTGGTGTTCCTCCGAAGCTG
AGAATAGGAAGTGGACAATTATGGCAGTGATGGTCAGCCTGCTGACTGATTATTC
ACCTCAGCTCCAGAAACCAAGTTCTGA

>pARM713 (SEQ ID NO: 146)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCTTCCGCAACGGCCACA
 ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
 GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
 CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
 CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
 CCGCACCCGCTGAGCACCGAGACAGGCCTGGCCCTGCTGGGCGGCCACCCCTG
 CTTCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
 CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
 GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
 GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
 GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
 CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
 CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
 GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGAGGC
 CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
 AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
 AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
 CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
 CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM714 (SEQ ID NO: 147)

ATGCTGTTCAACCTGCGAATCCTGCTGAACAACGCCGCTTTTCGGAACGGGCACA
 ACTTTATGGTGAAGAACTTTCGCTGCGGACAGCCCCCTCCAGAATAAGGTCCAGCT
 GAAGGGCAGGGACCTGCTGACCCTGAAAAATTTACAGGGGAGGAAATCAAGTA
 TATGCTGTGGCTGTCAGCTGATCTGAAGTTCCGGATCAAGCAGAAGGGCGAATA
 TCTGCCTCTGCTCCAGGGCAAAAGCCTGGGGATGATCTTCGAAAAGCGCAGTACT
 CGGACCAGACTGTCAACCGAGACTGGATTCTGCTCTGCTGGGAGGACACCCTTGTT
 TTCTGACCACTCAGGACATTCACCTGGGAGTGAACGAGTCCCTGACCGACACTGC
 TCGCGTCTGAGCTCTATGGCCGACGCTGTGCTAGCTCGAGTCTACAAACAGTCC
 GACCTGGATACCCTGGCCAAGGAAGCTTCTATCCCAATTATTAACGGCCTGTCAG
 ACCTGTATCACCCCATCCAGATTCTGGCCGATTACCTGACCCTCCAGGAGCACTA
 TTCTAGTCTGAAAGGGCTGACACTGAGTTGGATTGGGGACGGAAACAATATCCT
 GCACTCTATTATGATGTCAGCCGCCAAGTTTGGAAATGCACCTCCAGGCTGCAACC
 CAAAAGGCTACGAACCCGATGCCTCAGTGACAAAGCTGGCTGAACAGTACGCC
 AAAGAGAACGGCACTAAGCTGCTGCTGACCAACGACCCTCTGGAGGCCGCTCAC
 GGAGGCAACGTGCTGATCACCGATACCTGGATTAGTATGGGACAGGAGGAAGAG
 AAGAAGAAGCGGCTCCAGGCCTTCCAGGGCTACCAGGTGACAATGAAAACCGCT
 AAGGTGCGAGCCAGCGATTGGACCTTTCTGCACTGCCTGCCAGAAAGCCCGAA
 GAGGTGGACGACGAGGTCTTCTACTCTCCAGAAAGCCTGGTGTTCCTCGAAGCTG
 AGAATAGGAAGTGGACAATTATGGCAGTGATGGTCAGCCTGCTGACTGATTATTC
 ACCTCAGCTCCAGAAACCAAGTTCTGA

>pARM715 (SEQ ID NO: 148)

ATGCTGTTCAACCTGCGAATCCTGCTGAACAATGCCGCTTTTCGGAACGGGCACA
 ATTTTCATGGTGAAGAACTTTCGCTGCGGACAGCCCCCTCCAGAACAAGGTCCAGCT
 GAAGGGCAGGGACCTGCTGACCCTGAAAAATTTACAGGGGAGGAAATCAAGTA
 CATGCTGTGGCTGTCAGCCGATCTGAAGTTCCGGATCAAGCAGAAGGGCGAATA

TCTGCCTCTGCTCCAGGGCAAAAGCCTGGGGATGATCTTCGAAAAGCGCAGTACT
 CGGACCAGACTGTCAACAGAGACTGGATTTCGCACTGCTGGGAGGACACCCATGT
 TTTCTGACCACACAGGACATTTCATCTGGGAGTGAACGAGTCCCTGACCGACACA
 GCACGCGTCTGAGCTCCATGGCTGATGCAGTGTGGCTCGAGTCTACAAACAGT
 CTGACCTGGATACCCTGGCCAAGGAAGCTTCTATCCCAATCATTAAATGGCCTGAG
 TGACCTGTATCACCCCATCCAGATTCTGGCCGATTACCTGACCCTCCAGGAGCAT
 TATTCTAGTCTGAAAGGGCTGACACTGAGCTGGATTGGGGACGGAACAATATC
 CTGCACTCCATTATGATGAGCGCCGCCAAGTTTGGGAATGCACCTCCAGGCTGCAA
 CCCCCAAAAGGCTACGAACCCGATGCCTCCGTGACAAAGCTGGCAGAACAGTATG
 CCAAAGAGAACGGCACTAAGCTGCTGCTGACCAATGACCCTCTGGAGGCCGCTC
 ACGGAGGCAACGTGCTGATCACTGATACCTGGATTAGTATGGGACAGGAGGAAG
 AGAAGAAGAAGCGGCTCCAGGCCTTCCAGGGCTACCAGGTGACAATGAAAACCTG
 CTAAGGTGCGAGCCAGCGACTGGACCTTCTGCAATTGCCTGCCCAGAAAGCCTGA
 AGAGGTGGACGATGAGGTCTTCTACTCACCCAGAAGCCTGGTGTTCCTGAAGCT
 GAGAATAGGAAGTGGACAATCATGGCAGTGATGGTCAGCCTGCTGACTGATTAT
 TCCCTCAGCTCCAGAAACCAAAGTTCTGA

>pARM716 (SEQ ID NO: 149)

ATGCTTTTCAACCTTTCGCAATTCTCCTCAACAACGCCGCGTTTAGAAACGGACACA
 ACTTCATGGTCCGCAACTTCCGCTGCGGACAGCCGCTGCAGAACAAGGTCCAGCT
 CAAGGGTCGGGATCTCCTGACGCTGAAGAACTTTACCGGCGAAGAGATTAAAGTA
 CATGCTGTGGCTGTCCGCCGACCTTAAGTTCCGGATCAAGCAGAAGGGCGAATA
 CCTTCCCCTGCTGCAAGGAAAGTCCCTGGGCATGATCTTCGAGAAGCGCAGTACC
 AGAACCAGACTCTCCACTGAAACCGGGTTCGCGCTGCTTGGCGGCCACCCGTGTT
 TCCTCACTACGCAAGACATCCATCTTGGCGTGAACGAGTCCCTTACCGACACCGC
 CAGGGTGCTGTCAAGCATGGCCGACGCCGTCCTTGCGCGCGTGTACAAGCAGTC
 AGACCTTGATACTCTGGCCAAGGAAGCCTCCATCCCTATTATCAACGGCCTATCC
 GACCTTTACCACCCGATCCAGATCCTCGCTGACTACCTGACCCTGCAAGAACT
 ACAGCAGCCTCAAGGGACTGACTCTGTCTGGATCGGCGACGGGAACAACATCC
 TGCACCTCAATCATGATGAGCGCAGCCAAGTTCGGCATGCATCTCCAAGCCGCTAC
 ACCCAAGGGTTATGAACCGGACGCCTCTGTGACCAAGTTGGCAGAACAGTACGC
 CAAGGAGAACGGTACTAAGCTCCTTTTAACCAACGACCCCTCGAAGCAGCCCA
 TGGCGGGAATGTGCTCATTACCGATACCTGGATTTCGATGGGCCAGGAGGAGGA
 GAAGAAGAAGCGGCTGCAGGCGTTCCAGGGCTACCAGGTCACCATGAAAACCTGC
 CAAAGTGGCCGCCTCGGATTGGACCTTTCTCCACTGCCTGCCTCGGAAGCCTGAG
 GAGGTGGACGACGAAGTGTCTACTCCCCACGGTCCCTCGTGTTCCCGAGGCCG
 AAAATAGGAAGTGGACCATCATGGCCGTGATGGTGTCCCTCTTGACCGATTACA
 GCCCGCAGCTTCAGAAGCCTAAATTCTAG

>pARM717 (SEQ ID NO: 150)

ATGCTTTTCAATCTTTCGCACTCCTGTTGAACAACGCCGCCTTCCGCAATGGTCACA
 ACTTCATGGTCCGGAACCTCAGATGTGGACAGCCTCTCCAAAACAAGGTCCAGCT
 GAAGGGAAGGGACCTCTTAACCTCAAAAACCTTTACTGGAGAGGAGATCAAGTA
 CATGCTGTGGCTTAGCGCCGACCTTAAGTTCCGGATCAAGCAGAAGGGAGAGTA
 CCTCCCCTGCTGCAAGGAAAGAGTCTTGGGAATGATCTTCGAGAAGCGGTCCAC
 CAGAACTCGCCTCTCCACTGAAACCGGATTTCGCACTCCTGGGTGGACACCCGTGC
 TTTCTGACCACCAAGACATCCACCTCGGAGTGAACGAGAGCCTCACGGACACC
 GCGAGAGTGCTGTCATCCATGGCCGACGCCGTGCTTGCACGGGTCTACAAGCAG
 TCCGATCTGGACACTCTTGCCAAGGAAGCCTCCATTCCTATCATTAAACGGTCTGT
 CGGATCTGTACCACCCGATTCAGATCCTTGCGGACTACCTCACACTTCAAGAACA

CTATTCAAGCCTAAAGGGTCTGACCCTGTCCTGGATCGGAGATGGAAACAACATT
 CTCCATTCCATCATGATGAGCGCTGCCAAGTTCGGAATGCATCTCCAAGCAGCGA
 CTCCTAAGGGTTACGAGCCGGACGCCTCAGTGAATAAGCTGGCCGAGCAGTACG
 CCAAGGAGAACGGTACCAAACCTGTTGCTTACTAACGACCCGCTTGAAGCGGCC
 ATGGAGGAAACGTGCTGATTACCGACACCTGGATTTCGATGGGACAGGAAGAGG
 AGAAGAAGAAGCGGCTCCAGGCGTTCCAGGGATACCAGGTCACCATGAAAACG
 GCCAAAGTGGCCGCTAGCGATTGGACCTTTCTGCACTGCCTCCCGCGCAAGCCTG
 AAGAAGTGGACGACGAAGTGTCTACTCCCTCGCTCTCTTGTGTTCCCGGAAGC
 CGAAAACAGGAAGTGGACCATCATGGCCGTGATGGTGTCCCTCCTGACCGATTA
 CAGCCCGCAGCTGCAGAAGCCTAAGTTCTAG

>pARM718 (SEQ ID NO: 151)

ATGCTTTTCAATCTCCGCATCCTCCTCAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAGAACAAGGTCCAGCT
 CAAGGGCCCGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAAATCAAGTA
 CATGCTCTGGCTCTCCGCCGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATAC
 CTTCCGCTGCTGCAAGGAAAGTCGCTCGGCATGATCTTTGAGAAGCGCTCAACCC
 GCACCAGGCTGTCCACTGAAACCGGGTTCGCGCTGCTTGGTGGCCACCCCTGCTT
 CCTGACCACCCAAGACATTCACCTCGGAGTGAACGAATCGCTCACTGATACTGCC
 CGGGTGCTGTCTGTCGATGGCCGATGCAGTGTGGCCAGGGTGTACAAACAGTCC
 GATCTGGACACTCTGGCCAAGGAGGCGTCCATCCCTATTATCAACGGCCTTTCCG
 ACCTCTACCACCCGATTACAGATCCTTGCCGATTACCTCACCTGCAAGAACTACTA
 CTCGTCCTGAAGGGTCTGACCTTGTCTGATCGGCGACGGCAACAACATCCTC
 CATTCCATTATGATGTCCGCCGCCAAATTCCGCATGCATCTTCAAGCCGCAACCC
 CTAAGGGTTACGAGCCGGACGCTTCCGTGACCAAGCTCGCCGAGCAGTACGCTA
 AGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCCTAGAGGCAGCCACG
 GGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGACAGGAAGAAGAGA
 AGAAGAAGCGGTTACAGGCGTTCCAGGGCTATCAGGTCACCATGAAAACCGCCA
 AGGTCGCTGCCTCGGACTGGACCTTCCTGCATTGCCTGCCTCGCAAGCCCGAAGA
 AGTGGACGACGAGGTGTTCTACTCGCCACGGTCCCTTGTGTTCCCTGAGGCCGAG
 AATAGAAAGTGGACCATATGGCCGTGATGGTGTCCCTTCTCACCGACTACTCGC
 CGCAACTGCAGAAACCCAAGTTCTAG

>pARM719 (SEQ ID NO: 152)

ATGCTTTTCAATCTTCGCATCCTCCTCAACAACGCCGCTTCCGGAACGGTCACA
 ACTTCATGGTCCGGAACCTCCGCTGCGGCCAGCCGCTCCAAAACAAAGTGCAGCT
 TAAGGGCCCGGATCTCCTGACCCTGAAGAACTTACCGGAGAGGAATCAAGTA
 CATGCTGTGGCTCTCGGCGGACCTGAAGTTTAGGATTAAGCAGAAGGGGGAGTA
 TCTGCCGCTGCTCCAAGGGAAGTCCCTTGGCATGATCTTCGAAAAGAGGTCCACC
 CGGACTCGGCTCAGCACCGAAACAGGTTTTGCACTTCTGGGGGGCCACCCGTGCT
 TCCTGACGACCCAGGACATCCATCTGGGTGTCAACGAGAGTTTGACCGACACTGC
 CAGAGTGCTGTCATCCATGGCGGACGCGGTGCTCGCGAGAGTGTACAAGCAGTC
 CGATCTTGACACCCTGGCAAAAGAGGCTTCAATCCCGATCATTAAACGGACTCTCG
 GATCTGTACCACCCTATCCAAATCTTGGCCGACTACCTGACCCTGCAAGAACACT
 ACAGTCCCTGAAGGGCCTGACTCTTTCCTGGATTGGCGATGGAAACAACATTCT
 CCATTCTATTATGATGTCCGCCGCCAAGTTCGGCATGCACCTTCAAGCCGCCACC
 CCGAAGGGCTACGAACCTGACGCCTCCGTGACTAAGCTAGCCGAACAGTACGCT
 AAGGAGAACGGCACTAAGCTTCTCCTTACCAACGATCCGCTGGAGGCGGCCAT
 GGCGGAAATGTGCTTATCACCGACACCTGGATTAGCATGGGGCAGGAAGAAGAG
 AAGAAGAAACGGCTCCAGGCATTCCAGGGCTACCAGGTCACCATGAAAACCTGCC

AAGGTCGCCGCTAGCGACTGGACCTTCCTCCACTGTCTGCCTCGCAAGCCTGAAG
 AAGTGGACGACGAGGTGTTCTACTCCCCGCGCTCCCTCGTGTTTCCTGAGGCCGA
 GAACAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTTACGGACTACAG
 CCCGCAGCTGCAGAAGCCGAAGTTCTAG

>pARM720 (SEQ ID NO: 153)

ATGCTTTTTAACTTGAGAATCCTTCTGAACAACGCCGCTTTCCGCAACGGTCATA
 ACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCCCCTCCAAAACAAAGTGCAGCT
 GAAGGGCCGGGACCTTCTTACGCTGAAGAATTTACCGGCGAAGAAATCAAGTA
 CATGCTCTGGCTGTCCGCCGATCTTAAGTTCCGCATTAAGCAGAAGGGGGAATAC
 CTCCCGCTGCTGCAAGGGAAGTCGCTGGGCATGATTTTTGAGAAGCGGTCAACTC
 GCACCCGCCTGTCCACTGAAACTGGATTCGCACTGCTCGGTGGCCATCCCTGCTT
 CCTGACCACCCAAGACATCCACCTCGGCGTGAACGAGTCCCTGACTGACACCGC
 CCGGGTCTTATCCTCGATGGCCGATGCTGTGCTTGCGAGGGTGTACAAGCAGTCC
 GACCTCGACACACTCGCGAAGGAGGGCCTCCATCCCCATCATCAACGGCCTGTCCG
 ACCTTTACCACCCAATTCAGATCCTCGCCGATTACCTGACCCTGCAAGAGCACTA
 CTCGTCGCTCAAGGGGCTTACCCTCTCGTGGATTGGCGACGGCAACAACATCCTT
 CACTCCATCATGATGTCGGCAGCGAAGTTCGGCATGCATCTGCAAGCCGCCACGC
 CTAAGGGTTATGAACCGGATGCCTCAGTGACCAAGCTCGCCGAACAGTACGCGA
 AAGAGAATGGAACCAAGCTACTTCTGACCAACGACCCCCTGGAGGCCGCTCACG
 GCGGCAACGTCCTCATTACCGATACTTGGATTTTCGATGGGACAGGAAGAGGAAA
 AGAAGAAGAGACTGCAGGCGTTCCAGGGATACCAGGTCAACATGAAAACCTGCCA
 AAGTGGCAGCCTCCGACTGGACCTTCCTTCACTGCCTGCCGAGGAAGCCTGAAG
 AGGTGGACGACGAGGTGTTCTACTCCCCGCGCTCCTTGGTGTTTCCTGAGGCCGA
 AAACCGGAAGTGGACTATCATGGCCGTGATGGTGTCCCTCCTCACCGACTACTCG
 CCGCAACTGCAGAAGCCTAAGTTCTAG

>pARM721 (SEQ ID NO: 154)

ATGTTATTCAACCTTAGAATTCTCCTTAACAACGCCGCCTTCCGGAATGGGCATA
 ACTTTATGGTCCGCAATTTCCGCTGTGGACAGCCTCTGCAAAACAAGGTCCAGCT
 CAAGGGCCGGGATCTGCTGACTCTCAAGAACTTCACTGGGGAAGAAATCAAGTA
 CATGCTCTGGCTGAGCGCCGACCTCAAGTTCCGCATCAAGCAGAAGGGAGAGTA
 CCTCCCGCTGCTCCAAGGGAAGTCCCTGGGCATGATCTTCGAGAAGAGATCCACC
 CGCACCAGACTTTCCACTGAGACTGGCTTCGCCTTGCTGGGAGGCCACCATGCT
 TCCTGACGACCCAGGACATTACCTTGGCGTGAACGAGTCCCTGACTGACACCGC
 AAGGGTGTGTCTCGATGGCCGACGCCGTGCTTGCCCGGGTGTACAAGCAGAG
 CGATCTTGACACCCTGGCTAAGGAAGCTTCCATTCCCATCATCAACGGTCTGAGC
 GACCTGTACCACCCGATTCAAGATCCTGGCGGACTACCTAACCCTGCAAGAGCACT
 ATAGCTCCCTGAAGGGCCTCACACTTTCATGGATCGGCGACGGCAACAACATCCT
 GCACTCTATTATGATGAGCGCTGCCAAATTCGGCATGCACCTCCAAGCCGCCACG
 CCTAAAGGCTACGAGCCCGACGCCTCGGTGACCAAGCTTGCGGAGCAGTACGCG
 AAGGAAAACGGCACCAAGCTGCTTCTACCAACGATCCTCTGGAAGCGGCCCAT
 GGTGGCAACGTGCTCATTACCGACACTTGGATCTCCATGGGACAGGAGGAGGAA
 AAGAAGAAGCGGCTCCAGGCGTTTCAGGGTTACCAGGTCAACATGAAAACCGCC
 AAGGTGCGAGCCTCCGACTGGACCTTCCTTCACTTGCCTTCCGCGCAAGCCCGAAG
 AAGTGGACGATGAAGTGTTTTACTCACCTCGGTCACTCGTGTTCCCGGAAGCAGA
 GAACAGGAAATGGACATTATGGCCGTGATGGTGTCCCTGCTCACCGATTACAGT
 CCGCAACTGCAGAAGCCCAAGTTCTAG

>pARM722 (SEQ ID NO: 155)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
 GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGAATA
 CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCTTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAAATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
 TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCTAAGGGTTACGAACCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTGCTGCTGACTAACGACCCGCTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAGGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTTCTCACCGACTAC
 AGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM723 (SEQ ID NO: 156)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
 TAAGGGCCGGGATCTCCTCACCCCTTAAAACTTCACCGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACCTTAAGTTCCGCATTAAGCAGAAGGGGGAATAC
 CTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACCA
 GGACCAGGCTTTTCTACTGAAACTGGGTTCGCGCTTCTCGGCGGTTCATCCCTGCTT
 CCTCACGACCCAAGACATCCACCTCGGAGTGAACGAATCCCTCACGGATACTGC
 CCGCGTGCTTTTCGAGCATGGCAGACGCCGTGCTCGCCCGGGTGTACAAACAGTCC
 GATCTCGACACTCTCGCCAAGGAGGCGTCAATTCCTATTATCAACGGTCTTAGTG
 ACCTTTACCACCCGATCCAGATCCTCGCCGATTACCTCACACTCCAAGAACACTA
 CAGCTCCCTTAAGGGTCTTACCCTCTCCTGGATCGGCGACGGCAACAACATTCTC
 CACTCCATCATGATGTCCGCCGCAAGTTCGGCATGCATCTTCAAGCCGCCACCC
 CGAAGGGCTACGAGCCTGATGCTTCCGTGACTAAGCTCGCCGAGCAGTACGCTA
 AGGAGAACGGAACCAAGCTTCTTCTACTAACGACCCACTCGAAGCAGCCCATG
 GGGGCAACGTGCTTATCACTGACACCTGGATCTCCATGGGCCAGGAAGAAGAGA
 AGAAGAAGCGGCTCCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGCCA
 AGGTCGCTGCCTCCGACTGGACCTTTCTCCACTGCCTCCCTCGCAAACCTGAAGA
 AGTGGACGACGAGGTGTTCTACTCGCCCCGGAGCCTCGTGTTCCCCGAGGCCGA
 GAATAGAAAGTGGACCATATGGCCGTGATGGTGTCACTCCTCACCGACTACAG
 CCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM724 (SEQ ID NO: 157)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGACATA
 ACTTCATGGTCCGGAACCTTCAGATGTGGACAGCCGCTTCAAAACAAGGTCCAGCT
 GAAGGGTCGGGATCTTCTGACCCTGAAGAACTTTACCGGAGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGAGAATA
 CCTCCCGCTGCTTCAAGGAAAGAGCCTCGGAATGATTTTTGAGAAGCGCTCAACC

AGGACCCGCCTTTCTACTGAAACTGGATTTCGCGCTGCTGGGTGGACACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACTGATACCGC
 CCGGGTGTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGTC
 CGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATCATCAACGGACTTAGT
 GACCTCTACCATCCGATTCAAATCCTGGCCGACTACCTCACCTGCAAGAACACT
 ACAGCTCCCTGAAGGGTCTGACATTGTCTGATCGGAGATGGAAACAACATTCT
 CCACTCCATCATGATGTCCGCCGCAAAATTCGGAATGCATCTTCAAGCCGCCACG
 CCTAAGGGTTACGAACCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGCT
 AAGGAGAACGGTACCAAGCTTCTCCTGACCAACGACCCACTAGAAGCAGCCAC
 GGTGGAAACGTGCTTATTACTGACACTTGGATCTCCATGGGACAGGAGGAAGAG
 AAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGCC
 AAGGTCGCTGCCTCCGACTGGACCTTCTGCACTGCCTGCCTCGCAAGCCTGAAG
 AAGTGGACGACGAGGTGTTCTACTCGCCGCGGAGCCTCGTGTTCCTCCGAGGCCG
 AGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTACA
 GCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM725 (SEQ ID NO: 158)

ATGCTTTTCAACCTCCGCATTCTCCTCAACAACGCTGCCTTCCGGAATGGACATA
 ACTTCATGGTCCGGAACCTCAGATGCGGACAGCCGCTTCAGAACAAGGTCCAGC
 TTAAGGGGAGAGATCTCCTTACCCTCAAAAACCTTCACTGGCGAAGAAATCAAGT
 ACATGCTCTGGCTTAGTGCGGATCTCAAGTTCCGCATCAAGCAGAAGGGAGAAT
 ACCTCCCGCTCCTTCAAGGAAAGAGCCTCGGCATGATTTTGAAGAAGAGGTCCAC
 CAGAACTCGCCTTTCAACCGAGACTGGGTTCGCCCTGCTTGGCGGTACCCCTGC
 TTCCTCACTACCCAAGACATCCACCTCGGCGTGAACGAGAGCCTTACCGACACCG
 CCCGCGTGCTCTCCTCAATGGCCGACGCTGTGCTCGCCCGGGTGTACAAGCAGTC
 CGACCTTGATACTCTCGCCAAGGAGGCCTCCATCCCAATTATCAACGGGCTCTCT
 GATCTCTACCACCCTATCCAAATCCTCGCGGACTACCTCACCTCCAAGAGCACT
 ATAGCTCGCTCAAGGGCCTCACCTTTCTGATTTGGCGACGGCAACAACATTCT
 TCACTCGATCATGATGTCCGCCGCCAAGTTCGGCATGCATCTCCAAGCCGCGACC
 CCCAAGGGCTACGAGCCTGACGCATCCGTGACCAAGCTCGCCGAGCAGTACGCG
 AAGGAAAATGGCACCAAGCTTCTTCTACCAACGACCCCCTTGAGGCCGCTCATG
 GCGGCAACGTGCTCATCACTGACACTTGGATCAGCATGGGCCAGGAGGAGGAAA
 AGAAGAAGCGCCTTCAGGCATTCCAGGGTTACCAGGTCACCATGAAAACCGCCA
 AAGTGGCCGCCTCCGACTGGACCTTCTTCACTGTCTCCCGCGGAAGCCTGAAGA
 AGTGGATGACGAAGTGTTTTACTCCCTCGGTCACTCGTGTTCCTCCGGAAGCAGAA
 AACAGGAAGTGGACCATTATGGCGGTCAATGGTGTCCCTCCTCACCGACTACAGCC
 CGCAGCTTCAGAAACCCAAGTTCTAG

>pARM726 (SEQ ID NO: 159)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCAGCGTTTAGAAACGGTCACA
 ACTTCATGGTCCGGAACCTCCGCTGTGGACAGCCGCTTCAAACAAGGTCCAGCT
 GAAGGGTCGGGACCTTCTGACCCTGAAGAACTTTACTGGAGAAGAGATCAAGTA
 CATGCTTTGGCTGTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGAGAATA
 CCTTCCGCTGCTCCAAGGAAAGAGCCTGGGAATGATCTTTGAGAAGCGCTCAAC
 CAGGACCCGCTTTCTACTGAAACTGGATTTCGCGCTGCTGGGTGGTCACCCTTGC
 TTCCTGACGACCCAGGACATTCACCTCGGAGTGAACGAGTCCCTCACTGATACCG
 CCAGAGTGTTATCGAGCATGGCAGATGCCGTGCTGGCTAGGGTGTACAAACAGT
 CCGATCTGGACACCTGGCCAAGGAGGCATCAATTCCTATTATCAACGGACTTAG
 TGACCTCTACCATCCGATTCAAATCCTGGCCGATTACCTCACCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGAGATGGAAACAACATTC

TCCATTCCATCATGATGTCCGCGGCCAAGTTCGGAATGCATCTCCAAGCCGCCAC
 GCCGAAAGGATACGAGCCGGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCGCTAGAAGCCGCCA
 CGGTGGAAACGTGCTTATTACTGACACCTGGATCTCCATGGGACAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCCGCCTCCGACTGGACCTTCCTTCACTGCCTGCCTCGGAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCGCGGAGCCTCGTGTTCCCTGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTCCTCACCGACTAC
 AGCCCGCAGCTTCAGAAGCCTAAGTTCTAG

>pARM727 (SEQ ID NO: 160)

ATGCTTTTCAATCTCCGCATTCTCCTCAACAACGCAGCCTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCGCTTCAGAACAAGGTCCAGCT
 CAAGGGCCGGGACCTCCTCACCTCAAAAACCTTACCGGCGAAGAGATCAAGTA
 CATGCTCTGGCTTTCGGCCGACCTTAAGTTCCGCATCAAGCAGAAGGGGGGAATAC
 CTTCCGCTGCTTCAAGGAAAGTCCCTCGGCATGATCTTTGAAAAGCGCTCGACCA
 GGACCCGCCTTTCCACTGAAACCGGGTTTCGCGCTTCTCGGTGGCCACCCCTGCTT
 CCTCACCAACCAAGACATTCACCTCGGAGTGAACGAATCCCTTACCGATACCGCA
 AGAGTGCTTTCGTCGATGGCCGATGCCGTGCTTGCGCGGGTGTACAAGCAGTCAG
 ATCTCGACACTCTCGCCAAGGAGGCGTCCATTCTATTATCAACGGCCTTTCCGA
 CCTTTACCACCCGATTCAGATCCTCGCCGATTACCTCACCTGCAAGAGCACTAC
 TCGTCACTCAAGGGTCTTACCCTCTCCTGGATCGGCGACGGAAACAACATCCTCC
 ATTCGATCATGATGTCCGCCGCCAAATTCGGCATGCACCTCCAAGCCGCGACCCC
 GAAGGGTTACGAGCCCGACGCTTCCGTGACCAAGCTCGCCGAACAGTACGCTAA
 GGAAAACGGCACCAAGCTCCTCCTCACTAACGACCCTCTCGAAGCAGCCCATGG
 GGGCAACGTGCTCATTACTGACACTTGGATCTCGATGGGCCAGGAAGAGGAGAA
 AAAGAAGCGGCTTCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGCCAA
 GGTCGCTGCCTCGGACTGGACCTTCCTTCACTGCCTTCCGCGCAAGCCTGAAGAG
 GTGGACGATGAGGTGTTCTACTCCCCACGGTCCCTTGTGTTCCCCGAGGCCGAGA
 ATAGGAAGTGGACCATCATGGCCGTGATGGTGTGCTCCTCACTGACTACTCCCC
 GCAACTTCAGAAGCCTAAGTTCTAG

>pARM728 (SEQ ID NO: 161)

ATGCTGTTTAATCTGAGAATACTTCTAAACAACGCCGCCTTCCGGAATGGCCATA
 ACTTTATGGTTCGGAATTTCCGCTGCGGCCAGCCGCTGCAGAACAAGGTCCAGCT
 GAAGGGAAGAGACTTGCTGACCCTCAAGAACTTCACCGGAGAAGAAATCAAGTA
 TATGCTGTGGCTGTCCGCCGACCTGAAATTCGCATCAAGCAGAAGGGCGAATA
 TCTGCCGCTGTTGCAAGGGAAGTCCCTGGGGATGATCTTCGAGAAGAGGTCCAC
 CAGAACACGGCTTTCAACCGAAACCGGGTTTGCACTGCTGGGTGGACACCCCTGT
 TTTCTGACCCTCAAGATATCCACCTGGGCGTGAACGAGTCCCTTACCGACACTG
 CTAGGGTGTTGTCCAGCATGGCCGATGCCGTCTGGCTCGCGTGTACAAGCAGTC
 CGACCTGGATACCTGGCAAAGGAAGCGTCCATTCCCATTATCAACGGGCTGTCC
 GACCTGTACCATCCGATTCAAATCCTGGCGGACTACCTGACTCTGCAAGAGCATT
 ACAGCAGCTTGAAGGGGCTTACTCTCTCGTGGATCGGCGACGGGAACAACATCC
 TGCCTCCATCATGATGTCCGCCGCCAAGTTCGGGATGCATTTGCAAGCTGCGAC
 CCCGAAAGGTTACGAGCCCGATGCTAGCGTAACTAAGCTTGCCGAACAGTACGC
 CAAAGAGAATGGTACAAAACCTGCTTCTGACTAACGACCCGCTGGAAGCAGCCCA
 CGGCGGGAACGTGCTGATAACCGACACCTGGATTTCATGGGGCAGGAGGAAGA
 GAAGAAGAAGCGACTGCAGGCGTTCCAAGGCTATCAGGTTACCATGAAAACCGC
 CAAAGTGGCAGCCAGCGATTGGACTTTCCTGCACTGTCTGCCGCGGAAGCCCGA

GGAAGTTGATGACGAAGTATTCTACTCACCCCGGAGCCTCGTGTTCCCCGAGGCC
GAAAACCGGAAGTGGACTATTATGGCCGTGATGGTGTCTGCTGTTGACCGACTAC
AGCCCGCAACTGCAGAAGCCGAAGTTTTAG

>pARM729 (SEQ ID NO: 162)

ATGCTTTTCAACCTGAGGATCCTTTTGAACAACGCCGCCTTTCGCAACGGCCACA
ACTTTATGGTCCGCAATTTCCGCTGCGGGCAGCCGCTGCAGAACAAGGTCCAGCT
GAAGGGCCGGGATCTGCTGACCCTGAAGAACTTCAACGGGGAGGAAATCAAGTA
CATGCTTTGGCTCTCCGCCGATCTGAAGTTCAGAATCAAGCAGAAGGGAGAGTA
CCTCCCGTTGCTGCAAGGAAAGTCACTCGGAATGATTTTCGAAAAGAGAAGCAC
TAGGACCCGCCTCTCAACTGAAACCGGGTTTCGCGCTGCTCGGGGGCCATCCGTGT
TTCCTGACTACCCAAGACATCCACCTGGGAGTGAACGAGTCGCTGACCGACACC
GCACGCGTGCTGTTCATCCATGGCGGACGCAAGTGTGCTTGTCCCGGGTGTACAAGCAG
TCGGACCTGGACACTCTTGCCAAGGAGGCATCAATCCCCATCATTAAACGGACTGT
CCGATCTCTACCACCCGATTCAGATCCTGGCTGACTACCTAACCTGCAAGAGCA
CTACTCAAGCCTGAAGGGGCTGACCCTGTCTGGATCGGGGACGGCAACAACAT
TCTGCACTCCATCATGATGTCTGGCGGCTAAGTTCGGGATGCATTTGCAAGCGGCA
ACTCCGAAGGGTTATGAACCCGACGCCTCCGTGACCAAGCTGGCCGAACAGTAC
GCCAAGGAAAACGGAACCAAGTTGCTGCTGACTAATGATCCCCTGGAGGCGGCC
CACGGGGGGAACGTGCTGATAACCGATACCTGGATCTCCATGGGGCAGGAAGAA
GAGAAGAAAAAGCGGCTGCAGGCATTCCAGGGATACCAGGTACCATGAAAAC
CGCAAAAGTGGCAGCCAGCGACTGGACTTTCCTCCATTGCCTGCCGCGAAAGCC
GGAGGAGGTGATGACGAGGTGTTCTACTCCCCGCGGTCTGCTGGTGTTCGGGA
GGCGGAAAACCGGAAGTGGACCATTATGGCCGTGATGGTGTCACTCCTGACTGA
CTACAGCCCGCAACTGCAGAAGCCGAAGTTCTAG

>pARM1787 (SEQ ID NO: 163)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCGCGCATTAAGCAGAAGGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCTGCAAGAACAC
TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTACCATGAAAACCGC
CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
AGCCCGCAGCTTCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1788 (SEQ ID NO: 164)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCCTGGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCCGCTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGAGGC
CGCCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGA

>pARM1789 (SEQ ID NO: 165)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCCTGGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCCGCTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGAGGC
CGCCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGA

>pARM1790 (SEQ ID NO: 166)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC

AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTTGATCGGCGACGGCAACAACATTC
 TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
 AGCCCGCAGCTTCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1791 (SEQ ID NO: 167)

ATGCTTTTCAACCTGAGAATCCTCTTGAACAATGCTGCTTTTCGGAATGGCCACA
 ACTTTATGGTTCGGAACCTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
 GAAGGGCCGGGATTTGCTCACACTAAAGAACTTTACTGGAGAAGAGATCAAGTA
 CATGCTATGGCTGTGCGCCGACCTGAAGTTCCGTATCAAGCAGAAGGGAGAATA
 CTTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTCGATACCTTGGCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAG
 CGACCTGTACCACCCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCAC
 TACAGCAGCCTGAAGGGTCTGACCCTGTATGGATTGGCGATGGAAACAATATT
 CTGCACTCCATCATGATGTCCGCCGCAAGTTTCGGAATGCATCTGCAAGCCGCCA
 CTCCAAAAGGATACGAACCGGATGCATCCGTGACCAAGTTGGCGGAACAGTACG
 CGAAGGAGAACGGAACCAAGCTCCTGCTGACTAACGACCCGCTCGAGGCTGCGC
 ATGGGGGTAAACGTGCTGATTACGGACACCTGGATCTCCATGGGGCAGGAGGAAG
 AGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAACC
 GCAAAAGTGGCAGCTTCGGACTGGACTTTCCTGCAATTGCCTGCCGAGGAAGCCG
 GAGGAAGTCGACGACGAAGTGTCTACTCGCCTCGGTCCCTGGTGTCCCCGAGG
 CCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGTGCTGACTGACT
 ATAGCCCGCAGCTGCAGAAGCCTAAGTTCTAGATAAGTGAA

>pARM1792 (SEQ ID NO: 168)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
 ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAGGTGCAGCT
 GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
 CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
 CCTGCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
 CCGCACCCGCTGAGCACCGAGACAGGCCTGGCCCTGCTGGGCGGCCACCCCTG
 CTTCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
 CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
 GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
 GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
 GCCTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA

CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGA

>pARM1793 (SEQ ID NO: 169)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCGCTTCAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCTGCAAGAACAC
TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTACACCATGAAAACCGC
CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
AGCCCGCAGCTTCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1794 (SEQ ID NO: 170)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCCTGGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA

AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGA

>pARM1795 (SEQ ID NO: 171)

ATGCTTTTCAACCTGAGAATCCTCTTGAACAATGCTGCTTTTCGGAATGGCCACA
ACTTTATGGTTCGGAACCTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
GAAGGGCCGGGATTTGCTCACACTAAAGAACTTTACTGGAGAAGAGATCAAGTA
CATGCTATGGCTGTCGGCCGACCTGAAGTTCGTATCAAGCAGAAGGGAGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTCGATACCTTGGCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAG
CGACCTGTACCACCCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCAC
TACAGCAGCCTGAAGGGTCTGACCCTGTCATGGATTGGCGATGGAAACAATATT
CTGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCGCCA
CTCCAAAAGGATACGAACCGGATGCATCCGTGACCAAGTTGGCGGAACAGTACG
CGAAGGAGAACGGAACCAAGCTCCTGCTGACTAACGACCCGCTCGAGGCTGCGC
ATGGGGGTAAACGTGCTGATTACGGACACCTGGATCTCCATGGGGCAGGAGGAAG
AGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAACC
GCAAAAGTGGCAGCTTCGGACTGGACTTTCCTGCATTGCCTGCCGAGGAAGCCG
GAGGAAGTCGACGACGAAGTGTCTACTCGCCTCGGTCCCTGGTGTTCCTCGAGG
CCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGTCTGACTGACT
ATAGCCCGCAGCTGCAGAAGCCTAAGTTCTAGATAAGTGA

>pARM1796 (SEQ ID NO: 172)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCGCGATTAAGCAGAAGGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCTCGAGGCC
GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
AGCCCGCAGCTTCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1797 (SEQ ID NO: 173)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCCTGGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCCGCTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCTGTACAAGCA
GAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGA

>pARM1798 (SEQ ID NO: 174)

ATGCTTTTCAACCTGAGAATCCTCTTGAACAATGCTGCTTTTCGGAATGGCCACA
ACTTTATGGTTCGGAACCTTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
GAAGGGCCGGGATTTGCTCACACTAAAGAACTTTACTGGAGAAGAGATCAAGTA
CATGCTATGGCTGTGCGCCGACCTGAAGTTCCGTATCAAGCAGAAGGGAGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTCGATACCTTGGCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAG
CGACCTGTACCACCCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCAC
TACAGCAGCCTGAAGGGTCTGACCCTGTATGGATTGGCGATGGAAACAATATT
CTGCACTCCATCATGATGTCCGCCGCAAGTTCGGAATGCATCTGCAAGCCGCCA
CTCCAAAAGGATACGAACCGGATGCATCCGTGACCAAGTTGGCGGAACAGTACG
CGAAGGAGAACGGAACCAAGCTCCTGCTGACTAACGACCCGCTCGAGGCTGCGC
ATGGGGGTAAACGTGCTGATTACGGACACCTGGATCTCCATGGGGCAGGAGGAAG
AGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCACCATGAAAACC
GCAAAAGTGGCAGCTTCGGACTGGACTTTCCTGCATTGCCTGCCGAGGAAGCCG
GAGGAAGTCGACGACGAAGTGTCTACTCGCCTCGGTCCCTGGTGTTCCTCCGAGG
CCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGTGCTGACTGACT
ATAGCCCGCAGCTGCAGAAGCCTAAGTTCTAGATAAGTGA

>pARM1799 (SEQ ID NO: 175)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC

CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1800 (SEQ ID NO: 176)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1801 (SEQ ID NO: 177)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA

CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
CCGAGGCCGAGAACCGCAAGTGGAACATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1802 (SEQ ID NO: 178)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCTGTACAAGCA
GAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
CCGAGGCCGAGAACCGCAAGTGGAACATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGAA

>pARM1803 (SEQ ID NO: 179)

ATGGGCGTCTTCAACCTGCGGATCCTGCTGAACAACGCCGCCTTCCGGAACGGCC
ACAACTTCATGGTCCGCAACTTCAGATGCGGCCAGCCCCCTGCAGAACAAGGTGC
AGCTGAAGGGCCGGGACCTGCTGACCCTGAAGAACTTCACCGGCGAAGAGATCA
AGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGGATCAAGCAGAAGGGCG
AGTACCTGCCCCCTGCTGCAAGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGGA
GCACCCGGACCCGGCTGAGCACCGAGACAGGCTTTGCCCTGCTGGGAGGCCACC
CCTGCTTTTCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
ACACCGCCAGAGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGGGTGTACA
AGCAGAGCGACCTGGACACCCTGGCCAAAGAGGCCAGCATCCCCATCATCAACG
GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
GGAACACTACAGCTCCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCATCTGCA
GGCCGCCACCCCCAAGGGCTACGAGCCTGATGCCAGCGTGACCAAGCTGGCCGA
GCAGTACGCCAAAGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGA
AGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
GGAAGAGGAAAAGAAGAAGCGGCTGCAGGCCTTCCAGGGCTACCAGGTCACAA
TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC

GGAAGCCCGAAGAGGTGGACGACGAGGTGTTCTACAGCCCCCGGTCCCTGGTGT
TCCCCGAGGCCGAGAACCGBAAGTGGACCATTATGGCCGTGATGGTGTCCCTGC
TGACCGACTACTCCCCCAGCTGCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1804 (SEQ ID NO: 180)

ATGGGCGTCTTCAACCTGCGGATCCTGCTGAACAACGCCGCCTTCCGGAACGGCC
ACAACCTTCATGGTCCGCAACTTCAGATGCGGCCAGCCCCCTGCAGAACAGGGTGC
AGCTGAAGGGCCGGGACCTGCTGACCCTGAAGAACTTCACCGGCCAAGAGATCA
GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGGATCAAGCAGAAGGGCG
AGTACCTGCCCTGCTGCAAGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGGA
GCACCCGGACCCGGCTGAGCACCGAGACAGGCTTTGCCCTGCTGGGAGGCCACC
CCTGCTTTCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
ACACCGCCAGAGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCCGGGTGTACA
AGCAGAGCGACCTGGACACCCTGGCCAAAGAGGCCAGCATCCCCATCATCAACG
GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
GGAACACTACAGCTCCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCATCTGCA
GGCCGCCACCCCCAAGGGCTACGAGCCTGATGCCAGCGTGACCAAGCTGGCCGA
GCAGTACGCCAAAGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGA
AGCCGCCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
GGAAGAGGAAAAGAAGAAGCGGCTGCAGGCCTTCCAGGGCTACCAGGTCACAA
TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
GGAAGCCCGAAGAGGTGGACGACGAGGTGTTCTACAGCCCCCGGTCCCTGGTGT
TCCCCGAGGCCGAGAACCGBAAGTGGACCATTATGGCCGTGATGGTGTCCCTGC
TGACCGACTACTCCCCCAGCTGCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1805 (SEQ ID NO: 181)

ATGCTGGTCTTCAACCTGCGGATCCTGCTGAACAACGCCGCCTTCCGGAACGGCC
ACAACCTTCATGGTCCGCAACTTCAGATGCGGCCAGCCCCCTGCAGAACAGGGTGC
AGCTGAAGGGCCGGGACCTGCTGACCCTGAAGAACTTCACCGGCCAAGAGATCA
GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGGATCAAGCAGAAGGGCG
AGTACCTGCCCTGCTGCAAGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGGA
GCACCCGGACCCGGCTGAGCACCGAGACAGGCTTTGCCCTGCTGGGAGGCCACC
CCTGCTTTCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
ACACCGCCAGAGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCCGGGTGTACA
AGCAGAGCGACCTGGACACCCTGGCCAAAGAGGCCAGCATCCCCATCATCAACG
GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
GGAACACTACAGCTCCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCATCTGCA
GGCCGCCACCCCCAAGGGCTACGAGCCTGATGCCAGCGTGACCAAGCTGGCCGA
GCAGTACGCCAAAGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGA
AGCCGCCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
GGAAGAGGAAAAGAAGAAGCGGCTGCAGGCCTTCCAGGGCTACCAGGTCACAA
TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
GGAAGCCCGAAGAGGTGGACGACGAGGTGTTCTACAGCCCCCGGTCCCTGGTGT
TCCCCGAGGCCGAGAACCGBAAGTGGACCATTATGGCCGTGATGGTGTCCCTGC
TGACCGACTACTCCCCCAGCTGCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1806 (SEQ ID NO: 182)

ATGCTGTTCAACCTGAGGATCCTGCTGAACAACGCAGCTTTCAGGAACGGCCAC
AACTTCATGGTGAGGAACTTCCGGTGCGGCCAGCCCCTGCAGAACAAGGTGCAG
CTGAAGGGCAGGGACCTGCTGACCCTGAAGAACTTCACCGGAGAGGAGATCAAG
TACATGCTGTGGCTGAGCGCAGACCTGAAGTTCAGGATCAAGCAGAAGGGAGAG
TACCTGCCCCTGCTGCAGGGGAAGTCCCTGGGCATGATCTTCGAGAAGAGGAGT
ACCAGGACCAGGCTGAGCACCGAAACCGGCTTCGCCCTGCTGGGAGGACACCCC
TGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGTCTGACCGAC
ACCGCCAGGGTGCTGTCTAGCATGGCCGACGCCGTGCTGGCCAGGGTGTACAAG
CAGTCAGACCTGGACACCCTGGCTAAGGAGGGCCAGCATCCCCATCATCAACGGC
CTGAGCGACCTGTACCAACCCCATCCAGATCCTGGCTGACTACCTGACCCTGCAGG
AGCACTACAGCTCTCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGGAACA
ACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGG
CCGCTACCCCCAAGGGTTACGAGCCCGACGCCAGCGTGACCAAGCTGGCAGAGC
AGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGG
CCGCCACGGAGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGACAGG
AGGAGGAGAAGAAGAAGCGGCTGCAGGCTTTCAGGGTTACCAGGTGACCATGA
AGACCGCCAAGGTGGCTGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCAGGA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACTCTCCCAGGAGCCTGGTGTTC
CCGAGGCCGAGAACAGGAAGTGACCATCATGGCTGTGATGGTGTCCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGAA

>pARM1808 (SEQ ID NO: 183)

ATGCTGTTCAACCTGAGGATCCTGCTGAACAACGCAGCTTTCAGGAACGGCCAC
AACTTCATGGTGAGGAACTTCCGGTGCGGCCAGCCCCTGCAGAACAAGGTGCAG
CTGAAGGGCAGGGACCTGCTGACCCTGAAGAACTTCACCGGAGAGGAGATCAAG
TACATGCTGTGGCTGAGCGCAGACCTGAAGTTCAGGATCAAGCAGAAGGGAGAG
TACCTGCCCCTGCTGCAGGGGAAGTCCCTGGGCATGATCTTCGAGAAGAGGAGT
ACCAGGACCAGGCTGAGCACCGAAACCGGCTTCGCCCTGCTGGGAGGACACCCC
TGCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATA
CCGCCCGGGTGTTATCAAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAAC
AGTCCGATCTGGACACTCTGGCTAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCAACCCCATCCAGATCCTGGCTGACTACCTGACCCTGCAGGAG
CACTACAGCTCTCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGGAACAAC
ATCCTGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCG
CCACGCCAAAAGGATACGAACCGGATGCGCCCGTGACAAAGTTGGCGGAACAGT
ACGCTAAGGAGAACGGAACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGCCG
CCCACGGAGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGACAGGAGG
AGGAGAAGAAGAAGCGGCTGCAGGCTTTCAGGGTTACCAGGTGACCATGAAGA
CCGCCAAGGTGGCTGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCAGGAAGC
CCGAGGAGGTGGACGACGAGGTGTTCTACTCTCCCAGGAGCCTGGTGTTCCTCCG
AGGCCGAGAACAGGAAGTGACCATCATGGCTGTGATGGTGTCCCTGCTGACCG
ACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGAA

>pARM1809 (SEQ ID NO: 184)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC

CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
 CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
 CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
 GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
 GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
 GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
 CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
 CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
 GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCTGGAGGC
 CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
 AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
 AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
 CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
 CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGAA

>pARM1816 (SEQ ID NO: 185)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
 ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
 GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
 CATGCTGTGGCTGAGCGCCGACCTGAAGTTCGCGCATCAAGCAGAAGGGCGAGTA
 CCTGCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
 CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
 CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
 CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
 GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
 GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
 GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
 CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
 CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
 GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCTGGAGGC
 CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
 AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
 AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
 CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
 CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTGAA

>pARM1822 (SEQ ID NO: 186)

ATGCTTTTCAACTTGAGAATCCTGCTGAACAACGCCGCCTTTCGCAACGGTCACA
 ATTTTATGGTCAGAACTTCAGATGCGGACAGCCCCCTCCAAAACAAGGTCCAGCT
 GAAGGGCCGCGATCTCCTCACCTGAAGAACTTACGGGGGAGGAGATCAAGTA
 CATGCTGTGGCTCTCCGCTGACCTGAAGTTCAGGATCAAGCAGAAGGGAGAATA
 TCTGCCGCTGCTGCAAGGGAAGTCCCTGGGGATGATTTTCGAGAAGCGGAGCAC
 CCGGACTCGGCTCTCCACTGAACTGGTTTTCGCCCTTCTGGGCGGTCACCCCTGC
 TTCCTGACCACTCAAGACATTACCTCGGAGTGAACGAGTCCTTGACTGACACCG
 CCCGGGTGCTGTGAGCATGGCAGACGCCGTGCTAGCCCGCGTGTACAAGCAGT
 CAGACCTCGATACCTGGCCAAGGAGGCTTCGATCCCGATCATCAACGGGTTGTC
 CGACCTGTACCACCGATTTCAGATTCTCGCCGACTACCTCACCTGCAAGAGCAT
 TACAGCTCCCTGAAGGGGCTTACCCTGTCTGGATTGGCGACGGAAACAACATCC

TGCACTCCATTATGATGTCTGGCGGCCAAGTTCGGCATGCACCTCCAAGCCGCGAC
 CCCTAAGGGTTACGAACCAGACGCGTCAGTGACTAAGCTGGCCGAACAGTACGC
 AAAGGAAAATGGCACGAAGCTGCTCCTGACCAACGATCCGTTGGAAGCCGCCA
 TGGCGGAAATGTGCTCATCACCGACACCTGGATCTCGATGGGACAGGAGGAAGA
 GAAGAAGAAGCGGCTGCAGGCGTTCCAGGGCTACCAGGTCACCATGAAAACCTGC
 CAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTTCCGCGCAAGCCTGAG
 GAGGTGGACGATGAAGTGTCTACTCTCCACGGTCCCTGGTGTTCCTCCGAGGCGG
 AGAACCGCAAATGGACCATCATGGCTGTGATGGTCAGCCTGCTGACCGATTACA
 GCCCTCAGTTGCAAAAGCCGAAGTTTTGA

>pARM1823 (SEQ ID NO: 187)

ATGCTGTTCAACCTCCGCATCCTCCTCAACAACGCCGCATTCAGAAACGGGCACA
 ACTTCATGGTCAGAACTTCCGCTGCGGGCAACCCCTACAAAACAAGGTCCAGC
 TCAAGGGGCGGGACCTCCTGACCCTGAAGAACTTCACCGGCCAAGAGATCAAGT
 ACATGCTGTGGCTCTCCGCCGACCTGAAGTTCGCGCATCAAGCAGAAGGGAGAGT
 ACCTCCCGCTGCTGCAAGGGAAGTCGCTGGGGATGATCTTCGAGAAGCGGTCAA
 CCAGAACCCGGCTGTCAACCGAAACCGGGTTCGCACTGCTGGGGGGACACCCGT
 GCTTCCTGACCACCCAAGACATCCACCTGGGAGTGAACGAATCGCTGACCGACA
 CCGCCCGCGTGCTGAGCTCAATGGCGGACGCCGTGCTGGCCCGCGTGTACAAGC
 AGTCCGACCTGGACACCCTGGCCAAGGAAGCGTCCATCCCGATCATCAACGGAC
 TGTCCGACCTGTACCACCCGATCCAGATCCTGGCAGACTACCTGACCCTGCAAGA
 AACTACAGCTCCCTGAAGGGCCTGACCCTGTTCATGGATCGGGGACGGGAACAA
 CATCCTGCACTCCATAATGATGTCAGCCGCCAAGTTCGGAATGCACCTCCAAGCC
 GCAACCCCGAAGGGCTACGAACCGGACGCATCAGTGACCAAACTGGCCGAGCAG
 TACGCCAAGGAAAACGGCACCAAGCTCCTGCTGACCAACGACCCGCTGGAGGCC
 GCACACGGGGGGAACGTGCTGATCACCGACACCTGGATCTCCATGGGACAGGAG
 GAGGAAAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTACCAGGTCACCATGAA
 AACC CGAAGGTGCGCGCATCAGACTGGACCTTCCTGCACTGCCTGCCCCGGAA
 GCCGGAAGAGGTGGACGACGAGGTGTTCTACTCGCCGCGCTCGCTGGTGTTCCTCC
 GAGGCGGAGAACAGGAAGTGGACCATCATGGCGGTGATGGTCAGCCTCCTGACC
 GACTACTCGCCGCAGCTGCAGAAGCCGAAGTTCTGA

>pARM1840 (SEQ ID NO: 188)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAAAACAAGGTCCAGCT
 GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCGCGATTAAGCAGAAGGGGGGAATA
 CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCTTTCTACTGAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
 TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA

GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
AGCCCGCAGCTTCAGAAGCCCAAGTTCTGAATAAGTAGA

>pARM1841 (SEQ ID NO: 189)

ATGCTTTTCAACCTGAGAATCCTCTTGAACAATGCTGCTTTTCGGAATGGCCACA
ACTTTATGGTTCGGAACCTCCGTTGCGGCCAGCCTTTACAAAACAAGGTCCAGCT
GAAGGGCCGGGATTTGCTCACACTAAAGAACTTTACTGGAGAAGAGATCAAGTA
CATGCTATGGCTGTCGGCCGACCTGAAGTTCCGTATCAAGCAGAAGGGAGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTCGATACCTTGGCAAAGGAGGCTTCCATTCCCATCATCAACGGCCTGAG
CGACCTGTACCACCCAATCCAAATCCTGGCTGACTACCTGACCCTGCAAGAGCAC
TACAGCAGCCTGAAGGGTCTGACCCTGTCATGGATTGGCGATGGAAACAATATT
CTGCACTCCATCATGATGTCCGCCGCGAAGTTCGGAATGCATCTGCAAGCCGCCA
CTCCAAAAGGATACGAACCGGATGCATCCGTGACCAAGTTGGCGGAACAGTACG
CGAAGGAGAACGGAACCAAGCTCCTGCTGACTAACGACCCGCTCGAGGCTGCGC
ATGGGGGTAAACGTGCTGATTACGGACACCTGGATCTCCATGGGGCAGGAGGAAG
AGAAGAAGAAGAGACTGCAGGCATTCCAGGGGTACCAGGTCAACATGAAAACC
GCAAAAGTGGCAGCTTCGGACTGGACTTTCCTGCATTGCCTGCCGAGGAAGCCG
GAGGAAGTCGACGACGAAGTGTCTACTCGCCTCGGTCCCTGGTGTTCCTCCGAGG
CCGAAAACCGGAAGTGGACCATCATGGCCGTGATGGTGTCTTGCTGACTGACT
ATAGCCCGCAGCTGCAGAAGCCTAAGTTCTGAATAAGTAGA

>pARM1842 (SEQ ID NO: 190)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCAGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCCTGAGCACCGAGACAGGCCTGGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGAATAAGTAGA

>pARM1843 (SEQ ID NO: 191)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
AGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM1844 (SEQ ID NO: 192)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
AGGACCCGCCTTTCTACTGAAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
AGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM1845 (SEQ ID NO: 193)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAAACAAGGTCCAGCT
GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATA
CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC

AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTTGATCGGCGACGGCAACAACATTC
 TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
 AGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM1846 (SEQ ID NO: 194)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACAAGGTCCAGCT
 GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATA
 CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTTGATCGGCGACGGCAACAACATTC
 TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
 AGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM1847 (SEQ ID NO: 195)

ATGCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACAAGGTCCAGCT
 GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATA
 CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTTGATCGGCGACGGCAACAACATTC

TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
 AGCCCCGACGCTTCAGAAGCCCAAGTTCTAG

>pARM1882 (SEQ ID NO: 196)

ATGGTGTTC AACCTCCGCATCCTCCTCAACAACGCCGCATTCAGAAACGGGCACA
 ACTTCATGGTCAGAACTTCCGCTGCGGGCAACCCCTACAAAACAAGGTCCAGC
 TCAAGGGGGCGGGACCTCCTGACCCTGAAGAACTTCACCGGCCAAGAGATCAAGT
 ACATGCTGTGGCTCTCCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGAGAGT
 ACCTCCCGCTGCTGCAAGGGAAGTCGCTGGGGATGATCTTCGAGAAGCGGTCAA
 CCAGAACCCGGCTGTCAACCGAAACCGGGTTCGCACTGCTGGGGGGACACCCGT
 GCTTCCTGACCACCCAAGACATCCACCTGGGAGTGAACGAATCGCTGACCGACA
 CCGCCCCGCTGCTGAGCTCAATGGCGGACGCCGTGCTGGCCCCGCTGTACAAGC
 AGTCCGACCTGGACACCCTGGCCAAGGAAGCGTCCATCCCGATCATCAACGGAC
 TGTCCGACCTGTACCACCCGATCCAGATCCTGGCAGACTACCTGACCCTGCAAGA
 AACTACAGCTCCCTGAAGGGCCTGACCCTGTTCATGGATCGGGGACGGGAACAA
 CATCCTGCACTCCATAATGATGTCAGCCGCCAAGTTCGGAATGCACCTCCAAGCC
 GCAACCCCGAAGGGCTACGAACCGGACGCATCAGTGACCAAACCTGGCCGAGCAG
 TACGCCAAGGAAAACGGCACCAAGCTCCTGCTGACCAACGACCCGCTGGAGGCC
 GCACACGGGGGGAACGTGCTGATCACCGACACCTGGATCTCCATGGGACAGGAG
 GAGGAAAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTACCAGGTCACCATGAA
 AACC GCGAAGGTGCGCGCATCAGACTGGACCTTCCTGCACTGCCTGCCCCGGAA
 GCCGGAAGAGGTGGACGACGAGGTGTTCTACTCGCCGCGCTCGCTGGTGTTCCTCC
 GAGGCGGAGAACAGGAAGTGGACCATCATGGCGGTGATGGTCAGCCTCCTGACC
 GACTACTCGCCGACGCTGCAGAAGCCGAAGTTCTGA

>pARM1883 (SEQ ID NO: 197)

ATGGTGTTC AACCTCCGCATCCTCCTCAACAACGCCGCATTCAGAAACGGGCACA
 ACTTCATGGTCAGAACTTCCGCTGCGGGCAACCCCTACAAAACCGGGTCCAGCT
 CAAGGGGGCGGGACCTCCTGACCCTGAAGAACTTCACCGGCCAAGAGATCAAGTA
 CATGCTGTGGCTCTCCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGAGAGTA
 CCTCCCGCTGCTGCAAGGGAAGTCGCTGGGGATGATCTTCGAGAAGCGGTCAAC
 CAGAACCCGGCTGTCAACCGAAACCGGGTTCGCACTGCTGGGGGGACACCCGTG
 CTTCCTGACCACCCAAGACATCCACCTGGGAGTGAACGAATCGCTGACCGACAC
 CGCCCCGCTGCTGAGCTCAATGGCGGACGCCGTGCTGGCCCCGCTGTACAAGCA
 GTCCGACCTGGACACCCTGGCCAAGGAAGCGTCCATCCCGATCATCAACGGACT
 GTCCGACCTGTACCACCCGATCCAGATCCTGGCAGACTACCTGACCCTGCAAGAA
 CACTACAGCTCCCTGAAGGGCCTGACCCTGTTCATGGATCGGGGACGGGAACAAC
 ATCCTGCACTCCATAATGATGTCAGCCGCCAAGTTCGGAATGCACCTCCAAGCCG
 CAACCCCGAAGGGCTACGAACCGGACGCATCAGTGACCAAACCTGGCCGAGCAGT
 ACGCCAAGGAAAACGGCACCAAGCTCCTGCTGACCAACGACCCGCTGGAGGCCG
 CACACGGGGGGAACGTGCTGATCACCGACACCTGGATCTCCATGGGACAGGAGG
 AGGAAAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTACCAGGTCACCATGAAA
 ACCGCGAAGGTGCGCGCATCAGACTGGACCTTCCTGCACTGCCTGCCCCGGAAAG

CCGGAAGAGGTGGACGACGAGGTGTTCTACTCGCCGCGCTCGCTGGTGTTCCTCCG
AGGCGGAGAACAGGAAGTGGACCATCATGGCGGTGATGGTCAGCCTCCTGACCG
ACTACTCGCCGCAGCTGCAGAAGCCGAAGTTCTGA

>pARM1884 (SEQ ID NO: 198)

ATGGTGTTC AACCTCCGCATCCTCCTCAACAACGCCGCATTCAGAAACGGGCACA
ACTTCATGGTCAGAACTTCCGCTGCGGGCAACCCCTACAAAACCGGGTCCAGCT
CAAGGGGCGGGACCTCCTGACCCTGAAGAACTTCACCGGCGAAGAGATCCGGTA
CATGCTGTGGCTCTCCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGAGAGTA
CCTCCCGCTGCTGCAAGGGAAGTCGCTGGGGATGATCTTCGAGAAGCGGTCAAC
CAGAACCCGGCTGTCAACCGAAACCGGGTTCGCACTGCTGGGGGGACACCCGTG
CTTCTGACCACCCAAGACATCCACCTGGGAGTGAACGAATCGCTGACCGACAC
CGCCCGCTGCTGAGCTCAATGGCGGACGCCGTGCTGGCCCGCGTGTACAAGCA
GTCCGACCTGGACACCCTGGCCAAGGAAGCGTCCATCCCGATCATCAACGGACT
GTCCGACCTGTACCACCCGATCCAGATCCTGGCAGACTACCTGACCCTGCAAGAA
CACTACAGCTCCCTGAAGGGCCTGACCCTGTCATGGATCGGGGACGGGAACAAC
ATCCTGCACTCCATAATGATGTCAGCCGCCAAGTTCGGAATGCACCTCCAAGCCG
CAACCCCGAAGGGCTACGAACCGGACGCATCAGTGACCAAACCTGGCCGAGCAGT
ACGCCAAGGAAAACGGCACCAAGCTCCTGCTGACCAACGACCCGCTGGAGGCCG
CACACGGGGGGAACGTGCTGATCACCGACACCTGGATCTCCATGGGACAGGAGG
AGGAAAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTACCAGGTCACCATGAAA
ACCGCGAAGGTCGCGGCATCAGACTGGACCTTCCTGCACTGCCTGCCCCGGAAG
CCGGAAGAGGTGGACGACGAGGTGTTCTACTCGCCGCGCTCGCTGGTGTTCCTCCG
AGGCGGAGAACAGGAAGTGGACCATCATGGCGGTGATGGTCAGCCTCCTGACCG
ACTACTCGCCGCAGCTGCAGAAGCCGAAGTTCTGA

>pARM1885 (SEQ ID NO: 199)

ATGCTGGTCAACCTCCGCATCCTCCTCAACAACGCCGCATTCAGAAACGGGCACA
ACTTCATGGTCAGAACTTCCGCTGCGGGCAACCCCTACAAAACAAGGTCCAGC
TCAAGGGGCGGGACCTCCTGACCCTGAAGAACTTCACCGGCGAAGAGATCAAGT
ACATGCTGTGGCTCTCCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGAGAGT
ACCTCCCGCTGCTGCAAGGGAAGTCGCTGGGGATGATCTTCGAGAAGCGGTCAA
CCAGAACCCGGCTGTCAACCGAAACCGGGTTCGCACTGCTGGGGGGACACCCGT
GCTTCTGACCACCCAAGACATCCACCTGGGAGTGAACGAATCGCTGACCGACA
CCGCCCGCTGCTGAGCTCAATGGCGGACGCCGTGCTGGCCCGCGTGTACAAGC
AGTCCGACCTGGACACCCTGGCCAAGGAAGCGTCCATCCCGATCATCAACGGAC
TGTCGACCTGTACCACCCGATCCAGATCCTGGCAGACTACCTGACCCTGCAAGA
ACACTACAGCTCCCTGAAGGGCCTGACCCTGTCATGGATCGGGGACGGGAACAA
CATCCTGCACTCCATAATGATGTCAGCCGCCAAGTTCGGAATGCACCTCCAAGCC
GCAACCCCGAAGGGCTACGAACCGGACGCATCAGTGACCAAACCTGGCCGAGCAG
TACGCCAAGGAAAACGGCACCAAGCTCCTGCTGACCAACGACCCGCTGGAGGCC
GCACACGGGGGGAACGTGCTGATCACCGACACCTGGATCTCCATGGGACAGGAG
GAGGAAAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTACCAGGTCACCATGAA
AACCGCGAAGGTCGCGGCATCAGACTGGACCTTCCTGCACTGCCTGCCCCGGA
GCCGGAAGAGGTGGACGACGAGGTGTTCTACTCGCCGCGCTCGCTGGTGTTCCTCCG
GAGGCGGAGAACAGGAAGTGGACCATCATGGCGGTGATGGTCAGCCTCCTGACC
GACTACTCGCCGCAGCTGCAGAAGCCGAAGTTCTGA

>pARM1886 (SEQ ID NO: 200)

ATGCTGGTCAACCTCCGCATCCTCCTCAACAACGCCGCATTCAGAAACGGGCACA
ACTTCATGGTCAGAACTTCCGCTGCGGGCAACCCCTACAAAACCGGGTCCAGCT
CAAGGGGCGGGACCTCCTGACCCTGAAGAACTTCACCGGCGAAGAGATCAAGTA
CATGCTGTGGCTCTCCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGAGAGTA
CCTCCCCTGCTGCTGCAAGGGAAGTCGCTGGGGATGATCTTCGAGAAGCGGTCAAC
CAGAACCCGGCTGTCAACCGAAACCGGGTTTCGCACTGCTGGGGGGACACCCGTG
CTTCCTGACCACCAAGACATCCACCTGGGAGTGAACGAATCGCTGACCGACAC
CGCCCCGCTGCTGAGCTCAATGGCGGACGCCGTGCTGGCCCCGCTGTACAAGCA
GTCCGACCTGGACACCCTGGCCAAGGAAGCGTCCATCCCGATCATCAACGGACT
GTCCGACCTGTACCACCCGATCCAGATCCTGGCAGACTACCTGACCCTGCAAGAA
CACTACAGCTCCCTGAAGGGCCTGACCCTGTCATGGATCGGGGACGGGAACAAC
ATCCTGCACTCCATAATGATGTCAGCCGCCAAGTTCGGAATGCACCTCCAAGCCG
CAACCCCGAAGGGCTACGAACCGGACGCATCAGTGACCAAACCTGGCCGAGCAGT
ACGCCAAGGAAAACGGCACCAAGCTCCTGCTGACCAACGACCCGCTGGAGGCCG
CACACGGGGGGGAACGTGCTGATCACCGACACCTGGATCTCCATGGGACAGGAGG
AGGAAAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTACCAGGTCACCATGAAA
ACCGCGAAGGTTCGCGGCATCAGACTGGACCTTCCTGCACTGCCTGCCCCGGAAG
CCGGAAGAGGTGGACGACGAGGTGTTCTACTCGCCGCGCTCGCTGGTGTTCCCCG
AGGCGGAGAACAGGAAGTGGACCATCATGGCGGTGATGGTCAGCCTCCTGACCG
ACTACTCGCCGCAGCTGCAGAAGCCGAAGTTCTGA

>pARM1887 (SEQ ID NO: 201)

ATGCTGGTCAACCTCCGCATCCTCCTCAACAACGCCGCATTCAGAAACGGGCACA
ACTTCATGGTCAGAACTTCCGCTGCGGGCAACCCCTACAAAACCGGGTCCAGCT
CAAGGGGCGGGACCTCCTGACCCTGAAGAACTTCACCGGCGAAGAGATCCGGTA
CATGCTGTGGCTCTCCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGAGAGTA
CCTCCCCTGCTGCTGCAAGGGAAGTCGCTGGGGATGATCTTCGAGAAGCGGTCAAC
CAGAACCCGGCTGTCAACCGAAACCGGGTTTCGCACTGCTGGGGGGACACCCGTG
CTTCCTGACCACCAAGACATCCACCTGGGAGTGAACGAATCGCTGACCGACAC
CGCCCCGCTGCTGAGCTCAATGGCGGACGCCGTGCTGGCCCCGCTGTACAAGCA
GTCCGACCTGGACACCCTGGCCAAGGAAGCGTCCATCCCGATCATCAACGGACT
GTCCGACCTGTACCACCCGATCCAGATCCTGGCAGACTACCTGACCCTGCAAGAA
CACTACAGCTCCCTGAAGGGCCTGACCCTGTCATGGATCGGGGACGGGAACAAC
ATCCTGCACTCCATAATGATGTCAGCCGCCAAGTTCGGAATGCACCTCCAAGCCG
CAACCCCGAAGGGCTACGAACCGGACGCATCAGTGACCAAACCTGGCCGAGCAGT
ACGCCAAGGAAAACGGCACCAAGCTCCTGCTGACCAACGACCCGCTGGAGGCCG
CACACGGGGGGGAACGTGCTGATCACCGACACCTGGATCTCCATGGGACAGGAGG
AGGAAAAGAAGAAGCGGCTGCAGGCGTTCCAGGGGTACCAGGTCACCATGAAA
ACCGCGAAGGTTCGCGGCATCAGACTGGACCTTCCTGCACTGCCTGCCCCGGAAG
CCGGAAGAGGTGGACGACGAGGTGTTCTACTCGCCGCGCTCGCTGGTGTTCCCCG
AGGCGGAGAACAGGAAGTGGACCATCATGGCGGTGATGGTCAGCCTCCTGACCG
ACTACTCGCCGCAGCTGCAGAAGCCGAAGTTCTGA

>pARM1888 (SEQ ID NO: 202)

ATGCTGGTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCTGCAGAACAAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC

CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
 CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
 CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
 GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
 GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
 GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
 CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
 CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
 GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCTGGAGGC
 CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
 AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
 AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
 CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
 CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1889 (SEQ ID NO: 203)

ATGCTGGTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
 ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACCAGGTGCAGCT
 GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
 CATGCTGTGGCTGAGCGCCGACCTGAAGTTCGCGCATCAAGCAGAAGGGCGAGTA
 CCTGCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
 CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
 CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
 CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
 GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
 GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
 GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
 CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
 CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
 GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCTGGAGGC
 CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
 AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
 AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTCC
 CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
 CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1890 (SEQ ID NO: 204)

ATGCTTGTCATATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACAAGGTCCAGCT
 GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCGCGATTAAGCAGAAGGGGGAATA
 CCTTCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCTTTCTACTGAACTGGGTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCCCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC

TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
 AGCCCCGACGCTTCAGAAGCCCAAGTTCTAG

>pARM1891 (SEQ ID NO: 205)

ATGCTTGTCATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCCACA
 ACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCGCTTCAAACCGGGTCCAGCT
 GAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAAGTA
 CATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGAATA
 CCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCAACC
 AGGACCCGCTTTTCTACTGAAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCTGCT
 TCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATACCG
 CCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACAGT
 CCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTTAG
 TGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCTGCAAGAACAC
 TACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACATTC
 TCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGCCAC
 GCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTACGC
 TAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGCCCA
 CGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGAAGA
 GAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAACCGC
 CAAGGTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCCTGAA
 GAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGAGGCC
 GAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGACTAC
 AGCCCCGACGCTTCAGAAGCCCAAGTTCTAG

>pARM1898 (SEQ ID NO: 206)

ATGGGCCTTGTCATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
 ACAACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCGCTTCAAACAAGGTCC
 AGCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCA
 AGTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGG
 AATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTC
 AACCAGGACCCGCTTTTCTACTGAAACTGGGTTTCGCGCTGCTCGGTGGCCACCCC
 TGCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATA
 CCGCCCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAAC
 AGTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCT
 TAGTGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCTGCAAGAA
 CACTACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAAC
 ATTCTCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCG
 CCACGCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGT
 ACGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAG
 CCCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAG
 AAGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAA
 ACCGCCAAGGTGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGC

CTGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCTCCG
 AGGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCG
 ACTACAGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM1899 (SEQ ID NO: 207)

ATGGGCCTTGTCATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
 ACAACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACCGGGTCCA
 GCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAA
 GTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGA
 ATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCA
 ACCAGGACCCGCCTTTCTACTGAAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCT
 GCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATAC
 CGCCCGGGTGTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACA
 GTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTT
 AGTGACCTCTACCATCCGATTGAGATCCTGGCCGATTACCTCACCTGCAAGAAC
 ACTACAGCTCCCTGAAGGGTCTGACATTGTCTGATCGGCGACGGCAACAACA
 TTCTCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGC
 CACGCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTA
 CGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGC
 CCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGA
 AGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAA
 CCGCCAAAGTTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCC
 TGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCTCCGA
 GGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGA
 CTACAGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM1900 (SEQ ID NO: 208)

ATGGGCGGACTTGTCATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACG
 GCCACAACCTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAACCAAGG
 TCCAGCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGA
 TCAAGTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGG
 GGAATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCG
 CTCAACCAGGACCCGCCTTTCTACTGAAACTGGGTTTCGCGCTGCTCGGTGGCCAC
 CCCTGCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCG
 ATACCGCCCGGGTGTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACA
 AACAGTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGG
 CCTTAGTGACCTCTACCATCCGATTGAGATCCTGGCCGATTACCTCACCTGCAA
 GAACACTACAGCTCCCTGAAGGGTCTGACATTGTCTGATCGGCGACGGCAAC
 AACATTCTCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAG
 CCGCCACGCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGC
 AGTACGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAG
 CAGCCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGG
 AAGAAGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATG
 AAAACCGCCAAGGTTCGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCA
 AGCCTGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTC
 CCGAGGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCA
 CCGACTACAGCCCGCAGCTTCAGAAGCCCAAGTTCTAG

>pARM1903 (SEQ ID NO: 209)

ATGGCCCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
ACAACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAGGCAAGGTCC
AGCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCA
AGTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGG
AATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTC
AACCAGGACCCGCCTTTCTACTGAACTGGGTTCGCGCTGCTCGGTGGCCACCCC
TGCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATA
CCGCCCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAAC
AGTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCT
TAGTGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCTGCAAGAA
CACTACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAAC
ATTCTCCATTCCATCATGATGTCCGCCGAAAATTCGGCATGCATCTTCAAGCCG
CCACGCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGT
ACGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAG
CCCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAG
AAGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAA
ACCGCCAAGGTGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGC
CTGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCG
AGGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCG
ACTACAGCCCGCAGCTTCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1904 (SEQ ID NO: 210)

ATGGCCCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
ACAACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAGGCCGGGTCCA
GCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAA
GTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGA
ATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCA
ACCAGGACCCGCCTTTCTACTGAACTGGGTTCGCGCTGCTCGGTGGCCACCCCT
GCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATAC
CGCCCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACA
GTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTT
AGTGACCTCTACCATCCGATTCAGATCCTGGCCGATTACCTCACCTGCAAGAAC
ACTACAGCTCCCTGAAGGGTCTGACATTGTCTGGATCGGCGACGGCAACAACA
TTCTCCATTCCATCATGATGTCCGCCGAAAATTCGGCATGCATCTTCAAGCCGC
CACGCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTA
CGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGC
CCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGA
AGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAA
CCGCCAAGGTGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCC
TGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCCCGA
GGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGA
CTACAGCCCGCAGCTTCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1905 (SEQ ID NO: 211)

ATGGCCCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
ACAACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAGGCCGGGTCCA
GCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAG
GTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGGA
ATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCA

ACCAGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCT
 GCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATAC
 CGCCCGGGTGTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACA
 GTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTT
 AGTGACCTCTACCATCCGATTGAGATCCTGGCCGATTACCTCACCTGCAAGAAC
 ACTACAGCTCCCTGAAGGGTCTGACATTGTCTGATCGGCGACGGCAACAACA
 TTCTCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGC
 CACGCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTA
 CGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGC
 CCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGA
 AGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAAA
 CCGCCAAGGTGCTGCCTCCGACTGGACCTTCTGCACTGCCTGCCTCGCAAGCC
 TGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCTCGA
 GGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGA
 CTACAGCCCGCAGCTTCAGAAGCCCAAGTTCTAGATAAGTGAA

>pARM1906 (SEQ ID NO: 212)

ATGGCCCTTGTCATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
 ACAACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAGGCAGGGTCC
 AGCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCA
 AGTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGG
 AATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTC
 AACCAGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCC
 TGCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATA
 CCGCCCGGGTGTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAAC
 AGTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCT
 TAGTGACCTCTACCATCCGATTGAGATCCTGGCCGATTACCTCACCTGCAAGAA
 CACTACAGCTCCCTGAAGGGTCTGACATTGTCTGATCGGCGACGGCAACAAC
 ATTCTCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCG
 CCACGCCGAAGGGTTACGAGCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGT
 ACGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAG
 CCCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAG
 AAGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCACCATGAAA
 ACCGCCAAGGTGCTGCCTCCGACTGGACCTTCTGCACTGCCTGCCTCGCAAGC
 CTGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCTCG
 AGGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCG
 ACTACAGCCCGCAGCTTCAGAAGCCCAAGTTCTAAGTGAATAGA

>pARM1907 (SEQ ID NO: 213)

ATGGCCCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
 ACAACTTCATGGTCCGGAACCTCAGATGTGGCCAGCCGCTTCAAGTCAAGGTCCA
 GCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAA
 GTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGA
 ATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCA
 ACCAGGACCCGCCTTTCTACTGAAACTGGGTTCGCGCTGCTCGGTGGCCACCCCT
 GCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATAC
 CGCCCGGGTGTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACA
 GTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCCTATTATCAACGGCCTT
 AGTGACCTCTACCATCCGATTGAGATCCTGGCCGATTACCTCACCTGCAAGAAC
 ACTACAGCTCCCTGAAGGGTCTGACATTGTCTGATCGGCGACGGCAACAACA

TTCTCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGC
CACGCCGAAGGGTTACGAGCCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTA
CGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGC
CCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGA
AGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCAACCATGAAAA
CCGCCAAGGTGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCC
TGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCTCGA
GGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGA
CTACAGCCCCGACGCTTCAGAAGCCCCAAGTTCTAGATAAGTGAA

>pARM1908 (SEQ ID NO: 214)

ATGGCCCTTTTCAATCTCCGCATCCTCCTTAACAACGCCGCGTTTAGAAACGGCC
ACAACTTCATGGTCCGGAACCTTCAGATGTGGCCAGCCGCTTCAAGTCAGGGTCCA
GCTGAAGGGCCGGGATCTTCTGACCCTGAAGAACTTTACTGGCGAAGAGATCAA
GTACATGCTCTGGCTCTCCGCGGACTTGAAGTTCCGCATTAAGCAGAAGGGGGA
ATACCTTCCGCTGCTTCAAGGAAAGAGCCTCGGCATGATCTTTGAGAAGCGCTCA
ACCAGGACCCGCCTTTCTACTGAACTGGGTTTCGCGCTGCTCGGTGGCCACCCCT
GCTTCCTGACGACCCAGGACATCCACCTCGGAGTGAACGAATCCCTCACCGATAC
CGCCCGGGTGTTATCGAGCATGGCAGATGCCGTGCTGGCCAGGGTGTACAAACA
GTCCGATCTGGACACTCTGGCCAAGGAGGCGTCAATTCTATTATCAACGGCCTT
AGTGACCTCTACCATCCGATTACAGATCCTGGCCGATTACCTCACCTGCAAGAAC
ACTACAGCTCCCTGAAGGGTCTGACATTGTCTGATCGGCGACGGCAACAACA
TTCTCCATTCCATCATGATGTCCGCCGCAAAATTCGGCATGCATCTTCAAGCCGC
CACGCCGAAGGGTTACGAGCCCCGACGCTTCCGTGACTAAGCTCGCCGAGCAGTA
CGCTAAGGAGAACGGAACCAAGCTTCTGCTGACTAACGACCCACTAGAAGCAGC
CCACGGGGGCAACGTGCTTATTACTGACACCTGGATCTCCATGGGCCAGGAAGA
AGAGAAAAAGAAGCGGCTGCAGGCGTTCCAGGGATATCAGGTCAACCATGAAAA
CCGCCAAGGTGCTGCCTCCGACTGGACCTTCCTGCACTGCCTGCCTCGCAAGCC
TGAAGAAGTGGACGACGAGGTGTTCTACTCGCCACGGAGCCTCGTGTTCCTCGA
GGCCGAGAATAGAAAGTGGACCATCATGGCCGTGATGGTGTCACTGCTCACCGA
CTACAGCCCCGACGCTTCAGAAGCCCCAAGTTCTAGATAAGTGAA

>pARM1915 (SEQ ID NO: 215)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCCGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAGAAGAAGCGCCTGCAGGCTTCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA

AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1916 (SEQ ID NO: 216)

ATGGGAGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
ACAACCTTCATGGTGGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGC
AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCA
AGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
AGTACCTGCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA
GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
ACACCGCCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCCGCGTGTACA
AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
GGCCGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGA
GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGA
GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
GCAAGCCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
TCCCCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
TGACCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1917 (SEQ ID NO: 217)

ATGGGAGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
ACAACCTTCATGGTGGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACCAGGTGC
AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCC
GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
AGTACCTGCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA
GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
ACACCGCCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCCGCGTGTACA
AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
GGCCGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGA
GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGA
GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
GCAAGCCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
TCCCCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
TGACCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1918 (SEQ ID NO: 218)

ATGCTGGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
 ACAACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACCGGGTGC
 AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCC
 GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
 AGTACCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA
 GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
 CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
 ACACCGCCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACA
 AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
 GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
 GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
 CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
 GGCCGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGA
 GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGA
 GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
 GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
 TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
 GCAAGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
 TCCCCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
 TGACCGACTACAGCCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1919 (SEQ ID NO: 219)

ATGGGAGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
 ACAACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACAAAGGTGC
 AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCA
 AGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
 AGTACCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA
 GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
 CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
 ACACCGCCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACA
 AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
 GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
 GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
 CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
 GGCCGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGA
 GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGA
 GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
 GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
 TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
 GCAAGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
 TCCCCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
 TGACCGACTACAGCCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1920 (SEQ ID NO: 220)

ATGGGAGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
 ACAACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGAACCGGGTGC
 AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCC
 GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
 AGTACCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA

GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
 CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
 ACACCGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACA
 AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
 GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
 GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
 CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
 GGCCGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGA
 GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGA
 GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
 GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
 TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
 GCAAGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
 TCCCCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
 TGACCGACTACAGCCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1921 (SEQ ID NO: 221)

ATGCTGGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
 ACAACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACCGGGTGC
 AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGCGCAGGAGATCC
 GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
 AGTACCTGCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA
 GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
 CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
 ACACCGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACA
 AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
 GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
 GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
 CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
 GGCCGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGA
 GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGA
 GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
 GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
 TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
 GCAAGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
 TCCCCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
 TGACCGACTACAGCCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1925 (SEQ ID NO: 222)

ATGTTGTTCAACTTGAGGATCTTGTTGAACAACGCCGCCTTCAGGAACGGACACA
 ACTTCATGGTAAGGAACTTCAGGTGCGGACAGCCCTTGCAGAACAAGTACAGT
 TGAAAGGAAGGGACTTGTTGACATTGAAAACTTCACAGGAGAAGAAATCAAAT
 ACATGTTGTGGTTGTCGGCCGACTTGAAATTCAGGATCAAACAGAAAGGAGAAT
 ACTTGCCCTTGTTGCAGGGAAAATCGTTGGGAATGATCTTCGAAAAAAGGTCGA
 CAAGGACAAGGTTGTGACAGAAACAGGATTGCGCTTGTTGGGAGGACACCCCT
 GCTTCTTGACAACACAGGACATCCACTTGGGAGTAAACGAATCGTTGACAGACA
 CAGCCAGGGTATTGTCGTCGATGGCCGACGCCGTATTGGCCAGGGTATACAAAC
 AGTCGGACTTGGACACATTGGCCAAAGAAGCCTCGATCCCCATCATCAACGGAT
 TGTCGGACTTGTACCACCCCATCCAGATCTTGGCCGACTACTTGACATTGCAGGA
 ACATACTCGTCGTTGAAAGGATTGACATTGTCGTGGATCGGAGACGGAAACAA

CATCTTGCACTCGATCATGATGTCGGCCGCCAAATTCGGAATGCACTTGCAAGGCC
GCCACACCCAAAGGATACGAACCCGACGCCTCGGTAACAAAATTGGCCGAACAG
TACGCCAAAGAAAACGGAACAAAATTGTTGTTGACAAACGACCCCTTGGAAGCC
GCCCACGGAGGAAACGTATTGATCACAGACACATGGATCTCGATGGGACAGGAA
GAAGAAAAAAGGTTGCAGGCCTTCCAGGGATACCAGGTAACAATGAA
AACAGCCAAAGTAGCCGCCTCGGACTGGACATTCTTGCACTGCTTGCCAGGAA
ACCCGAAGAAGTAGACGACGAAGTATTCTACTCGCCCAGGTCGTTGGTATTCCCC
GAAGCCGAAAACAGGAAATGGACAATCATGGCCGTAATGGTATCGTTGTTGACA
GACTACTCGCCCCAGTTGCAGAAACCCAAATTCTGAATAGTGAA

>pARM1926 (SEQ ID NO: 223)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGGGCAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1927 (SEQ ID NO: 224)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCTGCAGGGCCGGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA

AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1928 (SEQ ID NO: 225)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGGGCCGGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCCGGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM1929 (SEQ ID NO: 226)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGGGCAAGGTGCAGCT
GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTCACCGGCGAGGAGATCAAGTA
CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
CGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
GAGCGACCTGGACACCCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
CGCCACCCCCAAGGGCTACGAGCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCTGGAGGC
CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM2016 (SEQ ID NO: 227)

ATGCTGTTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCCACA
 ACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACAAGGTGCAGCT
 GAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCAAGTA
 CATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCGAGTA
 CCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCAGCAC
 CCGCACCCGCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACCCCTG
 CTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCGACAC
 CGCCCCGCTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACAAGCA
 GAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACGGCCT
 GAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCAGGA
 GCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAACAA
 CATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCAGGC
 CGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGAGCA
 GTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGAGGC
 CGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCATGA
 AGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCCGCA
 AGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGTTC
 CCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGCTGA
 CCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM2260 (SEQ ID NO: 228)

ATGCTGGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
 ACAACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACCAGGTGC
 AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCC
 GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
 AGTACCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA
 GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
 CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
 ACACCGCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCGCGTGTACA
 AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
 GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
 GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
 CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
 GGCCGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGA
 GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGA
 GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
 GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
 TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
 GCAAGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
 TCCCCGAGGCCGAGAACCGCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
 TGACCGACTACAGCCCCAGCTGCAGAAGCCCAAGTTCTGA

>pARM2262 (SEQ ID NO: 229)

ATGCTGGTATTCAACCTGCGCATCCTGCTGAACAACGCCGCCTTCCGCAACGGCC
 ACAACTTCATGGTGCGCAACTTCCGCTGCGGCCAGCCCCCTGCAGAACCAGGTGC
 AGCTGAAGGGCCGCGACCTGCTGACCCTGAAGAACTTACCGGCGAGGAGATCC
 GGTACATGCTGTGGCTGAGCGCCGACCTGAAGTTCCGCATCAAGCAGAAGGGCG
 AGTACCTGCCCCCTGCTGCAGGGCAAGAGCCTGGGCATGATCTTCGAGAAGCGCA

GCACCCGCACCCGCCTGAGCACCGAGACAGGCTTCGCCCTGCTGGGCGGCCACC
 CCTGCTTCCTGACCACCCAGGACATCCACCTGGGCGTGAACGAGAGCCTGACCG
 ACACCGCCCCGCGTGCTGAGCAGCATGGCCGACGCCGTGCTGGCCCCGCGTGTACA
 AGCAGAGCGACCTGGACACCCTGGCCAAGGAGGCCAGCATCCCCATCATCAACG
 GCCTGAGCGACCTGTACCACCCCATCCAGATCCTGGCCGACTACCTGACCCTGCA
 GGAGCACTACAGCAGCCTGAAGGGCCTGACCCTGAGCTGGATCGGCGACGGCAA
 CAACATCCTGCACAGCATCATGATGAGCGCCGCCAAGTTCGGCATGCACCTGCA
 GGCCGCCACCCCCAAGGGCTACGAGCCCCGACGCCAGCGTGACCAAGCTGGCCGA
 GCAGTACGCCAAGGAGAACGGCACCAAGCTGCTGCTGACCAACGACCCCCCTGGA
 GGCCGCCACGGCGGCAACGTGCTGATCACCGACACCTGGATCAGCATGGGCCA
 GGAGGAGGAGAAGAAGAAGCGCCTGCAGGCCTTCCAGGGCTACCAGGTGACCA
 TGAAGACCGCCAAGGTGGCCGCCAGCGACTGGACCTTCCTGCACTGCCTGCCCC
 GCAAGCCCGAGGAGGTGGACGACGAGGTGTTCTACAGCCCCCGCAGCCTGGTGT
 TCCCCGAGGCCGAGAACCGCCAAGTGGACCATCATGGCCGTGATGGTGAGCCTGC
 TGACCGACTACAGCCCCCAGCTGCAGAAGCCCAAGTTCTGA

AT5G61250	AACCAAUCGAAAGAAACCAAA	SEQ ID NO: 230
AT5G46430	CUCUAAUCACCAGGAGUAAAA	SEQ ID NO: 231
AT5G47110	GAGAGAGAUCUUAACAAAAAA	SEQ ID NO: 232
AT1G03110	UGUGUAAACAACAACAACA	SEQ ID NO: 233
AT3G12380	CCGCAGUAGGAAGAGAAAGCC	SEQ ID NO: 234
AT5G45910	AAAAAAAAAAGAAAUCAUAAA	SEQ ID NO: 235
AT1G07260	GAGAGAAGAAAGAAGAAGACG	SEQ ID NO: 236
AT3G55500	CAAUUAAAAAUACUUACCAAA	SEQ ID NO: 237
AT3G46230	GCAAACAGAGUAAGCGAAACG	SEQ ID NO: 238
AT2G36170	GCGAAGAAGACGAACGCAAAG	SEQ ID NO: 239
AT1G10660	UUAGGACUGUAUUGACUGGCC	SEQ ID NO: 240
AT4G14340	AUCAUCGGAAUUCGGAAAAAG	SEQ ID NO: 241
AT1G49310	AAAACAAAAGUUAAGCAGAC	SEQ ID NO: 242
AT4G14360	UUUAUCUCAAUAAGAAGGCA	SEQ ID NO: 243
AT1G28520	GGUGGGGAGGUGAGAUUUCUU	SEQ ID NO: 244
AT1G20160	UGAUUAGGAAACUACAAAGCC	SEQ ID NO: 245
AT5G37370	CAUUUUUCAAUUUCAUAAAAC	SEQ ID NO: 246
AT4G11320	UUACUUUUAAGCCCAACAAA	SEQ ID NO: 247
AT5G40850	GGCGUGUGUGUGUGUUGUUGA	SEQ ID NO: 248
AT1G06150	GUGGUGAAGGGGAAGGUUAG	SEQ ID NO: 249
AT2G26080	UUGUUUUUUUUGGUUUGGUU	SEQ ID NO: 250

mARM2260 (SEQ ID NO: 251)

AGGAUUUUACAUCAAAACAAAAAGCCGCCACCAUGCUGGUAAUUAACCUGCG
 CAUCCUGCUGAACAAACGCCGCCUCCGCAACGGCCACAACUUCAUGGUGCGCA
 ACUUCCGCUGCGGCCAGCCCCUGCAGAACCGGGUGCAGCUGAAGGGCCGCGAC
 CUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCCGGUACAUGCUGUGGCU
 GAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGC
 UGCAGGGCAAGAGCCUGGGCAUGAUUUUCGAGAAGCGCAGCACCCGCACCCGC
 CUGAGCACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCUGAC
 CACCCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCG
 UGCUGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCGAC

CUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGA
 CCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGCACU
 ACAGCAGCCUGAAGGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAU
 CUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGC
 CACCCCCAAGGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGAGCAGU
 ACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCC
 GCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGA
 AGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGC
 AAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGU
 CCCCAGGGCCGAGAACCGCAAGUGGACCAUCAUGGGCCGUGAUGGUGAGCCUGC
 UGACCGACUACAGCCCCCAGCUGCAGAAGCCCCAAGUUCUGAGGUCUCUAGUAA
 UGAGCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCUCCCAACGGGC
 CCUCCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUG
 GGCAGCAUCUAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAA

mARM2262 (SEQ ID NO: 252)

AGGAUUUUACAUCAAAAACAAAAAGCCGCCACCAUGCUGGUUUUCAACCUGCG
 CAUCCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGGUGCGCA
 ACUUCGCGUGCGGCCAGCCCCUGCAGAACCGGGUGCAGCUGAAGGGCCGCGAC
 CUGCUGACCCUGAAGAACUUCACCGGCGAGGAGAUCCGGUACAUGCUGUGGCU
 GAGCGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGC
 UGCAGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGC
 CUGAGCACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCUGAC
 CACCCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCCGCG
 UGCUGAGCAGCAUGGCCGACGCCGUGCUGGGCCGCGUGUACAAGCAGAGCGAC
 CUGGACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGA
 CCUGUACCACCCCAUCCAGAUCUGGCCGACUACCUGACCCUGCAGGAGCACU
 ACAGCAGCCUGAAGGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAU
 CUGCACAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGC
 CACCCCCAAGGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGGCCGAGCAGU
 ACGCCAAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCC
 GCCACGGCGGCAACGUGCUGAUCACCGACACCUGGAUCAGCAUGGGCCAGGA
 GGAGGAGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGA
 AGACCGCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGC
 AAGCCCGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGU
 CCCCAGGGCCGAGAACCGCAAGUGGACCAUCAUGGGCCGUGAUGGUGAGCCUGC
 UGACCGACUACAGCCCCCAGCUGCAGAAGCCCCAAGUUCUGAGGUCUCUAGUAA
 UGAGCUGGAGCCUCGGUAGCCGUUCCUCCUGCCCGCUGGGCCUCCCAACGGGC
 CCUCCUCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUG
 GGCAGCAUCUAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAGCU

mARM2016 (SEQ ID NO: 253)

AGGAUUUUACAUCAAAAACAAAAAGCCGCCACCAUGCUGUUCAACCUGCGCAU
 CCUGCUGAACAACGCCGCCUUCGCAACGGCCACAACUUCAUGGUGCGCAACU
 UCCGCUGCGGCCAGCCCCUGCAGAACAAAGGUGCAGCUGAAGGGCCGCGACCUG


CUGACCCUGAAGAACUUCACCGGCGAGGAGAUCAAGUACAUGCUGUGGCUGAG
CGCCGACCUGAAGUUCGCAUCAAGCAGAAGGGCGAGUACCUGCCCCUGCUGC
AGGGCAAGAGCCUGGGCAUGAUCUUCGAGAAGCGCAGCACCCGCACCCGCCUG
AGCACCGAGACAGGCUUCGCCCUGCUGGGCGGCCACCCUGCUUCCUGACCAC
CCAGGACAUCCACCUGGGCGUGAACGAGAGCCUGACCGACACCGCCCGCGUGC
UGAGCAGCAUGGCCGACGCCGUGCUGGCCCGCGUGUACAAGCAGAGCGACCUG
GACACCCUGGCCAAGGAGGCCAGCAUCCCCAUCAUCAACGGCCUGAGCGACCU
GUACCACCCCAUCCAGAUCUCCUGGCCGACUACCUGACCCUGCAGGAGCACUACA
GCAGCCUGAAGGGCCUGACCCUGAGCUGGAUCGGCGACGGCAACAACAUCUG
CA
CAGCAUCAUGAUGAGCGCCGCCAAGUUCGGCAUGCACCUGCAGGCCGCCACCC
CCAAGGGCUACGAGCCCGACGCCAGCGUGACCAAGCUGGCCGAGCAGUACGCC
AAGGAGAACGGCACCAAGCUGCUGCUGACCAACGACCCCCUGGAGGCCGCCA
CGGCGGCAACGUGCUGAUCACCGACACCUUGGAUCAGCAUGGGCCAGGAGGAGG
AGAAGAAGAAGCGCCUGCAGGCCUUCAGGGCUACCAGGUGACCAUGAAGACC
GCCAAGGUGGCCGCCAGCGACUGGACCUUCCUGCACUGCCUGCCCCGCAAGCC
CGAGGAGGUGGACGACGAGGUGUUCUACAGCCCCCGCAGCCUGGUGUUCCCCG
AGGCCGAGAACCGCAAGUGGACCAUCAUGGCCGUGAUGGUGAGCCUGCUGACC
GACUACAGCCCCCAGCUGCAGAAGCCCAAGUUCUGAGGUCUCUAGUAAUGAGC
UGGAGCCUCGGUAGCCGUUCCUCCUGCCCUCUGGGCCUCCCAACGGGGCCCUCC
UCCCCUCCUUGCACCGGCCCUUCCUGGUCUUUGAAUAAAGUCUGAGUGGGCAG
CAUCUAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAA

CLAIMS

What is claimed is:

1. An ornithine transcarbamylase (OTC) protein comprising the amino acid sequence of SEQ ID NO:4 and having OTC enzymatic activity.
2. A polynucleotide encoding the protein of claim 1.
3. The polynucleotide of claim 2 comprising an optimized coding region encoding SEQ ID NO: 4.
4. The polynucleotide of claim 3, wherein the polynucleotide is DNA.
5. The polynucleotide of claim 3, wherein the polynucleotide is an mRNA.
6. The polynucleotide of claim 5 comprising a 3' poly A tail.
7. The polynucleotide of claim 6, wherein the 3' poly A tail comprises from about 60 sequential adenine nucleotides to about 125 sequential adenine nucleotides.
8. The polynucleotide of claim 7, wherein the 3' poly A tail comprises from about 100 sequential adenine nucleotides to about 125 sequential adenine nucleotides.
9. The polynucleotide of claim 5 comprising a non-human 5' untranslated region (5'UTR).
10. The polynucleotide of claim 9, wherein the 5'UTR is derived from a gene expressed by *Arabidopsis thaliana*.
11. The polynucleotide of claim 10, wherein the 5' UTR comprises SEQ ID NO: 6, SEQ ID NOS: 125-127 or SEQ ID NOS: 227-247.
12. The polynucleotide of claim 11, wherein the 5'UTR comprises SEQ ID NO: 6.

13. The polynucleotide of claim 5 comprising a 3' UTR.
14. The polynucleotide of claim 13, wherein the 3' UTR is selected from the group consisting of: SEQ ID NOS: 16-22.
15. The polynucleotide of claim 5 comprising a Kozak sequence of SEQ ID NO: 23 or a partial Kozak sequence of SEQ ID NO: 24.
16. The polynucleotide of claim 5 comprising a 5' cap.
17. The polynucleotide of claim 16, wherein the 5' cap is m7GpppGm having the following structure:



18. The polynucleotide of claim 4, wherein the optimized coding region comprises SEQ ID NO: 221.
19. The polynucleotide of claim 5 comprising SEQ ID NO: 119.
20. The polynucleotide of claim 5, wherein the percentage of uracil nucleobases in the coding region of the polynucleotide is reduced with respect to the percentage of uracil nucleobases in the wild-type OTC nucleic acid sequence.
21. The polynucleotide of claim 5, wherein 1-100% of the uridines are modified uridine analogs.

22. The polynucleotide of claim 21, wherein 100% of the uridine nucleotides are 5-methoxyuridine.
23. The polynucleotide of claim 22, wherein 100% of the uridine nucleotides are N¹-methylpseudouridine.
24. The polynucleotide of claim 5, comprising SEQ ID NO: 251 or SEQ ID NO: 252.
25. The polynucleotide of claim 19 or 24, wherein 1-100% of the uridines are modified uridine analogs.
26. The polynucleotide of claim 19 or 24, wherein 100% of the uridine nucleotides are 5-methoxyuridine.
27. The polynucleotide of claim 19 or 24, wherein 100% of the uridine nucleotides are N¹-methylpseudouridine.
28. A pharmaceutical composition comprising the polynucleotide of claim 19 or 24.
29. A pharmaceutical composition comprising the polynucleotide of claim 25.
30. A pharmaceutical composition comprising the polynucleotide of claim 26.
31. A pharmaceutical composition comprising the polynucleotide of claim 27.
32. The pharmaceutical composition of claim 28 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.
33. The pharmaceutical composition of claim 29 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.
34. The pharmaceutical composition of claim 30 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.

35. The pharmaceutical composition of claim 31 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.
36. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient, a pharmaceutical composition of any one of claims 28-35, wherein upon administration of the pharmaceutical composition to the patient, the protein of SEQ ID NO: 4 is expressed in the patient.
37. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient a polynucleotide of claim 5, wherein the polynucleotide expresses the protein of SEQ ID NO: 4 in the patient.
38. A vector comprising a polynucleotide of claim 4.
39. A host cell transformed with a vector of claim 38.
40. An mRNA encoding an OTC protein having the amino acid sequence of SEQ ID NO: 4, wherein the mRNA has the polynucleotide sequence of SEQ ID NO: 119, SEQ ID NO: 251 or SEQ ID NO: 252 and wherein the encoded protein has OTC enzymatic activity.
41. The mRNA of claim 40, wherein 1-100% of the uridines are modified uridine analogs.
42. The mRNA of claim 41, wherein 100% of the uridine nucleotides are 5-methoxyuridine.
43. The mRNA of claim 41, wherein 100% of the uridine nucleotides are N¹-methylpseudouridine.
44. A pharmaceutical composition comprising the mRNA of any one claims 40, 41, 42, or 43.
45. The pharmaceutical composition of claim 44 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.

46. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency comprising, administering to the patient an mRNA of claim 40, wherein the mRNA expresses the protein of SEQ ID NO: 4 in the patient.
47. An mRNA comprising a codon-optimized coding region encoding a human ornithine transcarbamylase (OTC) protein of SEQ ID NO: 3 and having OTC protein enzymatic activity wherein the mRNA comprises a 5'UTR derived from a gene expressed by *Arabidopsis thaliana* and wherein the mRNA is selected from the group consisting of SEQ ID NOS: 62, 67, 68, 69, 73, 113-118, and 121-124.
48. The mRNA of claim 47 comprising a 3' Poly A tail wherein the 3' Poly A tail comprises from about 100 nucleotides to about 125 nucleotides.
49. The mRNA of claim 47, wherein 1-100% of the uridine nucleotides are modified uridine analogs.
50. The mRNA of claim 49, wherein the modified uridine analogs are independently selected from 5-methoxyuridine and N¹-methylpseudouridine.
51. The mRNA of claim 50, wherein 100% of the uridine nucleotides are 5-methoxyuridine.
52. The mRNA of claim 50, wherein 100% of the uridine nucleotides are N¹-methylpseudouridine.
53. A pharmaceutical composition comprising an mRNA of any one of claims 47-52.
54. The pharmaceutical composition of claim 53 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.
55. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient, a pharmaceutical composition of claim

54, wherein upon administration of the pharmaceutical composition to the patient, the human OTC protein of SEQ ID NO: 3 is expressed in the patient.

56. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient an mRNA of any one of claims 47-52, wherein the mRNA expresses the human OTC protein of SEQ ID NO: 3 in the patient.

57. The mRNA of claim 47, wherein the mRNA comprises SEQ ID NO: 73.

58. The mRNA of claim 57 comprising a 3' Poly A tail wherein the 3' Poly A tail comprises from about 60 nucleotides to about 125 nucleotides.

59. The mRNA of claim 58, wherein the 3' Poly A tail comprises from about 100 nucleotides to about 125 nucleotides.

60. The mRNA of claim 57, wherein 1-100% of the uridine nucleotides are modified uridine analogs.

61. The mRNA of claim 60, wherein the modified uridine analogs are independently selected from the group consisting of: 5-methoxyuridine and N¹-methylpseudouridine.

62. The mRNA of claim 61, wherein 100% of the uridine nucleotides are 5-methoxyuridine.

63. The mRNA of claim 61, wherein 100% of the uridine nucleotides are N¹-methylpseudouridine.

64. A pharmaceutical composition comprising an mRNA of any one of claims 57-63.

65. The pharmaceutical composition of claim 64 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.

66. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient, a pharmaceutical composition of claim

65, wherein upon administration of the pharmaceutical composition to the patient, the protein of SEQ ID NO: 3 is expressed in the patient.

67. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient an mRNA of any one of claims 57-63, wherein the mRNA expresses the protein of SEQ ID NO: 3 in the patient.

68. The mRNA of claim 53, wherein the mRNA comprises SEQ ID NO: 253.

69. The mRNA of claim 68, wherein 1-100% of the uridine nucleotides are modified uridine analogs.

70. The mRNA of claim 69, wherein the modified uridine analogs are independently selected from the group consisting of: 5-methoxyuridine and N¹-methylpseudouridine.

71. The mRNA of claim 70, wherein 100% of the uridine nucleotides are 5-methoxyuridine.

72. The mRNA of claim 70, wherein 100% of the uridine nucleotides are N¹-methylpseudouridine.

73. A pharmaceutical composition comprising an mRNA of any one of claims 68-72.

74. The pharmaceutical composition of claim 73 comprising a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is a lipid formulation.

75. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient, a pharmaceutical composition of claim 74, wherein upon administration of the pharmaceutical composition to the patient, the protein of SEQ ID NO: 3 is expressed in the patient.

76. A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient an mRNA of any one of claims 68-72, wherein the mRNA expresses the protein of SEQ ID NO: 3 in the patient.





FIG. 1

AMENDED SHEET - IPEA/US


FIG. 2

Correlation Hepa1,6 - 24h




AMENDED SHEET - IPEA/US

FIG. 2 Cont'd.




AMENDED SHEET - IPEA/US

FIG. 3




AMENDED SHEET - IPEA/US

FIG. 3 Cont'd.




AMENDED SHEET - IPEA/US

FIG. 4



AMENDED SHEET - IPEA/US

FIG. 4 Cont'd.



AMENDED SHEET - IPEA/US




FIG. 5

AMENDED SHEET - IPEA/US




FIG. 6

Liver - OTC protein relative to WT, 3mg/kg




FIG. 7

AMENDED SHEET - IPEA/US




FIG. 8

AMENDED SHEET - IPEA/US




FIG. 9




FIG. 10

AMENDED SHEET - IPEA/US




FIG. 11

AMENDED SHEET - IPEA/US




FIG. 12

AMENDED SHEET - IPEA/US

16/18

REPLACEMENT SHEET




FIG. 13

AMENDED SHEET - IPEA/US




FIG. 14

AMENDED SHEET - IPEA/US




FIG. 15

AMENDED SHEET - IPEA/US

FIG. 1

